******These references are the same as in file 1 but now the sequences are displayed*****

```
=> d que l4
L2            42 SEA FILE=REGISTRY ABB=ON  PLU=ON  [G'SAR']A[G'SAR']['HYP'P]['HY
                 P'P]YN/SQSFP
L3            36 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L2
L4            14 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L3 AND (AY<2001 OR PY<2001 OR
                 PRY<2001)


=> d hitseq l4 tot

L4   ANSWER 1 OF 14  HCAPLUS  COPYRIGHT 2007 ACS on STN
IT   716607-51-1
     RL: BSU (Biological study, unclassified); BUU (Biological use,
     unclassified); PRP (Properties); BIOL (Biological study); USES (Uses)
        (amino acid sequence; rice nucleic acid mols. and encoded proteins and
        their uses for plant improvement)
RN   716607-51-1  HCAPLUS
CN   Protein (Oryza sativa clone PAT_MRT4530_21015C.1.pep fragment) (9CI)  (CA
     INDEX NAME)


SEQ      1 GGPLAPGGLF PLYKKPREKK APETAPRPKI PGEFGPRGRV GPGGYPFPEP
        51 PRKKKAPKRP EESPGEKKPP LLGGGPPYQG SRGGRRPPRK FPPPGWAIWG
       101 GKNLFFFPRG GFFFFQKVPA PPQ



L4   ANSWER 2 OF 14  HCAPLUS  COPYRIGHT 2007 ACS on STN
IT   651799-18-7
     RL: PRP (Properties)
        (unclaimed protein sequence; cDNAs encoding human NOVX proteins and
        their diagnostic and therapeutic use)
RN   651799-18-7  HCAPLUS
CN   103: PN: US20040018970 SEQID: 102 unclaimed protein (9CI)  (CA INDEX NAME)


SEQ      1 TGKVALVTGA SSGLGLAIAK RLAKEGAKVV VVDRREEKAE QVAAELKAEL
        51 GDRALFIQLD VTDEEQVKAA VAQAVERLGD RLDVLVNNAG ILGPGPPFEE
       101 LSEEDWERVI DVNLTGVFLL TQAVLPAMDH MLKRKGGRLV NISSVAGLNV
       151 GVPGLSAYSA SKAAVIGLTR SLALELAPHG TGLRVNAVAP GGVDTDMTKA
       201 LRSRLIEAKK KVREVADIAD PELEERITST ITPLGRYGVT PEEIANAVLF
       251 LASDGASYSV TGQTLNVDGG L



L4   ANSWER 3 OF 14  HCAPLUS  COPYRIGHT 2007 ACS on STN
IT   477095-44-6
     RL: BSU (Biological study, unclassified); BUU (Biological use,
     unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological
     study); USES (Uses)
        (amino acid sequence; essential genes in microorganisms and their use
        as targets for antisense inhibition of proliferation and antibiotic
        screening)
RN   477095-44-6  HCAPLUS
```

CN Protein (Mycobacterium avium clone MAV104574 essential) (9CI) (CA INDEX NAME)

SEQ
```
  1 MNAPMSMQPR SRRPLRRAQL SDEVAGHLRA AIMSGELRPG TFIRLDETAA
 51 ELGVSVTPVR EALLKLRGEG MVQLEPHRGX RGAAASPAKT SRTSSGCRRP
101 SPRSWPPRPP TTSPTPRSTS WIASTTRSPR RSGPATPRPS RASSSASTGS
151 STRPAAGSSW PGSCSTPPAT CRCWCTPPTR SGGGPPFDNH RQLIAASAPP
201 RHRRGDRAHG LAVHRRGGAA DRDARPHRDA EQPGVSSRPT ARRAA
```

L4 ANSWER 4 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN
IT *355151-33-6P 355151-45-0P 355151-46-1P 355151-47-2P*
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(synthesis of peptides and medical uses of intracellular communication facilitating compds.)
RN 355151-33-6 HCAPLUS
CN D-Asparagine, glycyl-D-alanylglycyl-(4S)-4-hydroxy-D-prolyl-D-prolyl-D-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 355151-45-0 HCAPLUS
CN Cyclo[L-alanylglycyl-(4R)-4-hydroxy-L-prolyl-L-prolyl-L-tyrosyl-L-glutaminylglycyl] (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 355151-46-1 HCAPLUS
CN Cyclo[L-alanylglycyl-(4R)-4-hydroxy-L-prolyl-L-prolyl-L-tyrosyl-L-asparaginylglycyl] (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 355151-47-2 HCAPLUS
CN Cyclo(L-alanylglycyl-L-prolyl-L-prolyl-L-tyrosyl-L-asparaginylglycyl) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT *463362-44-9*
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(synthesis of peptides and medical uses of intracellular communication

facilitating compds.)
RN 463362-44-9 HCAPLUS
CN L-Aspartamide, glycyl-L-alanylglycyl-(4R)-4-hydroxy-L-prolyl-L-prolyl-L-tyrosyl- (9CI) (CA INDEX NAME)

NTE modified

SEQ 1 GAGXPYN

Absolute stereochemistry.



L4 ANSWER 5 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN
IT *444214-05-5*
RL: PRP (Properties)
(unclaimed protein sequence; human cDNA sequences and their encoded proteins and diagnostic and therapeutic uses)
RN 444214-05-5 HCAPLUS
CN 50: PN: WO02059315 SEQID: 102 unclaimed protein (9CI) (CA INDEX NAME)

SEQ
1 TGKVALVTGA SSGIGLAIAK RLAKEGAKVV VVDRREEKAE QVAAELKAEL
51 GDRALFIQLD VTDEEQVKAA VAQAVERLGD RLDVLVNNAG ILGPGPPFEE
101 LSEEDWERVI DVNLTGVFLL TQAVLPAMDH MLKRKGGRIV NISSVAGLNV
151 GVPGLSAYSA SKAAVIGLTR SLALELAPHG TGIRVNAVAP GGVDTDMTKA
201 LRSRLIEAKK KVREVADIAD PELEERITST ITPLGRYGVT PEEIANAVLF
251 LASDGASYSV TGQTLNVDGG L

L4 ANSWER 6 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN
IT *408552-03-4P*
RL: ANT (Analyte); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)
(amino acid sequence; nucleic acids and their encoded polypeptides from human tissues)
RN 408552-03-4 HCAPLUS
CN Protein (human clone WO0231111-SEQID-704) (9CI) (CA INDEX NAME)

SEQ
1 MGEPRAGAAL DDGSGWTGSE EGSEEGTGGS EGAGGDGGPD AEGVWSPDIE
51 QSFQEALAIY PPCGRRKIIL SDEGKMYGRN ELIARYIKLR TGKTRTRKQV
101 SSHIQVLARR KSREIQSKLK DQVSKDKAFQ TMATMSSAQL ISAPSLQAKL
151 GPTGPQASEL FQFWSGGSGP PWNVPDVKPF SQTPFTLSLT PPSTDLPGYE

```
       201 PPQALSPLPP PTPSPPAWQA RGLGTARLQL VEFSAFVEPP DAVDSYQRHL
       251 FVHISQHCPS PGAPPLESVD VRQIYDKFPE KKGGLRELYD RGPPHAFFLV
       301 KFWADLNWGP SGEEAGAGGS ISSGGFYGVS SQYESLEHMT LTCSSKVCSF
       351 GKQVVEKVET ERAQLEDGRF VYRLLRSPMC EYLVNFLHKL RQLPERYMMN
       401 SVLENFTILQ VVTNRDTQEL LLCTAYVFEV STSERGAQHH IYRLVRD
```

L4 ANSWER 7 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN
IT *429718-39-8*
RL: ANT (Analyte); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(amino acid sequence; human nucleic acids and polypeptides and their diagnostic and therapeutic uses)
RN 429718-39-8 HCAPLUS
CN Protein (human clone WO0175067-SEQID-32147) (9CI) (CA INDEX NAME)

```
SEQ      1 XPRWGKPRAG AALDDGSGWT GSEEGSEEGT GGSEGAGGDG GPDAEGVWSP
        51 DIEQSFQEAL AIYPPCGRRK IILSDEGKMY GRNELIARYI KLRTGKTRTR
       101 KQVSSHIQVL ARRKSREIQS KLKALNVDQV SKDKAFQTMA TMSSAQLISA
       151 PSLQAKLGPT GPQVVQASEL FQFWSGGSGP PWNVPDVKPF SQTPFTLSLT
       201 PPSTDLPGYE PPQALSPLPP PTPSPPAWQA RGLGTARLQL VEFSAFVEPP
       251 DAVDSYQRHL FVHISQHCPS PGAPPLESVD VRQIYDKFPE KKGGLRELYD
       301 RGPPPCLLPG QFWADLNWGP SGEEAGAGGS ISSGGFYGVS SQYESLEHMT
       351 LTCSSKVCSF GKQVVEKVET ERAQLEDGRF VYRLLRSPMC EYLVNFLHKL
       401 RQLPERYMMN SVLENFTILQ VVTNRDTQEL LLCTAYVFEV STSERGAQHH
       451 IYRLVRD
```

L4 ANSWER 8 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN
IT *367620-13-1*
RL: ANT (Analyte); BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
(amino acid sequence; nucleic acids encoding human bone marrow-expressed polypeptides)
RN 367620-13-1 HCAPLUS
CN Bone marrow-specific protein (human clone WO0179447-SEQID-38 precursor) (9CI) (CA INDEX NAME)

```
SEQ      1 MQGDSKFSSQ GTGPPYQDLS TKSRIALNRA LLVAKGRTVN IYTDSKYAFA
        51 TLHAHGAIYK ERGLLTAGGK EIKEEILQLL EAVWAPDKVA VIHCKGHQTR
       101 GGIEAKGNRK ADREARQAAM SNSSTKKKTP TLLLLLEPSL PETPSYSPNE
       151 KAWFEQESGS YIQGGRWKFS DGRLAIPEAI APQFMKQFHQ GTHMGKTALE
       201 TLVGWHFYVP CLTAITRAVC EQCLTCAQNN PWQVPTQPPG IQETGATPCE
       251 NLLVDFTELP RARGYQYMLV FVCTFSGWVE AFPTRIEKAQ EVTRLLLKDI
       301 IPRFGLPLTL GSDNGPAFMA EVVQQLSQLL KIKWKLHIVY HPQSSGKVQW
       351 MNQTLKHLLK FCQEPHLRWD QVLPMGLSPS QVYPYQIDWA FTL
```

L4 ANSWER 9 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN
IT *355151-33-6P 355151-45-0P 355151-46-1P*

355151-47-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of novel antiarrhythmic peptides)

RN 355151-33-6 HCAPLUS
CN D-Asparagine, glycyl-D-alanylglycyl-(4S)-4-hydroxy-D-prolyl-D-prolyl-D-tyrosyl- (9CI) (CA INDEX NAME)

SEQ 1 GAGXPYN

Absolute stereochemistry.



RN 355151-45-0 HCAPLUS
CN Cyclo[L-alanylglycyl-(4R)-4-hydroxy-L-prolyl-L-prolyl-L-tyrosyl-L-glutaminylglycyl] (9CI) (CA INDEX NAME)

NTE cyclic

SEQ 1 AGXPYQG

RN 355151-46-1 HCAPLUS
CN Cyclo[L-alanylglycyl-(4R)-4-hydroxy-L-prolyl-L-prolyl-L-tyrosyl-L-asparaginylglycyl] (9CI) (CA INDEX NAME)

NTE cyclic

SEQ 1 AGXPYNG

RN 355151-47-2 HCAPLUS
CN Cyclo(L-alanylglycyl-L-prolyl-L-prolyl-L-tyrosyl-L-asparaginylglycyl) (9CI) (CA INDEX NAME)

NTE cyclic

SEQ 1 AGPPYNG

L4 ANSWER 10 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN
IT *295808-32-1*
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence; sequences of 100 cDNA clones of unknown human genes, named KIAA1444 to KIAA1543, from human adult and fetal brain cDNA libraries)
RN 295808-32-1 HCAPLUS
CN Protein (human clone fj01441 gene KIAA1466 fragment) (9CI) (CA INDEX NAME)

SEQ
1 ETNPLRTQTL NISQREAGLY QKGSAEPGMQ GDSKFSSQGT GPPYQDLSTK
51 SRIALNRALL VAKGRTVNIY TDSKYAFATL HAHGAIYKER GLLTAGGKEI
101 KEEILQLLEA VWAPDKVAVI HCKGHQTRGG IEAKGNRKAD REARQAAMSN
151 SSTKKKTPTL LLLLEPSLPE TPSYSPNEKA WFEQESGSYI QGGRWKFSDG
201 RLAIPEAIAP QFMKQFHQGT HMGKTALETL VGWHFYVPCL TAITRAVCEQ
251 CLTCAQNNPW QVPTQPPGIQ ETGATPCENL LVDFTELPRA RGYQYMLVFV
301 CTFSGWVEAF PTRIEKAQEV TRLLLKDIIP RFGLPLTLGS DNGPAFMAEV
351 VQQLSQLLKI KWKLHIVYHP QSSGKVQWMN QTLKHLLKFC QEPHLRWDQV
401 LPMAFLQVRC TLTKLTGLSP CEIVFGRPPP IINQVKGDLW ELGELTLKRQ
451 MQALGLAMQK IHGWVREKLP ISLTDPVHPF TPGDLVWVKK WNPTTLGPIW
501 DGPTL

L4 ANSWER 11 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN
IT *227783-92-8*
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence; complete genome sequence of Aeropyrum pernix K1)
RN 227783-92-8 HCAPLUS
CN 132Aa long protein (Aeropyrum pernix strain K1 gene APE1292) (9CI) (CA INDEX NAME)

SEQ
1 MEVCHAQIVL LIPCRGGEHY VGVYRGGGHP EVYCHQEVQL PLGGGPPYNL
51 LDEAPVHLLA HRLGHRAPQQ VLQEVLVALA AAAEEVSPPD EHDPNPVLRG
101 VRVLYRQLQL AALQKVYHVL HGILPKPPSL RR

L4 ANSWER 12 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN
IT *193843-04-8*, Cadherin 5 (mouse F-2 cell)
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence; in vivo evidence of critical role of cadherin-5 in murine vascular integrity)
RN 193843-04-8 HCAPLUS
CN Cadherin 5 (mouse F-2 cell) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT *173432-45-6*, Cadherin 5, prepro- (Mus musculus)
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(in vivo evidence of critical role of cadherin-5 in murine vascular integrity)
RN 173432-45-6 HCAPLUS

CN Cadherin 5, prepro- (Mus musculus) (9CI) (CA INDEX NAME)

SEQ
1 MQRLTELATA LGAFLGLLAV AAMAGPNFPQ IDTPNMLPAH HRQKRDWIWN
51 QMHIDEEKNE SLPHYVKDQS NVNRQNAKYV LQGEFAGKIF GVDANTGNVL
101 AYERLDREKV SEYFLTALIV DKNTNKNLEQ PSSFTVKVHD INDNWPVFSH
151 QVFNASVPEM SAIGTSVIRV TAVDADDPTV AGHATVLYQI VKGNEYFSID
201 NSGLIFTKIK NLDREKQAEY KIVVETQDAL GLRGESGTAT VMIRLEDIND
251 NFPVFTQSTY TFSVPEDIRV GKPLGFLTVV DPDEPQNRMT KYSIMQGEYR
301 DTFTIETDPK RNEGIIKPTK SLDYEVIQQY TFYIEATDPT IRYEYLSSTS
351 GKNKAMVTIN VLDVDEPPVF QRHFYHFKLP ENQKKPLIGT VVAKDPDKAQ
401 RSIGYSIRKT SDRGQFFRIT KQGNIYNEKE LDRETYAWYN LTVEANELDS
451 RGNPVGKESI VQVYIEVLDE NDNPPEFAQP YEPKVCENAA QGKLVVQISA
501 TDKDVVPVNP KFKFALKNED SNFTLINNHD NTANITVKYG QFNREHAKFH
551 YLPVLISDNG VPSLTGTSTL TVGVCKCNEQ GEFTFCEEMA AQAGVSIQAL
601 VAIFLCILTI TVITLLIILR RRIRKQAHAH SKSALEIHEQ LVTYDEEGGG
651 EMDTTSYDVS VLNSVRGGST KPLRSTMDAR PAVYTQVQKP PRLAPGLHGG
701 PREMATMIDV KKEEADNDGG GPPYDTLHIY GYEGAESIAE SLSSLSTNSS
751 DSDIDYDFLN DWGPRFKMLA ELYGSDPQEE LII

L4 ANSWER 13 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN
IT *181829-01-6*
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence; a novel family of developmentally regulated mammalian transcription factors containing the TEA/ATTS DNA binding domain)
RN 181829-01-6 HCAPLUS
CN RNA formation factor TEF-5 (human fragment reduced) (9CI) (CA INDEX NAME)

SEQ
1 GAGGDGGPDA EGVWSPDIEQ SFQEALAIYP PCGRRKIILS DEGKMYGRNE
51 LIARYIKLRT GKTRTRKQVS SHIQVLARRK SREIQSKLKD QVSKDKAFQT
101 MATMSSAQLI SALSLQAKLG PTGPQASELF QFWSGGSGPP WNVPDVKPFS
151 QTPFTLSLTP PSTDLPGYEP PQALSPLPPP TPSPPAWQAR GLGTARLQLV
201 EFSAFVEPPD AVDSYQRHLF VHISQHCPSP GAPPLESVDV RQIYDKFPEK
251 KGGLRELYDR GPPHAFFLVK FWADLNWGPS GEEAGAGGSI SSGGFYGVSS
301 QYESLEHMTL TCSSKVCSFG KQVVEKVETE RAQLED

L4 ANSWER 14 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN
IT *173432-45-6*, Cadherin 5, prepro- (Mus musculus)
173432-46-7, Cadherin 5 (Mus musculus)
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); OCCU (Occurrence)
(amino acid sequence; cDNA sequence and tissue distribution of murine vascular endothelial-cadherin in early stage development of cardiovascular system)
RN 173432-45-6 HCAPLUS
CN Cadherin 5, prepro- (Mus musculus) (9CI) (CA INDEX NAME)

SEQ
1 MQRLTELATA LGAFLGLLAV AAMAGPNFPQ IDTPNMLPAH HRQKRDWIWN
51 QMHIDEEKNE SLPHYVKDQS NVNRQNAKYV LQGEFAGKIF GVDANTGNVL
101 AYERLDREKV SEYFLTALIV DKNTNKNLEQ PSSFTVKVHD INDNWPVFSH
151 QVFNASVPEM SAIGTSVIRV TAVDADDPTV AGHATVLYQI VKGNEYFSID

```
       201 NSGLIFTKIK NLDREKQAEY KIVVETQDAL GLRGESGTAT VMIRLEDIND
       251 NFPVFTQSTY TFSVPEDIRV GKPLGFLTVV DPDEPQNRMT KYSIMQGEYR
       301 DTFTIETDPK RNEGIIKPTK SLDYEVIQQY TFYIEATDPT IRYEYLSSTS
       351 GKNKAMVTIN VLDVDEPPVF QRHFYHFKLP ENQKKPLIGT VVAKDPDKAQ
       401 RSIGYSIRKT SDRGQFFRIT KQGNIYNEKE LDRETYAWYN LTVEANELDS
       451 RGNPVGKESI VQVYIEVLDE NDNPPEFAQP YEPKVCENAA QGKLVVQISA
       501 TDKDVVPVNP KFKFALKNED SNFTLINNHD NTANITVKYG QFNREHAKFH
       551 YLPVLISDNG VPSLTGTSTL TVGVCKCNEQ GEFTFCEEMA AQAGVSIQAL
       601 VAIFLCILTI TVITLLIILR RRIRKQAHAH SKSALEIHEQ LVTYDEEGGG
       651 EMDTTSYDVS VLNSVRGGST KPLRSTMDAR PAVYTQVQKP PRLAPGLHGG
       701 PREMATMIDV KKEEADNDGG GPPYDTLHIY GYEGAESIAE SLSSLSTNSS
       751 DSDIDYDFLN DWGPRFKMLA ELYGSDPQEE LII

RN   173432-46-7  HCAPLUS
CN   Cadherin 5 (Mus musculus) (9CI)  (CA INDEX NAME)

SEQ      1 DWIWNQMHID EEKNESLPHY VKDQSNVNRQ NAKYVLQGEF AGKIFGVDAN
        51 TGNVLAYERL DREKVSEYFL TALIVDKNTN KNLEQPSSFT VKVHDINDNW
       101 PVFSHQVFNA SVPEMSAIGT SVIRVTAVDA DDPTVAGHAT VLYQIVKGNE
       151 YFSIDNSGLI FTKIKNLDRE KQAEYKIVVE TQDALGLRGE SGTATVMIRL
       201 EDINDNFPVF TQSTYTFSVP EDIRVGKPLG FLTVVDPDEP QNRMTKYSIM
       251 QGEYRDTFTI ETDPKRNEGI IKPTKSLDYE VIQQYTFYIE ATDPTIRYEY
       301 LSSTSGKNKA MVTINVLDVD EPPVFQRHFY HFKLPENQKK PLIGTVVAKD
       351 PDKAQRSIGY SIRKTSDRGQ FFRITKQGNI YNEKELDRET YAWYNLTVEA
       401 NELDSRGNPV GKESIVQVYI EVLDENDNPP EFAQPYEPKV CENAAQGKLV
       451 VQISATDKDV VPVNPKFKFA LKNEDSNFTL INNHDNTANI TVKYGQFNRE
       501 HAKFHYLPVL ISDNGVPSLT GTSTLTVGVC KCNEQGEFTF CEEMAAQAGV
       551 SIQALVAIFL CILTITVITL LIILRRRIRK QAHAHSKSAL EIHEQLVTYD
       601 EEGGGEMDTT SYDVSVLNSV RGGSTKPLRS TMDARPAVYT QVQKPPRLAP
       651 GLHGGPREMA TMIDVKKEEA DNDGGGPPYD TLHIYGYEGA ESIAESLSSL
       701 STNSSDSDID YDFLNDWGPR FKMLAELYGS DPQEELII


=> d his full

     (FILE 'HOME' ENTERED AT 13:10:47 ON 12 MAR 2007)

     FILE 'REGISTRY' ENTERED AT 13:11:19 ON 12 MAR 2007

     FILE 'LREGISTRY' ENTERED AT 13:13:27 ON 12 MAR 2007
L1            0 SEA ABB=ON  PLU=ON  [G'SAR']A[G'SAR']['HYP'P]['HYP'P]YN/SQSFP

     FILE 'REGISTRY' ENTERED AT 13:15:31 ON 12 MAR 2007
L2           42 SEA ABB=ON  PLU=ON  [G'SAR']A[G'SAR']['HYP'P]['HYP'P]YN/SQSFP

     FILE 'HCAPLUS' ENTERED AT 13:17:13 ON 12 MAR 2007
L3           36 SEA ABB=ON  PLU=ON  L2
L4           14 SEA ABB=ON  PLU=ON  L3 AND (AY<2001 OR PY<2001 OR PRY<2001)

     FILE 'REGISTRY' ENTERED AT 13:18:16 ON 12 MAR 2007
L5            0 SEA ABB=ON  PLU=ON  L2 AND MEDLINE/LC
L6            0 SEA ABB=ON  PLU=ON  L2 AND EMBASE/LC
L7            0 SEA ABB=ON  PLU=ON  L2 AND BIOSIS/LC
L8            0 SEA ABB=ON  PLU=ON  L2 AND CAOLD/LC
```

```
     FILE 'STNGUIDE' ENTERED AT 13:18:53 ON 12 MAR 2007

     FILE 'HCAPLUS' ENTERED AT 13:19:30 ON 12 MAR 2007
                E US2004-772774/APPS
L9                2 SEA ABB=ON  PLU=ON  US2004-772774/AP
                  D SCAN
                  SEL RN L9

     FILE 'REGISTRY' ENTERED AT 13:20:34 ON 12 MAR 2007
L10             107 SEA ABB=ON  PLU=ON  (159503-65-8/BI OR 355151-11-0/BI OR
                    355151-12-1/BI OR 355151-13-2/BI OR 355151-14-3/BI OR 355151-15
                    -4/BI OR 355151-16-5/BI OR 355151-17-6/BI OR 355151-18-7/BI OR
                    355151-19-8/BI OR 355151-20-1/BI OR 355151-23-4/BI OR 355151-25
                    -6/BI OR 355151-26-7/BI OR 355151-27-8/BI OR 355151-29-0/BI OR
                    355151-30-3/BI OR 355151-31-4/BI OR 355151-32-5/BI OR 355151-33
                    -6/BI OR 355151-34-7/BI OR 355151-35-8/BI OR 355151-36-9/BI OR
                    355151-37-0/BI OR 355151-38-1/BI OR 355151-39-2/BI OR 355151-40
                    -5/BI OR 355151-41-6/BI OR 355151-43-8/BI OR 355151-45-0/BI OR
                    355151-46-1/BI OR 355151-47-2/BI OR 355151-49-4/BI OR 355151-50
                    -7/BI OR 355151-51-8/BI OR 355151-52-9/BI OR 355151-53-0/BI OR
                    355151-54-1/BI OR 355151-55-2/BI OR 355151-56-3/BI OR 355151-74
                    -5/BI OR 81771-37-1/BI OR 111915-92-5/BI OR 133294-37-8/BI OR
                    212570-15-5/BI OR 355151-21-2/BI OR 355151-22-3/BI OR 355151-24
                    -5/BI OR 355151-28-9/BI OR 355151-42-7/BI OR 355151-44-9/BI OR
                    355151-48-3/BI OR 355151-57-4/BI OR 355151-58-5/BI OR 355151-59
                    -6/BI OR 355151-60-9/BI OR 355151-61-0/BI OR 355151-62-1/BI OR
                    355151-63-2/BI OR 355151-64-3/BI OR 355151-65-4/BI OR 355151-66
                    -5/BI OR 355151-67-6/BI OR 355151-68-7/BI OR 355151-69-8/BI OR
                    355151-70-1/BI OR 355151-71-2/BI OR 355151-72-3/BI OR 355151-73
                    -4/BI OR 355151-75-6/BI OR 355151-76-7/BI OR 35919-99-4/BI OR
                    366800-53-5/BI OR 463362-31-4/BI OR 463362-32-5/BI OR 463362-33
                    -6/BI OR 463362-34-7/BI OR 463362-35-8/BI OR 463362-36-9/BI OR
                    463362-37-0/BI OR 463362-38-1/BI OR 463362-40-5/BI OR 463362-42
                    -7/BI OR 463362-43-8/BI OR 463362-44-9/BI OR 463362-45-0/BI OR
                    463362-46-1/BI OR 463362-47-2/BI OR 463362-48-3/BI OR 463362-49
                    -4/BI OR 463362-50-7/BI OR 463362-51-8/BI OR 463362-52-9/BI OR
                    463362-53-0/BI OR 463362-54-1/BI OR 463362-55-2/BI OR 463362-56
                    -3/BI OR 463362-57-4/BI OR 463362-58-5/BI OR 463362-59-6/BI OR
                    463944-96-9/BI OR 476-70-0/BI OR 50-99-7/BI OR 501-36-0/BI OR
                    57381-26-7/BI OR 602-07-3/BI OR 7782-44-7/BI)
L11               5 SEA ABB=ON  PLU=ON  L10 AND L2

     FILE 'STNGUIDE' ENTERED AT 13:21:01 ON 12 MAR 2007

     FILE 'HCAPLUS' ENTERED AT 13:22:00 ON 12 MAR 2007
                E LARSEN B/AU
L12             177 SEA ABB=ON  PLU=ON  ("LARSEN B"/AU OR "LARSEN B DUE"/AU OR
                    "LARSEN BJARNE"/AU OR "LARSEN BJARNE D"/AU OR "LARSEN BJARNE
                    DUE"/AU)
                E PETERSEN J/AU
L*** DEL          0 S E3,E29,E122,E127,E129,E169,E175-E177.
L13             262 SEA ABB=ON  PLU=ON  ("PETERSEN J"/AU OR "PETERSEN J S"/AU OR
                    "PETERSEN JOERGEN"/AU OR "PETERSEN JOERGEN S"/AU OR "PETERSEN
                    JOERGEN SOEBERG"/AU OR "PETERSEN JORGEN"/AU OR "PETERSEN
                    JORGEN S"/AU OR "PETERSEN JORGEN SOBERG"/AU OR "PETERSEN
                    JORGEN SOEBERG"/AU)
                E MEIER E/AU
L14             118 SEA ABB=ON  PLU=ON  ("MEIER E"/AU OR "MEIER E A"/AU OR "MEIER
                    E F"/AU OR "MEIER E G"/AU OR "MEIER E J J"/AU OR "MEIER E M
```

```
                M"/AU OR "MEIER E P"/AU OR "MEIER E V"/AU OR "MEIER EDDI"/AU
                OR "MEIER EDDIE"/AU)
                E KJOLBYE A/AU
L15             7 SEA ABB=ON  PLU=ON  "KJOLBYE ANNE LOUISE"/AU
                E JORGENSEN N/AU
L16            31 SEA ABB=ON  PLU=ON  ("JORGENSEN N"/AU OR "JORGENSEN N R"/AU OR
                "JORGENSEN N RYE"/AU OR "JORGENSEN NIKLAS R"/AU OR "JORGENSEN
                NIKLAS RYE"/AU)
                E NIELSEN M/AU
L17           495 SEA ABB=ON  PLU=ON  ("NIELSEN M"/AU OR "NIELSEN M S"/AU OR
                "NIELSEN M S WEBER"/AU OR "NIELSEN MORTEN"/AU OR "NIELSEN
                MORTEN S"/AU OR "NIELSEN MORTEN SCHAK"/AU)
                E MARTINS J/AU
L18           138 SEA ABB=ON  PLU=ON  ("MARTINS J"/AU OR "MARTINS J B"/AU OR
                "MARTINS J B L"/AU OR "MARTINS JAMES"/AU OR "MARTINS JAMES
                B"/AU)
                E HOLSTEIN R/AU
L19            76 SEA ABB=ON  PLU=ON  ("HOLSTEIN R"/AU OR "HOLSTEIN RATHLOU N
                H"/AU OR "HOLSTEIN RATHLOU N H N H"/AU OR "HOLSTEIN RATHLOU
                NIELS H"/AU OR "HOLSTEIN RATHLOU NIELS HENRIK"/AU)
L20             2 SEA ABB=ON  PLU=ON  L12 AND L13 AND L14 AND L15 AND L16 AND
                L17 AND L18 AND L19
L21            13 SEA ABB=ON  PLU=ON  L12 AND (L13 OR L14 OR L15 OR L16 OR L17
                OR L18 OR L19)
L22            15 SEA ABB=ON  PLU=ON  L13 AND (L14 OR L15 OR L16 OR L17 OR L18
                OR L19)
L23             4 SEA ABB=ON  PLU=ON  L14 AND (L15 OR L16 OR L17 OR L18 OR L19)
L24             5 SEA ABB=ON  PLU=ON  L15 AND (L16 OR L17 OR L18 OR L19)
L25             2 SEA ABB=ON  PLU=ON  L16 AND (L17 OR L18 OR L19)
L26             3 SEA ABB=ON  PLU=ON  L17 AND (L18 OR L19)
L27             2 SEA ABB=ON  PLU=ON  L18 AND L19
L28            21 SEA ABB=ON  PLU=ON  (L20 OR L21 OR L22 OR L23 OR L24 OR L25 OR
                L26 OR L27)
L29             4 SEA ABB=ON  PLU=ON  L28 AND (AY<2001 OR PY<2001 OR PRY<2001)

    FILE 'HCAPLUS, MEDLINE, EMBASE, BIOSIS, DRUGU, WPIX' ENTERED AT 13:29:40
    ON 12 MAR 2007
L30          2579 SEA ABB=ON  PLU=ON  LARSEN B?/AU
L31          5774 SEA ABB=ON  PLU=ON  PETERSEN J?/AU
L32          1629 SEA ABB=ON  PLU=ON  MEIER E?/AU
L33            42 SEA ABB=ON  PLU=ON  KJOLBYE A?/AU
L34           977 SEA ABB=ON  PLU=ON  JORGENSEN N?/AU
L35          5171 SEA ABB=ON  PLU=ON  NIELSEN M?/AU
L36          2182 SEA ABB=ON  PLU=ON  MARTINS J?/AU
L37           595 SEA ABB=ON  PLU=ON  HOLSTEIN R?/AU
L38             2 SEA ABB=ON  PLU=ON  L30 AND L31 AND L32 AND L33 AND L34 AND
                L35 AND L36 AND L37
L39             0 SEA ABB=ON  PLU=ON  (L30 OR L31 OR L32 OR L33 OR L34 OR L35 OR
                L36 OR L37) AND (ANTI(2A) ARRYTHMIC?)
L40             2 SEA ABB=ON  PLU=ON  (L30 OR L31 OR L32 OR L33 OR L34 OR L35 OR
                L36 OR L37) AND (ANTIARRYTHMIC?)
L41             4 SEA ABB=ON  PLU=ON  (L38 OR L40)
L42           856 SEA ABB=ON  PLU=ON  (L30 OR L31 OR L32 OR L33 OR L34 OR L35 OR
                L36 OR L37) AND (PEPTIDE?)
L43             1 SEA ABB=ON  PLU=ON  L42 AND (ARRYTHM?)
L44             4 SEA ABB=ON  PLU=ON  (L43 OR L41)

    FILE 'STNGUIDE' ENTERED AT 13:33:02 ON 12 MAR 2007

    FILE 'REGISTRY' ENTERED AT 13:34:05 ON 12 MAR 2007
```

```
L45             STRUCTURE UPLOADED
L46             STRUCTURE UPLOADED
L47           0 SEA SSS SAM L46
L48           0 SEA SSS FUL L46

     FILE 'STNGUIDE' ENTERED AT 13:35:38 ON 12 MAR 2007

     FILE 'BEILSTEIN' ENTERED AT 13:35:43 ON 12 MAR 2007
L49           0 SEA SSS FUL L46

     FILE 'MARPAT' ENTERED AT 13:35:57 ON 12 MAR 2007

     FILE 'STNGUIDE' ENTERED AT 13:36:04 ON 12 MAR 2007

     FILE 'REGISTRY' ENTERED AT 13:38:12 ON 12 MAR 2007

     FILE 'STNGUIDE' ENTERED AT 14:02:36 ON 12 MAR 2007

     FILE 'REGISTRY' ENTERED AT 14:03:19 ON 12 MAR 2007
               D QUE L46
               D QUE L45
L50            STRUCTURE UPLOADED
               D QUE L50

     FILE 'STNGUIDE' ENTERED AT 14:04:58 ON 12 MAR 2007

     FILE 'REGISTRY' ENTERED AT 14:12:47 ON 12 MAR 2007
L51            STRUCTURE UPLOADED
L52            STRUCTURE UPLOADED
L53          50 SEA SSS SAM L52
               D QUE L52
L54        2075 SEA SSS FUL L52
               SAVE L54 TELLER/A TEMP
L55           0 SEA ABB=ON  PLU=ON  L54 AND L10

     FILE 'HCAPLUS' ENTERED AT 14:16:01 ON 12 MAR 2007
L56        1861 SEA ABB=ON  PLU=ON  L54

     FILE 'STNGUIDE' ENTERED AT 14:16:08 ON 12 MAR 2007

     FILE 'REGISTRY' ENTERED AT 14:22:05 ON 12 MAR 2007
L57            STRUCTURE UPLOADED
L58           0 SEA SUB=L54 SSS SAM L57
L59           4 SEA SUB=L54 SSS FUL L57

     FILE 'HCAPLUS' ENTERED AT 14:23:05 ON 12 MAR 2007
L60           2 SEA ABB=ON  PLU=ON  L59
                D BIB
                D BIB 2

     FILE 'REGISTRY' ENTERED AT 14:23:30 ON 12 MAR 2007
L61           0 SEA ABB=ON  PLU=ON  L59 AND MEDLINE/LC
L62           0 SEA ABB=ON  PLU=ON  L59 AND EMBASE/LC
L63           0 SEA ABB=ON  PLU=ON  L59 AND BIOSIS/LC
L64           0 SEA ABB=ON  PLU=ON  L59 AND CAOLD/LC
L65         528 SEA ABB=ON  PLU=ON  L54 AND (ALA OR ALANIN? OR GLY OR GLYCINE
                OR GLU OR GLUTAMIC? OR ASP OR ASPARTIC? OR DAB OR DOAMINOBUT?
                OR DAPA OR LYS OR LYSINE OR ASP OR ASPARAGINE OR GLN OR
                GLUTAMINE OR ORN OR ORNITHINE OR CYS OR CYSTEINE)
```

```
     FILE 'HCAPLUS' ENTERED AT 14:25:47 ON 12 MAR 2007
L66          300 SEA ABB=ON  PLU=ON  L65
L*** DEL 598742 S L10
                 D SCAN L9
L67           56 SEA ABB=ON  PLU=ON  L65 (L)(THU OR PKT OR BAC OR PAC OR
                 DMA)/RL
                 D KWIC
L68            1 SEA ABB=ON  PLU=ON  L66 AND (?ARRYTHM? OR ?THROMB? OR OSTEOPORO
                 SIS? OR CANCER?)
L69           56 SEA ABB=ON  PLU=ON  (L67 OR L68)
L70           50 SEA ABB=ON  PLU=ON  L69 AND (AY<2001 OR PY<2001 OR PRY<2001)
L71           48 SEA ABB=ON  PLU=ON  L69 AND (AY<2000 OR PY<2000 OR PRY<2000)
L72           38 SEA ABB=ON  PLU=ON  L70 AND (ALA OR ALANIN? OR GLY OR GLYCINE
                 OR GLU OR GLUTAMIC? OR ASP OR ASPARTIC? OR DAB OR DOAMINOBUT?
                 OR DAPA OR LYS OR LYSINE OR ASP OR ASPARAGINE OR GLN OR
                 GLUTAMINE OR ORN OR ORNITHINE OR CYS OR CYSTEINE)
                 D KWIC
L73           38 SEA ABB=ON  PLU=ON  L70 AND (ALA OR ALANIN? OR GLY OR GLYCINE
                 OR GLU OR GLUTAMIC? OR ASP OR ASPARTIC? OR DAB OR DIAMINOBUT?
                 OR DAPA OR LYS OR LYSINE OR ASP OR ASPARAGINE OR GLN OR
                 GLUTAMINE OR ORN OR ORNITHINE OR CYS OR CYSTEINE)
L74           38 SEA ABB=ON  PLU=ON  (L68 OR L72 OR L73)
L75           38 SEA ABB=ON  PLU=ON  L74 NOT (L29 OR L4 OR L9)

     FILE 'BEILSTEIN' ENTERED AT 14:32:13 ON 12 MAR 2007
L76            0 SEA SSS FUL L57

     FILE 'MARPAT' ENTERED AT 14:32:29 ON 12 MAR 2007

     FILE 'REGISTRY' ENTERED AT 14:33:37 ON 12 MAR 2007
L77            0 SEA ABB=ON  PLU=ON  L65 AND L10
L78            0 SEA ABB=ON  PLU=ON  L10 AND SQL/CI

     FILE 'STNGUIDE' ENTERED AT 14:36:57 ON 12 MAR 2007

     FILE 'REGISTRY' ENTERED AT 14:38:24 ON 12 MAR 2007
L79            0 SEA ABB=ON  PLU=ON  L10 AND SQL
L80            0 SEA ABB=ON  PLU=ON  L10 AND SQL?
L81           84 SEA ABB=ON  PLU=ON  L10 AND SQL<10
L82           23 SEA ABB=ON  PLU=ON  L10 NOT L81
                 D SCAN L82
L83          106 SEA ABB=ON  PLU=ON  L10 NOT O2/MF
L84          104 SEA ABB=ON  PLU=ON  L83 NOT C14H12O3
L85          104 SEA ABB=ON  PLU=ON  L83 NOT C14H12O3/MF
L86          103 SEA ABB=ON  PLU=ON  L85 NOT C19H21NO4/MF
L87          103 SEA ABB=ON  PLU=ON  L86 NOT C9H7C12N5/MF
L88          102 SEA ABB=ON  PLU=ON  L87 NOT C20H19NO6
L89          101 SEA ABB=ON  PLU=ON  L88 NOT C6H12O6/MF

     FILE 'HCAPLUS' ENTERED AT 14:43:59 ON 12 MAR 2007
L90          109 SEA ABB=ON  PLU=ON  L89
L91           66 SEA ABB=ON  PLU=ON  L89 (L)(THU OR BAC OR PAC OR DMA OR
                 PKT)/RL
L92           26 SEA ABB=ON  PLU=ON  L91 AND (AY<2001 OR PY<2001 OR PRY<2001)
                 D QUE L73
L93           20 SEA ABB=ON  PLU=ON  L91 AND (ALA OR ALANIN? OR GLY OR GLYCINE
                 OR GLU OR GLUTAMIC? OR ASP OR ASPARTIC? OR DAB OR DIAMINOBUT?
                 OR DAPA OR LYS OR LYSINE OR ASP OR ASPARAGINE  OR GLN OR
                 GLUTAMINE OR ORN OR ORNITHINE OR CYS OR CYSTEINE)
L94           35 SEA ABB=ON  PLU=ON  (L92 OR L93)
```

```
L95          33 SEA ABB=ON  PLU=ON  L94 NOT (L4 OR L29)
L96          14 SEA ABB=ON  PLU=ON  (L9 OR L4)

     FILE 'STNGUIDE' ENTERED AT 14:46:29 ON 12 MAR 2007
                D QUE L29
                D QUE L44
                D QUE L4
                D QUE L60

     FILE 'HCAPLUS, WPIX' ENTERED AT 14:46:57 ON 12 MAR 2007
L97          18 DUP REM L29 L44 L4 L60 (6 DUPLICATES REMOVED)
                     ANSWERS '1-18' FROM FILE HCAPLUS
                D QUE L29
                D QUE L41
                D QUE L29
                D QUE L44
                D QUE L95
L98          37 DUP REM L29 L44 L95 (4 DUPLICATES REMOVED)
                     ANSWERS '1-37' FROM FILE HCAPLUS
                D IBIB ABS HITIND HITSTR RETABLE L98 TOT
                D QUE L4
                D IBIB ABS HITIND HITSTR RETABLE L4 TOT
                D QUE L60
                D IBIB ABS HITIND HITSTR RETABLE L60 TOT

     FILE 'HCAPLUS' ENTERED AT 15:06:34 ON 12 MAR 2007
                D QUE L4
                D HITSEQ L4 TOT


     FILE HOME

     FILE REGISTRY
     Property values tagged with IC are from the ZIC/VINITI data file
     provided by InfoChem.

     STRUCTURE FILE UPDATES:   11 MAR 2007  HIGHEST RN 926007-42-3
     DICTIONARY FILE UPDATES:  11 MAR 2007  HIGHEST RN 926007-42-3

     New CAS Information Use Policies, enter HELP USAGETERMS for details.

     TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

       Please note that search-term pricing does apply when
       conducting SmartSELECT searches.

     REGISTRY includes numerically searchable data for experimental and
     predicted properties as well as tags indicating availability of
     experimental property data in the original document.  For information
     on property searching in REGISTRY, refer to:

     http://www.cas.org/ONLINE/UG/regprops.html

     FILE LREGISTRY
     LREGISTRY IS A STATIC LEARNING FILE

     NEW CAS INFORMATION USE POLICIES, ENTER HELP USAGETERMS FOR DETAILS.

     FILE HCAPLUS
```

FILE COVERS 1907 - 12 Mar 2007 VOL 146 ISS 12
FILE LAST UPDATED: 11 Mar 2007 (20070311/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE STNGUIDE
FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Mar 9, 2007 (20070309/UP).

FILE MEDLINE
FILE LAST UPDATED: 10 Mar 2007 (20070310/UP). FILE COVERS 1950 TO DATE.

All regular MEDLINE updates from November 15 to December 16 have been added to MEDLINE, along with 2007 Medical Subject Headings (MeSH(R)) and 2007 tree numbers.

The annual reload will be available in early 2007.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE EMBASE
FILE COVERS 1974 TO 12 Mar 2007 (20070312/ED)

EMBASE is now updated daily. SDI frequency remains weekly (default) and biweekly.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE BIOSIS
FILE COVERS 1969 TO DATE.
CAS REGISTRY NUMBERS AND CHEMICAL NAMES (CNs) PRESENT
FROM JANUARY 1969 TO DATE.

RECORDS LAST ADDED: 7 March 2007 (20070307/ED)

FILE DRUGU
FILE LAST UPDATED: 9 MAR 2007 <20070309/UP>
>>> DERWENT DRUG FILE (SUBSCRIBER) <<<

>>> FILE COVERS 1983 TO DATE <<<
>>> THESAURUS AVAILABLE IN /CT <<<

FILE WPIX

FILE LAST UPDATED: 5 MAR 2007 <20070305/UP>
MOST RECENT THOMSON SCIENTIFIC UPDATE: 200716 <200716/DW>
DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> YOU ARE IN THE NEW AND ENHANCED DERWENT WORLD PATENTS INDEX <<<

>>> New display format FRAGHITSTR available <<<
SEE ONLINE NEWS and
http://www.stn-international.de/archive/stn_online_news/fraghitstr_ex.pdf

>>> IPC Reform reclassification data for the backfile is being loaded into the database during January 2007.
There will not be any update date (UP) written for the reclassified documents, but they can be identified by 20060101/UPIC. <<<

FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE,
PLEASE VISIT:
http://www.stn-international.de/training_center/patents/stn_guide.pdf

FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE
http://scientific.thomson.com/support/patents/coverage/latestupdates/

PLEASE BE AWARE OF THE NEW IPC REFORM IN 2006, SEE
http://www.stn-international.de/stndatabases/details/ipc_reform.html and
http://scientific.thomson.com/media/scpdf/ipcrdwpi.pdf

>>> FOR DETAILS ON THE NEW AND ENHANCED DERWENT WORLD PATENTS INDEX
PLEASE SEE
http://www.stn-international.de/stndatabases/details/dwpi_r.html <<<

FILE BEILSTEIN
FILE LAST UPDATED ON JANUARY 10, 2007

FILE COVERS 1771 TO 2006.
FILE CONTAINS 9,780,003 SUBSTANCES

>>>PLEASE NOTE: Reaction Data and substance data are stored in separate documents and can not be searched together in one query. Reaction data for BEILSTEIN compounds may be displayed immediately with the display codes PRE (preparations) and REA (reactions). A substance answer set retrieved after the search for a chemical name, a compounds with available reaction information by combining with PRE/FA, REA/FA or more generally with RX/FA. The BEILSTEIN Registry Number (BRN) is the link between a BEILSTEIN compound and belonging reactions. For mo detailed reaction searches BRNs can be searched as reaction partner BRNs Reactant BRN (RX.RBRN) or Product BRN (RX.PBRN).<<<

>>> FOR SEARCHING PREPARATIONS SEE HELP PRE <<<

****
* PLEASE NOTE THAT THERE ARE NO FORMATS FREE OF COST. *
* SET NOTICE FEATURE: THE COST ESTIMATES CALCULATED FOR SET NOTICE *
* ARE BASED ON THE HIGHEST PRICE CATEGORY. THEREFORE; THESE *
* ESTIMATES MAY NOT REFLECT THE ACTUAL COSTS. *
* FOR PRICE INFORMATION SEE HELP COST *
****

NEW
* *PATENT NUMBERS (PN) AND BABS ACCESSION NUMBERS (BABSAN) CAN NOW BE*

SEARCHED, SELECTED AND TRANSFERRED.

* *NEW DISPLAY FORMATS ALLREF, ALLP AND BABSAN SHOW ALL REFERENCES, ALL PATENT REFERENCES, OR ALL BABS ACCESSION NUMBERS FOR A COMPOUND AT A GLANCE.*

FILE MARPAT
FILE CONTENT: 1961-PRESENT VOL 146 ISS 11 (20070309/ED)

SOME MARPAT RECORDS ARE DERIVED FROM INPI DATA FOR 1961-1987

MOST RECENT CITATIONS FOR PATENTS FROM MAJOR ISSUING AGENCIES
(COVERAGE TO THESE DATES IS NOT COMPLETE):

US	2007020715	25 JAN 2007
DE	102005032918	18 JAN 2007
EP	1743897	17 JAN 2007
JP	2007016265	25 JAN 2007
WO	2007012422	01 FEB 2007
GB	2427406	27 DEC 2006
FR	2888248	12 JAN 2007
RU	2291880	20 JAN 2007
CA	2551930	08 JAN 2007

Expanded G-group definition display now available.

Rebamipide protect the stomach against injury caused by NH2Cl, and (3) the mechanism underlying the protective action of irsogladine is partly mediated by endogenous nitric oxide while that of Rebamipide is in part mediated by endogenous prostaglandins.

CC 1-9 (Pharmacology)

IT *57381-26-7*, Irsogladine 90098-04-7, Rebamipide
RL: *BAC (Biological activity or effector, except adverse)*; BSU (Biological study, unclassified); *THU (Therapeutic use)*; BIOL (Biological study); USES (Uses)
(protective effect of irsogladine on monochloramine-induced gastric mucosal lesions in rats compared to Rebamipide)

IT *57381-26-7*, Irsogladine
RL: *BAC (Biological activity or effector, except adverse)*; BSU (Biological study, unclassified); *THU (Therapeutic use)*; BIOL (Biological study); USES (Uses)
(protective effect of irsogladine on monochloramine-induced gastric mucosal lesions in rats compared to Rebamipide)

RN 57381-26-7 HCAPLUS

CN 1,3,5-Triazine-2,4-diamine, 6-(2,5-dichlorophenyl)- (9CI) (CA INDEX NAME)



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Badwey, J	1980	46	695	Ann Rev Biochem	
Dekigai, H	1995	40	1332	Dig Dis Sci	MEDLINE
Graham, D	1989	96	615	Gastroenterology	
Grisham, M	1986	251	G567	Am J Physiol	HCAPLUS
Grisham, M	1984	259	10404	J Biol Chem	HCAPLUS
Ishihara, K	1992	42	1462	Arzneimittelforschun	HCAPLUS
Ivy, K	1970	59	683	Gastroenterology	
Kato, S	1977	42	2156	Dig Dis Sci	
Klevanoff, S	1980	93	480	Ann Intern Med	
Marshall, B	1983	1	1273	Lancet	
Marshall, B	1983	1	965	Lancet	
Murakami, M	1995	40	268	Dig Dis Sci	HCAPLUS
Murakami, M	1993	105	1710	Gastroenterology	HCAPLUS
Nishiwaki, H	1997	29	713	Gen Pharmacol	HCAPLUS
Okabe, S	1984	24	683	Pharmacometrics	
Svanes, K	1982	82	1409	Gastroenterology	HCAPLUS
Takeuchi, K	1989	49	235	Jpn J Pharmacol	HCAPLUS
Tepperman, B	1992	105	171	Br J Pharmacol	HCAPLUS
Ueda, F	1984	34P	474	Arzneimittelforschun	
Ueda, F	1984	34	478	Arzneimittelforschun	HCAPLUS
Whitehead, R	1972	25	1	J Clin Pathol	MEDLINE
Whittle, B	1990	99	607	Br J Pharmacol	HCAPLUS
Yamasaki, K	1987	142	23	Eur J Pharmacol	HCAPLUS
Yoshikawa, T	1993	43	363	Arzneimittelforschun	HCAPLUS

L98 ANSWER 16 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1998:714418 HCAPLUS Full-text
DOCUMENT NUMBER: 130:119294
TITLE: Effects of an antiarrhythmic peptide on intercellular coupling via gap junctions
AUTHOR(S): Dhein, Stefan; Gottwald, Michaela; Schaefer, Thomas; Muller, Andreas; Tudyka, Tatjana; Krusemann, Kathi; Grover, Rajiv
CORPORATE SOURCE: Institute of Pharmacology, University of Cologne, Cologne, D-50931, Germany
SOURCE: Gap Junctions, Proceedings of the International Gap Junction Conference, 8th, Key Largo, Fla., July 12-17, 1997 (*1998*), Meeting Date 1997, 163-167. Editor(s): Werner, Rudolf. IOS Press: Amsterdam, Neth.
CODEN: 66XYAX
DOCUMENT TYPE: Conference
LANGUAGE: English
AB We recently reported on a synthetic antiarrhythmic peptide (AAP10, NH2- *GLY-ALA-GLY*-HYP-PRO-TYR-CONH2) which was found to be effective against arrhythmia in the late ischemic period in isolated rabbit hearts. This peptide enhanced gap junctional current in pairs of adult guinea pig cardiomyocytes. In this study we wanted to investigate whether AAP10 acts on uncoupled guinea pig papillary muscles. After 30 min of equilibration at normoxic conditions the muscles were submitted to hypoxia with glucose free superfusion for 20 min with or without pretreatment with 10 nM AAP10. Under these conditions intracellular action potentials were recorded and the delay between stimulus and propagated action potential (stimulus-response interval, SRI) was evaluated. We found no effect of AAP10 under normoxic conditions on SRI or on action potential morphol. Resting membrane potential, amplitude, action potential duration, dU/dtmax were not altered. However, while in untreated muscles uncoupling occurred after 12 min, this was not the case in muscles treated with AAP10. In addnl. expts., we could demonstrate that uncoupling via 50 mM Na-propionate could be antagonized by 10 nM AAP10 without affecting other parameters than SRI. This AAP10 effect could be fully inhibited by 10 μM genistein and 1 μM bisindolylmaleimide I (a specific inhibitor of PKC), but not by 2 μM H8 (a specific PKA blocker) and not by 5 μM genistein. Using 14C-labeled AAP10 we found that the substance binds to membrane proteins but not to connexin 43. From these results we conclude that AAP10 can enhance intercellular coupling especially in situations with reduced coupling probably via a protein kinase C mediated mechanism.
CC 1-8 (Pharmacology)
IT *159503-65-8*, AAP10
RL: *BAC (Biological activity or effector, except adverse)*; BSU (Biological study, unclassified); *THU (Therapeutic use)*; BIOL (Biological study); USES (Uses)
(effects of an antiarrhythmic peptide on intercellular coupling via gap junctions)
IT *159503-65-8*, AAP10
RL: *BAC (Biological activity or effector, except adverse)*; BSU (Biological study, unclassified); *THU (Therapeutic use)*; BIOL (Biological study); USES (Uses)
(effects of an antiarrhythmic peptide on intercellular coupling via gap junctions)
RN 159503-65-8 HCAPLUS
CN retro-Antiarrhythmic peptide (cattle atrium), 6-L-tyrosinamide- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Aonuma, S	1980	28	3340	Chem Pharm Bull	HCAPLUS
Dhein, S	1997			Cardiac gap junction	
Dhein, S	1993	87	617	Circulation	HCAPLUS
Dhein, S	1995	92	I	Circulation	
Dhein, S	1996	94	I	Circulation	
Dhein, S	1995	49	851	Drugs	HCAPLUS
Dhein, S	1997	2	51	J Clin Exp Cardiol	
Dhein, S	1994	350	174	Naunyn Schmiedeberg'	HCAPLUS
Echt, D	1991	324	781	New Engl J Med	MEDLINE
Kwak, B	1995	6	1707	Mol Biol Cell	HCAPLUS
Lesh, M	1989	65	1426	Circ Res	MEDLINE
Manjunath, C	1987	142	228	Biochem Biophys Res	HCAPLUS
Muller, A	1993	88	11	Basic Res Cardiol	MEDLINE
Muller, A	1997	327	65	Eur J Pharmacol	MEDLINE
Muller, A	1997	356	76	Naunyn Schmiedeberg'	MEDLINE
Podrid, P	1985	29	33	Drugs	
Spray, D	1981	77	77	J Gen Physiol	MEDLINE
Takens-Kwak, B	1992	422	198	Pfluger's Arch	HCAPLUS
Weingart, R	1986	370	267	J Physiol (Lond)	MEDLINE

L98 ANSWER 17 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1997:278971 HCAPLUS Full-text
DOCUMENT NUMBER: 127:17689
TITLE: Process for preparation of triazine derivatives by cyclization
INVENTOR(S): Yagishita, Kenichi; Sato, Toyozo; Yokogoshi, Kiyonori
PATENT ASSIGNEE(S): Permachem Asia, Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 3 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 09087256	A	19970331	JP 1995-276084	19950920 <--
PRIORITY APPLN. INFO.:			JP 1995-276084	19950920 <--

OTHER SOURCE(S): CASREACT 127:17689
AB The title compds., useful for prevention and treatment of ulcer (no data), are prepared in an industrial manner efficiently and economically. Thus, 2,5-

dichlorobenzamidine is reacted with NaN(CN)2 in (HOCH2)2 to give 90% 2,4-diamino-6-(2,5-dichlorophenyl)-1,3,5-triazine.

IC ICM C07D251-18
ICS C07D251-18; A61K031-53

CC 28-14 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1

IT *57381-26-7P* 57381-27-8P
RL: *BAC (Biological activity or effector, except adverse)*; BSU (Biological study, unclassified); IMF (Industrial manufacture); SPN (Synthetic preparation); *THU (Therapeutic use)*; BIOL (Biological study); PREP (Preparation); USES (Uses)
(process for preparation of triazine derivs. by cyclization)

IT *57381-26-7P*
RL: *BAC (Biological activity or effector, except adverse)*; BSU (Biological study, unclassified); IMF (Industrial manufacture); SPN (Synthetic preparation); *THU (Therapeutic use)*; BIOL (Biological study); PREP (Preparation); USES (Uses)
(process for preparation of triazine derivs. by cyclization)

RN 57381-26-7 HCAPLUS
CN 1,3,5-Triazine-2,4-diamine, 6-(2,5-dichlorophenyl)- (9CI) (CA INDEX NAME)



L98 ANSWER 18 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:	1997:693510 HCAPLUS Full-text
DOCUMENT NUMBER:	128:18349
TITLE:	N-oxidation of irsogladine by the CYP2C subfamily in the rat, dog, monkey and man
AUTHOR(S):	Nakamura, A.; Hirota, T.; Morino, A.; Shimada, T.; Uematsu, T.
CORPORATE SOURCE:	Research Laboratories, Nippon Shinyaku Co., Ltd., Kyoto, 601, Japan
SOURCE:	Xenobiotica (*1997*), 27(10), 995-1003 CODEN: XENOBH; ISSN: 0049-8254
PUBLISHER:	Taylor & Francis
DOCUMENT TYPE:	Journal
LANGUAGE:	English

AB 1. The metabolism of irsogladine (ISG) was studied in hepatic microsomes from the rat, dog, monkey and man, and marked species differences were observed in N-oxidation of ISG. The rank order of the activity of the N-oxidation was shown to be man < monkey < dog < rat. 2. Anti-NADPH-P 450 reductase antibody inhibited the formation of the N-oxidized metabolite of ISG (ISG-N-oxide) in hepatic microsomes from rats by 74%. Anti-CYP2C11 antibody also inhibited the formation of ISG-N-oxide in hepatic microsomes from rat by 73 %, whereas anti-CYP2E1, 3A2 and 4A1 antibody did not inhibit N-oxidation Thus, CYP2C11 in the rat is at least partially responsible for the N-oxidation of ISG in the rat. 3. Anti-CYP2C11 antibody also inhibited the formation of ISG-N-oxide in hepatic microsomes from the dog and monkey by 61 and 46 % resp. Therefore, a isoform(s) similar to CYP2C11 partially contributed to the N-oxidation of ISG in the dog and monkey. In contrast, human CYP2C9, a member of the human CYP2C subfamily, did not catalyze the N-oxidation of ISG. 4. These findings show

that the marked species difference in the N-oxidation of ISG is caused by the difference in the catalytic properties of CYP2C among the species examined

CC 1-2 (Pharmacology)
Section cross-reference(s): 13

IT *57381-26-7*, Irsogladine
RL: BPR (Biological process); BSU (Biological study, unclassified); *THU (Therapeutic use)*; BIOL (Biological study); PROC (Process); USES (Uses)
(N-oxidation of irsogladine by CYP2C subfamily in rat, dog, monkey and man)

IT *57381-26-7*, Irsogladine
RL: BPR (Biological process); BSU (Biological study, unclassified); *THU (Therapeutic use)*; BIOL (Biological study); PROC (Process); USES (Uses)
(N-oxidation of irsogladine by CYP2C subfamily in rat, dog, monkey and man)

RN 57381-26-7 HCAPLUS
CN 1,3,5-Triazine-2,4-diamine, 6-(2,5-dichlorophenyl)- (9CI) (CA INDEX NAME)



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Ando, T	1989	36	1221	Arzneimittel Forschu	
Cashman, J	1993	21	492	Drug Metabolism and	HCAPLUS
Chiba, K	1995	10	391	Xenobiotic Metabolis	HCAPLUS
Funae, Y	1993		221	Handbook of Experime	HCAPLUS
Gonzalez, F	1993		239	Handbook of Experime	HCAPLUS
Imaoka, S	1996	51	1041	Biochemical Pharmaco	HCAPLUS
Komori, M	1989	38	235	Biochemical Pharmaco	HCAPLUS
Lowry, O	1981	193	265	Journal of Biologica	
Mani, C	1993	21	645	Drug Metabolism and	HCAPLUS
Mani, C	1993	21	657	Drug Metabolism and	HCAPLUS
Miura, T	1989	49	365	Japan Journal of Pha	HCAPLUS
Nakashima, M	1984	34	492	Arzneimittel Forschu	HCAPLUS
Nedelcheva, V	1994	24	1151	Xenobiotica	HCAPLUS
Ohta, O	1983	996	142	Biochimica et Biophy	
Prough, R	1977	180	363	Archives of Biochemi	HCAPLUS
Rodrigues, A	1994	22	788	Drug Metabolism and	HCAPLUS
Rouer, E	1987	15	524	Drug Metabolism and	HCAPLUS
Shimada, T	1994	270	414	Journal of Pharmacol	HCAPLUS
Smith, D	1991	23	355	Drug Metabolism Revi	HCAPLUS
Sugiyama, M	1989	36	1229	Arzneimittel Forschu	
Uchida, T	1990	38	644	Molecular Pharmacolo	HCAPLUS
Ueda, F	1984	34	474	Arzneimittel Forschu	HCAPLUS
Ueda, F	1984	34	478	Arzneimittel Forschu	HCAPLUS
Ueda, F	1991	57	321	Japan Journal of Pha	HCAPLUS
Ueda, F	1994	271	397	Journal of Pharmacol	HCAPLUS
Weaver, R	1994	47	763	Biochemical Pharmaco	HCAPLUS
Zins, G	1965	150	109	Journal of Pharmacol	HCAPLUS

Zins, G |1967 |159 |194 |Journal of Pharmacol|

L98 ANSWER 19 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1997:424142 HCAPLUS Full-text
DOCUMENT NUMBER: 127:130662
TITLE: Actions of the antiarrhythmic peptide AAP10 on intercellular coupling
AUTHOR(S): Mueller, Andreas; Schaefer, Thomas; Linke, Werner; Tudyka, Tatjana; Gottwald, Michaela; Klaus, Wolfgang; Dhein, Stefan
CORPORATE SOURCE: Institute of Pharmacology, University of Koln, Koln, D-50931, Germany
SOURCE: Naunyn-Schmiedeberg's Archives of Pharmacology (*1997*), 356(1), 76-82
CODEN: NSAPCC; ISSN: 0028-1298
PUBLISHER: Springer
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Disturbances in gap junction distribution and a decrease in the connexin43 content of the heart were shown to occur after myocardial infarction and in ischemic heart disease, resp. These changes are now thought to play an important role in the genesis of arrhythmias associated with these diseases. It is thought that agents that can increase cellular coupling might be beneficial in these situations. Recently, we presented data showing that the synthetic peptide AAP10 acts antiarrhythmically in a model of regional ischemia. The data suggested that AAP10 might act via an increase in cellular coupling. The goal of this study was to establish whether AAP10 can interact with cardiac gap junctions. Measurements of the stimulus-response-interval (SRI) in guinea pig papillary muscle showed that high concns. of AAP10 (1 μM) can decrease the SRI by about 10% under normoxic conditions. At lower concns. (10 nM) AAP10 had no effect on SRI under normoxic conditions but prevented the increase in the SRI induced by perfusion with hypoxic, glucose-free Tyrode's solution Double-cell voltage-clamp expts. confirmed that AAP10 can interact with cardiac gap junctions. 10 NM AAP10 could either diminish or reverse the run-down of gap junction conductance normally observed in pairs of guinea pig ventricular myocytes. During control gap junction conductance decreased with a rate of -2.5±2.0 nS/min. After application of 10 nM AAP10 gap junction conductance increased with a rate of +1.0±0.7 nS/min. After washout of AAP10 gap junction conductance decreased again with a rate not significantly different from control. Our results show that AAP10 does interact with gap junctions. Because no other effects of AAP10 on other electrophysiol. parameters could be found, this action on gap junctions might be the basis of AAP10's antiarrhythmic effect seen in previous studies.

CC 1-8 (Pharmacology)
IT *159503-65-8*, AAP 10
RL: *BAC (Biological activity or effector, except adverse)*; BSU (Biological study, unclassified); *THU (Therapeutic use)*; BIOL (Biological study); USES (Uses)
(actions of antiarrhythmic peptide AAP10 on intercellular coupling)
IT *159503-65-8*, AAP 10
RL: *BAC (Biological activity or effector, except adverse)*; BSU (Biological study, unclassified); *THU (Therapeutic use)*; BIOL (Biological study); USES (Uses)
(actions of antiarrhythmic peptide AAP10 on intercellular coupling)
RN 159503-65-8 HCAPLUS
CN retro-Antiarrhythmic peptide (cattle atrium), 6-L-tyrosinamide- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L98 ANSWER 20 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1997:331424 HCAPLUS Full-text
DOCUMENT NUMBER: 127:44651
TITLE: Increase in gap junction conductance by an antiarrhythmic peptide
AUTHOR(S): Mueller, Andreas; Gottwald, Michaela; Tudyka, Tatjana; Linke, Werner; Klaus, Wolfgang; Dhein, Stefan
CORPORATE SOURCE: Institute of Pharmacology, University of Koeln, Gleueler Strasse 24, Koln, D-50931, Germany
SOURCE: European Journal of Pharmacology (*1997*), 327(1), 65-72
CODEN: EJPHAZ; ISSN: 0014-2999
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Impaired cellular coupling is thought to be a very important factor for the genesis of cardiac arrhythmia. Cellular coupling is mediated by gap junctions. However, there are no therapeutic agents or exptl. substances yet that increase cellular coupling. In addition, it has been shown that most antiarrhythmic drugs available now possess serious adverse effects. Thus, there is an urgent need for new antiarrhythmic agents. Previous studies using epicardial mapping in isolated rabbit hearts provided indirect evidence supporting the hypothesis that a newly synthesized antiarrhythmic peptide (*Gly-Ala-Gly* -4Hyp-Pro-Tyr-CONH2 = AAP10) might act via an increase in cellular, i.e., gap junctional coupling. The aim of the present study was to test this hypothesis. Measurement of the stimulus-response interval in papillary muscle showed a decrease of about 10% after application of 1 μM AAP10. These results are compatible with the hypothesis of AAP10 acting on gap junctions. In order to prove this hypothesis, gap junction conductance was measured directly by performing double-cell voltage-clamp expts. in isolated pairs of guinea-pig myocytes. During a 10 min control period gap junction conductance slowly decreased with a rate of -2.5±2.0 nS/min. After application of 10 nM AAP10 this behavior reversed and gap junction conductance now increased with +1.0±0.7 nS/min. Upon washout of AAP10 gap junction conductance again decreased with a rate similar to that under control conditions. Another important finding was that we could not detect any other actions of AAP10 on cardiac myocytes. All parameters of the transmembrane action potential remained unchanged and, similarly, no changes in the IV relationship of single cardiac myocytes treated with 10 nM AAP10 could be observed We conclude that AAP10 increases gap junction conductance, i.e., cellular coupling in the heart. This finding might be the first step towards the development of a new class of antiarrhythmic agents.

CC 1-8 (Pharmacology)
IT Antiarrhythmics
(antiarrhythmic peptide AAP10 (*Gly-Ala-Gly*

-4Hyp-Pro-Tyr-CONH2) increases gap junction conductance)

IT Cell junction
(gap junction, coupling; antiarrhythmic peptide AAP10 (*Gly-Ala-Gly*-4Hyp-Pro-Tyr-CONH2) increases gap junction conductance)

IT *159503-65-8*, AAP 10
RL: *BAC (Biological activity or effector, except adverse)*; BSU (Biological study, unclassified); *THU (Therapeutic use)*; BIOL (Biological study); USES (Uses)
(antiarrhythmic peptide AAP10 (*Gly-Ala-Gly*-4Hyp-Pro-Tyr-CONH2) increases gap junction conductance 180268740)

IT *159503-65-8*, AAP 10
RL: *BAC (Biological activity or effector, except adverse)*; BSU (Biological study, unclassified); *THU (Therapeutic use)*; BIOL (Biological study); USES (Uses)
(antiarrhythmic peptide AAP10 (*Gly-Ala-Gly*-4Hyp-Pro-Tyr-CONH2) increases gap junction conductance 180268740)

RN 159503-65-8 HCAPLUS

CN retro-Antiarrhythmic peptide (cattle atrium), 6-L-tyrosinamide- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Aonuma, S	1980	28	3332	Chem Pharm Bull	HCAPLUS
Balke, C	1988	63	879	Circ Res	MEDLINE
Bastide, B	1993	73	1138	Circ Res	HCAPLUS
Cai, D	1994	41	217	IEEE Trans Biomed En	MEDLINE
Cole, W	1988	53	809	Biophys J	MEDLINE
de-Carvalho, C	1992	70	733	Circ Res	
Dhein, S	1995	49	851	Drugs	HCAPLUS
Dhein, S	1994	350	174	Naunyn-Schmiedeberg'	HCAPLUS
Halliwell, J	1994		17	Microelectrode Techn	
Hamill, O	1981	391	85	Pflug Arch	MEDLINE
Jarolimek, W	1993	425	491	Pflug Arch	HCAPLUS
Kleber, A	1987	61	271	Circ Res	MEDLINE
Kuo, C	1983	67	1356	Circulation	MEDLINE
Lesh, M	1989	65	1426	Circ Res	MEDLINE
Merx, W	1977	94	603	Am Heart J	MEDLINE
Metzger, P	1985	366	177	J Physiol (London)	MEDLINE
Muller, A	1993	88	11	Basic Res Cardiol	MEDLINE
Page, E	1992		1003	The Heart and Cardio	
Peters, N	1993	88	864	Circulation	HCAPLUS

Saffitz, J	1993	87	1742	Circulation	MEDLINE
Severs, N	1994	5	462	J Cardiovasc Electro	MEDLINE
Smith, J	1991	139	801	Am J Pathol	MEDLINE
Spach, M	1994	90	1103	Circulation	MEDLINE
Spray, D	1981	77	77	J Gen Physiol	MEDLINE
Steendijk, P	1993	88	167	Basic Res Cardiol	MEDLINE
Veenstra, R	1990	258	C662	Am J Physiol	MEDLINE
Wang, H	1992	63	139	Biophys J	HCAPLUS
Weingart, R	1988	63	72	Circ Res	MEDLINE
Weingart, R	1986	370	267	J Physiol (London)	MEDLINE
Wilders, R	1992	63	942	Biophys J	MEDLINE

L98 ANSWER 21 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1997:86895 HCAPLUS Full-text
DOCUMENT NUMBER: 126:194926
TITLE: Triazine derivatives inhibit rat hepatocarcinogenesis but do not enhance gap junctional intercellular communication
AUTHOR(S): Hori, Takaaki; Asamoto, Makoto; Krutovskikh, Vladimir; Iwahori, Yoshio; Maeda, Mitsuaki; Toriyama-Baba, Hiroyasu; Takasuka, Nobuo; Tsuda, Hiroyuki
CORPORATE SOURCE: Chemotherapy Division, National Cancer Center Research Institute, Tokyo, 104, Japan
SOURCE: Japanese Journal of Cancer Research (*1997*), 88(1), 12-17
CODEN: JJCREP; ISSN: 0910-5050
PUBLISHER: Japanese Cancer Association
DOCUMENT TYPE: Journal
LANGUAGE: English

AB We report here novel candidate chemopreventive agents active against exptl. hepatocarcinogenesis. The triazine derivs. 6-(2-chlorophenyl)-2,4- diamino-1,3,5-triazine (2CPDAT), 6-(3-chlorophenyl)-2,4-diamino-1,3,5- triazine (3CPDAT), 6-(4-chlorophenyl)-2,4-diamino-1,3,5-triazine (4CPDAT), 6-(4-pyridyl)-2,4-diamino-1,3,5-triazine (PyDAT), and 6-(pyridine N-oxid-4-yl)-2,4-diamino-1,3,5-triazine (PyNODAT), synthesized in our laboratory, in addition to 6-(2,5-dichlorophenyl)-2,4-diamino-1,3,5-triazine (DCPDAT), or irsogladine, which is a widely used anti-ulcer drug, were investigated for potential chemopreventive effects in a rat liver medium-term bioassay system. A significant inhibitory influence on enzyme-altered liver foci was found for 2CPDAT, 3CPDAT, 4CPDAT, and PyNODAT, but not for DCPDAT or PyDAT. The involvement of gap junctional intercellular communication in the inhibition was studied, but no change in gap junctional intercellular communication capacity in rat liver cells in vitro or in gap junction protein (connexin 32) expression in rat liver in vivo was noted. These results indicate that, although these irsogladine analogs exert inhibitory effects on rat liver carcinogenesis, their action is independent of modification of gap junctional intercellular communication.

CC 1-6 (Pharmacology)
IT 4514-53-8 4514-54-9 29366-77-6 33237-20-6 *57381-26-7* 187753-86-2
RL: *BAC (Biological activity or effector, except adverse)*; BSU (Biological study, unclassified); *THU (Therapeutic use)*; BIOL (Biological study); USES (Uses)
(triazine derivs. inhibit hepatocarcinogenesis but do not enhance gap junctional intercellular communication)
IT *57381-26-7*
RL: *BAC (Biological activity or effector, except adverse)*; BSU (Biological study, unclassified); *THU (Therapeutic use)*; BIOL (Biological study); USES (Uses)
(triazine derivs. inhibit hepatocarcinogenesis but do not enhance gap

junctional intercellular communication)
RN 57381-26-7 HCAPLUS
CN 1,3,5-Triazine-2,4-diamine, 6-(2,5-dichlorophenyl)- (9CI) (CA INDEX NAME)



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Asamoto, M	1991	4	322	Mol Carcinog	HCAPLUS
Bertram, J	1994	234	235	Methods Enzymol	HCAPLUS
Bertram, J	1989	18	562	Prev Med	HCAPLUS
Bex, V	1995	13	69	Cell Biochem Funct	HCAPLUS
Budunova, I	1994	10	71	Cell Biol Toxicol	HCAPLUS
Demilo, A	1981	29	82	J Agric Food Chem	HCAPLUS
El-Fouly, M	1987	168	422	Exp Cell Res	HCAPLUS
Hirose, Y	1996	87	549	Jpn J Cancer Res	HCAPLUS
Holder, J	1993	53	3475	Cancer Res	HCAPLUS
Hosokawa, T	1992	118	565	J Cancer Res Clin On	MEDLINE
Ito, N	1988	9	387	Carcinogenesis	HCAPLUS
Ito, N	1989	17	630	Toxicol Pathol	HCAPLUS
Jansen, L	1996	17	333	Carcinogenesis	HCAPLUS
Klaunig, J	1990	62	135	Lab Invest	HCAPLUS
Krutovskikh, V	1991	12	1701	Carcinogenesis	HCAPLUS
Kumar, N	1986	103	767	J Cell Biol	HCAPLUS
Lalezari, I	1971	16	117	J Chem Eng Data	HCAPLUS
Loewenstein, W	1979	560	1	Biochim Biophys Acta	HCAPLUS
McKarns, S	1992	8	89	Cell Biol Toxicol	HCAPLUS
Mesnil, M	1986	165	391	Exp Cell Res	HCAPLUS
Murray, A	1979	91	395	Biochem Biophys Res	HCAPLUS
Murray, A	1982	7	587	Carcinogenesis	MEDLINE
Ogino, A	1980	23	437	J Med Chem	HCAPLUS
Ruch, R	1987	87	111	Toxicol Appl Pharmac	HCAPLUS
Saez, J	1989	257	1	Am J Physiol	
Sato, Y	1993	322	155	FEBS Lett	HCAPLUS
Satoh, K	1985	82	3964	Proc Natl Acad Sci U	HCAPLUS
Slaga, T	1981	213	1023	Science	HCAPLUS
Smyrl, N	1982	19	493	J Heterocycl Chem	HCAPLUS
Sumi, N	1986	36	251	Pharmacometrics	
Trosko, J	1993	53	1	Life Sci	HCAPLUS
Tsushimoto, G	1983	12	721	Arch Environ Contam	HCAPLUS
Ueda, F	1984	34	478	Arzneim Forsch	HCAPLUS
Ueda, F	1991	57	321	Jpn J Pharmacol	HCAPLUS
Williams, G	1981	11	339	Cancer Lett	HCAPLUS
Yamasaki, H	1995	333	181	Mutat Res	HCAPLUS
Yotti, L	1979	206	1089	Science	HCAPLUS
Zhang, L	1991	12	2109	Carcinogenesis	HCAPLUS

L98 ANSWER 22 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1996:385934 HCAPLUS Full-text
DOCUMENT NUMBER: 125:41767

TITLE: Synthesis and formulation of triazine derivatives as hepatitis remedies

INVENTOR(S): Ueda, Fusao; Ozaki, Takayuki; Nakamura, Ken-ichi
PATENT ASSIGNEE(S): Nippon Shinyaku Co., Ltd., Japan

SOURCE: PCT Int. Appl., 56 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9604914	A1	19960222	WO 1995-JP1577	19950808 <--
W: AU, BR, CA, CN, FI, HU, JP, KR, MX, NO, NZ, RU, UA, US, VN				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2197091	A1	19960222	CA 1995-2197091	19950808 <--
AU 9531920	A	19960307	AU 1995-31920	19950808 <--
AU 703263	B2	19990325		
EP 775487	A1	19970528	EP 1995-927992	19950808 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, PT, SE				
CN 1155244	A	19970723	CN 1995-194521	19950808 <--
BR 9508539	A	19971028	BR 1995-8539	19950808 <--
HU 77735	A2	19980728	HU 1997-355	19950808 <--
RU 2147233	C1	20000410	RU 1997-103983	19950808 <--
US 5962453	A	19991005	US 1997-776992	19970206 <--
PRIORITY APPLN. INFO.:			JP 1994-185810 A	19940808 <--
			WO 1995-JP1577 W	19950808 <--

OTHER SOURCE(S): MARPAT 125:41767

GI



I

AB A medicine useful as a hepatitis remedy is claimed which contains as the active ingredient a triazine derivative represented by general formula (I), a solvate thereof, or a salt thereof, wherein R1 and R2 represent each independently hydrogen or (un)substituted alkyl, aralkyl or alkenyl, or NR1R2 represents a cyclic amino group which may bear, in addition to the pertinent nitrogen atom, nitrogen, oxygen or sulfur as the ring atom and may be substituted, provided the case where NR1R2 represents NH2 is excluded. Studies in mouse and rat models of hepatitis indicate the remedial efficacy of various I.

IC ICM A61K031-53
ICS A61K031-535; A61K031-54; A61K031-55

CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 1, 28

IT *57381-26-7DP*, derivs. 178105-27-6P 178105-28-7P 178105-29-8P 178105-31-2P 178105-32-3P 178105-48-1P 178105-57-2P 178105-59-4P

178105-60-7P 178105-61-8P 178105-65-2P 178105-85-6P 178105-91-4P
RL: *BAC (Biological activity or effector, except adverse)*; BSU (Biological study, unclassified); SPN (Synthetic preparation); *THU (Therapeutic use)*; BIOL (Biological study); PREP (Preparation); USES (Uses)
(synthesis and formulation of triazine derivs. as hepatitis remedies)

IT 51-35-4, 4-Hydroxyproline 56-40-6, *Glycine*, reactions 62-53-3, Aniline, reactions 64-04-0, Phenethylamine 68-12-2, N,N-Dimethylformamide, reactions 74-89-5, Methylamine, reactions 92-54-6, N-Phenylpiperazine 100-36-7, N,N-Diethylethylenediamine 100-46-9, Benzylamine, reactions 103-67-3, N-Methylbenzylamine 103-76-4, N-(2-Hydroxyethyl)piperazine 107-15-3, 1,2-Ethanediamine, reactions 108-18-9, Diisopropylamine 109-05-7, 2-Methylpiperidine 109-83-1, N-Methyl-N-(2-hydroxyethyl)amine 109-85-3, 2-Methoxyethylamine 109-96-6, 3-Pyrroline 110-85-0, Piperazine, reactions 110-89-4, Piperidine, reactions 110-91-8, Morpholine, reactions 111-42-2, reactions 111-49-9, Hexamethylenimine 123-75-1, Pyrrolidine, reactions 123-90-0, Thiomorpholine 124-40-3, Dimethylamine, reactions 124-63-0, Methanesulfonyl chloride 141-43-5, Ethanolamine, reactions 141-91-3, 2,6-Dimethylmorpholine 147-85-3, (s)-Proline, reactions 503-29-7, Azetidine 535-75-1, 2-Carboxypiperidine 598-41-4, Glycinamide 660-68-4, Diethylamine hydrochloride 841-77-0, 1-Diphenylmethylpiperazine 1499-56-5, trans-4-Hydroxy-L-proline methyl ester 1664-40-0, N-Phenylethylenediamine 1758-46-9, 2-Phenoxyethylamine 2038-03-1, 4-Morpholineethanamine 4360-51-4, Cinnamylamine 5082-74-6, 3-Hydroxymethylpyrrolidine 5382-16-1, 4-Hydroxypiperidine 5625-67-2, 2-Oxopiperazine 6457-49-4, 4-Hydroxymethylpiperidine 6859-99-0, 3-Hydroxypiperidine 18471-40-4, 3-Amino-1-benzylpyrrolidine 19130-96-2, 1,5-Dideoxy-1,5-imino-D-glucitol 20980-22-7 23356-96-9 24252-67-3 27578-60-5, 2-Piperidinoethylamine 31252-42-3, 4-Benzylpiperidine 40499-83-0, 3-Hydroxypyrrolidine 40807-61-2, 4-Hydroxy-4-phenylpiperidine 41661-47-6, 4-Oxopiperidine 45347-82-8, 3-Azetidinol 55276-43-2 68832-13-3 72351-36-1 81530-73-6 103706-76-9 138304-74-2 149366-79-0 178105-24-3 178105-25-4 178105-26-5 178105-46-9 178105-69-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(synthesis and formulation of triazine derivs. as hepatitis remedies)

IT *57381-26-7DP*, derivs.
RL: *BAC (Biological activity or effector, except adverse)*; BSU (Biological study, unclassified); SPN (Synthetic preparation); *THU (Therapeutic use)*; BIOL (Biological study); PREP (Preparation); USES (Uses)
(synthesis and formulation of triazine derivs. as hepatitis remedies)

RN 57381-26-7 HCAPLUS
CN 1,3,5-Triazine-2,4-diamine, 6-(2,5-dichlorophenyl)- (9CI) (CA INDEX NAME)



L98 ANSWER 23 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1996:203525 HCAPLUS Full-text
DOCUMENT NUMBER: 124:278316

TITLE: Inhibition of tumor growth and neovascularization by an anti-gastric ulcer agent irsogladine

AUTHOR(S): Ono, Mayumi; Kawahara, Naoyuki; Goto, Daisuke; Wakabayashi, Yukihiro; Ushiro, Shin; Yoshida, Shigeo; Izumi, Hiroto; Kuwano, Michihiko; Sato, Yashufumi

CORPORATE SOURCE: School Medicine, Kyushu Univ., Fukuoka, 812-82, Japan

SOURCE: Cancer Research (*1996*), 56(7), 1512-16
CODEN: CNREA8; ISSN: 0008-5472

PUBLISHER: American Association for Cancer Research

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Irsogladine used clin. as an anti-gastric ulcer agent, at 10-6-10-4 M, inhibited cell proliferation and tubular morphogenesis of vascular endothelial cells, but the proliferation of human epidermoid cancer of glioma cells was not inhibited by this drug, even at 10-4 M. In vivo studies demonstrated that p.o. administration of irsogladine significantly inhibited tumor growth of human glioma cells in mice, and histol. anal. showed a dramatic decrease of the neovascularization in the tumors. In mice transplanted with chambers containing human glioma cells or hepatic cancer cells, irsogladine also inhibited angiogenesis. These in vivo and in vitro assays demonstrate that irsogladine may be a unique and potent inhibitor of tumor angiogenesis.

CC 1-6 (Pharmacology)

IT *57381-26-7*, Irsogladine
RL: *BAC (Biological activity or effector, except adverse)*; BSU (Biological study, unclassified); *THU (Therapeutic use)*; BIOL (Biological study); USES (Uses)
(inhibition of tumor growth and neovascularization by irsogladine)

IT *57381-26-7*, Irsogladine
RL: *BAC (Biological activity or effector, except adverse)*; BSU (Biological study, unclassified); *THU (Therapeutic use)*; BIOL (Biological study); USES (Uses)
(inhibition of tumor growth and neovascularization by irsogladine)

RN 57381-26-7 HCAPLUS

CN 1,3,5-Triazine-2,4-diamine, 6-(2,5-dichlorophenyl)- (9CI) (CA INDEX NAME)



L98 ANSWER 24 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1996:387151 HCAPLUS Full-text

DOCUMENT NUMBER: 125:104423

TITLE: Suppressing effects of 6-(2,5-dichlorophenyl)-2,4-diamino-1,3,5-triazine and related synthetic compounds on azoxymethane-induced aberrant crypt foci in rat colon

AUTHOR(S): Hirose, Yoshinobu; Tanaka, Takuji; Makita, Hiroki; Yang, Muzheng; Satoh, Kumiko; Hara, Akira; Maeda, Mitsuaki; Toriyama, Hiroyasu Baba; Mori, Hideki; Tsuda, Hiroyuki

CORPORATE SOURCE: First Dep. Pathol., Gifu Univ. Sch. Med., Gifu, 500, Japan

SOURCE: Japanese Journal of Cancer Research (*1996*),

87(6), 549-554
CODEN: JJCREP; ISSN: 0910-5050
PUBLISHER: Japanese Cancer Association
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The modifying effects of dietary administration of 6-(2,5-dichlorophenyl)-2,4-diamino-1,3,5-triazine and 5 related compds. on the occurrence of azoxymethane (AOM)-induced colonic aberrant crypt foci (ACF) were investigated in rats. Male F344 rats were given s.c. injections of AOM (15 mg/kg body weight) once a wk for 3 wks to induce ACF. They also received a diet containing 200 ppm test compound for 5 wks, starting one wk before the first dosing of AOM. At the termination of the experiment, all of the compds. had caused a significant reduction in ACF frequency, which might by associated with suppression of the expression of proliferation biomarkers. The apoptotic index in the colonic mucosal epithelium of rats killed at 6 h after the first AOM exposure revealed no blocking activity of the compds.

CC 1-6 (Pharmacology)

IT 4514-53-8 4514-54-9 29366-77-6 33237-20-6 *57381-26-7* 178991-22-5
RL: *BAC (Biological activity or effector, except adverse)*; BSU (Biological study, unclassified); *THU (Therapeutic use)*; BIOL (Biological study); USES (Uses)
(suppressing effects of 6-(2,5-dichlorophenyl)-2,4-diamino-1,3,5-triazine and related synthetic compds. on azoxymethane-induced aberrant crypt foci in rat colon)

IT *57381-26-7*
RL: *BAC (Biological activity or effector, except adverse)*; BSU (Biological study, unclassified); *THU (Therapeutic use)*; BIOL (Biological study); USES (Uses)
(suppressing effects of 6-(2,5-dichlorophenyl)-2,4-diamino-1,3,5-triazine and related synthetic compds. on azoxymethane-induced aberrant crypt foci in rat colon)

RN 57381-26-7 HCAPLUS
CN 1,3,5-Triazine-2,4-diamine, 6-(2,5-dichlorophenyl)- (9CI) (CA INDEX NAME)



L98 ANSWER 25 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1995:750055 HCAPLUS Full-text
DOCUMENT NUMBER: 123:188182
TITLE: Irsogladine activates gap-junctional intercellular communication through M1 muscarinic acetylcholine receptor
AUTHOR(S): Ueda, Fusao; Ban, Keiko; Ishima, Tsuyoshi
CORPORATE SOURCE: Discovery Research Laboratories II, Nippon Shinyaku Co. Ltd., Kyoto, 601, Japan
SOURCE: Journal of Pharmacology and Experimental Therapeutics (*1995*), 274(2), 815-19
CODEN: JPETAB; ISSN: 0022-3565
PUBLISHER: Williams & Wilkins
DOCUMENT TYPE: Journal

LANGUAGE: English

AB Irsogladine, an agent that protects gastric mucosa against various ulcerogenic stimuli through increasing cAMP in surface mucous cells, has been reported to dose-dependently (10-7 to 10-5 M) facilitate gap-junctional intercellular communication (GJIC) in gastric epithelial cells. The beta adrenergic agonist, isoproterenol, stimulates GJIC in resting cells and inhibits GJIC in cells activated by 3-isobutyl-1- methylxanthine. In this study, we investigated whether irsogladine acts on GJIC in a manner similar to that shown by isoproterenol. Irsogladine, which bound to M1 muscarinic acetylcholine receptors (mAChR), did not inhibit, but failed to further facilitate the 3-isobutyl-1-methylxanthine- enhanced GJIC, measured by Lucifier yellow transfer. The enhancement of GJIC by irsogladine was inhibited by the M1 mAChR antagonist, pirenzepine. A selective M1 mAChR agonist, McN-A-343, enhanced GJIC. Isoproterenol (10-8 to 10-6 M), which alone did not affect GJIC, inhibited the GJIC enhanced by 10-5 M irsogladine. Conversely, 10-10 to 10-6 M irsogladine, which alone did not affect GJIC, inhibited the GJIC enhanced by 10-5 M isoproterenol. McN-A-343 also converted the action of 10-5 M isoproterenol from facilitation to inhibition of GJIC. These results indicate that GJIC is heterologously down-regulated by cross-talk between M1 mAChR and beta adrenergic receptors. In addition, the effects of irsogladine and isoproterenol at low concns. suggest the involvement of another mechanism for down-regulating GJIC.

CC 1-9 (Pharmacology)

IT *57381-26-7*, Irsogladine
RL: *BAC (Biological activity or effector, except adverse)*; BSU (Biological study, unclassified); *THU (Therapeutic use)*; BIOL (Biological study); USES (Uses)
(irsogladine activates gap-junctional intercellular communication through M1 muscarinic acetylcholine receptor)

IT *57381-26-7*, Irsogladine
RL: *BAC (Biological activity or effector, except adverse)*; BSU (Biological study, unclassified); *THU (Therapeutic use)*; BIOL (Biological study); USES (Uses)
(irsogladine activates gap-junctional intercellular communication through M1 muscarinic acetylcholine receptor)

RN 57381-26-7 HCAPLUS

CN 1,3,5-Triazine-2,4-diamine, 6-(2,5-dichlorophenyl)- (9CI) (CA INDEX NAME)



L98 ANSWER 26 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1995:633350 HCAPLUS Full-text

DOCUMENT NUMBER: 123:74593

TITLE: Effects of irsogladine, cimetidine and cetraxate on prostaglandin biosynthesis in cultured rabbit gastric epithelial cells

AUTHOR(S): Ueda, Fusao; Ideguchi, Kyoichi

CORPORATE SOURCE: Discovery Res. Lab., Nippon Shinyaku Co. Ltd., Kyoto, 601, Japan

SOURCE: Yakuri to Chiryo (*1995*), 23(2), 327-31
CODEN: YACHDS; ISSN: 0386-3603

PUBLISHER: Raifu Saiensu Shuppan K.K.
DOCUMENT TYPE: Journal
LANGUAGE: Japanese

AB The effects of antiulcer drugs on prostaglandin (PG) biosynthesis were investigated in 1-14C-arachidonic acid (AA)-prelabeled gastric epithelial cells. Irsogladine and cimetidine did not affect basal PG biosynthesis. Cetraxate decreased the release of polar substances (phospholipids and probably peptide leukotrienes) and increased AA release. All these antiulcer drugs inhibited norepinephrine-induced PGE2 biosynthesis. These results suggest that PGE2 is not important in gastric defense functions. In addition, the inhibition of PGE2 biosynthesis by the antiulcer drugs might be involved in their mechanisms for inhibiting gastric ulcers.

CC 1-9 (Pharmacology)

IT 34675-84-8, Cetraxate 51481-61-9, Cimetidine *57381-26-7*, Irsogladine
RL: *BAC (Biological activity or effector, except adverse)*; BSU (Biological study, unclassified); *THU (Therapeutic use)*; BIOL (Biological study); USES (Uses)
(effects of irsogladine, cimetidine and cetraxate on prostaglandin biosynthesis in cultured rabbit gastric epithelial cells)

IT *57381-26-7*, Irsogladine
RL: *BAC (Biological activity or effector, except adverse)*; BSU (Biological study, unclassified); *THU (Therapeutic use)*; BIOL (Biological study); USES (Uses)
(effects of irsogladine, cimetidine and cetraxate on prostaglandin biosynthesis in cultured rabbit gastric epithelial cells)

RN 57381-26-7 HCAPLUS
CN 1,3,5-Triazine-2,4-diamine, 6-(2,5-dichlorophenyl)- (9CI) (CA INDEX NAME)



L98 ANSWER 27 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1995:954085 HCAPLUS Full-text
DOCUMENT NUMBER: 124:21526
TITLE: Irsogladine inhibits ionomycin-induced decrease in intercellular communication in cultured rabbit gastric epithelial cells
AUTHOR(S): kameda, Yukiaki; Ueda, Fusao
CORPORATE SOURCE: Res. Lab., Nippon shinyaku Co., Ltd., Kyoto, 601, Japan
SOURCE: Japanese Journal of Pharmacology (*1995*), 69(3), 223-8
CODEN: JJPAAZ; ISSN: 0021-5198
PUBLISHER: Japanese Pharmacological Society
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Effects of irsogladine on ionomycin-induced decreased in intercellular communication and increase in intracellular concentration of Ca2+ ([Ca2+]i) were investigated in cultured rabbit gastric epithelial cells. Ionomycin (10-7-10-16 M) transiently and concentrate-dependently inhibited intercellular communication concomitantly with the elevation of [Ca2+]i in the presence and

absence of extracellular Ca2+. Irsogladine (0-5 M), which has been shown to facilitate intercellular communication, suppressed the ionomycin-induced elevation of [Ca2+]i and decrease in intercellular communication. The suppression of the ionomycin effects by irsogladine was independent of extracellular Ca2+. TMB-8 [8-(diethylamino)octyl-3,4,5- trimethoxybenzoate hydrochloride] (10-6 M) also suppressed the ionomycin-induced elevation of [Ca2+]i and decrease in intercellular communication. These results indicate that the ionomycin-induced decrease in intercellular communication may be due to Ca2+ mobilization from intracellular stores. Inhibitory effects of irsogladine and TMB-8 on the ionomycin-induced decrease in intercellular communication may be produced by suppressing Ca2+ mobilization.

CC 1-9 (Pharmacology)

IT *57381-26-7*, Irsogladine
RL: *BAC (Biological activity or effector, except adverse)*; BSU (Biological study, unclassified); *THU (Therapeutic use)*; BIOL (Biological study); USES (Uses)
(irsogladine inhibits ionomycin-induced decrease in intercellular communication in gastric epithelium)

IT *57381-26-7*, Irsogladine
RL: *BAC (Biological activity or effector, except adverse)*; BSU (Biological study, unclassified); *THU (Therapeutic use)*; BIOL (Biological study); USES (Uses)
(irsogladine inhibits ionomycin-induced decrease in intercellular communication in gastric epithelium)

RN 57381-26-7 HCAPLUS

CN 1,3,5-Triazine-2,4-diamine, 6-(2,5-dichlorophenyl)- (9CI) (CA INDEX NAME)



L98 ANSWER 28 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1995:126565 HCAPLUS Full-text

DOCUMENT NUMBER: 122:616

TITLE: A new synthetic antiarrhythmic peptide reduces dispersion of epicardial activation recovery interval and diminishes alterations of epicardial activation patterns induced by regional ischemia: a mapping study

AUTHOR(S): Dhein, S.; Manicone, N.; Muller, A.; Gerwin, R.; Ziskoven, U.; Irankhahi, A.; Minke, C.; Klaus, W.

CORPORATE SOURCE: Inst. Pharmakologie, Univ. Koln, Koln, D-50931, Germany

SOURCE: Naunyn-Schmiedeberg's Archives of Pharmacology (*1994*), 350(2), 174-84
CODEN: NSAPCC; ISSN: 0028-1298

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Common antiarrhythmic agents affect ionic membrane channels and thereby alter cellular elec. activity. Since this accounts for the proarrhythmic effects as well the authors tried to find new substances with different profiles of actions. A new antiarrhythmic peptide, H2,N-*Gly*- *Ala*-*Gly*-4 Hyp-Pro-Tyr-CONH2 (AAP 10), was synthesized using the Fmoc-strategy. This peptide was analyzed for its electrophysiol. profile of action in normal isolated rabbit hearts

perfused according to the Langendorff technique either under control conditions or after induction of a regional ischemia. For this purpose 256 channel epicardial mapping was employed allowing the determination of the time points of activation at each electrode thus identifying the origins of epicardial activation (so called breakthrough-points, BTP). Epicardial spread of activation was then described math. by activation vectors which gave direction and velocity of the epicardial activation wave at each electrode. Single heart beats were analyzed under control conditions and under treatment with AAP10 or under regional ischemia with or without AAP 10-pretreatment (10-8 mol./L). The authors calculated the percentage of similar vectors (VEC) with unaltered direction (deviation <5°) and the percentage of identical breakthrough points (deviation ≤ 1 mm) compared to control conditions. In addition, apparent epicardial velocities, total activation time of a given region and activation-recovery interval (ARI) as well as dispersion of ARI (i.e. standard deviation of ARI) and distribution of ARI were analyzed. Under control conditions treatment with AAP 10 (10-10 to 3+10-7 mol/L) led to a significant decrease in ARI-dispersion without alteration of any of the other parameters under investigation. Left ventricular regional ischemia resulted in a marked alteration of the activation patterns (a significant decrease in vector-field- and breakthrough point-similarity) which could be significantly inhibited by pretreatment with AAP10. In addition, the authors found that AAP10 depressed the increase in ARI-dispersion during the first minutes of ischemia and accelerated normalization of ARI-dispersion during reperfusion. In addnl. expts., it could be shown that AAP 10 did not alter action potential duration maximum dU/dt, amplitude or resting membrane potential of isolated guinea pig muscles using a common intracellular action potential recording technique. From these results it is concluded that (a) AAP 10 inhibits ischemia induced alterations of the activation pattern (b) that it decreases ARI-dispersion (c) that this effect seems not to be due to an action on ionic channels (d) that the effect of AAP 10 may be due to an improvement of cellular coupling and finally (e) that AAP 10 may be an interesting new approach to the problem of prophylaxis of ischemia-associated ventricular arrhythmias.

CC 1-8 (Pharmacology)

IT *159503-65-8*
RL: *BAC (Biological activity or effector, except adverse)*; BSU (Biological study, unclassified); *THU (Therapeutic use)*; BIOL (Biological study); USES (Uses)
(prevention of ischemia-associated ventricular arrhythmias by synthetic peptide AAP 10)

IT *159503-65-8*
RL: *BAC (Biological activity or effector, except adverse)*; BSU (Biological study, unclassified); *THU (Therapeutic use)*; BIOL (Biological study); USES (Uses)
(prevention of ischemia-associated ventricular arrhythmias by synthetic peptide AAP 10)

RN 159503-65-8 HCAPLUS

CN retro-Antiarrhythmic peptide (cattle atrium), 6-L-tyrosinamide- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L98 ANSWER 29 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1993:38951 HCAPLUS Full-text
DOCUMENT NUMBER: 118:38951
TITLE: Preparation of 2,4-diamino-6-phenyl-1,3,5-triazine derivatives as anticancer agents and anticancer pharmaceutical compositions containing them
INVENTOR(S): Mishina, Hitoshi; Ueda, Fusao
PATENT ASSIGNEE(S): Nippon Shinyaku Co., Ltd., Japan
SOURCE: PCT Int. Appl., 46 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9211247	A1	19920709	WO 1991-JP1734	19911219 <--
W: AU, BR, CA, FI, HU, JP, KR, NO, SU, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE				
AU 9190979	A	19920722	AU 1991-90979	19911219 <--
EP 563386	A1	19931006	EP 1992-901441	19911219 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, SE				

PRIORITY APPLN. INFO.: JP 1990-413461 A 19901220 <--
JP 1991-96372 A 19910401 <--
WO 1991-JP1734 A 19911219 <--

OTHER SOURCE(S): MARPAT 118:38951
GI



I

AB The title compds. (I; R1, R2 = H, halo, amino, aralkylamino, NO2, alkyl, alkoxy, alkoxyalkyl, aralkyloxy, acyl; R3, R4 = H, nicotinoyl, Bz, alkoxy; n = 0, 1) are prepared An anticancer pharmaceutical composition contains I. Thus, a mixture of p-HOC6H4CN, PhCH2Cl, and K2CO3 in MeCN was refluxed for 5 h to give p-PhCH2OC6H4CN which was heated with dicyandiamide and KOH in diethylene glycol di-Me ether at 100° for 8 h to give I (R1 = 4-PhCH2O, R2 = R3 = R4 = H, n = 0). I.maleate (R1 = 2-Cl, R2 = 5-Cl, R3 = R4 = H, n = 0) (irsogladine) (II), administered to mice at 10 mg/kg p.o. per day from day 14 to 18 after implantation of human colon cancer WiDr cells, showed the tumor volume ratio (the tumor volume after 18 days/the initial volume) 1.52 vs. 2.00 (control) and 1.52 for cyclophosphamide administered at 10 mg/kg i.p. once on day 14. I also enhanced the antitumor activity of 5-fluorouracil derivs., e.g. Mifurol and Sunfurol, and in vitro inhibited the uptake of 5-fluorouracil in MDCK cells. Clin. trials of II were also described. Tablet, powder, and injection solution formulations containing II were given.

IC ICM C07D251-18
ICS A61K031-53

CC 28-19 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1

IT 4514-54-9P 20317-65-1P 27374-29-4P 29366-71-0P 29366-73-2P
30354-89-3P 34095-30-2P 36303-44-3P *57381-26-7P*, Irsogladine
57381-33-6P, Irsogladine maleic acid salt 57381-45-0P 57381-50-7P
57381-57-4P 57381-58-5P 59386-77-5P 65052-46-2P 68215-75-8P
81530-52-1P 81530-54-3P 116118-75-3P 145176-29-0P 145176-30-3P
145176-31-4P 145176-32-5P 145176-33-6P 145176-34-7P 145176-35-8P
145176-36-9P 145176-37-0P 145176-38-1P 145176-39-2P
RL: *BAC (Biological activity or effector, except adverse)*; BSU (Biological study, unclassified); SPN (Synthetic preparation); *THU (Therapeutic use)*; BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as anticancer agent)

IT *57381-26-7P*, Irsogladine
RL: *BAC (Biological activity or effector, except adverse)*; BSU (Biological study, unclassified); SPN (Synthetic preparation); *THU (Therapeutic use)*; BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as anticancer agent)

RN 57381-26-7 HCAPLUS
CN 1,3,5-Triazine-2,4-diamine, 6-(2,5-dichlorophenyl)- (9CI) (CA INDEX NAME)



L98 ANSWER 30 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1990:515835 HCAPLUS Full-text
DOCUMENT NUMBER: 113:115835
TITLE: Antiarrhythmic activity of a novel analog of AAP
AUTHOR(S): Kundu, Bijoy; Rizvi, Shaheena Yasmeen; Mathur, Krishna Behari; Kar, Karunamoy
CORPORATE SOURCE: Div. Biopolym., Cent. Drug Res. Inst., Lucknow, 226 001, India
SOURCE: Collection of Czechoslovak Chemical Communications (

1990), 55(2), 575-80
CODEN: CCCCAK; ISSN: 0010-0765
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Antiarrhythmic peptide (AAP) analogs H-*Gly*-X-X1-*Gly*- *Ala*-*Gly*-OH [I; X-X1 = Sar-Pro (Sar = MeGly), Pro-Sar, Sar-Sar] have been synthesized in order to obtain peptides with enhanced antiarrhythmic activity. Their antiarrhythmic activity has been evaluated against aconitine induced arrhythmia in rats. I (X-X1 = Sar-Sar) is more active than AAP (I, X-X1 = Pro-Hyp). It is equipotent to the commonly used antiarrhythmic drug quinidine, so far as delay in the onset of ventricular tachycardia, ventricular fibrillation and cardiac arrest are concerned. Relationships of biol. activities of these peptides with their CD spectra are discussed. The spatial structure of I (X-X1 = Sar-Sar) attributed to Sar2-Sar3 linkage might be contributing to its higher antiarrhythmic activity.

CC 34-3 (Amino Acids, Peptides, and Proteins)
Section cross-reference(s): 1

IT *81771-37-1DP*, Antiarrhythmic peptide (ox atrium), analogs
129164-97-2P 129164-98-3P 129164-99-4P 129165-00-0P 129165-01-1P
129165-02-2P
RL: *BAC (Biological activity or effector, except adverse)*; BSU (Biological study, unclassified); SPN (Synthetic preparation); *THU (Therapeutic use)*; BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and antiarrhythmic activity of)

IT *81771-37-1DP*, Antiarrhythmic peptide (ox atrium), analogs
RL: *BAC (Biological activity or effector, except adverse)*; BSU (Biological study, unclassified); SPN (Synthetic preparation); *THU (Therapeutic use)*; BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and antiarrhythmic activity of)

RN 81771-37-1 HCAPLUS
CN Antiarrhythmic peptide (cattle atrium) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L98 ANSWER 31 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1989:568091 HCAPLUS Full-text
DOCUMENT NUMBER: 111:168091
TITLE: Antiarrhythmic peptide has no direct cardiac actions
AUTHOR(S): Argentieri, T.; Cantor, E.; Wiggins, J. R.
CORPORATE SOURCE: Berlex Lab., Inc., Cedar Knolls, NJ, 07927, USA
SOURCE: Experientia (*1989*), 45(8), 737-8
CODEN: EXPEAM; ISSN: 0014-4754
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The electrophysiol., inotropic, and muscarinic effects of antiarrhythmic peptide (AAP) were examined in canine cardiac Purkinje fibers, ferret papillary muscle, and canine cardiac membranes, resp. Aside from a prolongation of time to peak force in papillary muscle, no biol. significant effects of AAP could be determined in any preparation, suggesting that its antiarrhythmic effects are not mediated by direct membrane actions.

CC 2-10 (Mammalian Hormones)

IT *81771-37-1*, Antiarrhythmic peptide
RL: *BAC (Biological activity or effector, except adverse)*; BSU (Biological study, unclassified); BIOL (Biological study)
(heart response to)

IT *81771-37-1*, Antiarrhythmic peptide
RL: *BAC (Biological activity or effector, except adverse)*; BSU (Biological study, unclassified); BIOL (Biological study)
(heart response to)

RN 81771-37-1 HCAPLUS

CN Antiarrhythmic peptide (cattle atrium) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L98 ANSWER 32 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1989:147197 HCAPLUS Full-text

DOCUMENT NUMBER: 110:147197

TITLE: Effect of N-3-(4-hydroxyphenyl)propionyl Pro-Pro-*Gly-Ala-Gly* on calcium-induced arrhythmias

AUTHOR(S): Kohama, Yasuhiro; Kuwahara, Shigeki; Yamamoto, Koji; Okabe, Masaru; Mimura, Tsutomu; Fukaya, Chikara; Watanabe, Masahiro; Yokoyama, Kazumasa

CORPORATE SOURCE: Fac. Pharm. Sci., Osaka Univ., Suita, 565, Japan

SOURCE: Chemical & Pharmaceutical Bulletin (*1988*), 36(11), 4597-9
CODEN: CPBTAL; ISSN: 0009-2363

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The present investigation was done to examine whether or not the presence of hydroxyproline in N-3-(4-hydroxyphenyl)propionyl Pro-Hyp-*Gly- Ala-Gly* (HP-5) is essential for its antiarrhythmic activity. Pretreatment of mice with 10 mg/kg of [Pro2]-HP-5 provided better protection against calcium-induced arrhythmias than did pretreatment with HP-5. Thus, the prolyl residue was more favorable than the hydroxyprolyl residue for antiarrhythmic activity of these analogs.

CC 1-3 (Pharmacology)
Section cross-reference(s): 2, 34

IT *111915-92-5*
RL: *BAC (Biological activity or effector, except adverse)*; BSU (Biological study, unclassified); *THU (Therapeutic use)*; BIOL

(Biological study); USES (Uses)
(antiarrhythmic activity of, structure in relation to)

IT *111915-92-5*
RL: *BAC (Biological activity or effector, except adverse)*; BSU (Biological study, unclassified); *THU (Therapeutic use)*; BIOL (Biological study); USES (Uses)
(antiarrhythmic activity of, structure in relation to)

RN 111915-92-5 HCAPLUS

CN Antiarrhythmic peptide (cattle atrium), 1-deglycine-2-[1-[3-(4-hydroxyphenyl)-1-oxopropyl]-L-proline]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L98 ANSWER 33 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1988:16410 HCAPLUS Full-text

DOCUMENT NUMBER: 108:16410

TITLE: A new antiarrhythmic peptide, N-3-(4-hydroxyphenyl)propionyl Pro-Hyp-*Gly*-*Ala*-*Gly*

AUTHOR(S): Kohama, Yasuhiro; Okimoto, Naotsugu; Mimura, Tsutomu; Fukaya, Chikara; Watanabe, Masahiro; Yokoyama, Kazumasa

CORPORATE SOURCE: Fac. Pharm. Sci., Osaka Univ., Suita, 565, Japan

SOURCE: Chemical & Pharmaceutical Bulletin (*1987*), 35(9), 3928-30
CODEN: CPBTAL; ISSN: 0009-2363

DOCUMENT TYPE: Journal

LANGUAGE: English

AB In order to increase the antiarrhythmic activity of the naturally occurring antiarrhythmic peptide (Pro-Hyp-*Gly*-*Ala*- *Gly*; (P-5)), P-5 analogs with 3 diffeent hydrophobic substituents, N-3-(4-hydroxyphenyl)propionyl (H), N-3-phenylpropionyl (I) and N-3-phenylpropyl (P), were prepared and their activities were evaluated in CaCl2-induced arrhythmias in mice. HP-5 showed potent antiarrhythmic activity at 1 mg/kg, i.v. and its potency was much higher than that of P-5 at 10 mg/kg, i.v. IP-5 showed similar potency to P-5, but PP-5 was inactive. Pro-Hyp-*Gly*-*Ala*, Pro-Hyp-*Gly* and Pro-Hyp with the substituent H, were also ineffective. Thus, 3-(4-hydroxyphenyl)propionylation of the imino nitrogen of Pro in P-5 led to increased potency.

CC 2-2 (Mammalian Hormones)

IT 111915-91-4DP, analogs *111915-92-5P* 111915-93-6P 111915-94-7P 111915-95-8P 111915-96-9P 111915-97-0P
RL: *BAC (Biological activity or effector, except adverse)*; BSU (Biological study, unclassified); SPN (Synthetic preparation); *THU (Therapeutic use)*; BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and antiarrhythmic activity of, structure in relation to)

IT *111915-92-5P*
RL: *BAC (Biological activity or effector, except adverse)*; BSU (Biological study, unclassified); SPN (Synthetic preparation); *THU (Therapeutic use)*; BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and antiarrhythmic activity of, structure in relation to)
RN 111915-92-5 HCAPLUS
CN Antiarrhythmic peptide (cattle atrium), 1-deglycine-2-[1-[3-(4-hydroxyphenyl)-1-oxopropyl]-L-proline]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L98 ANSWER 34 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1984:133284 HCAPLUS Full-text
DOCUMENT NUMBER: 100:133284
TITLE: Studies on heart. XXXIV. Inhibitory effect of antiarrhythmic peptide (AAP) on experimental thromboses
AUTHOR(S): Aonuma, Shigeru; Kohama, Yasuhiro; Makino, Toshitake; Hattori, Kunihiro; Kawahara, Yusuke
CORPORATE SOURCE: Fac. Pharm. Sci., Osaka Univ., Suita, 565, Japan
SOURCE: Chemical & Pharmaceutical Bulletin (*1984*), 32(1), 219-27
CODEN: CPBTAL; ISSN: 0009-2363
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The antithrombotic action of antiarrhythmic peptide (*Gly* -Pro-Hyp-*Gly*-*Ala*-*Gly*)(aAP) [81771-37-1] was studied by using various in vivo thrombosis models. AAP (1, 10, or 100 mg/kg, i.v.; 10 mg/kg, i.p.; or 100 mg/kg, orally) significantly inhibited white thrombus formation on a silk thread in the extracorporeal shunt models in rats, its ED50 being about 30 mg/kg, i.v. AAP (10 mg/kg, i.v.) was effective in protecting rats against the decrease in platelet count, against the incidence of electrocardiog. alterations (T-wave inversion and ST-segment depression) typical of myocardial ischemia, and against development of ectopic beats during coronary thromboembolism induced by i.v. infusion of ADP. The peptide (10 mg/kg, i.p.) was also effective in preventing thrombus formation in the lung and the decrease of platelet count induced by lactic acidosis in rats, and it (10 mg/kg, i.v.) clearly inhibited thromboembolic death induced by rapid i.v. injection of collagen in mice. Daily treatments with the peptide (10 mg/kg/d, i.p.) resulted in significant delay of the progression of gangrene and mummification in laurate-induced peripheral arterial occlusive disease in rats. AAP did not affect venous thrombus formation, blood flow through the carotid artery, plasma recalcification time or fibrinolytic activity in rats. It is likely that the potent antithrombotic action of AAP is mainly due to its anti-platelet-aggregating action in vivo. Ticlopidine (100 mg/kg, orally) also showed a

comparatively wide antithrombotic spectrum, like AAP, in the present thrombosis models; but ticlopidine, like aspirin (50 mg/kg, s.c.), lacked activity against myocardial ischemia.

CC 2-9 (Mammalian Hormones)

IT *81771-37-1*
RL: *BAC (Biological activity or effector, except adverse)*; BSU (Biological study, unclassified); BIOL (Biological study)
(antithrombotic activity of)

IT *81771-37-1*
RL: *BAC (Biological activity or effector, except adverse)*; BSU (Biological study, unclassified); BIOL (Biological study)
(antithrombotic activity of)

RN 81771-37-1 HCAPLUS

CN Antiarrhythmic peptide (cattle atrium) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L98 ANSWER 35 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1983:482255 HCAPLUS Full-text

DOCUMENT NUMBER: 99:82255

TITLE: Studies on heart. XXII. Inhibitory effect of an atrial peptide (AAP) on several drug-induced arrhythmias in vivo

AUTHOR(S): Aonuma, Shigeru; Kohama, Yasuhiro; Makino, Toshitake; Hattori, Kunihiro

CORPORATE SOURCE: Fac. Pharm. Sci., Osaka Univ., Suita, 565, Japan

SOURCE: Yakugaku Zasshi (*1983*), 103(6), 662-6
CODEN: YKKZAJ; ISSN: 0031-6903

DOCUMENT TYPE: Journal

LANGUAGE: Japanese

AB The effect of an atrial peptide, *Gly*-Pro-4Hyp-*Gly*- *Ala*-*Gly* (AAP) [81771-37-1], on several drug-induced arrhythmias in anesthetized dogs, rats and mice was investigated. AAP (10 mg/kg, i.v.) significantly reversed the persistent arrhythmias consisting of atrio-ventricular (A-V) block, ectopic beat, and/or ventricular tachycardia induced by aconitine pretreatment prevented development of ventricular fibrillation in dogs and rats. AAP (10, 25 mg/kg, i.v.) prolonged onset time of A-V block or ectopic beat and onset time of ventricular tachycardia induced by aconitine infusion in mice. This peptide (10 mg/kg, i.v.) significantly prolonged the onset time of A-V block or ectopic beat induced by CaCl2 infusion and the time until ventricular fibrillation induced by ouabain infusion in mice, and shortened the duration of arrhythmia induced by ADP in rats, but did not affect the mouse epinephrine-induced arrhythmia. The peptide (25 mg/kg, i.v.) prolonged the QTc interval and had no effect on the PQ interval heart rate, respiratory rate, and blood pressure in dogs. AAP (1 g/kg, i.v.v., i.p., and orally) did not show acute toxicity in mice. AAP had antiarrhythmic activity with few side effects.

CC 1-8 (Pharmacology)
Section cross-reference(s): 2
IT *81771-37-1*
RL: *BAC (Biological activity or effector, except adverse)*; BSU (Biological study, unclassified); *THU (Therapeutic use)*; BIOL (Biological study); USES (Uses)
(antiarrhythmic activity of)
IT *81771-37-1*
RL: *BAC (Biological activity or effector, except adverse)*; BSU (Biological study, unclassified); *THU (Therapeutic use)*; BIOL (Biological study); USES (Uses)
(antiarrhythmic activity of)
RN 81771-37-1 HCAPLUS
CN Antiarrhythmic peptide (cattle atrium) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L98 ANSWER 36 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1980:157536 HCAPLUS Full-text
DOCUMENT NUMBER: 92:157536
TITLE: Structure-activity study of antiulcerous and antiinflammatory drugs by discriminant analysis
AUTHOR(S): Ogino, Akio; Matsumura, Shingo; Fujita, Toshio
CORPORATE SOURCE: Res. Lab., Nippon Shinyaku Co., Ltd., Kyoto, 601, Japan
SOURCE: Journal of Medicinal Chemistry (*1980*), 23(4), 437-44
CODEN: JMCMAR; ISSN: 0022-2623
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

II

III

AB The structure activity of 34 antiulcer benzoguanamines I (R = H, halogen, Me, NO2, SCF3, etc.; n = 0-2),and that of 22 antiinflammatory phenylacetic acids II (R = H, OH, Me, OEt, Ph, etc.; n = 0-2), and 24 aminouracils III (R1 = Et, Me, Ph, substituted Ph, etc.; R2 = alkyl, CH2CH2OH, etc.; NR3N4 = NHPr, NMe2, NHBu, morpholins, etc.) were studied in rats by discriminant anal. For antiulcer activity the drug effect was evaluated in terms of averaged ulcer indexes and the percent inhibition value against the injury was expressed relative to the averaged index of the control group; the error involved was <10%. For the antiinflammatory activity the inhibitory effect was represented as the percent value relative to the average volume of control; the error in the percent value was <10%. The discriminant variables were selected from the physicochem. parameters used to analyze the variation in hydrophobicity due to structural modifications. The potency scores divided into 3 groups for each of the 3 series of compds. were predicted with >80% accuracy.

CC 1-3 (Pharmacodynamics)
Section cross-reference(s): 22

IT 91-76-9 91-76-9D, derivs. 4514-53-8 4514-54-9 19338-12-6
29366-71-0 29366-72-1 29366-73-2 29366-77-6 30101-52-1
30508-75-9 30508-78-2 30530-43-9 30530-44-0 30530-48-4
57381-26-7 57381-35-8 57381-38-1 57381-40-5 57381-42-7
57381-45-0 57381-46-1 57381-50-7 57381-54-1 57381-57-4
57381-60-9 65052-47-3 65052-49-5 65052-50-8 65052-53-1
65052-55-3 72775-79-2 72775-80-5 72775-81-6 72781-91-0
RL: *BAC (Biological activity or effector, except adverse)*; BSU (Biological study, unclassified); *THU (Therapeutic use)*; BIOL (Biological study); USES (Uses)
(antiulcer activity of, discriminant anal. in evaluation of)

IT *57381-26-7*
RL: *BAC (Biological activity or effector, except adverse)*; BSU (Biological study, unclassified); *THU (Therapeutic use)*; BIOL (Biological study); USES (Uses)
(antiulcer activity of, discriminant anal. in evaluation of)

RN 57381-26-7 HCAPLUS
CN 1,3,5-Triazine-2,4-diamine, 6-(2,5-dichlorophenyl)- (9CI) (CA INDEX NAME)



L98 ANSWER 37 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1975:606332 HCAPLUS Full-text
DOCUMENT NUMBER: 83:206332
TITLE: Benzoguanamine derivatives
INVENTOR(S): Murai, Hiromu; Ohata, Katsuya; Aoyagi, Yoshiaki; Ueda, Fusao; Kitano, Masahiko; Takata, Satoshi; Tada, Shinichi
PATENT ASSIGNEE(S): Nippon Shinyaku Co., Ltd., Japan
SOURCE: Ger. Offen., 24 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2506814	A1	19750828	DE 1975-2506814	19750218 <--
DE 2506814	C3	19791115		
DE 2506814	B2	19790322		
JP 50111085	A	19750901	JP 1974-19211	19740218 <--
JP 55004751	B	19800131		
JP 50111086	A	19750901	JP 1974-19212	19740218 <--
JP 52046955	B	19771129		
US 3966728	A	19760629	US 1975-544176	19750127 <--
CH 592638	A5	19771031	CH 1975-1300	19750204 <--
CH 592639	A5	19771031	CH 1975-1301	19750204 <--
SE 7501273	A	19750819	SE 1975-1273	19750205 <--
SE 425245	B	19820913	SE 1975-1274	19750205 <--
SE 425245	C	19821230		
DK 7500436	A	19751020	DK 1975-436	19750207 <--
DK 138268	C	19790212		
DK 138116	B	19780717	DK 1975-437	19750207 <--
DK 138116	C	19781204		
NL 7501574	A	19750820	NL 1975-1574	19750211 <--
NL 157901	B	19780915		
NL 157902	B	19780915	NL 1975-1575	19750211 <--
FR 2261009	A1	19750912	FR 1975-4690	19750214 <--
BE 825673	A1	19750616	BE 1975-153471	19750218 <--
AT 7501200	A	19770315	AT 1975-1200	19750218 <--
AT 339909	B	19771110		
AT 7501197	A	19770515	AT 1975-1197	19750218 <--
AT 340941	B	19780110		

PRIORITY APPLN. INFO.: JP 1974-19211 A 19740218 <--
JP 1974-19212 A 19740218 <--

GI For diagram(s), see printed CA Issue.

AB Triazines I (R = 2-Cl, 2-F, 2-Br, 3-Cl, R1 = 5-Cl; R = 2-Cl, R1 = 5-Br, 4-Cl, 3-Cl, 6-Cl, 5-F; R = 2-Br, 2-F, R1 = 5-F, 5-Br, 4-Cl; R = 3-Cl, R1 = 4-Br) were prepared by treating RR1C6H3CN with dicyandiamide or dihalobenzoic acid derivs. with biguanide. I inhibit ulceration. Thus 20 mg/kg I (R = 2-Cl, R1 = 5-Cl) i.p. in rats gave total inhibition of Shay ulcers.

IC C07D

CC 28-21 (Heterocyclic Compounds (More Than One Hetero Atom))

IT *57381-26-7P* 57381-35-8P 57381-38-1P 57381-40-5P
57381-42-7P 57381-45-0P 57381-46-1P 57381-50-7P 57381-53-0P
57381-54-1P 57381-55-2P
RL: *BAC (Biological activity or effector, except adverse)*; BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and antiulcer activity of)

IT *57381-26-7P*
RL: *BAC (Biological activity or effector, except adverse)*; BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and antiulcer activity of)

RN 57381-26-7 HCAPLUS

CN 1,3,5-Triazine-2,4-diamine, 6-(2,5-dichlorophenyl)- (9CI) (CA INDEX NAME)



********REFERENCES TO QUERY ON CLAIM 56, STRUCTURE WAS SEARCHED WITH LIMITATIONS GIVEN BY EXAMINER*******

=> d que l4
L2 42 SEA FILE=REGISTRY ABB=ON PLU=ON [G'SAR']A[G'SAR']['HYP'P]['HYP'P]YN/SQSFP
L3 36 SEA FILE=HCAPLUS ABB=ON PLU=ON L2
L4 14 SEA FILE=HCAPLUS ABB=ON PLU=ON L3 AND (AY<2001 OR PY<2001 OR PRY<2001)

=> d ibib abs hitind hitstr retable l4 tot

L4 ANSWER 1 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:546915 HCAPLUS Full-text
DOCUMENT NUMBER: 141:83631
TITLE: Rice nucleic acid molecules and encoded proteins and their uses for plant improvement
INVENTOR(S): La Rosa, Thomas J.; Kovalic, David K.; Zhou, Yihua; Cao, Yongwei; Wu, Wei; Boukharov, Andrey A.; Barbazuk, Brad W.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 14 pp., Cont.-in-part of U.S. Ser. No. 837,604.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 27
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2004123343	A1	20040624	US 2003-437963		20030514 <--
US 2004123343	A1	20040624	US 2003-437963		20030514 <--
PRIORITY APPLN. INFO.:			US 2000-197872P	P	20000419 <--
			US 2001-837604	A2	20010418
			US 2003-437963	A	20030514

AB The present invention provides 102,483 cDNA sequences and their encoded protein sequences from rice (Oryza sativa). Bioinformatic anal. identified putative functions and uses for the nucleic acids/polypeptides. The disclosed polynucleotides and polypeptides find use in production of transgenic plants to produce plants having improved properties. [This abstract record is one of forty-one records for this document necessitated by the large number of index

entries required to fully index the document and publication system constraints.].

IC ICM A01H001-00
ICS C12N015-82; C07H021-04; C12N009-24; C12N005-04

INCL 800278000; 435069100; 435200000; 435201000; 435419000; 536023200

CC 3-3 (Biochemical Genetics)
Section cross-reference(s): 6, 11

IT 716607-00-0 716607-01-1 716607-02-2 716607-03-3 716607-04-4
716607-05-5 716607-06-6 716607-07-7 716607-08-8 716607-09-9
716607-10-2 716607-11-3 716607-12-4 716607-13-5 716607-14-6
716607-15-7 716607-16-8 716607-17-9 716607-18-0 716607-19-1
716607-20-4 716607-21-5 716607-22-6 716607-23-7 716607-24-8
716607-25-9 716607-26-0 716607-27-1 716607-28-2 716607-29-3
716607-30-6 716607-31-7 716607-32-8 716607-33-9 716607-34-0
716607-35-1 716607-36-2 716607-37-3 716607-38-4 716607-39-5
716607-40-8 716607-41-9 716607-42-0 716607-43-1 716607-44-2
716607-45-3 716607-46-4 716607-47-5 716607-48-6 716607-49-7
716607-50-0 *716607-51-1* 716607-52-2 716607-53-3
716607-54-4 716607-55-5 716607-56-6 716607-57-7 716607-58-8
716607-59-9 716607-60-2 716607-61-3 716607-62-4 716607-63-5
716607-64-6 716607-65-7 716607-66-8 716607-67-9 716607-68-0
716607-69-1 716607-70-4 716607-71-5 716607-72-6 716607-73-7
716607-74-8 716607-75-9 716607-76-0 716607-77-1 716607-78-2
716607-79-3 716607-80-6 716607-81-7 716607-82-8 716607-83-9
716607-84-0 716607-85-1 716607-86-2 716607-87-3 716607-88-4
716607-89-5 716607-90-8 716607-91-9 716607-92-0 716607-93-1
716607-94-2 716607-95-3 716607-96-4 716607-97-5 716607-98-6
716607-99-7 716608-00-3 716608-01-4 716608-02-5 716608-03-6
716608-04-7 716608-05-8 716608-06-9 716608-07-0 716608-08-1
716608-09-2 716608-10-5 716608-11-6 716608-12-7 716608-13-8
716608-14-9 716608-15-0 716608-16-1 716608-17-2 716608-18-3
716608-19-4 716608-20-7 716608-21-8 716608-22-9 716608-23-0
716608-24-1 716608-25-2 716608-26-3 716608-27-4 716608-28-5
716608-29-6 716608-30-9 716608-31-0 716608-32-1 716608-33-2
716608-34-3 716608-35-4 716608-36-5 716608-37-6 716608-38-7
716608-39-8 716608-40-1 716608-41-2 716608-42-3 716608-43-4
716608-44-5 716608-45-6 716608-46-7 716608-47-8 716608-48-9
716608-49-0 716608-50-3 716608-51-4 716608-52-5 716608-53-6
716608-54-7 716608-55-8 716608-56-9 716608-57-0 716608-58-1
716608-59-2 716608-60-5 716608-61-6 716608-62-7 716608-63-8
716608-64-9 716608-65-0 716608-66-1 716608-67-2 716608-68-3
716608-69-4 716608-70-7 716608-71-8 716608-72-9 716608-73-0
716608-74-1 716608-75-2 716608-76-3 716608-77-4 716608-78-5
716608-79-6 716608-80-9 716608-81-0 716608-82-1 716608-83-2
716608-84-3 716608-85-4 716608-86-5 716608-87-6 716608-88-7
716608-89-8 716608-90-1 716608-91-2 716608-92-3 716608-93-4
716608-94-5 716608-95-6 716608-96-7 716608-97-8 716608-98-9
716608-99-0 716609-00-6 716609-01-7 716609-02-8 716609-03-9
716609-04-0 716609-05-1 716609-06-2 716609-07-3 716609-08-4
716609-09-5 716609-10-8 716609-11-9 716609-12-0 716609-13-1
716609-14-2 716609-15-3 716609-16-4 716609-17-5 716609-18-6
716609-19-7 716609-20-0 716609-21-1 716609-22-2 716609-23-3
716609-24-4 716609-25-5 716609-26-6 716609-27-7 716609-28-8
716609-29-9 716609-30-2 716609-31-3 716609-32-4 716609-33-5
716609-34-6
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); PRP (Properties); BIOL (Biological study); USES (Uses)
(amino acid sequence; rice nucleic acid mols. and encoded proteins and their uses for plant improvement)

IT *716607-51-1*

RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); PRP (Properties); BIOL (Biological study); USES (Uses)
(amino acid sequence; rice nucleic acid mols. and encoded proteins and their uses for plant improvement)
RN 716607-51-1 HCAPLUS
CN Protein (Oryza sativa clone PAT_MRT4530_21015C.1.pep fragment) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L4 ANSWER 2 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:80331 HCAPLUS Full-text
DOCUMENT NUMBER: 140:140710
TITLE: cDNAs encoding human NOVX proteins and their diagnostic and therapeutic use
INVENTOR(S): Shimkets, Richard A.; Patturajan, Meera; Vernet, Corine A. M.; Casman, Stacie J.; Malyankar, Uriel M.; Shenoy, Suresh G.; Spytek, Kimberly A.; Gangolli, Esha A.; Miller, Charles E.; Boldog, Ferenc L.; Li, Li; Taupier, Raymond J.; Kekuda, Ramesh; Smithson, Glennda; Zerhusen, Bryan D.; Liu, Xiaohong; Colman, Steven D.; Tchernev, Velizar T.; Si, Jingsheng; Edinger, Shlomit R.; Stone, David J.; Sciore, Paul; Millet, Isabelle; Rothenberg, Mark E.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 240 pp., Cont.-in-part of U.S. Ser. No. 28,248.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 173
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE	
US 2004018970	A1	20040129	US 2002-107782		20020327	<--
US 2003235882	A1	20031225	US 2001-28248		20011219	<--
US 2003203363	A1	20031030	US 2002-94466		20020307	
CA 2440337	A1	20020919	CA 2002-2440337		20020308	
CA 2440345	A1	20020919	CA 2002-2440345		20020308	
EP 1427749	A2	20040616	EP 2002-713788		20020308	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR						
AU 2005200106	A1	20050210	AU 2005-200106		20050112	<--
AU 2006201467	A1	20060504	AU 2006-201467		20060407	<--
PRIORITY APPLN. INFO.:			US 2000-256619P	P	20001219	<--
			US 2001-262959P	P	20010119	
			US 2001-272408P	P	20010228	
			US 2001-279344P	P	20010328	
			US 2001-285189P	P	20010420	
			US 2001-308039P	P	20010726	
			US 2001-311266P	P	20010809	
			US 2001-28248	A2	20011219	
			AU 2000-37360	A3	20000309	<--
			AU 2000-78680	A3	20001006	<--
			US 2001-274191P	P	20010308	
			US 2001-274194P	P	20010308	
			US 2001-274281P	P	20010308	
			US 2001-274322P	P	20010308	
			US 2001-274849P	P	20010309	

US 2001-275235P	P	20010312
US 2001-275578P	P	20010313
US 2001-275579P	P	20010313
US 2001-275601P	P	20010313
US 2001-276000P	P	20010314
US 2001-276776P	P	20010316
US 2001-276994P	P	20010319
US 2001-277239P	P	20010320
US 2001-277321P	P	20010320
US 2001-277327P	P	20010320
US 2001-277338P	P	20010320
US 2001-277791P	P	20010321
US 2001-277833P	P	20010322
US 2001-278152P	P	20010323
US 2001-278894P	P	20010326
US 2001-278999P	P	20010327
US 2001-279036P	P	20010327
US 2001-279995P	P	20010330
US 2001-280233P	P	20010330
US 2001-280802P	P	20010402
US 2001-280822P	P	20010402
US 2001-280900P	P	20010402
US 2001-281194P	P	20010404
US 2001-283675P	P	20010413
US 2001-287424P	P	20010430
US 2001-288066P	P	20010502
US 2001-288148P	P	20010502
US 2001-288342P	P	20010503
US 2001-288528P	P	20010503
US 2001-291190P	P	20010515
US 2001-291099P	P	20010516
US 2001-291240P	P	20010516
US 2001-294485P	P	20010530
US 2001-294821P	P	20010531
US 2001-294889P	P	20010531
US 2001-294899P	P	20010531
US 2001-335302P	P	20011031
US 2001-338375P	P	20011204

AB The present invention provides cDNAs encoding human NOVX proteins and their diagnostic and therapeutic use.

IC ICM C12Q001-68
ICS G01N033-53; C07K014-47; C12P021-02; C12N005-06; A61K038-17; C07K016-22; C07H021-04

INCL 514012000; 435069100; 435320100; 435325000; 530350000; 536023500; 530388150; 435006000; 435007100

CC 3-3 (Biochemical Genetics)
Section cross-reference(s): 1, 6, 13, 14

IT 651798-56-0 651798-57-1 651798-58-2 651798-64-0 651798-65-1
651798-66-2 651798-73-1, Protein NOV4b (human) 651798-79-7
651798-80-0 651798-81-1 651798-87-7 651798-93-5 651798-94-6
651799-00-7 651799-01-8 651799-07-4 651799-12-1 *651799-18-7*
651799-23-4 651799-29-0
RL: PRP (Properties)
(unclaimed protein sequence; cDNAs encoding human NOVX proteins and their diagnostic and therapeutic use)

IT *651799-18-7*
RL: PRP (Properties)
(unclaimed protein sequence; cDNAs encoding human NOVX proteins and their diagnostic and therapeutic use)

RN 651799-18-7 HCAPLUS

CN 103: PN: US20040018970 SEQID: 102 unclaimed protein (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L4 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:781492 HCAPLUS Full-text
DOCUMENT NUMBER: 138:1096
TITLE: Essential genes in microorganisms and their use as targets for antisense inhibition of proliferation and antibiotic screening
INVENTOR(S): Wang, Liangus; Zamudio, Carlos; Malone, Cheryl; Haselbeck, Robert; Ohlsen, Kari L.; Zyskind, Judith W.; Wall, Daniel; Trawick, John D.; Carr, Grant J.; Yamamoto, Robert; Forsyth, R. Allyn; Xu, H. Howard
PATENT ASSIGNEE(S): Elitra Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 1766 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 22
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002077183	A2	20021003	WO 2002-XO9107	20020321
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2002061569	A1	20020523	US 2001-815242	20010321 <--
WO 2002077183	A2	20021003	WO 2002-US9107	20020321
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.:		
US 2001-815242	A	20010321
US 2001-948993	A	20010906
US 2001-342923P	P	20011025
US 2002-72851	A	20020208
US 2002-362699P	P	20020306
WO 2002-US9107	A	20020321
US 2000-191078P	P	20000321 <--
US 2000-206848P	P	20000523 <--
US 2000-207727P	P	20000526 <--
US 2000-242578P	P	20001023 <--
US 2000-253625P	P	20001127 <--
US 2000-257931P	P	20001222 <--
US 2001-269308P	P	20010216

AB The sequences of antisense nucleic acids which inhibit the proliferation of prokaryotes are disclosed. Thus, 6213 nucleic acid fragments are identified

for which expression inhibits proliferation or is required for proliferation in Enterococcus faecalis, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Salmonella typhimurium, and Staphylococcus aureus. Cell-based assays which employ the antisense nucleic acids to identify and develop antibiotics are also disclosed. The antisense nucleic acids can also be used to identify proteins required for proliferation, express these proteins or portions thereof, obtain antibodies capable of specifically binding to the expressed proteins, and to use those expressed proteins as a screen to isolate candidate mols. for rational drug discovery programs. The nucleic acids can also be used to screen for homologous nucleic acids that are required for proliferation in cells other than Staphylococcus aureus, Salmonella typhimurium, Klebsiella pneumoniae, and Pseudomonas aeruginosa. The invention provides 38,184 such proliferation-required gene sequences (plus their encoded protein sequences). The nucleic acids of the present invention can also be used in various assay systems to screen for proliferation required genes in other organisms. [This abstract record is one of twenty records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.].

IC ICM C12N

CC 3-3 (Biochemical Genetics)
Section cross-reference(s): 1, 6, 10

IT

477094-57-8	477094-58-9	477094-59-0	477094-60-3	477094-61-4
477094-62-5	477094-63-6	477094-64-7	477094-65-8	477094-66-9
477094-67-0	477094-68-1	477094-69-2	477094-70-5	477094-71-6
477094-72-7	477094-73-8	477094-74-9	477094-75-0	477094-76-1
477094-77-2	477094-78-3	477094-79-4	477094-80-7	477094-81-8
477094-82-9	477094-83-0	477094-84-1	477094-85-2	477094-86-3
477094-87-4	477094-88-5	477094-89-6	477094-90-9	477094-91-0
477094-92-1	477094-93-2	477094-94-3	477094-95-4	477094-96-5
477094-97-6	477094-98-7	477094-99-8	477095-00-4	477095-01-5
477095-02-6	477095-03-7	477095-04-8	477095-05-9	477095-06-0
477095-07-1	477095-08-2	477095-09-3	477095-10-6	477095-11-7
477095-12-8	477095-13-9	477095-14-0	477095-15-1	477095-16-2
477095-17-3	477095-18-4	477095-19-5	477095-20-8	477095-21-9
477095-22-0	477095-23-1	477095-24-2	477095-25-3	477095-26-4
477095-27-5	477095-28-6	477095-29-7	477095-30-0	477095-31-1
477095-32-2	477095-33-3	477095-34-4	477095-35-5	477095-36-6
477095-37-7	477095-38-8	477095-39-9	477095-40-2	477095-41-3
477095-42-4	477095-43-5	*477095-44-6*	477095-45-7	
477095-46-8	477095-47-9	477095-48-0	477095-49-1	477095-50-4
477095-51-5	477095-52-6	477095-53-7	477095-54-8	477095-55-9
477095-56-0	477095-57-1	477095-58-2	477095-59-3	477095-60-6
477095-61-7	477095-62-8	477095-63-9	477095-64-0	477095-65-1
477095-66-2	477095-67-3	477095-68-4	477095-69-5	477095-70-8
477095-71-9	477095-72-0	477095-73-1	477095-74-2	477095-75-3
477095-76-4	477095-77-5	477095-78-6	477095-79-7	477095-80-0
477095-81-1	477095-82-2	477095-83-3	477095-84-4	477095-85-5
477095-86-6	477095-87-7	477095-88-8	477095-89-9	477095-90-2
477095-91-3	477095-92-4	477095-93-5	477095-94-6	477095-95-7
477095-96-8	477095-97-9	477095-98-0	477095-99-1	477096-00-7
477096-01-8	477096-02-9	477096-03-0	477096-04-1	477096-05-2
477096-06-3	477096-07-4	477096-08-5	477096-09-6	477096-10-9
477096-11-0	477096-12-1	477096-13-2	477096-14-3	477096-15-4
477096-16-5	477096-17-6	477096-18-7	477096-19-8	477096-20-1
477096-21-2	477096-22-3	477096-23-4	477096-24-5	477096-25-6
477096-26-7	477096-27-8	477096-28-9	477096-29-0	477096-30-3
477096-31-4	477096-32-5	477096-33-6	477096-34-7	477096-35-8
477096-36-9	477096-37-0	477096-38-1	477096-39-2	477096-40-5
477096-41-6	477096-42-7	477096-43-8	477096-44-9	477096-45-0
477096-46-1	477096-47-2	477096-48-3	477096-49-4	477096-50-7

477096-51-8 477096-52-9 477096-53-0 477096-54-1 477096-55-2
477096-56-3 477096-57-4 477096-58-5 477096-59-6 477096-60-9
477096-61-0 477096-62-1 477096-63-2 477096-64-3 477096-65-4
477096-66-5 477096-67-6 477096-68-7 477096-69-8 477096-70-1
477096-71-2 477096-72-3 477096-73-4 477096-74-5 477096-75-6
477096-76-7 477096-77-8 477096-78-9 477096-79-0 477096-80-3
477096-81-4 477096-82-5 477096-83-6 477096-84-7 477096-85-8
477096-86-9 477096-87-0 477096-88-1 477096-89-2 477096-90-5
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(amino acid sequence; essential genes in microorganisms and their use as targets for antisense inhibition of proliferation and antibiotic screening)

IT *477095-44-6*
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(amino acid sequence; essential genes in microorganisms and their use as targets for antisense inhibition of proliferation and antibiotic screening)

RN 477095-44-6 HCAPLUS
CN Protein (Mycobacterium avium clone MAV104574 essential) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L4 ANSWER 4 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:754415 HCAPLUS Full-text
DOCUMENT NUMBER: 137:263304
TITLE: Synthesis of peptides and medical uses of intracellular communication facilitating compounds
INVENTOR(S): Larsen, Bjarne Due; Petersen, Jorgen Soberg; Meier, Eddie; Kjolbye, Anne Louise; Jorgensen, Niklas Rye; Nielsen, Morten Schak; Holstein-Rathlou, Niels-Henrik; Martins, James B.
PATENT ASSIGNEE(S): Zealand Pharmaceuticals A/S, Den.
SOURCE: PCT Int. Appl., 233 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002077017	A2	20021003	WO 2002-US5773	20020222
WO 2002077017	A3	20031009		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
WO 2001062775	A2	20010830	WO 2001-DK127	20010222 <--
WO 2001062775	A3	20020131		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 2003092609	A1	20030515	US 2001-792286		20010222 <--
CA 2439101	A1	20021003	CA 2002-2439101		20020222
EP 1370276	A2	20031217	EP 2002-723240		20020222
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
JP 2005506295	T	20050303	JP 2002-576275		20020222
BR 2002007476	A	20060124	BR 2002-7476		20020222
NO 2003003641	A	20031020	NO 2003-3641		20030815
US 2005113293	A1	20050526	US 2003-646294		20030822 <--
IN 2003DN01336	A	20050527	IN 2003-DN1336		20030822
US 2005075280	A1	20050407	US 2004-772774		20040204 <--
PRIORITY APPLN. INFO.:			US 2001-792286	A	20010222
			WO 2001-DK127	A	20010222
			US 2001-314470P	P	20010823
			DK 2000-288	A	20000223 <--
			DK 2000-738	A	20000504 <--
			US 2000-251659P	P	20001206 <--
			WO 2002-US5773	W	20020222

OTHER SOURCE(S): MARPAT 137:263304

AB The invention relates to novel peptides, including novel antiarrhythmic peptides of linear or cyclic structure, having improved stability in vitro and/or in vivo, to compns. comprising these peptides, and to uses of the peptides for the preparation of medicaments. The invention also relates to the use of compds. that facilitate the intercellular communication for the preparation of medicaments for the treatment of a range of diseases characterized in impaired intercellular gap junctional communication. The invention further relates to a method of treating diseases, such as bladder incontinence, disorders of alveolar tissue and bronchial tissue, impaired hearing due to diseases of the cochlea, endothelial lesions, diabetic retinopathy and diabetic neuropathy, ischemia of the central nervous system and spinal cord, dental tissue disorders including periodontal disease, kidney diseases leading to hypertension, and a method of preventing failures of bone marrow transplantation. Ac-D-Tyr-D-Pro-D-4Hyp-Gly-D-Ala-Gly-NH2 (Hyp = hydroxyprolyl) was prepared by the solid-phase method and assayed for biol. activity. Graphs include those for relative cell-to-cell conductance, PI-turnover in neonatal rat cardiomyocytes, and ventricular APD90 dispersion.

IC ICM C07K007-00

CC 34-3 (Amino Acids, Peptides, and Proteins)
Section cross-reference(s): 1, 6, 63

IT 81771-37-1P, Antiarrhythmic peptide (cattle atrium) 111915-92-5P
159503-65-8P 355151-11-0P 355151-12-1P 355151-13-2P 355151-14-3P
355151-15-4P 355151-16-5P 355151-17-6P 355151-18-7P 355151-19-8P
355151-20-1P 355151-23-4P 355151-25-6P 355151-26-7P 355151-27-8P
355151-29-0P 355151-30-3P 355151-31-4P 355151-32-5P
355151-33-6P 355151-34-7P 355151-35-8P 355151-36-9P
355151-37-0P 355151-38-1P 355151-39-2P 355151-40-5P 355151-41-6P
355151-43-8P *355151-45-0P* *355151-46-1P*
355151-47-2P 355151-49-4P 355151-50-7P 355151-51-8P
355151-52-9P 355151-53-0P 355151-54-1P 355151-55-2P 355151-56-3P
355151-74-5P 463362-31-4P 463362-32-5P 463362-33-6P 463362-34-7P
463362-35-8P 463362-36-9P 463362-37-0P 463362-38-1P 463362-40-5P
463362-42-7P 463944-96-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(synthesis of peptides and medical uses of intracellular communication facilitating compds.)

IT 35919-99-4 212570-15-5 366800-53-5 463362-43-8 *463362-44-9*
463362-45-0 463362-46-1 463362-47-2 463362-48-3 463362-49-4
463362-50-7 463362-51-8 463362-52-9 463362-53-0 463362-54-1
463362-55-2 463362-56-3
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(synthesis of peptides and medical uses of intracellular communication facilitating compds.)

IT *355151-33-6P 355151-45-0P 355151-46-1P*
355151-47-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(synthesis of peptides and medical uses of intracellular communication facilitating compds.)

RN 355151-33-6 HCAPLUS
CN D-Asparagine, glycyl-D-alanylglycyl-(4S)-4-hydroxy-D-prolyl-D-prolyl-D-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 355151-45-0 HCAPLUS
CN Cyclo[L-alanylglycyl-(4R)-4-hydroxy-L-prolyl-L-prolyl-L-tyrosyl-L-glutaminylglycyl] (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 355151-46-1 HCAPLUS
CN Cyclo[L-alanylglycyl-(4R)-4-hydroxy-L-prolyl-L-prolyl-L-tyrosyl-L-asparaginylglycyl] (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 355151-47-2 HCAPLUS
CN Cyclo(L-alanylglycyl-L-prolyl-L-prolyl-L-tyrosyl-L-asparaginylglycyl) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT *463362-44-9*
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(synthesis of peptides and medical uses of intracellular communication facilitating compds.)

RN 463362-44-9 HCAPLUS
CN L-Aspartamide, glycyl-L-alanylglycyl-(4R)-4-hydroxy-L-prolyl-L-prolyl-L-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 5 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:575239 HCAPLUS Full-text
DOCUMENT NUMBER: 137:136135
TITLE: Human cDNA sequences and their encoded proteins and diagnostic and therapeutic uses
INVENTOR(S): Shimkets, Richard A.; Patturajan, Meera; Vernet, Corine A. M.; Casman, Stacie J.; Malyankar, Uriel; Shenoy, Suresh; Spytek, Kimberly A.; Gangolli, Esha; Miller, Charles; Boldog, Ferenc; Li, Li; Taupier, Raymond J., Jr.; Kekuda, Ramesh; Smithson, Glennda; Zerhusen, Bryan D.; Liu, Xiaohong; Colman, Steven D.; Tchernev, Velizar; Si, Jingsheng; Edinger, Schlomit; Stone, David; Sciore, Paul; Millet, Isabelle; Rothenberg, Mark
PATENT ASSIGNEE(S): Curagen Corporation, USA
SOURCE: PCT Int. Appl., 363 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 173
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2002059315	A2	20020801	WO 2001-US50076		20011219 <--
WO 2002059315	A3	20031009			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
AU 2002246808	A1	20020806	AU 2002-246808		20011219 <--
AU 2005200106	A1	20050210	AU 2005-200106		20050112 <--
AU 2006201467	A1	20060504	AU 2006-201467		20060407 <--
PRIORITY APPLN. INFO.:			US 2000-256619P	P	20001219 <--

US 2001-262959P	P	20010119	
US 2001-272408P	P	20010228	
US 2001-285189P	P	20010420	
US 2001-308039P	P	20010726	
US 2001-311266P	P	20010809	
AU 2000-37360	A3	20000309	<--
AU 2000-78680	A3	20001006	<--
WO 2001-US50076	W	20011219	

AB Disclosed herein are 20 cDNA sequences that encode novel human polypeptides that are members of the following protein families: stabilin, CD44-like precursor/fascilin domain, polydom, transmembrane IIIb protein, serine proteinase, Wnt-7a protein, apical endosomal glycoprotein, ADAM13, leucine-rich F box-containing protein, steroid-binding protein, steroid dehydrogenase, myosin heavy chain, and pancreatitis-associated protein. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies, which immunospecifically-bind to the polypeptide, as well as derivs., variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.

IC ICM C12N015-12
ICS C07K014-47

CC 3-3 (Biochemical Genetics)
Section cross-reference(s): 1, 6, 9, 13

IT 444213-89-2 444213-92-7 444213-96-1 444213-97-2 444213-98-3
444214-00-0 444214-01-1 444214-02-2 444214-03-3 444214-04-4
444214-05-5 444214-06-6 444214-07-7
RL: PRP (Properties)
(unclaimed protein sequence; human cDNA sequences and their encoded proteins and diagnostic and therapeutic uses)

IT *444214-05-5*
RL: PRP (Properties)
(unclaimed protein sequence; human cDNA sequences and their encoded proteins and diagnostic and therapeutic uses)

RN 444214-05-5 HCAPLUS
CN 50: PN: WO02059315 SEQID: 102 unclaimed protein (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L4 ANSWER 6 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:293812 HCAPLUS Full-text
DOCUMENT NUMBER: 136:290020
TITLE: Nucleic acids and their encoded polypeptides from human tissues
INVENTOR(S): Tang, Y. Tom; Liu, Chenghua; Zhou, Ping; Asundi, Vinod; Zhang, Jie; Zhao, Qing A.; Ren, Feiyan; Xue, Aidong J.; Yang, Yonghong; Wehrman, Tom; Drmanac, Radoje T.
PATENT ASSIGNEE(S): Hyseq, Inc., USA
SOURCE: PCT Int. Appl., 357 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 127
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
WO 2002031111	A2	20020418	WO 2001-US27760	20011011	<--
WO 2002031111	A3	20021017			

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2425827	A1	20020418	CA 2001-2425827		20011011 <--
AU 200196235	A	20020422	AU 2001-96235		20011011 <--
EP 1325120	A2	20030709	EP 2001-977088		20011011 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
PRIORITY APPLN. INFO.:			US 2000-687527	A2	20001012 <--
			WO 2001-US27760	W	20011011

AB The present invention provides novel nucleic acids, novel polypeptide sequences encoded by these nucleic acids and uses thereof. Thus, 446 novel nucleic acids were obtained from cDNA libraries prepared from various human tissues and in some cases isolated from a genomic library derived from human chromosomes using standard PCR, SBH (sequencing-by-hybridization) sequence signature anal., and Sanger sequencing techniques. Novel contigs of the invention were assembled from sequences that were obtained from a cDNA library by the above methods, and in some cases sequences obtained from one or more public databases, using a recursive algorithm to extend the seed EST into an extended assemblage. Tissue expression profiles and nearest neighbor sequence homologies are provided. The sequences of this invention have applications in nucleic acid or polypeptide arrays, in the identification of binding mols., and in treatment of diseases.

IC ICM C12N

CC 3-3 (Biochemical Genetics)
Section cross-reference(s): 6, 13, 63

IT

408551-77-9P	408551-78-0P	408551-79-1P	408551-80-4P	408551-81-5P
408551-82-6P	408551-83-7P	408551-84-8P	408551-85-9P	408551-86-0P
408551-87-1P	408551-88-2P	408551-89-3P	408551-90-6P	408551-91-7P
408551-92-8P	408551-93-9P	408551-94-0P	408551-95-1P	408551-96-2P
408551-97-3P	408551-98-4P	408551-99-5P	408552-00-1P	408552-01-2P
408552-02-3P	*408552-03-4P*	408552-04-5P	408552-05-6P	
408552-06-7P	408552-07-8P	408552-08-9P	408552-09-0P	408552-10-3P
408552-11-4P	408552-12-5P	408552-13-6P	408552-14-7P	408552-15-8P
408552-16-9P	408552-17-0P	408552-18-1P	408552-19-2P	408552-20-5P
408552-21-6P	408552-22-7P	408552-23-8P	408552-24-9P	408552-25-0P
408552-26-1P	408552-27-2P	408552-28-3P	408552-29-4P	408552-30-7P
408552-31-8P	408552-32-9P	408552-33-0P	408552-34-1P	408552-35-2P
408552-36-3P	408552-37-4P	408552-38-5P	408552-39-6P	408552-40-9P
408552-41-0P	408552-42-1P	408552-43-2P	408552-44-3P	408552-45-4P
408552-46-5P	408552-47-6P	408552-48-7P	408552-49-8P	408552-50-1P
408552-51-2P	408552-52-3P	408552-53-4P	408552-54-5P	408552-55-6P
408552-56-7P	408552-57-8P	408552-58-9P	408552-59-0P	408552-60-3P
408552-61-4P	408552-62-5P	408552-63-6P	408552-64-7P	408552-65-8P
408552-66-9P	408552-67-0P	408552-68-1P	408552-69-2P	408552-70-5P
408552-71-6P	408552-72-7P	408552-73-8P	408552-74-9P	408552-75-0P
408552-76-1P	408552-77-2P	408552-78-3P	408552-79-4P	408552-80-7P
408552-81-8P	408552-82-9P	408552-83-0P	408552-84-1P	408552-85-2P
408552-86-3P	408552-87-4P	408552-88-5P	408552-89-6P	408552-90-9P
408552-91-0P	408552-92-1P	408552-93-2P	408552-94-3P	408552-95-4P
408552-96-5P	408552-97-6P	408552-98-7P	408552-99-8P	408553-00-4P
408553-01-5P	408553-02-6P	408553-03-7P	408553-04-8P	408553-05-9P
408553-06-0P	408553-07-1P	408553-08-2P	408553-09-3P	408553-10-6P
408553-11-7P	408553-12-8P	408553-13-9P	408553-14-0P	408553-15-1P

408553-16-2P 408553-17-3P 408553-18-4P 408553-19-5P 408553-20-8P
408553-21-9P 408553-22-0P 408553-23-1P 408553-24-2P 408553-25-3P
408553-26-4P 408553-27-5P 408553-28-6P 408553-29-7P 408553-30-0P
408553-31-1P 408553-32-2P 408553-33-3P 408553-34-4P 408553-35-5P
408553-36-6P 408553-37-7P 408553-38-8P 408553-39-9P 408553-40-2P
408553-41-3P 408553-42-4P 408553-43-5P 408553-44-6P 408553-45-7P
408553-46-8P 408553-47-9P 408553-48-0P 408553-49-1P 408553-50-4P
408553-51-5P 408553-52-6P 408553-53-7P 408553-54-8P 408553-55-9P
408553-56-0P 408553-57-1P 408553-58-2P 408553-59-3P 408553-60-6P
408553-61-7P 408553-62-8P 408553-63-9P 408553-64-0P 408553-65-1P
408553-66-2P 408553-67-3P 408553-68-4P 408553-69-5P 408553-70-8P
408553-71-9P 408553-72-0P 408553-73-1P 408553-74-2P 408553-75-3P
408553-76-4P 408553-77-5P 408553-78-6P 408553-79-7P 408553-80-0P
408553-81-1P 408553-82-2P 408553-83-3P 408553-84-4P 408553-85-5P
408553-86-6P 408553-87-7P 408553-88-8P 408553-89-9P 408553-90-2P

RL: ANT (Analyte); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)
(amino acid sequence; nucleic acids and their encoded polypeptides from human tissues)

IT *408552-03-4P*

RL: ANT (Analyte); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)
(amino acid sequence; nucleic acids and their encoded polypeptides from human tissues)

RN 408552-03-4 HCAPLUS
CN Protein (human clone WO0231111-SEQID-704) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L4 ANSWER 7 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:828442 HCAPLUS Full-text
DOCUMENT NUMBER: 136:396989
TITLE: Human nucleic acids and polypeptides and their diagnostic and therapeutic uses
INVENTOR(S): Drmanac, Rodoje T.; Liu, Chenghua; Tang, Y. Tom
PATENT ASSIGNEE(S): Hyseq, Inc., USA
SOURCE: PCT Int. Appl., 103 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 127
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001075067	A2	20011011	WO 2001-XF8631	20010330 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
WO 2001075067	A2	20011011	WO 2001-US8631	20010330 <--
WO 2001075067	A3	20020404		
WO 2001075067	A9	20021031		

WO 2001075067 A8 20041014
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2000-540217 A 20000331 <--
US 2000-649167 A 20000823 <--
WO 2001-US8631 W 20010330

AB The present invention provides 30,368 nucleic acids and the 30,368 novel human polypeptide sequences encoded by these nucleic acids. A plurality of novel nucleic acids are obtained from cDNA libraries prepared from various human tissues and in some cases isolated from a genomic library derived from human chromosomes using standard PCR, sequencing by hybridization signature anal., and Sanger sequencing techniques. Nearest neighbor results are identified by sequence homol. searching. The invention also relates to therapeutic, diagnostic, and research utilities for these polynucleotides and proteins. [This abstract record is one of 10 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.].

IC ICM C12N

CC 3-3 (Biochemical Genetics)
Section cross-reference(s): 6, 13, 63

IT

429717-74-8	429717-75-9	429717-76-0	429717-77-1	429717-78-2
429717-79-3	429717-80-6	429717-81-7	429717-82-8	429717-83-9
429717-84-0	429717-85-1	429717-86-2	429717-87-3	429717-88-4
429717-89-5	429717-90-8	429717-91-9	429717-92-0	429717-93-1
429717-94-2	429717-95-3	429717-96-4	429717-97-5	429717-98-6
429717-99-7	429718-00-3	429718-01-4	429718-02-5	429718-03-6
429718-04-7	429718-05-8	429718-06-9	429718-07-0	429718-08-1
429718-09-2	429718-10-5	429718-11-6	429718-12-7	429718-13-8
429718-14-9	429718-15-0	429718-16-1	429718-17-2	429718-18-3
429718-19-4	429718-20-7	429718-21-8	429718-22-9	429718-23-0
429718-24-1	429718-25-2	429718-26-3	429718-27-4	429718-28-5
429718-29-6	429718-30-9	429718-31-0	429718-32-1	429718-33-2
429718-34-3	429718-35-4	429718-36-5	429718-37-6	429718-38-7
429718-39-8	429718-40-1	429718-41-2	429718-42-3	
429718-43-4	429718-44-5	429718-45-6	429718-46-7	429718-47-8
429718-48-9	429718-49-0	429718-50-3	429718-51-4	429718-52-5
429718-53-6	429718-54-7	429718-55-8	429718-56-9	429718-57-0
429718-58-1	429718-59-2	429718-60-5	429718-61-6	429718-62-7
429718-63-8	429718-64-9	429718-65-0	429718-66-1	429718-67-2
429718-68-3	429718-69-4	429718-70-7	429718-71-8	429718-72-9
429718-73-0	429718-74-1	429718-75-2	429718-76-3	429718-77-4
429718-78-5	429718-79-6	429718-80-9	429718-81-0	429718-82-1
429718-83-2	429718-84-3	429718-85-4	429718-86-5	429718-87-6
429718-88-7	429718-89-8	429718-90-1	429718-91-2	429718-92-3
429718-93-4	429718-94-5	429718-95-6	429718-96-7	429718-97-8
429718-98-9	429718-99-0	429719-00-6	429719-01-7	429719-02-8
429719-03-9	429719-04-0	429719-05-1	429719-06-2	429719-07-3
429719-08-4	429719-09-5	429719-10-8	429719-11-9	429719-12-0
429719-13-1	429719-14-2	429719-15-3	429719-16-4	429719-17-5
429719-18-6	429719-19-7	429719-20-0	429719-21-1	429719-22-2
429719-23-3	429719-24-4	429719-25-5	429719-26-6	429719-27-7
429719-28-8	429719-29-9	429719-30-2	429719-31-3	429719-32-4
429719-33-5	429719-34-6	429719-35-7	429719-36-8	429719-37-9

429719-38-0 429719-39-1 429719-40-4 429719-41-5 429719-42-6
429719-43-7 429719-44-8 429719-45-9 429719-46-0 429719-47-1
429719-48-2 429719-49-3 429719-50-6 429719-51-7 429719-52-8
429719-53-9 429719-54-0 429719-55-1 429719-56-2 429719-57-3
429719-58-4 429719-59-5 429719-60-8 429719-61-9 429719-62-0
429719-63-1 429719-64-2 429719-65-3 429719-66-4 429719-67-5
429719-68-6 429719-69-7 429719-70-0 429719-71-1 429719-72-2
429719-73-3 429719-74-4 429719-75-5 429719-76-6 429719-77-7
429719-78-8 429719-79-9 429719-80-2 429719-81-3 429719-82-4
429719-83-5 429719-84-6 429719-85-7 429719-86-8 429719-87-9
429719-88-0 429719-89-1 429719-90-4 429719-91-5 429719-92-6
429719-93-7 429719-94-8 429719-95-9 429719-96-0 429719-97-1
429719-98-2 429719-99-3 429720-00-3 429720-01-4 429720-02-5
429720-03-6 429720-04-7 429720-05-8 429720-06-9

RL: ANT (Analyte); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(amino acid sequence; human nucleic acids and polypeptides and their diagnostic and therapeutic uses)

IT *429718-39-8*

RL: ANT (Analyte); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(amino acid sequence; human nucleic acids and polypeptides and their diagnostic and therapeutic uses)

RN 429718-39-8 HCAPLUS
CN Protein (human clone WO0175067-SEQID-32147) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L4 ANSWER 8 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:781081 HCAPLUS Full-text
DOCUMENT NUMBER: 135:314493
TITLE: Novel nucleic acids encoding human bone marrow-expressed polypeptides
INVENTOR(S): Ford, John E.; Boyle, Bryan J.; Tang, Y. Tom; Asundi, Vinod; Yang, Yonghong; Liu, Chenghua; Drmanac, Radoje T.
PATENT ASSIGNEE(S): Hyseq, Inc., USA
SOURCE: PCT Int. Appl., 203 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 127
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001079447	A2	20011025	WO 2001-US12607	20010418 <--
WO 2001079447	A8	20030724		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 200155454	A	20011030	AU 2001-55454		20010418 <--
US 2003113847	A1	20030619	US 2002-232484		20020830 <--
PRIORITY APPLN. INFO.:			US 2000-552929	A	20000418 <--
			US 2000-695783	A	20001024 <--
			US 2000-250583P	P	20001130 <--
			US 2001-770160	A	20010126
			WO 2001-US12607	W	20010418

AB The present invention provides 67 novel bone marrow-expressed nucleic acids, novel polypeptide sequences encoded by these nucleic acids, and uses thereof. The novel nucleic acids were assembled from expressed sequence tags (ESTs) isolated mainly by sequencing by hybridization, Sanger sequencing techniques, and in some cases, sequences obtained from one or more public databases. A recursive algorithm was used to extend some of the seed ESTs into an extended assemblage, by pulling addnl. sequences from different databases. Clusters were identified which were expressed in bone marrow tissue cDNA libraries, but not in other tissues. The polynucleotides and polypeptides of the invention have uses in diagnosis and therapy, detecting bone-marrow cells or tissues, and in arrays to screen for binding agents.

IC ICM C12N

CC 3-3 (Biochemical Genetics)
Section cross-reference(s): 6, 13, 63

IT 218776-18-2 321453-13-8 367452-08-2 367620-05-1 367620-06-2
367620-07-3 367620-08-4 367620-09-5 367620-10-8 367620-11-9
367620-12-0 *367620-13-1* 367620-14-2 367620-15-3
367620-16-4 367620-17-5 367620-18-6 367620-19-7 367620-20-0
367620-21-1 367620-22-2 367620-47-1 367620-48-2 367620-49-3
367620-50-6 367620-51-7 367620-52-8 367620-53-9 367620-54-0
367620-55-1 367620-56-2 367620-57-3 367620-58-4 367620-59-5
367620-60-8 367620-61-9 367620-62-0 367620-63-1 367620-64-2
367620-65-3 367620-66-4 367620-67-5 367935-34-0 367935-37-3
367935-43-1 367935-50-0 367935-54-4 367935-57-7 367935-63-5
367935-65-7 367935-71-5 367935-78-2 367935-81-7 367943-61-1
367943-64-4 367943-67-7
RL: ANT (Analyte); BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
(amino acid sequence; nucleic acids encoding human bone marrow-expressed polypeptides)

IT *367620-13-1*
RL: ANT (Analyte); BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
(amino acid sequence; nucleic acids encoding human bone marrow-expressed polypeptides)

RN 367620-13-1 HCAPLUS

CN Bone marrow-specific protein (human clone WO0179447-SEQID-38 precursor) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L4 ANSWER 9 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:	2001:636085 HCAPLUS Full-text
DOCUMENT NUMBER:	135:180957
TITLE:	Preparation of novel antiarrhythmic peptides
INVENTOR(S):	Larsen, Bjarne Due; Petersen, Jorgen Soberg; Meier, Eddi; Kjolbye, Anne Louise; Jorgensen, Niklas Rye; Nielsen, Morten Schak; Holstein-Rathlou, Niels-Henrik; Martins, James B.
PATENT ASSIGNEE(S):	Zealand Pharmaceuticals A/S, Den.
SOURCE:	PCT Int. Appl., 189 pp.

CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE	
WO 2001062775	A2	20010830	WO 2001-DK127		20010222	<--
WO 2001062775	A3	20020131				
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW						
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG						
CA 2385659	A1	20010830	CA 2001-2385659		20010222	<--
EP 1226160	A2	20020731	EP 2001-907393		20010222	<--
EP 1226160	B1	20041215				
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR						
JP 2003528826	T	20030930	JP 2001-562556		20010222	<--
AT 284896	T	20050115	AT 2001-907393		20010222	<--
ES 2228807	T3	20050416	ES 2001-1907393		20010222	<--
PT 1226160	T	20050429	PT 2001-907393		20010222	<--
AU 781674	B2	20050602	AU 2001-35362		20010222	<--
CA 2439101	A1	20021003	CA 2002-2439101		20020222	
WO 2002077017	A2	20021003	WO 2002-US5773		20020222	
WO 2002077017	A3	20031009				
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW						
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG						
EP 1370276	A2	20031217	EP 2002-723240		20020222	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR						
JP 2005506295	T	20050303	JP 2002-576275		20020222	
BR 2002007476	A	20060124	BR 2002-7476		20020222	
NO 2003003641	A	20031020	NO 2003-3641		20030815	
US 2005113293	A1	20050526	US 2003-646294		20030822	<--
US 2005075280	A1	20050407	US 2004-772774		20040204	<--
AU 2005205785	A1	20050929	AU 2005-205785		20050902	<--
PRIORITY APPLN. INFO.:			DK 2000-288	A	20000223	<--
			DK 2000-738	A	20000504	<--
			US 2000-251659P	P	20001206	<--
			US 2001-792286	A	20010222	
			WO 2001-DK127	W	20010222	
			US 2001-314470P	P	20010823	
			WO 2002-US5773	W	20020222	

OTHER SOURCE(S): MARPAT 135:180957

AB Peptides X-A-B-Y and cyclo(X-A-B-Y) [A and B represents chemical moieties having an amino group (radical) and a carboxy group; X represents a peptide

sequence of 1 to 3 D- or L-amino acid residues or an N-terminal modification of the group A-B when Y represents a C-terminal peptide sequence of 2 to 5 D- or L-amino acid residues; X represents a peptide sequence of 2 to 5 D- or L-amino acid residues when Y represents a C-terminal peptide sequence of 1 to 3 D- or L-amino acid residues; for the linear peptide, X is optionally chemical modified at its N-terminal and has an optional linking group comprising 0-8 backbone atoms] and their mirror image or a retro analogs or pharmaceutically acceptable derivs. were prepared for treating cardiac arrhythmias. Thus, Ac-D-Tyr-D-pro-D-4Hyp-Gly- D-Ala-Gly-NH2 (4Hyp = 4-hydroxyprolyl) was prepared by the solid-phase method using TentaGel-S-Ram and examined for biol. activity [assays included effect on gap junction intercellular communication (GJIC) in cardiomyocytes, binding to tissue prepns. of murine heart, and effect on cAMP formation in CHO cells].

IC ICM C07K007-00

CC 34-3 (Amino Acids, Peptides, and Proteins)
Section cross-reference(s): 1, 63

IT 81771-37-1P, Antiarrhythmic peptide (cattle atrium) 159503-65-8P
355151-11-0P 355151-14-3P 355151-15-4P 355151-16-5P 355151-17-6P
355151-18-7P 355151-19-8P 355151-20-1P 355151-21-2P 355151-22-3P
355151-23-4P 355151-24-5P 355151-25-6P 355151-26-7P 355151-27-8P
355151-28-9P 355151-29-0P 355151-30-3P 355151-31-4P 355151-32-5P
355151-33-6P 355151-34-7P 355151-35-8P 355151-36-9P
355151-37-0P 355151-38-1P 355151-39-2P 355151-40-5P 355151-42-7P
355151-44-9P *355151-45-0P* *355151-46-1P*
355151-47-2P 355151-48-3P 355151-49-4P 355151-50-7P
355151-51-8P 355151-52-9P 355151-53-0P 355151-54-1P 355151-55-2P
355151-56-3P 355151-57-4P 355151-58-5P 355151-59-6P 355151-60-9P
355151-61-0P 355151-62-1P 355151-63-2P 355151-64-3P 355151-65-4P
355151-66-5P 355151-67-6P 355151-68-7P 355151-69-8P 355151-70-1P
355151-71-2P 355151-72-3P 355151-73-4P 355151-74-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of novel antiarrhythmic peptides)

IT *355151-33-6P* *355151-45-0P* *355151-46-1P*
355151-47-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of novel antiarrhythmic peptides)

RN 355151-33-6 HCAPLUS

CN D-Asparagine, glycyl-D-alanylglycyl-(4S)-4-hydroxy-D-prolyl-D-prolyl-D-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 355151-45-0 HCAPLUS
CN Cyclo[L-alanylglycyl-(4R)-4-hydroxy-L-prolyl-L-prolyl-L-tyrosyl-L-glutaminylglycyl] (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 355151-46-1 HCAPLUS
CN Cyclo[L-alanylglycyl-(4R)-4-hydroxy-L-prolyl-L-prolyl-L-tyrosyl-L-asparaginylglycyl] (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 355151-47-2 HCAPLUS
CN Cyclo(L-alanylglycyl-L-prolyl-L-prolyl-L-tyrosyl-L-asparaginylglycyl) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L4 ANSWER 10 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2000:325646 HCAPLUS Full-text
DOCUMENT NUMBER: 133:247911
TITLE: Prediction of the coding sequences of unidentified human genes. XVII. the complete sequences of 100 new cDNA clones from brain which code for large proteins in vitro
AUTHOR(S): Nagase, Takahiro; Kikuno, Reiko; Ishikawa, Ken-Ichi; Hirosawa, Makoto; Ohara, Osamu
CORPORATE SOURCE: Kazusa DNA Research Institute, Chiba, 292-0812, Japan
SOURCE: DNA Research (*2000*), 7(2), 143-150
CODEN: DARSE8; ISSN: 1340-2838
PUBLISHER: Universal Academy Press
DOCUMENT TYPE: Journal
LANGUAGE: English
AB To provide information regarding the coding sequences of unidentified human genes, the authors have conducted a sequencing project of human cDNAs which encode large proteins. The authors herein present the entire sequences of 100 cDNA clones of unknown human genes, named KIAA1444 to KIAA1543, from two sets of size-fractionated human adult and fetal brain cDNA libraries. The average sizes of the inserts and corresponding open reading frames of cDNA clones analyzed here were 4.4 kb and 2.6 kb (856 amino acid residues), resp. Database searches of the predicted amino acid sequences classified 53 predicted gene products into the following five functional categories: cell signaling/communication, nucleic acid management, cell structure/motility, protein management and metabolism It was also revealed that homologues for 32 KIAA gene products were detected in the databases, which were similar in sequence through almost their entire regions. Addnl., the chromosomal loci of the genes were determined by using human-rodent hybrid panels unless their chromosomal loci were already assigned in the public databases. The expression levels of the genes were monitored in spinal cord, fetal brain and fetal liver, as well as in 10 human tissues and 8 brain regions, by reverse transcription-coupled polymerase chain reaction, products of which were quantified by ELISA.
CC 3-3 (Biochemical Genetics)
IT 295808-10-5 295808-11-6 295808-12-7 295808-13-8 295808-14-9
295808-15-0 295808-16-1 295808-17-2 295808-18-3 295808-19-4
295808-20-7 295808-21-8 295808-22-9 295808-23-0 295808-24-1
295808-25-2 295808-26-3 295808-27-4 295808-28-5 295808-29-6
295808-30-9 295808-31-0 *295808-32-1* 295808-33-2
295808-34-3 295808-35-4 295808-36-5 295808-37-6 295808-38-7
295808-39-8 295808-40-1 295808-41-2 295808-42-3 295808-43-4
295808-44-5 295808-45-6 295808-46-7 295808-47-8 295808-48-9
295808-49-0 295808-50-3 295808-51-4 295808-52-5 295808-53-6

295808-54-7 295808-55-8 295808-56-9 295808-57-0 295808-58-1
295808-59-2 295808-60-5 295808-61-6 295808-62-7 295808-63-8
295808-64-9 295808-65-0 295808-66-1 295808-67-2 295808-68-3
295808-69-4 295808-70-7 295808-71-8 295808-72-9 295808-73-0
295808-74-1 295808-75-2 295808-76-3 295808-77-4 295808-78-5
295808-79-6 295808-80-9 295808-81-0 295808-82-1 295808-83-2
295808-84-3 295808-85-4 295808-86-5 295808-87-6 295808-88-7
295808-89-8 295808-90-1 295808-91-2 295808-92-3 295808-93-4
295808-94-5 295808-95-6 295808-96-7 295808-97-8 295808-98-9
295808-99-0 295809-00-6 295809-01-7 295809-02-8 295809-03-9
295809-04-0 295809-05-1 295809-06-2 295809-07-3 295809-08-4
295809-09-5

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence; sequences of 100 cDNA clones of unknown human genes, named KIAA1444 to KIAA1543, from human adult and fetal brain cDNA libraries)

IT *295808-32-1*

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence; sequences of 100 cDNA clones of unknown human genes, named KIAA1444 to KIAA1543, from human adult and fetal brain cDNA libraries)

RN 295808-32-1 HCAPLUS

CN Protein (human clone fj01441 gene KIAA1466 fragment) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Anon	1998	282	2012	Science	
Bateman, A	1999	27	260	Nucleic Acids Res	HCAPLUS
Bleasby, A	1994	22	3574	Nucleic Acids Res	HCAPLUS
Deguchi, M	1998	273	26269	J Biol Chem	HCAPLUS
Dunham, I	1999	402	489	Nature	HCAPLUS
Goffeau, A	1996	274	546	Science	HCAPLUS
Gyapay, G	1996	5	339	Hum Mol Genet	HCAPLUS
Hirosawa, M	1999	6	329	DNA Res	HCAPLUS
Ishikawa, K	1997	4	307	DNA Res	HCAPLUS
Kikuno, R	2000	28	331	Nucleic Acids Res	HCAPLUS
Nagase, T	1998	5	277	DNA Res	HCAPLUS
Nagase, T	1998	5	31	DNA Res	HCAPLUS
Nagase, T	2000	7	65	DNA Res	HCAPLUS
Nomura, N	1994	1	27	DNA Res	HCAPLUS
Ohara, O	1997	4	53	DNA Res	HCAPLUS
Taguchi, A	1996	35	31	Brain Res Mol Brain	HCAPLUS

L4 ANSWER 11 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1999:379001 HCAPLUS Full-text

DOCUMENT NUMBER: 131:54612

TITLE: Complete genome sequence of an aerobic hyper-thermophilic crenarchaeon, Aeropyrum pernix K1

AUTHOR(S): Kawarabayasi, Yutaka; Hino, Yumi; Horikawa, Hiroshi; Yamazaki, Syuji; Haikawa, Yuji; Jin-No, Koji; Takahashi, Mikio; Sekine, Mitsuo; Baba, Sin-Ichi; Ankai, Akiho; Kosugi, Hiroki; Hosoyama, Akira; Fukui, Shigehiro; Nagai, Yoshimi; Nishijima, Keiko; Nakazawa, Hidekazu; Takamiya, Minako; Masuda, Sayaka; Funahashi,

Tomomichi; Tanaka, Toshihiro; Kudoh, Yutaka; Yamazaki, Jun; Kushida, Norihiro; Oguchi, Akio; Aoki, Ken-ichi; Kubota, Kenji; Nakamura, Yoshinobu; Nomura, Norimichi; Sako, Yoshihiko; Kikuchi, Hisasi
CORPORATE SOURCE: National Institute of Technology and Evaluation, Tokyo, 151-0066, Japan
SOURCE: DNA Research (*1999*), 6(2), 83-101, 145-152
CODEN: DARSE8; ISSN: 1340-2838
PUBLISHER: Universal Academy Press
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The complete sequence of the genome of an aerobic hyper-thermophilic crenarchaeon, Aeropyrum pernix K1, which optimally grows at 95°, was determined by the whole genome shotgun method with some modifications. The entire length of the genome was 1,669,695 bp. The authenticity of the entire sequence was supported by restriction anal. of long PCR products, which were directly amplified from the genomic DNA. As the potential protein-coding regions, a total of 2694 open reading frames (ORFs) were assigned. By similarity search against public databases, 633 (23.5%) of the ORFs were related to genes with putative function and 523 (19.4%) to the sequences registered but with unknown function. All the genes in the TCA cycle except for that of α-ketoglutarate dehydrogenase were included, and instead of the α-ketoglutarate dehydrogenase gene, the genes coding for the 2 subunits of 2-oxoacid:ferredoxin oxidoreductase were identified. The remaining 1538 ORFs (57.1%) did not show any significant similarity to the sequences in the databases. Sequence comparison among the assigned ORFs suggested that a considerable member of ORFs were generated by sequence duplication. The RNA genes identified were a single 16S-23S rRNA operon, two 5S rRNA genes, and 47 tRNA genes including 14 genes with intron structures. All the assigned ORFs and RNA coding regions occupied 89.12% of the whole genome. The data presented in this paper are available on the internet homepage (http://www.mild.nite.go.jp).

CC 3-3 (Biochemical Genetics)
Section cross-reference(s): 6, 10

IT

227780-17-8	227780-18-9	227780-19-0	227780-20-3	227780-21-4
227780-22-5	227780-23-6	227780-24-7	227780-25-8	227780-26-9
227780-27-0	227780-28-1	227780-29-2	227780-30-5	227780-32-7
227780-34-9	227780-35-0	227780-45-2	227780-49-6	227780-50-9
227780-51-0	227780-52-1	227780-53-2	227780-54-3	227780-55-4
227780-56-5	227780-57-6	227780-59-8	227780-63-4	227780-68-9
227780-69-0	227780-70-3	227780-71-4	227780-72-5	227780-73-6
227780-74-7	227780-75-8	227780-76-9	227780-77-0	227780-78-1
227780-92-9	227781-11-5	227781-12-6	227781-13-7	227781-14-8
227781-15-9	227781-16-0	227781-17-1	227781-18-2	227781-19-3
227781-20-6	227781-21-7	227781-22-8	227781-23-9	227781-24-0
227781-25-1	227781-33-1	227781-45-5	227781-54-6	227781-62-6
227781-74-0	227781-76-2	227781-77-3	227781-78-4	227781-79-5
227781-80-8	227781-81-9	227781-83-1	227781-88-6	227781-91-1
227781-95-5	227781-96-6	227782-00-5	227782-05-0	227782-15-2
227782-16-3	227782-17-4	227782-18-5	227782-19-6	227782-20-9
227782-24-3	227782-25-4	227782-26-5	227782-27-6	227782-28-7
227782-29-8	227782-30-1	227782-31-2	227782-32-3	227782-33-4
227782-34-5	227782-35-6	227782-36-7	227782-37-8	227782-38-9
227782-39-0	227782-40-3	227782-41-4	227782-42-5	227782-43-6
227782-44-7	227782-45-8	227782-46-9	227782-47-0	227782-48-1
227782-49-2	227782-50-5	227782-51-6	227782-52-7	227782-53-8
227782-54-9	227782-55-0	227782-56-1	227782-57-2	227782-58-3
227782-59-4	227782-60-7	227782-61-8	227782-62-9	227782-63-0
227782-65-2	227782-66-3	227782-69-6	227782-70-9	227782-71-0
227782-72-1	227782-73-2	227782-74-3	227782-75-4	227782-78-7

227782-79-8 227782-81-2 227782-82-3 227782-83-4 227782-89-0
227782-93-6 227782-94-7 227782-95-8 227782-97-0 227783-01-9
227783-11-1 227783-18-8 227783-19-9 227783-20-2 227783-21-3
227783-22-4 227783-23-5 227783-24-6 227783-25-7 227783-27-9
227783-29-1 227783-31-5 227783-32-6 227783-33-7 227783-34-8
227783-35-9 227783-36-0 227783-37-1 227783-38-2 227783-39-3
227783-40-6 227783-41-7 227783-42-8 227783-43-9 227783-44-0
227783-45-1 227783-46-2 227783-47-3 227783-48-4 227783-49-5
227783-50-8 227783-51-9 227783-52-0 227783-53-1 227783-54-2
227783-55-3 227783-56-4 227783-57-5 227783-58-6 227783-59-7
227783-60-0 227783-61-1 227783-62-2 227783-64-4 227783-65-5
227783-66-6 227783-67-7 227783-68-8 227783-69-9 227783-70-2
227783-71-3 227783-72-4 227783-73-5 227783-74-6 227783-75-7
227783-76-8 227783-77-9 227783-78-0 227783-79-1 227783-80-4
227783-81-5 227783-82-6 227783-83-7 227783-84-8 227783-88-2
227783-90-6 227783-91-7 *227783-92-8* 227783-93-9
227783-94-0 227783-95-1 227783-96-2 227783-97-3 227783-98-4
227783-99-5 227784-00-1 227784-01-2 227784-02-3 227784-03-4
227784-04-5 227784-05-6 227784-06-7 227784-07-8 227784-08-9
227784-09-0 227784-10-3 227784-11-4 227784-12-5 227784-13-6
227784-14-7 227784-15-8 227784-16-9 227784-17-0 227784-18-1
227784-19-2 227784-20-5 227784-21-6
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence; complete genome sequence of Aeropyrum pernix K1)

IT *227783-92-8*
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence; complete genome sequence of Aeropyrum pernix K1)

RN 227783-92-8 HCAPLUS
CN 132Aa long protein (Aeropyrum pernix strain K1 gene APE1292) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Bult, C	1996	273	1058	Science	HCAPLUS
Ewing, B	1998	8	175	Genome Res	HCAPLUS
Ewing, B	1998	8	186	Genome Res	HCAPLUS
Hirata, R	1990	265	6726	J Biol Chem	HCAPLUS
Kane, P	1990	250	651	Science	HCAPLUS
Kawarabayasi, Y			147	DNA Res	
Kawarabayasi, Y	1998	5	55	DNA Res	HCAPLUS
Klenk, H	1997	390	364	Nature	HCAPLUS
Lowe, T	1997	25	955	Nuc Acids Res	HCAPLUS
Nakamura, Y	1997	2	299	Microbial & Comparat	HCAPLUS
Niehaus, F	1997	204	153	Gene	HCAPLUS
Nomura, N	1998	180	3635	J Bacteriol	HCAPLUS
Peler, F	1992	89	5577	Proc Natl Acad Sci	
Perler, F	1997	25	1087	Nuc Acids Res	HCAPLUS
Pietrokovski, S	1994	3	2340	Protein Science	HCAPLUS
Riera, J	1990	94	475	Proc Natl Acad Sci	
Sako, Y	1996	46	1070	International Journa	MEDLINE
Smith, C	1987	236	1448	Science	HCAPLUS
Smith, D	1997	179	7135	J Bacteriol	HCAPLUS
Smith, T	1981	147	195	J Mol Biol	MEDLINE
Takagi, M	1997	63	4504	Appl Environ Microbi	HCAPLUS
Xu, M	1993	75	1371	Cell	HCAPLUS

Zhang, Q |1996 |120 |587 |J Biochem |HCAPLUS

L4 ANSWER 12 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1997:474887 HCAPLUS Full-text
DOCUMENT NUMBER: 127:174474
TITLE: In vivo evidence of the critical role of cadherin-5 in murine vascular integrity
AUTHOR(S): Matsuyoshi, Norihisa; Toda, Ken-Ichi; Horiguchi, Yuji; Tanaka, Toshihiro; Nakagawa, Shinichi; Takeichi, Masatoshi; Imamura, Sadao
CORPORATE SOURCE: Department of Dermatology, Graduate School of Medicine, Faculty of Science, Kyoto University, Kyoto, 606-01, Japan
SOURCE: Proceedings of the Association of American Physicians (*1997*), 109(4), 362-371
CODEN: PAAPFD; ISSN: 1081-650X
PUBLISHER: Blackwell
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Vascular endothelial cell-cell adhesion is crucial for the regulation of vascular functions and is associated with many circulatory disorders. We isolated a rat monoclonal antibody (VECD1) recognizing the mouse vascular endothelial cell adhesion mol. and found that it inhibited vascular endothelial cell-cell association We sequenced a full-length cDNA of the antigen that was identical to mouse cadherin-5. L-cells transfected with its cDNA acquired cell-cell adhesiveness, and these transfectants reacted with VECD1 at cell-cell contact areas. We studied the role of mouse cadherin-5 in vascular functions. The addition of VECD1 antibody to a cultured vascular endothelial cell line (F-2) caused the detachment of each cell. Although normal F-2 cells formed tubular structures on Matrigel, VECD1 disturbed the tubulogenesis. VECD1 also increased the permeability through the F-2 cell layer. To clarify the in vivo function of mouse cadherin-5, we i.p. injected the hybridomas producing VECD1 into adult mice. Severe venous stasis and s.c. hemorrhage were induced within several days after the injection, resulting in the early death of the animals. These findings are evidence of an essential role of cadherin-5 in the regulation of vascular endothelial cell-cell adhesion in vivo.

CC 13-6 (Mammalian Biochemistry)
Section cross-reference(s): 6

IT *193843-04-8*, Cadherin 5 (mouse F-2 cell)
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence; in vivo evidence of critical role of cadherin-5 in murine vascular integrity)

IT *173432-45-6*, Cadherin 5, prepro- (Mus musculus)
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(in vivo evidence of critical role of cadherin-5 in murine vascular integrity)

IT *193843-04-8*, Cadherin 5 (mouse F-2 cell)
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence; in vivo evidence of critical role of cadherin-5 in murine vascular integrity)

RN 193843-04-8 HCAPLUS
CN Cadherin 5 (mouse F-2 cell) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT *173432-45-6*, Cadherin 5, prepro- (Mus musculus)
RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); PRP (Properties); BIOL (Biological study)
(in vivo evidence of critical role of cadherin-5 in murine vascular integrity)
RN 173432-45-6 HCAPLUS
CN Cadherin 5, prepro- (Mus musculus) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L4 ANSWER 13 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1996:556341 HCAPLUS Full-text
DOCUMENT NUMBER: 125:239971
TITLE: A novel family of developmentally regulated mammalian transcription factors containing the TEA/ATTS DNA binding domain
AUTHOR(S): Jacquemin, Patrick; Hwang, Jung-Joo; Martial, Joseph A.; Dolle, Pascal; Davidson, Irwin
CORPORATE SOURCE: Inst. Genetique Biologie Moleculaire Cellulaire, College France, Illkirch, 163-67404, Fr.
SOURCE: Journal of Biological Chemistry (*1996*), 271(36), 21775-21785
CODEN: JBCHA3; ISSN: 0021-9258
PUBLISHER: American Society for Biochemistry and Molecular Biology
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The authors describe the mol. cloning of two novel human and murine transcription factors containing the TEA/ATTS DNA binding domain and related to transcriptional enhancer factor-1 (TEF-1). These factors bind to the consensus TEA/ATTS cognate binding site exemplified by the GT-IIC and Sph enhansons of the SV40 enhancer but differ in their ability to bind cooperatively to tandemly repeated sites. The human TEFs are differentially expressed in cultured cell lines and the mouse (m)TEFs are differentially expressed in embryonic and extra-embryonic tissues in early post-implantation embryos. Strikingly, at later stages of embryogenesis, mTEF-3 is specifically expressed in skeletal muscle precursors, whereas mTEF-1 is expressed not only in developing skeletal muscle but also in the myocardium. Together with previous data, these results point to important, partially redundant, roles for these TEF proteins in myogenesis and cardiogenesis. In addition, mTEF-1 is strongly coexpressed with mTEF-4 in mitotic neuroblasts, while accentuated mTEF-4 expression is also observed in the gut and the nephrogenic region of the kidney. These observations suggest addnl. roles for the TEF proteins in central nervous system development and organogenesis.
CC 3-4 (Biochemical Genetics)
Section cross-reference(s): 6, 13
IT 181829-00-5 *181829-01-6* 181829-02-7 181829-03-8
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence; a novel family of developmentally regulated mammalian transcription factors containing the TEA/ATTS DNA binding domain)
IT *181829-01-6*
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence; a novel family of developmentally regulated mammalian transcription factors containing the TEA/ATTS DNA binding domain)
RN 181829-01-6 HCAPLUS
CN RNA formation factor TEF-5 (human fragment reduced) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L4 ANSWER 14 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1996:49097 HCAPLUS Full-text
DOCUMENT NUMBER: 124:137260
TITLE: Molecular cloning and expression of murine vascular endothelial-cadherin in early stage development of cardiovascular system
AUTHOR(S): Breier, G.; Breviario, F.; Caveda, L.; Berthier, R.; Schnuerch, H.; Gotsch, U.; Vestweber, D.; Risau, W.; Dejana, E.
CORPORATE SOURCE: Max-Planck-Institut physiologische klinische Forschung, Bad Nauheim, Germany
SOURCE: Blood (*1996*), 87(2), 630-41
CODEN: BLOOAW; ISSN: 0006-4971
PUBLISHER: Saunders
DOCUMENT TYPE: Journal
LANGUAGE: English
AB An early step in the formation of the extraembryonic and intraembryonic vasculature is endothelial cell differentiation and organization in blood islands and vascular structures. This involves the expression and function of specific adhesive mols. at cell-to-cell junctions. Previous work showed that endothelial cells express a cell-specific cadherin (vascular endothelial [VE]-cadherin, or 7B4/cadherin-5) that is organized at cell-to-cell contacts in cultured cells and is able to promote intercellular adhesion. In this study, we investigated whether VE-cadherin could be involved in early cardiovascular development in the mouse embryo. We first cloned and sequenced the mouse VE-cadherin cDNA. At the protein level, murine VE-cadherin presented 75% identity (90%, considering conservative amino acid substitutions) with the human homolog. Transfection of murine VE-cadherin cDNA in L cells induced Ca++-dependent cell-to-cell aggregation and reduced cell detachment from monolayers. In situ hybridization of adult tissues showed that the murine mol. is specifically expressed by endothelial cells. In mouse embryos, VE-cadherin transcripts were detected at the very earliest stages of vascular development (E7.5) in mesodermal cells of the yolk sac mesenchyme. At E9.5, expression of VE-cadherin was restricted to the peripheral cell layer of blood islands that gives rise to endothelial cells. Hematopoietic cells in the center of blood islands were not labeled. At later embryonic stages, VE-cadherin transcripts were detected in vascular structures of all organs examined, e.g., in the ventricle of the heart, the inner cell lining of the atrium and the dorsal aorta, in intersomitic vessels, and in the capillaries of the developing brain. A comparison with flk-1 expression during brain angiogenesis revealed that brain capillaries expressed relatively low amts. of VE-cadherin. In the adult brain, the level of VE-cadherin transcript was further reduced. By immunohistochem., murine VE-cadherin protein was detected at cell-to-cell junctions of endothelial cells. Overall, these data demonstrate that VE-cadherin is an early, constitutive, and specific marker of endothelial cells. This distinguishes this mol. from other cadherins and suggests that its expression is associated with the early assembly of vascular structures.
CC 3-3 (Biochemical Genetics)
Section cross-reference(s): 6, 13
IT *173432-45-6*, Cadherin 5, prepro- (Mus musculus)
173432-46-7, Cadherin 5 (Mus musculus)
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); OCCU (Occurrence)
(amino acid sequence; cDNA sequence and tissue distribution of murine vascular endothelial-cadherin in early stage development of cardiovascular system)
IT *173432-45-6*, Cadherin 5, prepro- (Mus musculus)
173432-46-7, Cadherin 5 (Mus musculus)
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); OCCU (Occurrence)

(amino acid sequence; cDNA sequence and tissue distribution of murine vascular endothelial-cadherin in early stage development of cardiovascular system)

RN 173432-45-6 HCAPLUS
CN Cadherin 5, prepro- (Mus musculus) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 173432-46-7 HCAPLUS
CN Cadherin 5 (Mus musculus) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

******BELOW ARE REFERENCES TO QUERY ON CLAIM 41, WHERE A AND B ARE EQUAL TO 1 NOT A RANGE OF 0-1**********

=> d que l60
L52 STR



Structure attributes must be viewed using STN Express query preparation.
L54 2075 SEA FILE=REGISTRY SSS FUL L52
L57 STR



Structure attributes must be viewed using STN Express query preparation.
L59 4 SEA FILE=REGISTRY SUB=L54 SSS FUL L57
L60 2 SEA FILE=HCAPLUS ABB=ON PLU=ON L59

=> d ibib abs hitind hitstr retable l60 tot

L60 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:465364 HCAPLUS Full-text
DOCUMENT NUMBER: 144:460820
TITLE: Peptide antitumor agents
INVENTOR(S): Rosenberg, Martin Jay
PATENT ASSIGNEE(S): New York University, USA
SOURCE: PCT Int. Appl., 44 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006052775	A2	20060518	WO 2005-US40078	20051104
WO 2006052775	A3	20060720		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 2006258573	A1	20061116	US 2005-264684	20051031
US 7173110	B2	20070206		

PRIORITY APPLN. INFO.: US 2004-626220P P 20041108

AB Disclosed herein are isolated, purified peptides, biol. active fragments and analogs of the peptides having anti-tumor activity in mammals, pharmaceutical

formulations comprising the peptides, fragments and analogs and methods of treating mammals suffering from tumors using such materials.

CC 1-6 (Pharmacology)
Section cross-reference(s): 34, 63

IT *886751-53-7P* 886751-54-8P 886751-55-9P 886751-56-0P
886751-57-1P 886751-58-2P
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(peptide antitumor agents)

IT *886751-53-7P*
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(peptide antitumor agents)

RN 886751-53-7 HCAPLUS

CN Cyclo[(2S)-2-amino-4-(methylsulfinyl)butanoyl-(2S)-2-amino-4-(methylsulfinyl)butanoyl-L-cysteinyl-L-valyl-L-threonyl-L-histidyl-L-cysteinyl-L-asparaginylglycylglycyl], cyclic (3→7)-disulfide (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L60 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1995:615187 HCAPLUS Full-text
DOCUMENT NUMBER: 123:27638
TITLE: Peptides for neutralizing the toxicity of lipid A
INVENTOR(S): Porro, Massimo
PATENT ASSIGNEE(S): Biosynth S.r.L., Italy
SOURCE: PCT Int. Appl., 24 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9503327	A2	19950202	WO 1994-EP2413	19940721
WO 9503327	A3	19950504		
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN				
RW: KE, MW, SD, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5652211	A	19970729	US 1993-97830	19930726
CA 2167087	A1	19950202	CA 1994-2167087	19940721
AU 9474602	A	19950220	AU 1994-74602	19940721
AU 683920	B2	19971127		
EP 711307	A1	19960515	EP 1994-924272	19940721
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 09503489	T	19970408	JP 1994-504948	19940721

PRIORITY APPLN. INFO.:

US 1993-97830	A	19930726
US 1991-658744	B2	19910211
US 1992-819893	A2	19920116
US 1993-49871	A2	19930419
WO 1994-EP2413	W	19940721

AB A peptide composition for neutralizing the toxicity of lipid A exhibits the formula: (1) (A)n (A= Lys, Arg; n=integer ≥7); (2) (AB)m (A as in (1); B= Val,

Leu, Ile, Tyr, Phe, Try; m=integer ≥3); or (3) (ABC)p (A=Lys, Arg; B, C=Leu, Ile, Tyr, Phe, Try; p=integer ≥2). The composition binds lipid-A of endotoxins and provides therapeutic and prophylactic uses. Novel 29 peptides capable of neutralizing the toxicity of lipid A are provided and their use on treating septic shock is claimed.

IC ICM C07K014-00
ICS C07K007-00

CC 4-9 (Toxicology)
Section cross-reference(s): 1

IT 25104-18-1, Polylysine 38000-06-5, Polylysine 163912-71-8
164123-00-6 164123-01-7 164123-02-8 164123-03-9 164123-04-0
164123-05-1 164123-06-2 164123-07-3 164123-08-4 164123-09-5
164123-10-8 164123-11-9 164123-12-0
164123-13-1 164123-14-2 164123-15-3 164123-16-4 164123-17-5
164123-18-6 164123-19-7 164123-20-0 164123-21-1 164123-22-2
164123-23-3 164123-24-4 164176-08-3 164176-09-4
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(peptides for neutralizing the toxicity of lipid A of endotoxins)

IT *164123-10-8 164123-11-9 164123-12-0*
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(peptides for neutralizing the toxicity of lipid A of endotoxins)

RN 164123-10-8 HCAPLUS
CN Cyclo(L-cysteinyl-L-lysyl-L-phenylalanyl-L-lysyl-L-cysteinyl-L-lysyl-L-phenylalanyl-L-lysyl-L-phenylalanyl-L-lysyl), cyclic (1→5)-disulfide (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 164123-11-9 HCAPLUS
CN Cyclo(L-cysteinyl-L-lysyl-L-leucyl-L-lysyl-L-cysteinyl-L-lysyl-L-leucyl-L-lysyl-L-leucyl-L-lysyl), cyclic (1→5)-disulfide (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 164123-12-0 HCAPLUS
CN Cyclo(L-arginyl-L-arginyl-L-cysteinyl-L-arginyl-L-threonyl-L-arginyl-L-cysteinyl-L-arginyl-L-phenylalanyl-L-lysyl), cyclic (3→7)-disulfide (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

=> d his full

(FILE 'HOME' ENTERED AT 13:10:47 ON 12 MAR 2007)

FILE 'REGISTRY' ENTERED AT 13:11:19 ON 12 MAR 2007

FILE 'LREGISTRY' ENTERED AT 13:13:27 ON 12 MAR 2007
L1 0 SEA ABB=ON PLU=ON [G'SAR']A[G'SAR']['HYP'P]['HYP'P]YN/SQSFP

FILE 'REGISTRY' ENTERED AT 13:15:31 ON 12 MAR 2007
L2 42 SEA ABB=ON PLU=ON [G'SAR']A[G'SAR']['HYP'P]['HYP'P]YN/SQSFP

FILE 'HCAPLUS' ENTERED AT 13:17:13 ON 12 MAR 2007
L3 36 SEA ABB=ON PLU=ON L2
L4 14 SEA ABB=ON PLU=ON L3 AND (AY<2001 OR PY<2001 OR PRY<2001)

FILE 'REGISTRY' ENTERED AT 13:18:16 ON 12 MAR 2007
L5 0 SEA ABB=ON PLU=ON L2 AND MEDLINE/LC

```
L6              0 SEA ABB=ON  PLU=ON  L2 AND EMBASE/LC
L7              0 SEA ABB=ON  PLU=ON  L2 AND BIOSIS/LC
L8              0 SEA ABB=ON  PLU=ON  L2 AND CAOLD/LC

     FILE 'STNGUIDE' ENTERED AT 13:18:53 ON 12 MAR 2007

     FILE 'HCAPLUS' ENTERED AT 13:19:30 ON 12 MAR 2007
                E US2004-772774/APPS
L9              2 SEA ABB=ON  PLU=ON  US2004-772774/AP
                D SCAN
                SEL RN L9

     FILE 'REGISTRY' ENTERED AT 13:20:34 ON 12 MAR 2007
L10           107 SEA ABB=ON  PLU=ON  (159503-65-8/BI OR 355151-11-0/BI OR
                  355151-12-1/BI OR 355151-13-2/BI OR 355151-14-3/BI OR 355151-15
                  -4/BI OR 355151-16-5/BI OR 355151-17-6/BI OR 355151-18-7/BI OR
                  355151-19-8/BI OR 355151-20-1/BI OR 355151-23-4/BI OR 355151-25
                  -6/BI OR 355151-26-7/BI OR 355151-27-8/BI OR 355151-29-0/BI OR
                  355151-30-3/BI OR 355151-31-4/BI OR 355151-32-5/BI OR 355151-33
                  -6/BI OR 355151-34-7/BI OR 355151-35-8/BI OR 355151-36-9/BI OR
                  355151-37-0/BI OR 355151-38-1/BI OR 355151-39-2/BI OR 355151-40
                  -5/BI OR 355151-41-6/BI OR 355151-43-8/BI OR 355151-45-0/BI OR
                  355151-46-1/BI OR 355151-47-2/BI OR 355151-49-4/BI OR 355151-50
                  -7/BI OR 355151-51-8/BI OR 355151-52-9/BI OR 355151-53-0/BI OR
                  355151-54-1/BI OR 355151-55-2/BI OR 355151-56-3/BI OR 355151-74
                  -5/BI OR 81771-37-1/BI OR 111915-92-5/BI OR 133294-37-8/BI OR
                  212570-15-5/BI OR 355151-21-2/BI OR 355151-22-3/BI OR 355151-24
                  -5/BI OR 355151-28-9/BI OR 355151-42-7/BI OR 355151-44-9/BI OR
                  355151-48-3/BI OR 355151-57-4/BI OR 355151-58-5/BI OR 355151-59
                  -6/BI OR 355151-60-9/BI OR 355151-61-0/BI OR 355151-62-1/BI OR
                  355151-63-2/BI OR 355151-64-3/BI OR 355151-65-4/BI OR 355151-66
                  -5/BI OR 355151-67-6/BI OR 355151-68-7/BI OR 355151-69-8/BI OR
                  355151-70-1/BI OR 355151-71-2/BI OR 355151-72-3/BI OR 355151-73
                  -4/BI OR 355151-75-6/BI OR 355151-76-7/BI OR 35919-99-4/BI OR
                  366800-53-5/BI OR 463362-31-4/BI OR 463362-32-5/BI OR 463362-33
                  -6/BI OR 463362-34-7/BI OR 463362-35-8/BI OR 463362-36-9/BI OR
                  463362-37-0/BI OR 463362-38-1/BI OR 463362-40-5/BI OR 463362-42
                  -7/BI OR 463362-43-8/BI OR 463362-44-9/BI OR 463362-45-0/BI OR
                  463362-46-1/BI OR 463362-47-2/BI OR 463362-48-3/BI OR 463362-49
                  -4/BI OR 463362-50-7/BI OR 463362-51-8/BI OR 463362-52-9/BI OR
                  463362-53-0/BI OR 463362-54-1/BI OR 463362-55-2/BI OR 463362-56
                  -3/BI OR 463362-57-4/BI OR 463362-58-5/BI OR 463362-59-6/BI OR
                  463944-96-9/BI OR 476-70-0/BI OR 50-99-7/BI OR 501-36-0/BI OR
                  57381-26-7/BI OR 602-07-3/BI OR 7782-44-7/BI)
L11             5 SEA ABB=ON  PLU=ON  L10 AND L2

     FILE 'STNGUIDE' ENTERED AT 13:21:01 ON 12 MAR 2007

     FILE 'HCAPLUS' ENTERED AT 13:22:00 ON 12 MAR 2007
                E LARSEN B/AU
L12           177 SEA ABB=ON  PLU=ON  ("LARSEN B"/AU OR "LARSEN B DUE"/AU OR
                  "LARSEN BJARNE"/AU OR "LARSEN BJARNE D"/AU OR "LARSEN BJARNE
                  DUE"/AU)
                E PETERSEN J/AU
L*** DEL        0 S E3,E29,E122,E127,E129,E169,E175-E177.
L13           262 SEA ABB=ON  PLU=ON  ("PETERSEN J"/AU OR "PETERSEN J S"/AU OR
                  "PETERSEN JOERGEN"/AU OR "PETERSEN JOERGEN S"/AU OR "PETERSEN
                  JOERGEN SOEBERG"/AU OR "PETERSEN JORGEN"/AU OR "PETERSEN
                  JORGEN S"/AU OR "PETERSEN JORGEN SOBERG"/AU OR "PETERSEN
                  JORGEN SOEBERG"/AU)
```

```
                 E MEIER E/AU
L14          118 SEA ABB=ON  PLU=ON  ("MEIER E"/AU OR "MEIER E A"/AU OR "MEIER
                 E F"/AU OR "MEIER E G"/AU OR "MEIER E J J"/AU OR "MEIER E M
                 M"/AU OR "MEIER E P"/AU OR "MEIER E V"/AU OR "MEIER EDDI"/AU
                 OR "MEIER EDDIE"/AU)
                 E KJOLBYE A/AU
L15            7 SEA ABB=ON  PLU=ON  "KJOLBYE ANNE LOUISE"/AU
                 E JORGENSEN N/AU
L16           31 SEA ABB=ON  PLU=ON  ("JORGENSEN N"/AU OR "JORGENSEN N R"/AU OR
                 "JORGENSEN N RYE"/AU OR "JORGENSEN NIKLAS R"/AU OR "JORGENSEN
                 NIKLAS RYE"/AU)
                 E NIELSEN M/AU
L17          495 SEA ABB=ON  PLU=ON  ("NIELSEN M"/AU OR "NIELSEN M S"/AU OR
                 "NIELSEN M S WEBER"/AU OR "NIELSEN MORTEN"/AU OR "NIELSEN
                 MORTEN S"/AU OR "NIELSEN MORTEN SCHAK"/AU)
                 E MARTINS J/AU
L18          138 SEA ABB=ON  PLU=ON  ("MARTINS J"/AU OR "MARTINS J B"/AU OR
                 "MARTINS J B L"/AU OR "MARTINS JAMES"/AU OR "MARTINS JAMES
                 B"/AU)
                 E HOLSTEIN R/AU
L19           76 SEA ABB=ON  PLU=ON  ("HOLSTEIN R"/AU OR "HOLSTEIN RATHLOU N
                 H"/AU OR "HOLSTEIN RATHLOU N H N H"/AU OR "HOLSTEIN RATHLOU
                 NIELS H"/AU OR "HOLSTEIN RATHLOU NIELS HENRIK"/AU)
L20            2 SEA ABB=ON  PLU=ON  L12 AND L13 AND L14 AND L15 AND L16 AND
                 L17 AND L18 AND L19
L21           13 SEA ABB=ON  PLU=ON  L12 AND (L13 OR L14 OR L15 OR L16 OR L17
                 OR L18 OR L19)
L22           15 SEA ABB=ON  PLU=ON  L13 AND (L14 OR L15 OR L16 OR L17 OR L18
                 OR L19)
L23            4 SEA ABB=ON  PLU=ON  L14 AND (L15 OR L16 OR L17 OR L18 OR L19)
L24            5 SEA ABB=ON  PLU=ON  L15 AND (L16 OR L17 OR L18 OR L19)
L25            2 SEA ABB=ON  PLU=ON  L16 AND (L17 OR L18 OR L19)
L26            3 SEA ABB=ON  PLU=ON  L17 AND (L18 OR L19)
L27            2 SEA ABB=ON  PLU=ON  L18 AND L19
L28           21 SEA ABB=ON  PLU=ON  (L20 OR L21 OR L22 OR L23 OR L24 OR L25 OR
                 L26 OR L27)
L29            4 SEA ABB=ON  PLU=ON  L28 AND (AY<2001 OR PY<2001 OR PRY<2001)

     FILE 'HCAPLUS, MEDLINE, EMBASE, BIOSIS, DRUGU, WPIX' ENTERED AT 13:29:40
     ON 12 MAR 2007
L30         2579 SEA ABB=ON  PLU=ON  LARSEN B?/AU
L31         5774 SEA ABB=ON  PLU=ON  PETERSEN J?/AU
L32         1629 SEA ABB=ON  PLU=ON  MEIER E?/AU
L33           42 SEA ABB=ON  PLU=ON  KJOLBYE A?/AU
L34          977 SEA ABB=ON  PLU=ON  JORGENSEN N?/AU
L35         5171 SEA ABB=ON  PLU=ON  NIELSEN M?/AU
L36         2182 SEA ABB=ON  PLU=ON  MARTINS J?/AU
L37          595 SEA ABB=ON  PLU=ON  HOLSTEIN R?/AU
L38            2 SEA ABB=ON  PLU=ON  L30 AND L31 AND L32 AND L33 AND L34 AND
                 L35 AND L36 AND L37
L39            0 SEA ABB=ON  PLU=ON  (L30 OR L31 OR L32 OR L33 OR L34 OR L35 OR
                 L36 OR L37) AND (ANTI(2A) ARRYTHMIC?)
L40            2 SEA ABB=ON  PLU=ON  (L30 OR L31 OR L32 OR L33 OR L34 OR L35 OR
                 L36 OR L37) AND (ANTIARRYTHMIC?)
L41            4 SEA ABB=ON  PLU=ON  (L38 OR L40)
L42          856 SEA ABB=ON  PLU=ON  (L30 OR L31 OR L32 OR L33 OR L34 OR L35 OR
                 L36 OR L37) AND (PEPTIDE?)
L43            1 SEA ABB=ON  PLU=ON  L42 AND (ARRYTHM?)
L44            4 SEA ABB=ON  PLU=ON  (L43 OR L41)
```

```
     FILE 'STNGUIDE' ENTERED AT 13:33:02 ON 12 MAR 2007

     FILE 'REGISTRY' ENTERED AT 13:34:05 ON 12 MAR 2007
L45              STRUCTURE UPLOADED
L46              STRUCTURE UPLOADED
L47            0 SEA SSS SAM L46
L48            0 SEA SSS FUL L46

     FILE 'STNGUIDE' ENTERED AT 13:35:38 ON 12 MAR 2007

     FILE 'BEILSTEIN' ENTERED AT 13:35:43 ON 12 MAR 2007
L49            0 SEA SSS FUL L46

     FILE 'MARPAT' ENTERED AT 13:35:57 ON 12 MAR 2007

     FILE 'STNGUIDE' ENTERED AT 13:36:04 ON 12 MAR 2007

     FILE 'REGISTRY' ENTERED AT 13:38:12 ON 12 MAR 2007

     FILE 'STNGUIDE' ENTERED AT 14:02:36 ON 12 MAR 2007

     FILE 'REGISTRY' ENTERED AT 14:03:19 ON 12 MAR 2007
               D QUE L46
               D QUE L45
L50            STRUCTURE UPLOADED
               D QUE L50

     FILE 'STNGUIDE' ENTERED AT 14:04:58 ON 12 MAR 2007

     FILE 'REGISTRY' ENTERED AT 14:12:47 ON 12 MAR 2007
L51            STRUCTURE UPLOADED
L52            STRUCTURE UPLOADED
L53           50 SEA SSS SAM L52
               D QUE L52
L54         2075 SEA SSS FUL L52
               SAVE L54 TELLER/A TEMP
L55            0 SEA ABB=ON  PLU=ON  L54 AND L10

     FILE 'HCAPLUS' ENTERED AT 14:16:01 ON 12 MAR 2007
L56         1861 SEA ABB=ON  PLU=ON  L54

     FILE 'STNGUIDE' ENTERED AT 14:16:08 ON 12 MAR 2007

     FILE 'REGISTRY' ENTERED AT 14:22:05 ON 12 MAR 2007
L57            STRUCTURE UPLOADED
L58            0 SEA SUB=L54 SSS SAM L57
L59            4 SEA SUB=L54 SSS FUL L57

     FILE 'HCAPLUS' ENTERED AT 14:23:05 ON 12 MAR 2007
L60            2 SEA ABB=ON  PLU=ON  L59
               D BIB
               D BIB 2

     FILE 'REGISTRY' ENTERED AT 14:23:30 ON 12 MAR 2007
L61            0 SEA ABB=ON  PLU=ON  L59 AND MEDLINE/LC
L62            0 SEA ABB=ON  PLU=ON  L59 AND EMBASE/LC
L63            0 SEA ABB=ON  PLU=ON  L59 AND BIOSIS/LC
L64            0 SEA ABB=ON  PLU=ON  L59 AND CAOLD/LC
L65          528 SEA ABB=ON  PLU=ON  L54 AND (ALA OR ALANIN? OR GLY OR GLYCINE
               OR GLU OR GLUTAMIC? OR ASP OR ASPARTIC? OR DAB OR DOAMINOBUT?
```

```
                OR DAPA OR LYS OR LYSINE OR ASP OR ASPARAGINE OR GLN OR
                GLUTAMINE OR ORN OR ORNITHINE OR CYS OR CYSTEINE)

     FILE 'HCAPLUS' ENTERED AT 14:25:47 ON 12 MAR 2007
L66          300 SEA ABB=ON  PLU=ON  L65
L*** DEL 598742 S L10
                D SCAN L9
L67           56 SEA ABB=ON  PLU=ON  L65 (L)(THU OR PKT OR BAC OR PAC OR
                DMA)/RL
                D KWIC
L68            1 SEA ABB=ON  PLU=ON  L66 AND (?ARRYTHM? OR ?THROMB? OR OSTEOPORO
                SIS? OR CANCER?)
L69           56 SEA ABB=ON  PLU=ON  (L67 OR L68)
L70           50 SEA ABB=ON  PLU=ON  L69 AND (AY<2001 OR PY<2001 OR PRY<2001)
L71           48 SEA ABB=ON  PLU=ON  L69 AND (AY<2000 OR PY<2000 OR PRY<2000)
L72           38 SEA ABB=ON  PLU=ON  L70 AND (ALA OR ALANIN? OR GLY OR GLYCINE
                OR GLU OR GLUTAMIC? OR ASP OR ASPARTIC? OR DAB OR DOAMINOBUT?
                OR DAPA OR LYS OR LYSINE OR ASP OR ASPARAGINE OR GLN OR
                GLUTAMINE OR ORN OR ORNITHINE OR CYS OR CYSTEINE)
                D KWIC
L73           38 SEA ABB=ON  PLU=ON  L70 AND (ALA OR ALANIN? OR GLY OR GLYCINE
                OR GLU OR GLUTAMIC? OR ASP OR ASPARTIC? OR DAB OR DIAMINOBUT?
                OR DAPA OR LYS OR LYSINE OR ASP OR ASPARAGINE OR GLN OR
                GLUTAMINE OR ORN OR ORNITHINE OR CYS OR CYSTEINE)
L74           38 SEA ABB=ON  PLU=ON  (L68 OR L72 OR L73)
L75           38 SEA ABB=ON  PLU=ON  L74 NOT (L29 OR L4 OR L9)

     FILE 'BEILSTEIN' ENTERED AT 14:32:13 ON 12 MAR 2007
L76            0 SEA SSS FUL L57

     FILE 'MARPAT' ENTERED AT 14:32:29 ON 12 MAR 2007

     FILE 'REGISTRY' ENTERED AT 14:33:37 ON 12 MAR 2007
L77            0 SEA ABB=ON  PLU=ON  L65 AND L10
L78            0 SEA ABB=ON  PLU=ON  L10 AND SQL/CI

     FILE 'STNGUIDE' ENTERED AT 14:36:57 ON 12 MAR 2007

     FILE 'REGISTRY' ENTERED AT 14:38:24 ON 12 MAR 2007
L79            0 SEA ABB=ON  PLU=ON  L10 AND SQL
L80            0 SEA ABB=ON  PLU=ON  L10 AND SQL?
L81           84 SEA ABB=ON  PLU=ON  L10 AND SQL<10
L82           23 SEA ABB=ON  PLU=ON  L10 NOT L81
                D SCAN L82
L83          106 SEA ABB=ON  PLU=ON  L10 NOT O2/MF
L84          104 SEA ABB=ON  PLU=ON  L83 NOT C14H12O3
L85          104 SEA ABB=ON  PLU=ON  L83 NOT C14H12O3/MF
L86          103 SEA ABB=ON  PLU=ON  L85 NOT C19H21NO4/MF
L87          103 SEA ABB=ON  PLU=ON  L86 NOT C9H7C12N5/MF
L88          102 SEA ABB=ON  PLU=ON  L87 NOT C20H19NO6
L89          101 SEA ABB=ON  PLU=ON  L88 NOT C6H12O6/MF

     FILE 'HCAPLUS' ENTERED AT 14:43:59 ON 12 MAR 2007
L90          109 SEA ABB=ON  PLU=ON  L89
L91           66 SEA ABB=ON  PLU=ON  L89 (L)(THU OR BAC OR PAC OR DMA OR
                PKT)/RL
L92           26 SEA ABB=ON  PLU=ON  L91 AND (AY<2001 OR PY<2001 OR PRY<2001)
                D QUE L73
L93           20 SEA ABB=ON  PLU=ON  L91 AND (ALA OR ALANIN? OR GLY OR GLYCINE
                OR GLU OR GLUTAMIC? OR ASP OR ASPARTIC? OR DAB OR DIAMINOBUT?
```

```
                OR DAPA OR LYS OR LYSINE OR ASP OR ASPARAGINE  OR GLN OR
                GLUTAMINE OR ORN OR ORNITHINE OR CYS OR CYSTEINE)
L94           35 SEA ABB=ON  PLU=ON  (L92 OR L93)
L95           33 SEA ABB=ON  PLU=ON  L94 NOT (L4 OR L29)
L96           14 SEA ABB=ON  PLU=ON  (L9 OR L4)

     FILE 'STNGUIDE' ENTERED AT 14:46:29 ON 12 MAR 2007
                D QUE L29
                D QUE L44
                D QUE L4
                D QUE L60

     FILE 'HCAPLUS, WPIX' ENTERED AT 14:46:57 ON 12 MAR 2007
L97           18 DUP REM L29 L44 L4 L60 (6 DUPLICATES REMOVED)
                     ANSWERS '1-18' FROM FILE HCAPLUS
                D QUE L29
                D QUE L41
                D QUE L29
                D QUE L44
                D QUE L95
L98           37 DUP REM L29 L44 L95 (4 DUPLICATES REMOVED)
                     ANSWERS '1-37' FROM FILE HCAPLUS
                D IBIB ABS HITIND HITSTR RETABLE L98 TOT
                D QUE L4
                D IBIB ABS HITIND HITSTR RETABLE L4 TOT
                D QUE L60
                D IBIB ABS HITIND HITSTR RETABLE L60 TOT


     FILE HOME

     FILE REGISTRY
     Property values tagged with IC are from the ZIC/VINITI data file
     provided by InfoChem.

     STRUCTURE FILE UPDATES:   11 MAR 2007  HIGHEST RN 926007-42-3
     DICTIONARY FILE UPDATES:  11 MAR 2007  HIGHEST RN 926007-42-3

     New CAS Information Use Policies, enter HELP USAGETERMS for details.

     TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

       Please note that search-term pricing does apply when
       conducting SmartSELECT searches.

     REGISTRY includes numerically searchable data for experimental and
     predicted properties as well as tags indicating availability of
     experimental property data in the original document.  For information
     on property searching in REGISTRY, refer to:

     http://www.cas.org/ONLINE/UG/regprops.html

     FILE LREGISTRY
     LREGISTRY IS A STATIC LEARNING FILE

     NEW CAS INFORMATION USE POLICIES, ENTER HELP USAGETERMS FOR DETAILS.

     FILE HCAPLUS

     Copyright of the articles to which records in this database refer is
```

held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 12 Mar 2007 VOL 146 ISS 12
FILE LAST UPDATED: 11 Mar 2007 (20070311/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE STNGUIDE
FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Mar 9, 2007 (20070309/UP).

FILE MEDLINE
FILE LAST UPDATED: 10 Mar 2007 (20070310/UP). FILE COVERS 1950 TO DATE.

All regular MEDLINE updates from November 15 to December 16 have been added to MEDLINE, along with 2007 Medical Subject Headings (MeSH(R)) and 2007 tree numbers.

The annual reload will be available in early 2007.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE EMBASE
FILE COVERS 1974 TO 12 Mar 2007 (20070312/ED)

EMBASE is now updated daily. SDI frequency remains weekly (default) and biweekly.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE BIOSIS
FILE COVERS 1969 TO DATE.
CAS REGISTRY NUMBERS AND CHEMICAL NAMES (CNs) PRESENT FROM JANUARY 1969 TO DATE.

RECORDS LAST ADDED: 7 March 2007 (20070307/ED)

FILE DRUGU
FILE LAST UPDATED: 9 MAR 2007 <20070309/UP>
>>> DERWENT DRUG FILE (SUBSCRIBER) <<<

>>> FILE COVERS 1983 TO DATE <<<
>>> THESAURUS AVAILABLE IN /CT <<<

FILE WPIX
FILE LAST UPDATED: 5 MAR 2007 <20070305/UP>

MOST RECENT THOMSON SCIENTIFIC UPDATE: 200716 <200716/DW>
DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> YOU ARE IN THE NEW AND ENHANCED DERWENT WORLD PATENTS INDEX <<<

>>> New display format FRAGHITSTR available <<<
SEE ONLINE NEWS and
http://www.stn-international.de/archive/stn_online_news/fraghitstr_ex.pdf

>>> IPC Reform reclassification data for the backfile is being loaded into the database during January 2007.
There will not be any update date (UP) written for the reclassified documents, but they can be identified by 20060101/UPIC. <<<

FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE,
PLEASE VISIT:
http://www.stn-international.de/training_center/patents/stn_guide.pdf

FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE
http://scientific.thomson.com/support/patents/coverage/latestupdates/

PLEASE BE AWARE OF THE NEW IPC REFORM IN 2006, SEE
http://www.stn-international.de/stndatabases/details/ipc_reform.html and
http://scientific.thomson.com/media/scpdf/ipcrdwpi.pdf

>>> FOR DETAILS ON THE NEW AND ENHANCED DERWENT WORLD PATENTS INDEX
PLEASE SEE
http://www.stn-international.de/stndatabases/details/dwpi_r.html <<<

FILE BEILSTEIN
FILE LAST UPDATED ON JANUARY 10, 2007

FILE COVERS 1771 TO 2006.
FILE CONTAINS 9,780,003 SUBSTANCES

>>>PLEASE NOTE: Reaction Data and substance data are stored in separate documents and can not be searched together in one query. Reaction data for BEILSTEIN compounds may be displayed immediately with the display codes PRE (preparations) and REA (reactions). A substance answer set retrieved after the search for a chemical name, a compounds with available reaction information by combining with PRE/FA, REA/FA or more generally with RX/FA. The BEILSTEIN Registry Number (BRN) is the link between a BEILSTEIN compound and belonging reactions. For mo detailed reaction searches BRNs can be searched as reaction partner BRNs Reactant BRN (RX.RBRN) or Product BRN (RX.PBRN).<<<

>>> FOR SEARCHING PREPARATIONS SEE HELP PRE <<<

****
* PLEASE NOTE THAT THERE ARE NO FORMATS FREE OF COST. *
* SET NOTICE FEATURE: THE COST ESTIMATES CALCULATED FOR SET NOTICE *
* ARE BASED ON THE HIGHEST PRICE CATEGORY. THEREFORE; THESE *
* ESTIMATES MAY NOT REFLECT THE ACTUAL COSTS. *
* FOR PRICE INFORMATION SEE HELP COST *
****

NEW
* *PATENT NUMBERS (PN) AND BABS ACCESSION NUMBERS (BABSAN) CAN NOW BE SEARCHED, SELECTED AND TRANSFERRED.*

* *NEW DISPLAY FORMATS ALLREF, ALLP AND BABSAN SHOW ALL REFERENCES, ALL PATENT REFERENCES, OR ALL BABS ACCESSION NUMBERS FOR A COMPOUND AT A GLANCE.*

FILE MARPAT
FILE CONTENT: 1961-PRESENT VOL 146 ISS 11 (20070309/ED)

SOME MARPAT RECORDS ARE DERIVED FROM INPI DATA FOR 1961-1987

MOST RECENT CITATIONS FOR PATENTS FROM MAJOR ISSUING AGENCIES
(COVERAGE TO THESE DATES IS NOT COMPLETE):

US	2007020715	25 JAN 2007
DE	102005032918	18 JAN 2007
EP	1743897	17 JAN 2007
JP	2007016265	25 JAN 2007
WO	2007012422	01 FEB 2007
GB	2427406	27 DEC 2006
FR	2888248	12 JAN 2007
RU	2291880	20 JAN 2007
CA	2551930	08 JAN 2007

Expanded G-group definition display now available.

Uploading l1.str



chain nodes :
31 32 33 34 35 36 37 38 39 40
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
24 25 26 27 28 29 30 41
chain bonds :
2-31 5-32 8-33 11-34 14-39 17-38 20-37 24-40 27-36 28-35
ring bonds :
1-2 1-23 2-3 3-4 4-5 5-6 6-7 7-8 7-41 8-9 9-10 10-11 11-25 12-13 12-
24
13-14 14-15 14-41 15-16 16-17 17-18 18-19 19-20 20-21 21-22 22-27 23-24
25-26 26-28
27-30 28-29 29-30
exact/norm bonds :
1-2 1-23 2-3 2-31 3-4 4-5 5-6 5-32 6-7 7-8 7-41 8-9 8-33 9-10 10-11
11-25 11-34 12-13 12-24 13-14 14-15 14-39 14-41 15-16 16-17 17-18 17-38
18-19 19-20
20-21 20-37 21-22 22-27 23-24 24-40 25-26 26-28 27-30 27-36 28-29 28-35
29-30

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom
22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom
31:CLASS 32:CLASS
33:CLASS 34:CLASS 35:CLASS 36:CLASS 37:CLASS 38:CLASS 39:CLASS 40:CLASS
41:Atom

Uploading l2.str



chain nodes :
31 32 33 34 35 36 37 38 39 40
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 41
chain bonds :
2-31 5-32 8-33 11-34 14-39 17-38 20-37 24-40 27-36 28-35
ring bonds :
1-2 1-23 2-3 3-4 4-5 5-6 6-7 7-8 7-41 8-9 9-10 10-11 11-25 12-13 12-24
13-14 14-15 14-41 15-16 16-17 17-18 18-19 19-20 20-21 21-22 22-27 23-24 25-26 26-28
27-30 28-29 29-30
exact/norm bonds :
1-2 1-23 2-3 2-31 3-4 4-5 5-6 5-32 6-7 7-8 7-41 8-9 8-33 9-10 10-11 11-25 11-34 12-13 12-24 13-14 14-15 14-39 14-41 15-16 16-17 17-18 17-38 18-19 19-20 20-21 20-37 21-22 22-27 23-24 24-40 25-26 26-28 27-30 27-36 28-29 28-35 29-30

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom 31:CLASS 32:CLASS 33:CLASS 34:CLASS 35:CLASS 36:CLASS 37:CLASS 38:CLASS 39:CLASS 40:CLASS 41:Atom

Uploading 13.str



chain nodes :
31 32 33 34 35 36 37 38 39 40
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
24 25 26 27 28 29 30 41
chain bonds :
2-31 5-32 8-33 11-34 14-39 17-38 20-37 24-40 27-36 28-35
ring bonds :
1-2 1-23 2-3 3-4 4-5 5-6 6-7 7-8 7-41 8-9 9-10 10-11 11-25 12-13 12-
24
13-14 14-15 14-41 15-16 16-17 17-18 18-19 19-20 20-21 21-22 22-27 23-24
25-26 26-28
27-30 28-29 29-30
exact/norm bonds :
1-2 1-23 2-3 2-31 3-4 4-5 5-6 5-32 6-7 7-8 7-41 8-9 8-33 9-10 10-11
11-25 11-34 12-13 12-24 13-14 14-15 14-39 14-41 15-16 16-17 17-18 17-38
18-19 19-20
20-21 20-37 21-22 22-27 23-24 24-40 25-26 26-28 27-30 27-36 28-29 28-35
29-30

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom
22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom
31:CLASS 32:CLASS
33:CLASS 34:CLASS 35:CLASS 36:CLASS 37:CLASS 38:CLASS 39:CLASS 40:CLASS
41:Atom

Uploading 14.str



chain nodes :
31 32 33 34 35 36 37 38 39 40
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
24 25 26 27 28 29 30 41
chain bonds :
2-31 5-32 8-33 11-34 14-39 17-38 20-37 24-40 27-36 28-35
ring bonds :
1-2 1-23 2-3 3-4 4-5 5-6 6-7 7-8 7-41 8-9 9-10 10-11 11-25 12-13 12-
24
13-14 14-15 14-41 15-16 16-17 17-18 18-19 19-20 20-21 21-22 22-27 23-24
25-26 26-28
27-30 28-29 29-30

exact/norm bonds :
1-2 1-23 2-3 2-31 3-4 4-5 5-6 5-32 6-7 7-8 7-41 8-9 8-33 9-10 10-11
11-25 11-34 12-13 12-24 13-14 14-15 14-39 14-41 15-16 16-17 17-18 17-38
18-19 19-20
20-21 20-37 21-22 22-27 23-24 24-40 25-26 26-28 27-30 27-36 28-29 28-35
29-30

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom
22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom
31:CLASS 32:CLASS
33:CLASS 34:CLASS 35:CLASS 36:CLASS 37:CLASS 38:CLASS 39:CLASS 40:CLASS
41:Atom

Uploading l50.str



chain nodes :
31 32 33 34 35 36 37 38 39 40
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
24 25 26 27 28 29 30
chain bonds :
2-31 5-32 8-33 11-34 14-39 17-38 20-37 24-40 27-36 28-35
ring bonds :
1-2 1-23 2-3 3-4 4-5 5-6 6-7 7-8 8-9 9-10 10-11 11-25 12-13 12-24 13-
14
14-15 15-16 16-17 17-18 18-19 19-20 20-21 21-22 22-27 23-24 25-26 26-28
27-30 28-29
29-30
exact/norm bonds :
1-2 1-23 2-3 2-31 3-4 4-5 5-6 5-32 6-7 7-8 8-9 8-33 9-10 10-11 11-25
11-34 12-13 12-24 13-14 14-15 14-39 15-16 16-17 17-18 17-38 18-19 19-20
20-21 20-37
21-22 22-27 23-24 24-40 25-26 26-28 27-30 27-36 28-29 28-35 29-30

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom
22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom
31:CLASS 32:CLASS

33:CLASS 34:CLASS 35:CLASS 36:CLASS 37:CLASS 38:CLASS 39:CLASS 40:CLASS

Uploading l51.str



chain nodes :
31 32 33 34 35 36 37 38 39 40
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
chain bonds :
2-31 5-32 8-33 11-34 14-39 17-38 20-37 24-40 27-36 28-35
ring bonds :
1-2 1-23 2-3 3-4 4-5 5-6 6-7 7-8 8-9 9-10 10-11 11-25 12-13 12-24 13-14
14-15 15-16 16-17 17-18 18-19 19-20 20-21 21-22 22-27 23-24 25-26 26-28 27-30 28-29
29-30
exact/norm bonds :
1-2 1-23 2-3 2-31 3-4 4-5 5-6 5-32 6-7 7-8 8-9 8-33 9-10 10-11 11-25 11-34 12-13 12-24 13-14 14-15 14-39 15-16 16-17 17-18 17-38 18-19 19-20 20-21 20-37
21-22 22-27 23-24 24-40 25-26 26-28 27-30 27-36 28-29 28-35 29-30

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom
22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom 31:CLASS 32:CLASS
33:CLASS 34:CLASS 35:CLASS 36:CLASS 37:CLASS 38:CLASS 39:CLASS 40:CLASS

Uploading l52.str



chain nodes :
31 32 33 34 35 36 37 38 39 40
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
24 25 26 27 28 29 30
chain bonds :
2-31 5-32 8-33 11-34 14-39 17-38 20-37 24-40 27-36 28-35
ring bonds :
1-2 1-23 2-3 3-4 4-5 5-6 6-7 7-8 8-9 9-10 10-11 11-25 12-13 12-24 13-
14
14-15 15-16 16-17 17-18 18-19 19-20 20-21 21-22 22-27 23-24 25-26 26-28
27-30 28-29
29-30
exact/norm bonds :
1-2 1-23 2-3 2-31 3-4 4-5 5-6 5-32 6-7 7-8 8-9 8-33 9-10 10-11 11-25
11-34 12-13 12-24 13-14 14-15 14-39 15-16 16-17 17-18 17-38 18-19 19-20
20-21 20-37
21-22 22-27 23-24 24-40 25-26 26-28 27-30 27-36 28-29 28-35 29-30

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom
22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom
31:CLASS 32:CLASS
33:CLASS 34:CLASS 35:CLASS 36:CLASS 37:CLASS 38:CLASS 39:CLASS 40:CLASS

Uploading l53.str



chain nodes :
31 32 33 34 35 36 37 38 39 40

ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
24 25 26 27 28 29 30
chain bonds :
2-31 5-32 8-33 11-34 14-39 17-38 20-37 24-40 27-36 28-35
ring bonds :
1-2 1-23 2-3 3-4 4-5 5-6 6-7 7-8 8-9 9-10 10-11 11-25 12-13 12-24 13-
14
14-15 15-16 16-17 17-18 18-19 19-20 20-21 21-22 22-27 23-24 25-26 26-28
27-30 28-29
29-30
exact/norm bonds :
1-2 1-23 2-3 2-31 3-4 4-5 5-6 5-32 6-7 7-8 8-9 8-33 9-10 10-11 11-25
11-34 12-13 12-24 13-14 14-15 14-39 15-16 16-17 17-18 17-38 18-19 19-20
20-21 20-37
21-22 22-27 23-24 24-40 25-26 26-28 27-30 27-36 28-29 28-35 29-30

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom
22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom
31:CLASS 32:CLASS
33:CLASS 34:CLASS 35:CLASS 36:CLASS 37:CLASS 38:CLASS 39:CLASS 40:CLASS

Uploading 157.str



chain nodes :
31 32 33 34 35 36 37 38 39 40
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
24 25 26 27 28 29 30 41
chain bonds :
2-31 5-32 8-33 11-34 14-39 17-38 20-37 24-40 27-36 28-35
ring bonds :
1-2 1-23 2-3 3-4 4-5 5-6 6-7 7-8 7-41 8-9 9-10 10-11 11-25 12-13 12-
24
13-14 14-15 15-16 15-41 16-17 17-18 18-19 19-20 20-21 21-22 22-27 23-24
25-26 26-28
27-30 28-29 29-30
exact/norm bonds :
1-2 1-23 2-3 2-31 3-4 4-5 5-6 5-32 6-7 7-8 7-41 8-9 8-33 9-10 10-11
11-25 11-34 12-13 12-24 13-14 14-15 14-39 15-16 15-41 16-17 17-18 17-38
18-19 19-20

20-21 20-37 21-22 22-27 23-24 24-40 25-26 26-28 27-30 27-36 28-29 28-35
29-30

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom
22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom
31:CLASS 32:CLASS
33:CLASS 34:CLASS 35:CLASS 36:CLASS 37:CLASS 38:CLASS 39:CLASS 40:CLASS
41:Atom

********BELOW ARE INVENTOR RESULTS ALONG WITH INVENTOR REGISTRY NUMBERS LIMITED BY THERAPEUTIC USE******

=> d que l29
L12 177 SEA FILE=HCAPLUS ABB=ON PLU=ON ("LARSEN B"/AU OR "LARSEN B DUE"/AU OR "LARSEN BJARNE"/AU OR "LARSEN BJARNE D"/AU OR "LARSEN BJARNE DUE"/AU)
L13 262 SEA FILE=HCAPLUS ABB=ON PLU=ON ("PETERSEN J"/AU OR "PETERSEN J S"/AU OR "PETERSEN JOERGEN"/AU OR "PETERSEN JOERGEN S"/AU OR "PETERSEN JOERGEN SOEBERG"/AU OR "PETERSEN JORGEN"/AU OR "PETERSEN JORGEN S"/AU OR "PETERSEN JORGEN SOBERG"/AU OR "PETERSEN JORGEN SOEBERG"/AU)
L14 118 SEA FILE=HCAPLUS ABB=ON PLU=ON ("MEIER E"/AU OR "MEIER E A"/AU OR "MEIER E F"/AU OR "MEIER E G"/AU OR "MEIER E J J"/AU OR "MEIER E M M"/AU OR "MEIER E P"/AU OR "MEIER E V"/AU OR "MEIER EDDI"/AU OR "MEIER EDDIE"/AU)
L15 7 SEA FILE=HCAPLUS ABB=ON PLU=ON "KJOLBYE ANNE LOUISE"/AU
L16 31 SEA FILE=HCAPLUS ABB=ON PLU=ON ("JORGENSEN N"/AU OR "JORGENSE N N R"/AU OR "JORGENSEN N RYE"/AU OR "JORGENSEN NIKLAS R"/AU OR "JORGENSEN NIKLAS RYE"/AU)
L17 495 SEA FILE=HCAPLUS ABB=ON PLU=ON ("NIELSEN M"/AU OR "NIELSEN M S"/AU OR "NIELSEN M S WEBER"/AU OR "NIELSEN MORTEN"/AU OR "NIELSEN MORTEN S"/AU OR "NIELSEN MORTEN SCHAK"/AU)
L18 138 SEA FILE=HCAPLUS ABB=ON PLU=ON ("MARTINS J"/AU OR "MARTINS J B"/AU OR "MARTINS J B L"/AU OR "MARTINS JAMES"/AU OR "MARTINS JAMES B"/AU)
L19 76 SEA FILE=HCAPLUS ABB=ON PLU=ON ("HOLSTEIN R"/AU OR "HOLSTEIN RATHLOU N H"/AU OR "HOLSTEIN RATHLOU N H N H"/AU OR "HOLSTEIN RATHLOU NIELS H"/AU OR "HOLSTEIN RATHLOU NIELS HENRIK"/AU)
L20 2 SEA FILE=HCAPLUS ABB=ON PLU=ON L12 AND L13 AND L14 AND L15 AND L16 AND L17 AND L18 AND L19
L21 13 SEA FILE=HCAPLUS ABB=ON PLU=ON L12 AND (L13 OR L14 OR L15 OR L16 OR L17 OR L18 OR L19)
L22 15 SEA FILE=HCAPLUS ABB=ON PLU=ON L13 AND (L14 OR L15 OR L16 OR L17 OR L18 OR L19)
L23 4 SEA FILE=HCAPLUS ABB=ON PLU=ON L14 AND (L15 OR L16 OR L17 OR L18 OR L19)
L24 5 SEA FILE=HCAPLUS ABB=ON PLU=ON L15 AND (L16 OR L17 OR L18 OR L19)
L25 2 SEA FILE=HCAPLUS ABB=ON PLU=ON L16 AND (L17 OR L18 OR L19)
L26 3 SEA FILE=HCAPLUS ABB=ON PLU=ON L17 AND (L18 OR L19)

```
L27             2 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L18 AND L19
L28            21 SEA FILE=HCAPLUS ABB=ON  PLU=ON  (L20 OR L21 OR L22 OR L23 OR
                  L24 OR L25 OR L26 OR L27)
L29             4 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L28 AND (AY<2001 OR PY<2001
                  OR PRY<2001)


=> d que l44
L30          2579 SEA LARSEN B?/AU
L31          5774 SEA PETERSEN J?/AU
L32          1629 SEA MEIER E?/AU
L33            42 SEA KJOLBYE A?/AU
L34           977 SEA JORGENSEN N?/AU
L35          5171 SEA NIELSEN M?/AU
L36          2182 SEA MARTINS J?/AU
L37           595 SEA HOLSTEIN R?/AU
L38             2 SEA L30 AND L31 AND L32 AND L33 AND L34 AND L35 AND L36 AND
                  L37
L40             2 SEA (L30 OR L31 OR L32 OR L33 OR L34 OR L35 OR L36 OR L37) AND
                  (ANTIARRYTHMIC?)
L41             4 SEA (L38 OR L40)
L42           856 SEA (L30 OR L31 OR L32 OR L33 OR L34 OR L35 OR L36 OR L37) AND
                  (PEPTIDE?)
L43             1 SEA L42 AND (ARRYTHM?)
L44             4 SEA (L43 OR L41)


=> d que 195
L2             42 SEA FILE=REGISTRY ABB=ON  PLU=ON  [G'SAR']A[G'SAR']['HYP'P]['HY
                  P'P]YN/SQSFP
L3             36 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L2
L4             14 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L3 AND (AY<2001 OR PY<2001 OR
                  PRY<2001)
L10           107 SEA FILE=REGISTRY ABB=ON  PLU=ON  (159503-65-8/BI OR 355151-11-
                  0/BI OR 355151-12-1/BI OR 355151-13-2/BI OR 355151-14-3/BI OR
                  355151-15-4/BI OR 355151-16-5/BI OR 355151-17-6/BI OR 355151-18
                  -7/BI OR 355151-19-8/BI OR 355151-20-1/BI OR 355151-23-4/BI OR
                  355151-25-6/BI OR 355151-26-7/BI OR 355151-27-8/BI OR 355151-29
                  -0/BI OR 355151-30-3/BI OR 355151-31-4/BI OR 355151-32-5/BI OR
                  355151-33-6/BI OR 355151-34-7/BI OR 355151-35-8/BI OR 355151-36
                  -9/BI OR 355151-37-0/BI OR 355151-38-1/BI OR 355151-39-2/BI OR
                  355151-40-5/BI OR 355151-41-6/BI OR 355151-43-8/BI OR 355151-45
                  -0/BI OR 355151-46-1/BI OR 355151-47-2/BI OR 355151-49-4/BI OR
                  355151-50-7/BI OR 355151-51-8/BI OR 355151-52-9/BI OR 355151-53
                  -0/BI OR 355151-54-1/BI OR 355151-55-2/BI OR 355151-56-3/BI OR
                  355151-74-5/BI OR 81771-37-1/BI OR 111915-92-5/BI OR 133294-37-
                  8/BI OR 212570-15-5/BI OR 355151-21-2/BI OR 355151-22-3/BI OR
                  355151-24-5/BI OR 355151-28-9/BI OR 355151-42-7/BI OR 355151-44
                  -9/BI OR 355151-48-3/BI OR 355151-57-4/BI OR 355151-58-5/BI OR
                  355151-59-6/BI OR 355151-60-9/BI OR 355151-61-0/BI OR 355151-62
                  -1/BI OR 355151-63-2/BI OR 355151-64-3/BI OR 355151-65-4/BI OR
                  355151-66-5/BI OR 355151-67-6/BI OR 355151-68-7/BI OR 355151-69
                  -8/BI OR 355151-70-1/BI OR 355151-71-2/BI OR 355151-72-3/BI OR
                  355151-73-4/BI OR 355151-75-6/BI OR 355151-76-7/BI OR 35919-99-
                  4/BI OR 366800-53-5/BI OR 463362-31-4/BI OR 463362-32-5/BI OR
                  463362-33-6/BI OR 463362-34-7/BI OR 463362-35-8/BI OR 463362-36
                  -9/BI OR 463362-37-0/BI OR 463362-38-1/BI OR 463362-40-5/BI OR
                  463362-42-7/BI OR 463362-43-8/BI OR 463362-44-9/BI OR 463362-45
                  -0/BI OR 463362-46-1/BI OR 463362-47-2/BI OR 463362-48-3/BI OR
                  463362-49-4/BI OR 463362-50-7/BI OR 463362-51-8/BI OR 463362-52
```

-9/BI OR 463362-53-0/BI OR 463362-54-1/BI OR 463362-55-2/BI OR 463362-56-3/BI OR 463362-57-4/BI OR 463362-58-5/BI OR 463362-59-6/BI OR 463944-96-9/BI OR 476-70-0/BI OR 50-99-7/BI OR 501-36-0/BI OR 57381-26-7/BI OR 602-07-3/BI OR 7782-44-7/BI)

L12 177 SEA FILE=HCAPLUS ABB=ON PLU=ON ("LARSEN B"/AU OR "LARSEN B DUE"/AU OR "LARSEN BJARNE"/AU OR "LARSEN BJARNE D"/AU OR "LARSEN BJARNE DUE"/AU)

L13 262 SEA FILE=HCAPLUS ABB=ON PLU=ON ("PETERSEN J"/AU OR "PETERSEN J S"/AU OR "PETERSEN JOERGEN"/AU OR "PETERSEN JOERGEN S"/AU OR "PETERSEN JOERGEN SOEBERG"/AU OR "PETERSEN JORGEN"/AU OR "PETERSEN JORGEN S"/AU OR "PETERSEN JORGEN SOBERG"/AU OR "PETERSEN JORGEN SOEBERG"/AU)

L14 118 SEA FILE=HCAPLUS ABB=ON PLU=ON ("MEIER E"/AU OR "MEIER E A"/AU OR "MEIER E F"/AU OR "MEIER E G"/AU OR "MEIER E J J"/AU OR "MEIER E M M"/AU OR "MEIER E P"/AU OR "MEIER E V"/AU OR "MEIER EDDI"/AU OR "MEIER EDDIE"/AU)

L15 7 SEA FILE=HCAPLUS ABB=ON PLU=ON "KJOLBYE ANNE LOUISE"/AU

L16 31 SEA FILE=HCAPLUS ABB=ON PLU=ON ("JORGENSEN N"/AU OR "JORGENSE N N R"/AU OR "JORGENSEN N RYE"/AU OR "JORGENSEN NIKLAS R"/AU OR "JORGENSEN NIKLAS RYE"/AU)

L17 495 SEA FILE=HCAPLUS ABB=ON PLU=ON ("NIELSEN M"/AU OR "NIELSEN M S"/AU OR "NIELSEN M S WEBER"/AU OR "NIELSEN MORTEN"/AU OR "NIELSEN MORTEN S"/AU OR "NIELSEN MORTEN SCHAK"/AU)

L18 138 SEA FILE=HCAPLUS ABB=ON PLU=ON ("MARTINS J"/AU OR "MARTINS J B"/AU OR "MARTINS J B L"/AU OR "MARTINS JAMES"/AU OR "MARTINS JAMES B"/AU)

L19 76 SEA FILE=HCAPLUS ABB=ON PLU=ON ("HOLSTEIN R"/AU OR "HOLSTEIN RATHLOU N H"/AU OR "HOLSTEIN RATHLOU N H N H"/AU OR "HOLSTEIN RATHLOU NIELS H"/AU OR "HOLSTEIN RATHLOU NIELS HENRIK"/AU)

L20 2 SEA FILE=HCAPLUS ABB=ON PLU=ON L12 AND L13 AND L14 AND L15 AND L16 AND L17 AND L18 AND L19

L21 13 SEA FILE=HCAPLUS ABB=ON PLU=ON L12 AND (L13 OR L14 OR L15 OR L16 OR L17 OR L18 OR L19)

L22 15 SEA FILE=HCAPLUS ABB=ON PLU=ON L13 AND (L14 OR L15 OR L16 OR L17 OR L18 OR L19)

L23 4 SEA FILE=HCAPLUS ABB=ON PLU=ON L14 AND (L15 OR L16 OR L17 OR L18 OR L19)

L24 5 SEA FILE=HCAPLUS ABB=ON PLU=ON L15 AND (L16 OR L17 OR L18 OR L19)

L25 2 SEA FILE=HCAPLUS ABB=ON PLU=ON L16 AND (L17 OR L18 OR L19)

L26 3 SEA FILE=HCAPLUS ABB=ON PLU=ON L17 AND (L18 OR L19)

L27 2 SEA FILE=HCAPLUS ABB=ON PLU=ON L18 AND L19

L28 21 SEA FILE=HCAPLUS ABB=ON PLU=ON (L20 OR L21 OR L22 OR L23 OR L24 OR L25 OR L26 OR L27)

L29 4 SEA FILE=HCAPLUS ABB=ON PLU=ON L28 AND (AY<2001 OR PY<2001 OR PRY<2001)

L83 106 SEA FILE=REGISTRY ABB=ON PLU=ON L10 NOT O2/MF

L85 104 SEA FILE=REGISTRY ABB=ON PLU=ON L83 NOT C14H12O3/MF

L86 103 SEA FILE=REGISTRY ABB=ON PLU=ON L85 NOT C19H21NO4/MF

L87 103 SEA FILE=REGISTRY ABB=ON PLU=ON L86 NOT C9H7C12N5/MF

L88 102 SEA FILE=REGISTRY ABB=ON PLU=ON L87 NOT C20H19NO6

L89 101 SEA FILE=REGISTRY ABB=ON PLU=ON L88 NOT C6H12O6/MF

L91 66 SEA FILE=HCAPLUS ABB=ON PLU=ON L89 (L)(THU OR BAC OR PAC OR DMA OR PKT)/RL

L92 26 SEA FILE=HCAPLUS ABB=ON PLU=ON L91 AND (AY<2001 OR PY<2001 OR PRY<2001)

L93 20 SEA FILE=HCAPLUS ABB=ON PLU=ON L91 AND (ALA OR ALANIN? OR GLY OR GLYCINE OR GLU OR GLUTAMIC? OR ASP OR ASPARTIC? OR DAB OR DIAMINOBUT? OR DAPA OR LYS OR LYSINE OR ASP OR ASPARAGINE OR GLN OR GLUTAMINE OR ORN OR ORNITHINE OR CYS OR CYSTEINE)

```
L94          35 SEA FILE=HCAPLUS ABB=ON  PLU=ON  (L92 OR L93)
L95          33 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L94 NOT (L4 OR L29)


=> dup rem l29,l44,l95
PROCESSING COMPLETED FOR L29
PROCESSING COMPLETED FOR L44
PROCESSING COMPLETED FOR L95
L98          37 DUP REM L29 L44 L95 (4 DUPLICATES REMOVED)
                ANSWERS '1-37' FROM FILE HCAPLUS

=> d ibib abs hitind hitstr retable l98 tot

L98  ANSWER 1 OF 37  HCAPLUS  COPYRIGHT 2007 ACS on STN DUPLICATE 1
ACCESSION NUMBER:         2002:754415  HCAPLUS  Full-text
DOCUMENT NUMBER:          137:263304
TITLE:                    Synthesis of peptides and medical uses of
                          intracellular communication facilitating compounds
INVENTOR(S):              Larsen, Bjarne Due; Petersen, Jorgen
                          Soberg; Meier, Eddie; Kjolbye,
                          Anne Louise; Jorgensen, Niklas Rye;
                          Nielsen, Morten Schak; Holstein-Rathlou,
                          Niels-Henrik; Martins, James B.
PATENT ASSIGNEE(S):        Zealand Pharmaceuticals A/S, Den.
SOURCE:                   PCT Int. Appl., 233 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   2
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.          DATE
     ---------------      ----   --------    --------------------     --------
     WO 2002077017         A2    20021003    WO 2002-US5773           20020222
     WO 2002077017         A3    20031009
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
             UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB,
             GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA,
             GN, GQ, GW, ML, MR, NE, SN, TD, TG
     WO 2001062775         A2    20010830    WO 2001-DK127            20010222 <--
     WO 2001062775         A3    20020131
         W:  AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,
             CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,
             IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,
             MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,
             SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
             DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     US 2003092609         A1    20030515    US 2001-792286           20010222 <--
     CA 2439101            A1    20021003    CA 2002-2439101          20020222
     EP 1370276            A2    20031217    EP 2002-723240           20020222
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
```

JP 2005506295	T	20050303	JP 2002-576275		20020222
BR 2002007476	A	20060124	BR 2002-7476		20020222
NO 2003003641	A	20031020	NO 2003-3641		20030815
US 2005113293	A1	20050526	US 2003-646294		20030822 <--
IN 2003DN01336	A	20050527	IN 2003-DN1336		20030822
US 2005075280	A1	20050407	US 2004-772774		20040204 <--
PRIORITY APPLN. INFO.:			US 2001-792286	A	20010222
			WO 2001-DK127	A	20010222
			US 2001-314470P	P	20010823
			DK 2000-288	A	20000223 <--
			DK 2000-738	A	20000504 <--
			US 2000-251659P	P	20001206 <--
			WO 2002-US5773	W	20020222

OTHER SOURCE(S): MARPAT 137:263304

AB The invention relates to novel peptides, including novel antiarrhythmic peptides of linear or cyclic structure, having improved stability in vitro and/or in vivo, to compns. comprising these peptides, and to uses of the peptides for the preparation of medicaments. The invention also relates to the use of compds. that facilitate the intercellular communication for the preparation of medicaments for the treatment of a range of diseases characterized in impaired intercellular gap junctional communication. The invention further relates to a method of treating diseases, such as bladder incontinence, disorders of alveolar tissue and bronchial tissue, impaired hearing due to diseases of the cochlea, endothelial lesions, diabetic retinopathy and diabetic neuropathy, ischemia of the central nervous system and spinal cord, dental tissue disorders including periodontal disease, kidney diseases leading to hypertension, and a method of preventing failures of bone marrow transplantation. Ac-D-Tyr-D-Pro-D-4Hyp-Gly-D-Ala-Gly-NH2 (Hyp = hydroxyprolyl) was prepared by the solid-phase method and assayed for biol. activity. Graphs include those for relative cell-to-cell conductance, PI-turnover in neonatal rat cardiomyocytes, and ventricular APD90 dispersion.

IC ICM C07K007-00

CC 34-3 (Amino Acids, Peptides, and Proteins)
Section cross-reference(s): 1, 6, 63

L98 ANSWER 2 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 2

ACCESSION NUMBER: 2001:636085 HCAPLUS Full-text

DOCUMENT NUMBER: 135:180957

TITLE: Preparation of novel antiarrhythmic peptides

INVENTOR(S): *Larsen, Bjarne Due; Petersen, Jorgen Soberg; Meier, Eddi; Kjolbye, Anne Louise; Jorgensen, Niklas Rye; Nielsen, Morten Schak; Holstein-Rathlou, Niels-Henrik; Martins, James B.*

PATENT ASSIGNEE(S): Zealand Pharmaceuticals A/S, Den.

SOURCE: PCT Int. Appl., 189 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001062775	A2	20010830	WO 2001-DK127	20010222 <--
WO 2001062775	A3	20020131		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,

SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2385659	A1	20010830	CA 2001-2385659	20010222	<--
EP 1226160	A2	20020731	EP 2001-907393	20010222	<--
EP 1226160	B1	20041215			

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

JP 2003528826	T	20030930	JP 2001-562556	20010222	<--
AT 284896	T	20050115	AT 2001-907393	20010222	<--
ES 2228807	T3	20050416	ES 2001-1907393	20010222	<--
PT 1226160	T	20050429	PT 2001-907393	20010222	<--
AU 781674	B2	20050602	AU 2001-35362	20010222	<--
CA 2439101	A1	20021003	CA 2002-2439101	20020222	
WO 2002077017	A2	20021003	WO 2002-US5773	20020222	
WO 2002077017	A3	20031009			

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1370276	A2	20031217	EP 2002-723240	20020222	

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

JP 2005506295	T	20050303	JP 2002-576275	20020222	
BR 2002007476	A	20060124	BR 2002-7476	20020222	
NO 2003003641	A	20031020	NO 2003-3641	20030815	
US 2005113293	A1	20050526	US 2003-646294	20030822	<--
US 2005075280	A1	20050407	US 2004-772774	20040204	<--
AU 2005205785	A1	20050929	AU 2005-205785	20050902	<--

PRIORITY APPLN. INFO.:	DK 2000-288	A	20000223	<--
	DK 2000-738	A	20000504	<--
	US 2000-251659P	P	20001206	<--
	US 2001-792286	A	20010222	
	WO 2001-DK127	W	20010222	
	US 2001-314470P	P	20010823	
	WO 2002-US5773	W	20020222	

OTHER SOURCE(S): MARPAT 135:180957

AB Peptides X-A-B-Y and cyclo(X-A-B-Y) [A and B represents chemical moieties having an amino group (radical) and a carboxy group; X represents a peptide sequence of 1 to 3 D- or L-amino acid residues or an N-terminal modification of the group A-B when Y represents a C-terminal peptide sequence of 2 to 5 D- or L-amino acid residues; X represents a peptide sequence of 2 to 5 D- or L-amino acid residues when Y represents a C-terminal peptide sequence of 1 to 3 D- or L-amino acid residues; for the linear peptide, X is optionally chemical modified at its N-terminal and has an optional linking group comprising 0-8 backbone atoms] and their mirror image or a retro analogs or pharmaceutically acceptable derivs. were prepared for treating cardiac arrhythmias. Thus, Ac-D-Tyr-D-pro-D-4Hyp-Gly- D-Ala-Gly-NH2 (4Hyp = 4-hydroxyprolyl) was prepared by the solid-phase method using TentaGel-S-Ram and examined for biol. activity [assays included effect on gap junction intercellular communication (GJIC) in cardiomyocytes, binding to tissue prepns. of murine heart, and effect on cAMP formation in CHO cells].

IC ICM C07K007-00

CC 34-3 (Amino Acids, Peptides, and Proteins)
Section cross-reference(s): 1, 63

L98 ANSWER 3 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:100738 HCAPLUS Full-text
DOCUMENT NUMBER: 144:198849
TITLE: Novel dosage form comprising modified-release and immediate-release active ingredients
INVENTOR(S): Vaya, Navin; Karan, Rajesh Singh; Sadanand, Sunil; Gupta, Vinod Kumar
PATENT ASSIGNEE(S): India
SOURCE: U.S. Pat. Appl. Publ., 49 pp., Cont.-in-part of U.S. Ser. No. 630,446.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006024365	A1	20060202	US 2005-134633	20050519
IN 193042	A1	20040626	IN 2002-MU697	20020805
IN 2003MU00080	A	20050204	IN 2003-MU80	20030122
IN 2003MU00082	A	20050204	IN 2003-MU82	20030122
US 2004096499	A1	20040520	US 2003-630446	20030729

PRIORITY APPLN. INFO.:

IN 2002-MU697	A	20020805
IN 2002-MU699	A	20020805
IN 2003-MU80	A	20030122
IN 2003-MU82	A	20030122
US 2003-630446	A2	20030729

AB A dosage form comprising of a high dose, high solubility active ingredient as modified release and a low dose active ingredient as immediate release where the weight ratio of immediate release active ingredient and modified release active ingredient is from 1:10 to 1:15000 and the weight of modified release active ingredient per unit is from 500 mg to 1500 mg; a process for preparing the dosage form. Tablets containing 10 mg sodium pravastatin and 1000 mg niacin were prepared The release of sodium pravastatin after 24 h was 67.7%, and the release of niacin after 1 h was 84.1%.

INCL 424468000
CC 63-6 (Pharmaceuticals)
IT 50-02-2, Dexamethasone 50-04-4, Cortisone acetate 50-06-6, Phenobarbital, biological studies 50-12-4, Mephenytoin 50-13-5, Meperidine hydrochloride 50-18-0, Cyclophosphamide 50-19-1, Hydroxyphenamate 50-23-7, Hydrocortisone 50-24-8, Prednisolone 50-27-1, Estriol 50-28-2, Estra-1,3,5(10)-triene-3,17-diol (17β)-, biological studies 50-33-9, Phenylbutazone, biological studies 50-34-0, Propantheline bromide 50-35-1, Thalidomide 50-36-2, Cocaine 50-52-2, Thioridazine 50-53-3, Chlorpromazine, biological studies 50-55-5, Reserpine 50-56-6, Oxytocin, biological studies 50-57-7, Lypressin 50-58-8, Phendimetrazine tartrate 50-59-9, Cephaloridine 50-65-7, Niclosamide 50-76-0, Dactinomycin 50-78-2, Aspirin 50-91-9, Floxuridine 51-05-8, Procaine hydrochloride 51-15-0, Pralidoxime chloride 51-21-8, Fluorouracil 51-30-9, Isoproterenol hydrochloride 51-40-1, Norepinephrine bitartrate 51-43-4, Epinephrine 51-52-5, Propylthiouracil 51-55-8, Atropine, biological studies 51-56-9, Homatropine hydrobromide 51-57-0, Methamphetamine hydrochloride 51-64-9, Dextroamphetamine 51-83-2, Carbachol 52-01-7, Spironolactone 52-24-4, Thiotepa 52-49-3, Trihexyphenidyl hydrochloride 52-68-6, Metrifonate 52-76-6, Lynestrenol 52-86-8, Haloperidol 52-88-0,

Methylatropine nitrate 52-89-1, *Cysteine* hydrochloride 53-03-2, Prednisone 53-16-7D, Estrone, esters 53-19-0, Mitotane 53-34-9, Fluprednisolone 53-39-4, Oxandrolone 53-43-0, Dehydroepiandrosterone 53-60-1, Promazine hydrochloride 53-73-6, Angiotensin amide 53-79-2, Puromycin 53-84-9, Nadide 53-86-1, Indometacin 54-03-5, Hexobendine 54-05-7, Chloroquine 54-21-7, Sodium salicylate 54-31-9, Furosemide 54-35-3, Penicillingprocaine 54-36-4, Metyrapone 54-42-2, Idoxuridine 54-64-8, Thimerosal 54-84-2, Cinanserin hydrochloride 54-85-3, Isoniazid 54-91-1, Pipobroman 55-03-8, Levothyroxine sodium 55-06-1, Liothyronine sodium 55-63-0, Nitroglycerin 55-86-7, Mechlorethamine hydrochloride 55-91-4, Isoflurophate 55-98-1, Busulfan 56-45-1, Serine, biological studies 56-47-3, Desoxycorticosterone acetate 56-53-1, Diethylstilbestrol 56-59-7, Felypressin 56-75-7, Chloramphenicol 56-84-8, *Aspartic* acid, biological studies 56-87-1, *Lysine*, biological studies 56-89-3, Cystine, biological studies 56-94-0, Demecarium bromide 57-13-6, Urea, biological studies 57-41-0, Phenytoin 57-47-6, Physostigmine 57-53-4, Meprobamate 57-63-6, Ethinyl estradiol 57-65-8, Thyromedan hydrochloride 57-66-9, Probenecid 57-68-1, Sulfamethazine 57-83-0, Progesterone, biological studies 57-91-0, 17-α Estradiol 57-94-3, Tubocurarine chloride 57-96-5, Sulfinpyrazone 58-08-2, Caffeine, biological studies 58-14-0, Pyrimethamine 58-18-4, Methyltestosterone 58-22-0, Testosterone 58-25-3, Chlordiazepoxide 58-28-6, Desipramine hydrochloride 58-32-2, Dipyridamole 58-33-3, Promethazine hydrochloride 58-38-8, Prochlorperazine 58-39-9, Perphenazine 58-54-8, Ethacrynic acid 58-55-9, Theophylline, biological studies 58-71-9, Cephalothin sodium 58-86-6, Xylose, biological studies 58-93-5, Hydrochlorothiazide 58-94-6, Chlorothiazide 59-05-2, Methotrexate 59-30-3, Folic acid, biological studies 59-33-6, Pyrilamine maleate 59-52-9, Dimercaprol 59-63-2, Isocarboxazid 59-67-6, Niacin, biological studies 59-87-0, Nitrofurazone 59-92-7, Levodopa, biological studies 59-97-2, Tolazoline hydrochloride 60-13-9, Amphetamine sulfate 60-18-4, Tyrosine, biological studies 60-23-1, Cysteamine 60-29-7, Ether, biological studies 60-45-7, Fenimide 60-54-8, Tetracycline 60-56-0, Methimazole 60-80-0, Antipyrine 60-99-1, Methotrimeprazine 61-25-6, Papaverine hydrochloride 61-56-3, Sulthiame 61-57-4, Niridazole 61-68-7, Mefenamic acid 61-73-4, Methylene blue 61-75-6, Bretylium tosylate 61-76-7, Phenylephrine hydrochloride 61-90-5, Leucine, biological studies 62-51-1, Methacholine chloride 62-68-0, Proadifen hydrochloride 62-73-7, Dichlorvos 62-90-8, Nandrolone phenpropionate 63-05-8, Androstenedione 63-12-7, Benzquinamide 63-39-8, Uridine triphosphate 63-45-6, Primaquine phosphate 63-68-3, Methionine, biological studies 63-89-8, Colfosceril palmitate 63-91-2, Phenylalanine, biological studies 63-92-3, Phenoxybenzamine hydrochloride 63-98-9, Phenacemide 64-31-3, Morphine sulfate 64-43-7, Amobarbital sodium 64-55-1, Mebutamate 64-77-7, Tolbutamide 64-86-8, Colchicine 65-28-1, Phentolamine mesylate 65-29-2, Gallamine triethiodide 65-45-2, Salicylamide 66-75-1, Uracil mustard 66-76-2, Dicumarol 66-81-9, Cycloheximide 67-20-9, Nitrofurantoin 67-43-6, Pentetic acid 67-45-8, Furazolidone 67-63-0, Isopropyl alcohol, biological studies 67-68-5, Dimethyl sulfoxide, biological studies 67-73-2, Fluocinolone acetonide 67-92-5, Dicyclomine hydrochloride 67-95-8, Quingestrone 67-96-9, Dihydrotachysterol 68-22-4, Norethindrone 68-23-5, Norethynodrel 68-35-9, Sulfadiazine 68-41-7, Cycloserine 68-89-3, Dipyrone 68-91-7, Trimethaphan camsylate 68-96-2, 17 Hydroxy progesterone 69-44-3, Amodiaquine hydrochloride 69-53-4, Ampicillin 69-57-8, Penicillingsodium 69-65-8, Mannitol 69-72-7, Salicylic acid, biological studies 69-74-9, Cytarabine hydrochloride 70-00-8, Trifluridine 70-10-0, Ticlatone 70-30-4,

Hexachlorophene 71-00-1, Histidine, biological studies 71-27-2, Succinylcholine chloride 71-58-9, Medroxyprogesterone acetate 71-63-6, Digitoxin 71-68-1, Hydromorphone hydrochloride 71-73-8, Thiopental sodium 71-81-8, Isopropamide iodide 72-18-4, Valine, biological studies 72-19-5, Threonine, biological studies 72-33-3, Mestranol 72-44-6, Methaqualone 73-09-6, Etozolin 73-22-3, Tryptophan, biological studies 73-31-4, Melatonin 73-32-5, Isoleucine, biological studies 73-48-3, Bendroflumethiazide 74-79-3, Arginine, biological studies 75-00-3, Ethyl chloride 75-19-4, Cyclopropane 76-38-0, Methoxyflurane 76-42-6, Oxycodone 76-43-7, Fluoxymesterone 76-57-3, Codeine 76-73-3, Secobarbital 76-74-4, Pentobarbital 76-90-4, Mepenzolate bromide 77-21-4, Glutethimide 77-26-9, Butalbital 77-27-0, Thiamylal 77-36-1, Chlorthalidone 77-41-8, Methsuximide 77-46-3, Acedapsone 77-67-8, Ethosuximide 77-86-1, Trometamol 78-11-5, Pentaerythritol tetranitrate 78-44-4, Carisoprodol 79-09-4, Propionic acid, biological studies 79-17-4, Pimagedine 79-57-2, Oxytetracycline 79-64-1, Dimethisterone 80-08-0, Dapsone 80-50-2, Anisotropine methylbromide 81-04-9, 1,5-Naphthalenedisulfonic acid 81-13-0, Dexpanthenol 81-23-2, Dehydrocholic acid 81-54-9, Purpurin 82-92-8, Cyclizine 83-43-2, Methylprednisolone 83-73-8, Iodoquinol 83-74-9, Ibogaine 84-17-3, Dienestrol
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(novel dosage form comprising modified-release and immediate-release active ingredients)

IT 55268-75-2, Cefuroxime 55294-15-0, Muzolimine 55298-68-5, Neomycin palmitate 55453-87-7, Isoxepac 55560-96-8, Tixocortol pivalate 55694-87-6, Pentizidone sodium 55695-56-2, Cloroperone hydrochloride 55721-11-4, Secalciferol 55774-33-9, Azathioprine sodium 55779-18-5, Arprinocid 55837-27-9, Piretanide 55837-29-1, Tiropramide 55870-64-9, Pentisomicin 55881-07-7, Miokamycin 55905-53-8, Clebopride 55981-09-4, Nitazoxanide 56030-54-7, Sufentanil 56049-88-8, Indacrinone 56079-80-2, Ropitoin hydrochloride 56093-45-9, Selenium sulfide 56119-96-1, Furodazole 56187-89-4, Ximoprofen 56208-01-6, Pifarnine 56211-40-6, Torasemide 56219-57-9, Arildone 56281-36-8, Motretinide 56290-94-9, Medroxalol 56383-05-2, Zindotrine 56391-55-0, Octazamide 56391-57-2, Netilmicin sulfate 56420-45-2, Epirubicin 56430-99-0, Flumecinol 56470-64-5, Anordrin 56605-16-4D, Spiromustine, di-Ph derivs. 56611-65-5, Oxagrelate 56689-42-0, Repromicin 56689-44-2, Nitramisole hydrochloride 56717-18-1, Isotiquimide 56741-95-8, Bropirimine 56784-39-5, Ozolinone 56796-20-4, Cefmetazole 56917-29-4, Fluretofen 56980-93-9, Celiprolol 56995-20-1, Flupirtine 57010-32-9, Tiapamil hydrochloride 57041-67-5, Desflurane 57067-46-6, Isamoxole 57109-90-7, Clorazepate dipotassium 57149-07-2, Naftopidil 57166-13-9, Napactadine hydrochloride 57248-88-1, Pamidronate disodium 57262-94-9, Setiptiline 57285-09-3, Folliculostatin *57381-26-7*, Irsogladine 57432-61-8, Methylergonovine maleate 57441-90-4, Nivimedone sodium 57540-79-1, Nisbuterol mesylate 57645-05-3, Sermetacin 57653-26-6, Fenobam 57666-60-1, Nitrafudam hydrochloride 57726-65-5, Nufenoxole 57773-63-4, Triptorelin 57773-65-6, Deslorelin 57775-22-1, Etoperidone hydrochloride 57781-15-4, Halopredone 57801-81-7, Brotizolam 57808-65-8, Closantel 57982-78-2, Budipine 57998-68-2, Diaziquone 58019-50-4, Menabitan hydrochloride 58019-65-1, Nabazenil 58066-85-6, Miltefosine 58152-03-7, Isepamicin 58167-78-5, Tandamine hydrochloride 58239-89-7, Moxazocine 58261-91-9, Mefenidil 58473-74-8, Cinromide 58493-49-5, Olvanil 58497-00-0, Procinonide 58503-79-0, Meobentine sulfate 58524-83-7, Ciprocinonide 58525-82-9, Azatyrosine 58581-89-8, Azelastine 58712-69-9, Traxanox 58795-03-2, Apalcillin sodium 58934-46-6, Lorcainide hydrochloride 58944-73-3, Sinefungin 58957-92-9, Idarubicin 58970-76-6, Ubenimex 59017-64-0, Ioxaglic acid

59018-13-2, Ioxaglate meglumine 59070-06-3, Ticarcillin cresyl sodium 59122-46-2, Misoprostol 59160-29-1, Lidofenin 59170-23-9, Bevantolol 59179-95-2, Lorzafone 59227-89-3, Laurocapram 59263-76-2, Meptazinol hydrochloride 59333-90-3, Exaprolol hydrochloride 59467-96-8, Midazolam hydrochloride 59497-39-1, Naflocort 59653-73-5, Teroxirone 59703-84-3, Piperacillin sodium 59729-33-8, Citalopram 59733-86-7, Butikacin 59756-39-7, Enolicam sodium 59794-18-2, Paulomycin 59803-98-4, Brimonidine 59804-37-4, Tenoxicam 59831-63-9, Doconazole 59831-64-0, Milenperone 59831-65-1, Halopemide 59917-39-4, Vindesine sulfate 59937-28-9, Malotilate 59954-01-7, Pamatolol sulfate 60019-19-4, Iotetric acid 60050-95-5, Sulfoxamine 60084-10-8, Tiazofurin 60086-22-8, Clopipazan mesylate 60135-22-0, Flumoxonide 60142-96-3, Gabapentin 60166-93-0, Iopamidol 60200-06-8, Clorsulon 60207-31-0, Azaconazole 60209-20-3, Lycetamine 60282-87-3, Gestodene 60325-46-4, Sulprostone 60398-23-4, Iodoamiloride 60400-92-2, Proxicromil 60525-15-7, Zimelidine hydrochloride 60560-33-0, Pinacidil 60569-19-9, Propiverine 60607-34-3, Oxatomide 60607-35-4, Topterone 60628-96-8, Bifonazole 60653-25-0, Orpanoxin 60719-84-8, Amrinone 60719-85-9, Ciprefadol succinate 60762-57-4, Pirlindole 60857-08-1, Prostratin 60925-61-3, Ceforanide 60940-34-3, Ebselen 60976-05-8 61036-62-2, Teicoplanin 61177-45-5, Clavulanate potassium 61220-69-7, Tiopinac 61260-05-7, Prenalterol hydrochloride 61263-35-2, Meteneprost 61270-78-8, Cefonicid sodium 61318-91-0, Sulconazole nitrate 61325-80-2, Flumezapine 61379-65-5, Rifapentine 61380-27-6, Carfentanil citrate 61380-41-4, Lofentanil oxalate 61413-54-5, Rolipram 61444-62-0, Nifluridide 61477-94-9, Pirmenol hydrochloride 61481-30-9, Dicranin 61484-39-7, Pareptide sulfate 61489-71-2, Menotropin 61570-90-9, Tioxidazole 61622-34-2, Cefotiam 61825-94-3, Oxaliplatin 61849-14-7, Epoprostenol sodium 61869-08-7, Paroxetine 62013-04-1, Dirithromycin 62087-72-3, Pentigetide 62134-34-3, Butoprozine hydrochloride 62220-58-0, Bipenamol hydrochloride 62265-68-3, Quinfamide 62304-98-7, Thymalfasin 62435-42-1, Perfosfamide 62488-57-7 62571-86-2, Captopril 62571-87-3, Minaxolone 62587-73-9, Cefsulodin 62613-82-5, Oxiracetam 62625-19-8, Pirogliride tartrate 62658-63-3, Bopindolol 62666-20-0, Progabide 62732-44-9, Ipidacrine 62816-98-2, Ormaplatin 62851-43-8, Zidometacin 62893-20-3, Cefoperazone sodium 62928-11-4, Iproplatin 62929-91-3, Procaterol hydrochloride 62973-76-6, Azanidazole 62973-77-7, Parconazole hydrochloride 62989-33-7, Sapropterin 62996-74-1, Staurosporine 63119-27-7, Anitrazafen 63198-97-0, Viroxime 63204-23-9, Oxmetidine hydrochloride 63245-28-3, Etifenin 63251-39-8, Sulfinalol hydrochloride 63269-31-8, Ciramadol 63358-49-6, Aspoxicillin 63534-64-5, Iosulamide meglumine 63585-09-1, Foscarnet sodium 63590-19-2, Balanol 63590-64-7, Terazosin 63612-50-0, Nilutamide 63659-18-7, Betaxolol 63659-19-8, Betaxolol hydrochloride 63675-72-9, Nisoldipine 63774-77-6, Somatomedin B 63941-73-1, Ioglucol 63941-74-2, Ioglucomide 63950-06-1, Esorubicin hydrochloride 64019-93-8, Dipivefrin hydrochloride 64059-66-1, Cetaben sodium 64063-83-8, Picotrin diolamine 64092-48-4, Zomepirac sodium 64211-45-6, Oxiconazole 64221-86-9, Imipenem 64228-81-5, Atracurium besylate 64318-79-2, Gemeprost 64379-93-7, Cinflumide 64420-40-2, Etibendazole 64461-82-1, Tizanidine hydrochloride 64485-93-4, Cefotaxime sodium 64706-54-3, Bepridil 64808-48-6, Lobenzarit sodium 64872-77-1, Butoconazole nitrate 64924-67-0, Halofuginone hydrobromide 64953-12-4, Moxalactam disodium 65009-35-0, Lidamidine hydrochloride 65043-22-3, Indeloxazine hydrochloride 65052-63-3, Cefetamet 65057-90-1, Talisomycin 65093-40-5, Cytarabine ocfosfate 65141-46-0, Nicorandil 65222-35-7, Pazelliptine 65271-80-9, Mitoxantrone 65277-42-1, Ketoconazole 65322-72-7, Endralazine mesylate 65454-13-9, Lateritin

RL: *THU (Therapeutic use)*; BIOL (Biological study); USES (Uses)
(novel dosage form comprising modified-release and immediate-release active ingredients)

IT *57381-26-7*, Irsogladine
RL: *THU (Therapeutic use)*; BIOL (Biological study); USES (Uses)
(novel dosage form comprising modified-release and immediate-release active ingredients)

RN 57381-26-7 HCAPLUS

CN 1,3,5-Triazine-2,4-diamine, 6-(2,5-dichlorophenyl)- (9CI) (CA INDEX NAME)



L98 ANSWER 4 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:1036916 HCAPLUS Full-text

DOCUMENT NUMBER: 142:33307

TITLE: Stable analogs of peptide and polypeptide therapeutics

INVENTOR(S): Bachovchin, William W.; Lai, Hung-Sen; Sanford, David George

PATENT ASSIGNEE(S): Trustees of Tufts College, USA

SOURCE: PCT Int. Appl., 83 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004103390	A2	20041202	WO 2004-US15488	20040517
WO 2004103390	A3	20050630		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004240630	A1	20041202	AU 2004-240630	20040517
CA 2525574	A1	20041202	CA 2004-2525574	20040517
US 2005049177	A1	20050303	US 2004-847220	20040517
EP 1633384	A2	20060315	EP 2004-752496	20040517
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
CN 1822851	A	20060823	CN 2004-80019850	20040517

PRIORITY APPLN. INFO.:			
	US 2003-471411P	P	20030515
	WO 2004-US15488	W	20040517

AB The present invention relates to compns. of peptide and polypeptide analogs that are resistant to proteolysis, pharmaceutical uses thereof, and methods of preparation thereof. The peptide and polypeptide analogs are resistant to cleavage by proteinases, i.e., a serine proteinase, metalloproteinase, *aspartic* proteinase, or *cysteine* e proteinase. For example, two substitutions at the P'1 *glutamic* acid of GLP1-(7-37) were made to obtain GLP-1 (3DMA), wherein the P'1 substitution was 3-dimethylaspartate, and GLP-1-(BM), wherein the P'1 substitution was 3-butylmethylglycine. Both GLP-1 (3DMA) and GLP-1-(BM) displayed robust resistance to degradation by the serine protease dipeptidyl peptidase IV (DPP IV) and retained biol. activities of native glucagon-like peptide 1 (GLP-1). They both retained the ability to bind to GLP-1 receptors of COS-7 cells, as well as to potentiate GLP-1 signaling via the GLP-1 receptor to an extent indistinguishable from native GLP-1.

IC ICM A61K038-00

CC 2-10 (Mammalian Hormones)
Section cross-reference(s): 1, 63

IT 50-56-6D, Oxytocin, analogs 58-82-2D, Bradykinin, analogs 581-05-5D, α-Melanotropin (swine), analogs 1393-25-5D, Secretin, analogs 1405-97-6D, Gramicidin, analogs 2002-44-0D, analogs 3397-23-7D, Ornipressin, analogs 9002-60-2D, Adrenocorticotropic hormone, analogs 9002-72-6D, Growth hormone, analogs 9002-76-0D, Gastrin, analogs 9002-79-3D, Melanocyte stimulating hormone, analogs 9004-10-8D, Insulin, analogs 9007-12-9D, Calcitonin, analogs 9007-92-5D, Glucagon, analogs 9011-97-6D, Cholecystokinin, analogs 9014-42-0D, Thrombopoietin, analogs 9015-71-8D, Corticotropin-releasing factor, analogs 9034-39-3D, Growth hormone releasing factor, analogs 9034-40-6D, Gonadotropin-releasing hormone, analogs 9034-50-8D, Vasotocin, analogs 9041-90-1D, Angiotensin I, analogs 11000-17-2D, Vasopressin, analogs 11002-13-4D, Angiotensinogen, analogs 11096-26-7D, Erythropoietin, analogs 11128-99-7D, Angiotensin II, analogs 24305-27-9D, Thyrotropin-releasing hormone, analogs 33507-63-0D, Substance P, analogs 39379-15-2D, Neurotensin, analogs 40077-57-4D, Vasoactive intestinal octacosapeptide (swine), analogs 51110-01-1D, Somatostatin, analogs 52232-67-4D, Human parathyroid hormone (1-34), analogs 52906-92-0D, Motilin, analogs 55123-66-5D, Leupeptin, analogs 58569-55-4D, Met-enkephalin, analogs 58822-25-6D, Leu-enkephalin, analogs 59392-49-3D, GIP, analogs 59763-91-6D, Pancreatic polypeptide, analogs 60118-07-2D, Endorphin, analogs 61912-98-9D, Insulin-like growth factor, analogs 62229-50-9D, Epidermal growth factor, analogs 64190-70-1D, FMRF-amide, analogs 67382-96-1D, Melanin-concentrating hormone, analogs 69431-45-4D, δ-Sleep inducing peptide, analogs 70904-56-2D, Kyotorphin, analogs 74913-18-1D, Dynorphin, analogs 80043-53-4D, Gastrin-releasing peptide, analogs 80448-90-4D, Dynorphin A (swine), analogs 80802-79-5D, Cecropin, analogs 81608-30-2D, Neuromedin C, analogs *81771-37-1D* , Antiarrhythmic peptide, analogs 82785-45-3D, Neuropeptide Y, analogs 83150-76-9D, Octreotide, analogs 83335-41-5D, Dynorphin B (swine), analogs 83652-28-2D, Calcitonin gene-related peptide, analogs 85637-73-6D, Atriopeptin, analogs 86933-74-6D, Neurokinin A, analogs 86933-75-7D, Neurokinin B (swine spinal cord), analogs 87616-84-0D, Growth hormone-releasing peptide 6, analogs 88526-44-7D, Paracelsin, analogs 89105-94-2, Fibrinogen-binding inhibitor peptide 89750-14-1D, GLP 1, analogs 89750-15-2D, Glucagon-like peptide II, analogs 97793-28-7D, Atriopeptin III, analogs 98084-68-5D, Atriopeptin I, analogs 98084-69-6D, Atriopeptin II, analogs 98824-26-1D, Calcitonin gene-related peptide II, analogs 99566-27-5D, Neuropeptide FF (cattle), analogs 102577-25-3D, Neuromedin N, analogs 103131-69-7D, Kinetensin (human), analogs 103220-14-0D, Corticostatin, analogs 103370-86-1D, Parathyroid hormone related peptide, analogs 106021-96-9D, analogs 106388-42-5D, Peptide YY, analogs 106441-70-7D, Neuropeptide K, analogs 111745-44-9D, Neuromedin U, analogs 114471-18-0D, Brain natriuretic

peptide, analogs 115150-59-9D, Antagonist G, analogs 116243-73-3D, Endothelin, analogs 119418-04-1D, Galanin, analogs 122752-15-2D, Deltorphin I, analogs 122752-16-3D, Deltorphin II, analogs 127830-04-0D, C-type natriuretic peptide, analogs 128245-93-2D, analogs 133249-66-8D, Elafin, analogs 137061-48-4D, Pituitary adenylate cyclase activating polypeptide, analogs 140896-21-5D, Indolicidin, analogs 141636-44-4, GR 83074 141801-26-5D, Endomorphin-2, analogs 151039-33-7D, PD-142893, analogs 151039-37-1D, PD-145065, analogs 154835-90-2D, Adrenomedullin, analogs 168317-35-9D, Guamerin, analogs 169494-85-3D, Leptin, analogs 170713-75-4D, Nociceptin, analogs 180201-29-0D, analogs 186901-48-4D, Cortistatin 14, analogs 188627-80-7D, Eptifibatide, analogs 189388-22-5D, Endomorphin-1, analogs 309247-07-2D, analogs 800379-40-2 800379-41-3D, analogs
RL: *THU (Therapeutic use)*; BIOL (Biological study); USES (Uses)
(proteinase-resistant analogs of peptide and polypeptide therapeutics)

IT 9002-04-4, Thrombin 37259-58-8, Serine proteinase 37353-41-6, *Cysteine* proteinase 54249-88-6, Dipeptidyl peptidase IV 78169-47-8, *Aspartic* proteinase 81669-70-7
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(resistance to; proteinase-resistant analogs of peptide and polypeptide therapeutics)

IT *81771-37-1D*, Antiarrhythmic peptide, analogs
RL: *THU (Therapeutic use)*; BIOL (Biological study); USES (Uses)
(proteinase-resistant analogs of peptide and polypeptide therapeutics)

RN 81771-37-1 HCAPLUS
CN Antiarrhythmic peptide (cattle atrium) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L98 ANSWER 5 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:394338 HCAPLUS Full-text
DOCUMENT NUMBER: 140:400107
TITLE: Compositions and methods for modulating connexin hemichannels for treating diseases
INVENTOR(S): Jensen, Peter Holme; Larsen, Bjarne Due; Hansen, Lars Bo Laurenborg; Petersen, Jorgen Soberg; Neve, Soren; Nielsen, Morten Schak; Meier, Eddi; Steiness, Eva
PATENT ASSIGNEE(S): Zealand Pharma A/S, Den.
SOURCE: U.S. Pat. Appl. Publ., 43 pp., Cont.-in-part of U.S. Provisional Ser. No. 352,717.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

US 2004092429	A1	20040513	US 2003-353549	20030129
US 7153822	B2	20061226		
CN 1638790	A	20050713	CN 2003-804968	20030129
US 2007042964	A1	20070222	US 2006-501402	20060809
PRIORITY APPLN. INFO.:			US 2002-352717P	P 20020129
			US 2003-353549	A3 20030129

AB Disclosed are compns. and methods for modulating hemichannel function in a cell, tissue or organ. The invention also relates to useful screens for detecting such compds., particularly those capable of modulating connexin phosphorylation. Further provided are therapeutic methods for preventing or treating conditions impacted by undesired hemichannel function in a mammal such as heart arrhythmia. Rats subjected to myocardial infarction but treated with Compound 1 (Ac-D-Tyr-D-Pro-D-4Hyp-*Gly*-D- *Ala*-*Gly*-NH2) for three weeks, had an improved cardiac function with less congestion in the left ventricle as demonstrated by a reduced left ventricular end-diastolic pressure.

IC ICM A61K038-17
INCL 514002000
CC 1-12 (Pharmacology)
Section cross-reference(s): 9
IT *355151-12-1 355151-50-7*
RL: BSU (Biological study, unclassified); *PAC (Pharmacological activity)*; PRP (Properties); *THU (Therapeutic use)*; BIOL (Biological study); USES (Uses)
(peptide compns. and methods for modulating connexin hemichannels for treating diseases)
IT *355151-12-1 355151-50-7*
RL: BSU (Biological study, unclassified); *PAC (Pharmacological activity)*; PRP (Properties); *THU (Therapeutic use)*; BIOL (Biological study); USES (Uses)
(peptide compns. and methods for modulating connexin hemichannels for treating diseases)
RN 355151-12-1 HCAPLUS
CN Glycinamide, N-acetyl-D-tyrosyl-D-prolyl-(4S)-4-hydroxy-D-prolylglycyl-D-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 355151-50-7 HCAPLUS
CN L-Tyrosinamide, N-acetylglycyl-L-asparaginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Abdullah, K	1999	10	35	Endocrine	HCAPLUS
Actions	1997	356	76	Naunyn Schmiedebergs	
Adibi	1982			US 4340592 A	HCAPLUS
Alexandre Stewart	2001			Abstract from Americ	
Alford, A	2001	208	L680	Am J Physiol Lung Ce	
Anon					
Anon	1993			DE 4122885 A1	HCAPLUS
Anon	1993			WO 9314777	HCAPLUS
Anon	1994			CA 2156618	HCAPLUS
Anon	1994			DE 4314260 A1	HCAPLUS
Anon	1994			WO 9403468	HCAPLUS
Anon	1994			WO 9412181	HCAPLUS
Anon	1994			WO 9414817	HCAPLUS
Anon	1994			WO 9415908	HCAPLUS
Anon	1995			WO 9513069	HCAPLUS
Anon	1996			WO 9619494	HCAPLUS
Anon	1996			WO 9621674 A1	HCAPLUS
Anon	1996			WO 9630395	HCAPLUS
Anon	1996			WO 9633209	HCAPLUS
Anon	1997			WO 9705889	HCAPLUS
Anon	1998			WO 9810653	HCAPLUS
Anon	1998			WO 9831359	HCAPLUS
Anon	1999			DE 19816932 A1	HCAPLUS
Anon	1999			WO 9911606	HCAPLUS
Anon	1999			WO 9931049	HCAPLUS
Anon	2000			WO 0075286	HCAPLUS
Anon	2001			WO 0100610 A1	HCAPLUS
Anon	2001			WO 0162775	HCAPLUS
Anon	2001			WO 0190085 A1	HCAPLUS
Anon	2001			WO 0192236 A1	HCAPLUS
Anon	2002			WO 02077017 A2	HCAPLUS
Anon	2002			WO 02077017	HCAPLUS
Anon	2002			WO 02101007 A2	HCAPLUS
Anon	2004			WO 2004028466 A2	HCAPLUS
Anon	2004			WO 2004048400 A1	HCAPLUS
Ashino, Y	2000	279	L5	Am J Physiol Lung Mo	HCAPLUS
Audia	2005			US 6888022 B1	HCAPLUS
Bailey	2001			US 6291640 B1	HCAPLUS
Bascom	1996			US 5492894 A	HCAPLUS
Beardslee, M	2000	87	656	Circ. Res.	HCAPLUS
Bennett, M	1991	6	305	Neuron	HCAPLUS
Beny	1994	266	H1465	Physiol Heart Circ P	MEDLINE
Black	2000			US 6136787 A	
Blasits, S	2000	440	710	Phlugers Arch	HCAPLUS

Bolanos	1996	66	2019	J Neurochem	
Bommarius	2001			US 6251625 B1	HCAPLUS
Brudnak	2004			US 20040005304 A1	HCAPLUS
Bruzzone, R	1996	238	1	Eur. J. Biochem.	HCAPLUS
Bruzzone, R	1997	9	1	J Eur Neurosci	MEDLINE
Bursell	1992	11	287	Curr Eye Res	MEDLINE
Buysse	2003			US 20030092634 A1	
Cai	2001	33	957	J Mol Cell Cardiol	HCAPLUS
Campos De Carvalbo	1994	5	686	Journal of Cardiovas	
Carmeliet, E	1999	79	917	Physiol Rev	HCAPLUS
Castro Pineiro	2003			US 20030114387 A1	
Charash, W	1993	148	467	Am Rev Respir Dis	MEDLINE
Chatterjee	2004			US 20040102609 A1	
Chen	1996			US 5492920 A	HCAPLUS
Chen, X	1998	111	263	Chem Biol Interact	
Christ, G	1996	79	631	Circ Res.	HCAPLUS
Christ, G	2000	12	s15	Int J Import Res	
Colarusso	2004			US 20040142876 A1	
Collier	2003			US 20030202989 A1	
Colwell, C	2000	43	379	J Neurobiol	MEDLINE
Cook	1973			US 3740438 A	HCAPLUS
Cotrina, M	2000	20	2835	J Neurosci	HCAPLUS
Cotrina, M	1998	95	15735	Proc Natl Acad. Sci.	HCAPLUS
Cowsar	2003			US 20030228353 A1	
Cunha-Vaz	1975	59	649	Br J Ophthalmol	MEDLINE
Dankwardt	2002			US 20020169133 A1	
Darrow, B	1995	76		Circulation Research	HCAPLUS
Demuth	2002			US 20020049164 A1	
Demuth	2003			US 20030135023 A1	
Demuth	2004			US 20040171555 A1	
Do Carmo, A	1998	67	569	Exp Eye Res	HCAPLUS
Drauz	1996			US 5534538 A	HCAPLUS
Drauz	1996			US 5543397 A	HCAPLUS
Duerig, J	2000	111	416	Brit J Haematol	
Duggan	2000			US 6017925 A	HCAPLUS
Endo, K	1995	10	589	J Gastroenterol Hepa	MEDLINE
Eugenin	2001	98	4190	Proc. Natl. Acad. Sc	HCAPLUS
Fukuda	2000			US 6162828 A	HCAPLUS
Fukumoto, M	2001	69	247	Life Sciences	HCAPLUS
Gallant	1998			US 5798442 A	HCAPLUS
Gluckman	2001			US 6187906 B1	HCAPLUS
Gluckman	2004			US 6780848 B1	HCAPLUS
Gordon	1993			US 5223486 A	HCAPLUS
Griffith	2003			US 20030105165 A1	
Grubb	1991			US 5037957 A	HCAPLUS
Guerineau, N	1998	273	10389	J Biol Chem.	HCAPLUS
Guerrero	1997	99	1991	J Clin Invest	HCAPLUS
Gupta, P	1998	91	3724	Blood	HCAPLUS
Haefliger	2001	60	190	Kidney Int	HCAPLUS
Hagendorff, A	1999	99	1508	Circulation	MEDLINE
Hans-Ulrich	2001			US 20010020006 A1	
Hansson, L	2000	36	122	Nutrition and Cancer	
Hashitani, H	2001	530	273	J Physiol	HCAPLUS
Haslanger	1991			US 5061710 A	HCAPLUS
Henriques, J	2002	23	1112	Eur Heart J	MEDLINE
Iguchi, Y	1984	29	489	Arch Oral Biol	
Jarvinen	2005			US 20050059608 A1	
Jensen	2004			US 20040092429 A1	HCAPLUS
Johnstone, B	1989	408	77	J Physiol	MEDLINE
Kaprielian, R	1998	97	651	Circulation	MEDLINE

Kettner	1987			US 4636492 A	HCAPLUS
Kettner	1987			US 4652552 A	HCAPLUS
Kitaura	1987			US 4666890 A	HCAPLUS
Klaunig, J	1990	62	135	Lab Investigation	HCAPLUS
Knuetter	2004	21	61	European Journal of	
Koenig, W				Succinimidbildung be	
Kohner, E	1995	44	603	Diabetes	HCAPLUS
Kondo	2000	32	1859	J. Mol. Cell. Cardio	HCAPLUS
Kotake	2001			US 6255285 B1	HCAPLUS
Kuhner	2003			US 20030050247 A1	
Kuhner	2003			US 20030194445 A1	HCAPLUS
Kumar, N	1996	84	381	Cell	HCAPLUS
Kurtz	1997			US 5643955 A	HCAPLUS
Kwak, B	2001	12	831	Molec Biol Cell	HCAPLUS
Kyung-Sun Kang	2001	166	147	Cancer Letters	
Lagostena, L	2001	531	693	J Physiol	HCAPLUS
Lampe	2000	384	205	Archives of Biochemi	HCAPLUS
Larsen	2002			US 6353023 B1	HCAPLUS
Larsen	2002			US 6410585 B1	HCAPLUS
Larsen	2003			US 20030092609 A1	
Larsen	2005			US 20050075280 A1	
Larsen	2005			US 20050113293 A1	
Leoni	2002			US 6342481 B1	HCAPLUS
Levy, D	1999	260	207	Neurosci Lett	HCAPLUS
Li, F	2001	33	2145	J. Mol. Cell. Cardio	HCAPLUS
Lin, R	2001	154	815	The Journal Of Cell	HCAPLUS
Lipsky	1991			US 5047401 A	HCAPLUS
Lipsky	1993			US 5206221 A	HCAPLUS
Low, P	1991	40	873	Diabetes	HCAPLUS
Lynch, J	1981	3	49	J Cardiovasc. Pharma	MEDLINE
Madar	2004			US 20040121964 A1	
Masaya Tanno	2001			Abstract from Americ	
Masuda, M	2001	262	137	Anat Rec	HCAPLUS
Meier, E	2001			International Gap Ju	
Melman, A	2001	28	217	Urol Clinic North Am	MEDLINE
Mohammad Hossain	2000			Science's Stke, Pers	
Morriello	1996			US 5492916 A	HCAPLUS
Morriello	1996			US 5494919 A	HCAPLUS
Morriello	1997			US 5622973 A	HCAPLUS
Munoz	1999			US 5872101 A	HCAPLUS
Murakami, S	2001	203	367	Anat Embryol	HCAPLUS
Myers	1993			US 5252560 A	HCAPLUS
Nadya Lumelsky	2001	292	1389	Science	
Nagy, J	1996	7	745	Cell Growth Diff	HCAPLUS
Nargund	1999			US 5877182 A	HCAPLUS
Nicolson, G	1998	85	473	Proc. Natl Acad Sci	
Oku, H	2001	142	1915	Invest Ophthalmol Vi	
Orlic	2001	410	701	Nature	HCAPLUS
Oviedo-Orta	2001	15	768	FASEB	HCAPLUS
Oviedo-Orta	2000	99	578	Immunology	HCAPLUS
Pavia	1995			US 5446023 A	HCAPLUS
Pavia	1997			US 5637564 A	HCAPLUS
Pavia	1997			US 5650393 A	HCAPLUS
Penney	1999			US 5980913 A	HCAPLUS
Peters	1998	97	1746	Circulation	MEDLINE
Peters, N	1993	88	864	Circulation	HCAPLUS
Petersen, J	1991	258	1	J Pharmacol. Esp. Th	HCAPLUS
Phipps	2005			US 20050020482 A1	
Pitre, D	2001	303	67	Neurosci Lett	HCAPLUS
Pitt	2004			US 20040235752 A1	

Polacek, D	1997	34	19	J Vasc Res	HCAPLUS
Posposilik	2005			US 20050107308 A1	
Powers	1996			US 5514694 A	HCAPLUS
Powers	1997			US 5610297 A	HCAPLUS
Powers	1997			US 5650508 A	HCAPLUS
Powers	2001			US 6235929 B1	HCAPLUS
Powers	2004			US 20040127427 A1	
Quist, A	2000	148	1063	J. Cell Biol	HCAPLUS
Rehman, J	1997	272	H1960	AM J Physiol	HCAPLUS
Repolles Moliner	1995			US 5432159 A	
Riniker	1975			US 3862113 A	HCAPLUS
Ritzeler	2002			US 6358978 B1	HCAPLUS
Rodriguez	2004			US 20040167106 A1	
Rosendaal, M	1991	23	457	Tissue Cell	MEDLINE
Saffitz, J	1999	42	309	Cardiovascular Resea	HCAPLUS
Sakagami, K	1999	521	637	J Physiol (Lond)	HCAPLUS
Saunders, M	2001	61	1765	Cancer Res	HCAPLUS
Sawa Kostin	2001			Abstract from Americ	
Schuster, A	2001	280	H1088	Am J Physiol Heart C	HCAPLUS
Sharma	2004			US 20040167201 A1	HCAPLUS
Shigeto Kanno	2001			Abstract from Americ	
Shinohara, K	2000	286	107	Neurosci Lett.	HCAPLUS
Simon	1998			US 5811387 A	HCAPLUS
Simon, A	1998	8	295	Curr Biol	HCAPLUS
Stammler	2002			US 6384272 B1	HCAPLUS
Stevens, R	1999	2777	C448	Am J Physiol	
Sundstrom	2004			US 20040106560 A1	
Szeto	2004			US 20040029796 A1	
Taugner, R	1980	206	65	Cell Tissue Res	MEDLINE
Teetz	1989			US 4797471 A	HCAPLUS
Teilman, S	2001			International Gap Ju	
Thiele	1997			US 5602102 A	HCAPLUS
Todt, I	2001	181	107	J Membrane Biol	HCAPLUS
Tomoko Nao	2001			Abstract from Americ	
Torikata, C	1985	52	399	Lab Invest	HCAPLUS
Tung	1998			US 5849711 A	HCAPLUS
Turner, W	1997	75	77	Pharmacol Therap	HCAPLUS
Vitale, M	2001	64	625	Biol Reporo	HCAPLUS
Wang	2001	281	C75	Am J Physiol Cell Ph	HCAPLUS
Wang	2002	55	25	Cardiovasc Res	HCAPLUS
Wang	2001	6A	111	Urology	
Wang, Y	1995	270	26581	The Journal Of Biolo	HCAPLUS
Weisheng Bao	2001			Abstract from Americ	
Wolburg, H	1995	157	315	Int Rev Cytol	HCAPLUS
Wright, A	1998	80	89	Pharmacol Ther	HCAPLUS
Yamanaka, I	1997	72	166	European Journal Of	HCAPLUS
Yeh	1997	17	3174	Arterioscle Thromb V	HCAPLUS
Yoshida, M	1998	72	192	Arch Toxicol	HCAPLUS
Zhou, Z	2001	102	959	Neuroscience	HCAPLUS

L98 ANSWER 6 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:155086 HCAPLUS Full-text
DOCUMENT NUMBER: 138:188077
TITLE: Preparation of novel peptide conjugates
INVENTOR(S): *Larsen, Bjarne Due; Petersen, Jorgen Soberg*; Kapusta, Daniel R.; Harlow, Kenneth W.
PATENT ASSIGNEE(S): Zealand Pharmaceuticals A/S, Den.
SOURCE: U.S. Pat. Appl. Publ., 36 pp., Cont.-in-part of U. S. Provisional Ser. No. 298,186.
CODEN: USXXCO

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE	
US 2003040472	A1	20030227	US 2001-882291		20010615	<--
US 2006052284	A1	20060309	US 2005-102564		20050408	<--
PRIORITY APPLN. INFO.:			DK 2000-944	A	20000616	<--
			DK 2000-1485	A	20001005	<--
			US 2000-251671P	P	20001206	<--
			US 2001-298186P	P	20010613	
			US 2001-882291	A1	20010615	

OTHER SOURCE(S): MARPAT 138:188077

AB Disclosed are peptide conjugates R1-Z-A1-A2-A3-A4-A5-A6-Z'-R2 (A1, A4, R6 = Arg, Lys, His; A2 = Tyr, Trp, Phe; A3 = Tyr, Asn, Trp, Phe; A5 = Phe, Tyr, Trp, Leu, Val, Ile, where each amino acid residue in the hexapeptide may be in the L or D form; Z, Z' each represent a charged peptide chain of 4 to 20 amino acid residues having the D or L configuration or is missing, provided that not both Z and Z' are missing; R1 = H, acyl group; R2 is an amino group or OH) which are optionally further linked to a transport moiety, as well as their salts, hydrates, solvates, and C-terminally amidated or esterified derivs. Also provided are antibodies that specifically bind the peptide conjugates. The invention has a wide spectrum of important applications including use in the treatment of disorders impacted by nociceptin and related opioid-like peptides. Thus, Ac-Arg-Tyr-Tyr-Arg-Trp-Lys-Lys-Lys-Lys-Lys-Lys-Lys-NH2 was prepared on TentaGel resin and assayed for antibody production

IC ICM A61K038-16
ICS A61K038-10; A61K038-08; C07K007-08; C07K007-06
INCL 514012000; 514013000; 514014000; 514015000; 530324000; 530325000; 530326000; 530327000; 530328000
CC 34-3 (Amino Acids, Peptides, and Proteins)
Section cross-reference(s): 1, 15, 63

L98 ANSWER 7 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:610285 HCAPLUS Full-text
DOCUMENT NUMBER: 139:144011
TITLE: Compositions and methods for modulating connexin hemichannels for disease treatment
INVENTOR(S): Petersen, Jorgen Soberg; Neve, Soren; Nielsen, Morten Schak; Meier, Eddi; Steiness, Eva; Jensen, Peter Holme; Larsen, Bjarne Due; Hansen, Lars Bo Laurenborg
PATENT ASSIGNEE(S): Zealand Pharma A/S, Den.
SOURCE: PCT Int. Appl., 94 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003063891	A1	20030807	WO 2003-DK56	20030129

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2474788	A1	20030807	CA 2003-2474788		20030129
EP 1469875	A1	20041027	EP 2003-701478		20030129
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
BR 2003007279	A	20041228	BR 2003-7279		20030129
JP 2005516054	T	20050602	JP 2003-563580		20030129
CN 1638790	A	20050713	CN 2003-804968		20030129
NO 2004003590	A	20040827	NO 2004-3590		20040827
PRIORITY APPLN. INFO.:			US 2002-352717P	P	20020129
			WO 2003-DK56	W	20030129

AB Disclosed are compns. and methods for modulating hemichannel function in a cell, tissue or organ. The invention also relates to useful screens for detecting such compds., particularly those capable of modulating connexin phosphorylation. Further provided are therapeutic methods for preventing or treating conditions impacted by undesired hemichannel function in a mammal such as heart arrhythmia. More preferred compds. suitable for use with the present invention include those represented by the following Formula (I, R1(NHR2(CH2)s(CO)p)aNHR3(CH2)t(CO)qNHR4COR5) wherein R1= H or Ac; R2,R4= a sidechain of one of the amino acids G, Y, D-Y, F and D-F; R3 = any amino acid sidechain; R5 = OH or NH2; and a, S, T, P and Q are integers and independently = 0 or 1. More specific compds. include those having the following Formula (II, R1-X1-X2-X3-R2) wherein X1 = 0, ***Ala***, ***Gly***, β-***Ala***, Tyr, D-Tyr, ***Asp*** ; X2 is 0, ***Ala***-***Gly***-T4c-Pro, ***Ala***-Sar-Hyp-Pro, ***Ala***-Asn, D-Asn-D-***Ala***, D-Asn, ***Gly***, ***Ala*** , D-***Ala***, β-***Ala***, Asn; X3 = Tyr, D-Tyr, ***Gly*** , or Phe; R1 = H or Ac, with the proviso that X1 and X2 are not both 0; and R2= OH, NH2.

IC ICM A61K038-08
ICS A61P009-06

CC 1-12 (Pharmacology)

IT ***355151-12-1 355151-50-7***
RL: ***PAC (Pharmacological activity)***; ***THU (Therapeutic use)***; BIOL (Biological study); USES (Uses)
(immunoassay method for screening compds. that modulate connexin hemichannel function for use in disease treatment)

IT ***355151-12-1 355151-50-7***
RL: ***PAC (Pharmacological activity)***; ***THU (Therapeutic use)***; BIOL (Biological study); USES (Uses)
(immunoassay method for screening compds. that modulate connexin hemichannel function for use in disease treatment)

RN 355151-12-1 HCAPLUS

CN Glycinamide, N-acetyl-D-tyrosyl-D-prolyl-(4S)-4-hydroxy-D-prolylglycyl-D-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 355151-50-7 HCAPLUS
CN L-Tyrosinamide, N-acetylglycyl-L-asparaginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Henrik, H	2001			WO 0162775 A	HCAPLUS
Holstein-Rathlou, N	2002			WO 02077017 A	HCAPLUS

L98 ANSWER 8 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:241921 HCAPLUS Full-text
DOCUMENT NUMBER: 138:260539
TITLE: Apparatus and method for flow electroporation of biological samples
INVENTOR(S): Dzekunov, Sergey M.; Lee, Hyung J.; Li, Linhong; Singh, Vininder; Liu, Linda; Holaday, John W.
PATENT ASSIGNEE(S): Maxcyte, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 59 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003059945	A1	20030327	US 2002-80272	20020221
US 7029916	B2	20060418		
PRIORITY APPLN. INFO.:			US 2001-269867P P	20010221
			US 2001-269868P P	20010221

AB The present invention relates to methods and apparatus for the encapsulation of biol.-active substances in various cell populations. More particularly, the present invention relates to a method and apparatus for the encapsulation of biol.-active substances in various cell populations in blood by electroporation to achieve therapeutically desirable changes in the phys. characteristics of the various cell populations in blood. Primary lymphocytes were suspended in B and K buffer (125 mM KCl, 15 mM NaCl, 1.2 mM MgCl2, 3 mM glucose, 25 mM Hepes, pH 7.4) and cell concentration was set from 1x107 cells/mL to 6x108 cells/mL together with DNA plasmid from 50 to 1 mg/mL. Electroporation, 2.3 kV/cm, 400 μs, 4 pulses for small volume expts. (15 μl) or 2.2 kV/cm, 1.6 ms, 1 pulse for large volume expts. (0.5 mL-2 mL) was performed at room temperature Following electroporation, cells were incubated in B&K buffer for 20 min at 37° C. for small volume expts., or diluted by 10+ volume of culture medium (RPMI-1640+10% fetal bovine serum+1% Pen-strep+2 mM

L-*glutamine*) for large volume expts. Cells were cultured in culture medium for various periods (up to 72 h) and the transfection efficiency was analyzed. Primary quiescence lymphocytes were shown refractory to retrovirus based gene transfer. HIV-based vector could transduce primary lymphocytes, but the efficiency is extremely low in the absence of HIV accessory genes. Other non-viral transfection methods also gave very low transfection efficiency. This is the first demonstration of high efficiency of transfection of primary lymphocytes by a non-viral method.

IC ICM C12M001-42
ICS C12N015-87

INCL 435461000; X43-528.52

CC 63-7 (Pharmaceuticals)
Section cross-reference(s): 3, 9

IT 50-35-1D, Thalidomide, derivs. 50-81-7D, Ascorbic acid, ethers, biological studies 52-01-7, Spironolactone 53-05-4, Tetrahydrocortisone 60-33-3, Linoleic acid, biological studies 60-54-8D, Tetracycline, derivs. 68-96-2, 17α-Hydroxyprogesterone 128-13-2, Ursodeoxycholic acid 145-63-1, Suramin 152-58-9, Cortexolone 302-79-4, Retinoic acid 362-07-2, 2-Methoxyestradiol 446-72-0, Genistein 465-21-4, Bufalin 566-35-8 1406-16-2D, Vitamin D, derivs. 2609-46-3, Amiloride 4431-00-9, Aurintricarboxylic acid 9001-91-6, Plasminogen 9061-61-4, NGF 10118-90-8, Minocycline 11096-26-7, Erythropoietin 12772-57-5, Radicicol 19545-26-7, Wortmannin 33069-62-4, Taxol 34031-32-8, Auranofin 37270-94-3, Platelet factor 4 37300-21-3, Pentosan polysulfate 38096-31-0, Diaminoanthraquinone 50903-99-6, L-NAME *57381-26-7*, Irsogladine 62031-54-3, Fibroblast growth factor 62571-86-2, Captopril 62683-29-8, Colony stimulating factor 62996-74-1, Staurosporine 65646-68-6, Fenretinide 70563-58-5, Herbimycin A 79831-76-8, Castanospermine 81627-83-0, M-CSF 83869-56-1, GM-CSF 86090-08-6, Angiostatin 86102-31-0, TIMP 98724-27-7, Proliferin-related protein 99519-84-3 100827-28-9, Erbstatin 103909-75-7, 22-Oxa-1α,25-dihydroxyvitamin D3 105219-56-5, WEB 2086 106096-93-9, Basic fibroblast growth factor 110124-55-5, MDL 27032 125697-92-9, Lavendustin A 126509-46-4, Eponemycin 127464-60-2, Vascular endothelial growth factor 129298-91-5, AGM-1470 130370-60-4, Batimastat 134633-29-7, Tecogalan sodium 142186-14-9, FR-118487 143011-72-7, G-CSF 148717-90-2, Squalamine 154039-60-8, Marimastat 169494-85-3, Leptin 171784-03-5, Louisianine A 171784-05-7, Louisianine C 171784-06-8, Louisianine D 187888-07-9, Endostatin 188417-67-6, CM101 204005-46-9, SU5416 271597-12-7, Myostatin
RL: *THU (Therapeutic use)*; BIOL (Biological study); USES (Uses)
(apparatus and method for flow electroporation of biol. samples)

IT *57381-26-7*, Irsogladine
RL: *THU (Therapeutic use)*; BIOL (Biological study); USES (Uses)
(apparatus and method for flow electroporation of biol. samples)

RN 57381-26-7 HCAPLUS

CN 1,3,5-Triazine-2,4-diamine, 6-(2,5-dichlorophenyl)- (9CI) (CA INDEX NAME)



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Abatti	1992	39	43	IEEE Trans. Biomed.	MEDLINE
Achelpohl	1984			US 4440386 A	
Andal Corp				Multi-Arc Scientific	
Anon	1975			DE 2405119	HCAPLUS
Anon	1985			EP 0137504	HCAPLUS
Anon	1987			DE 3603029	HCAPLUS
Anon	1987			JP 62151174	
Anon	1987			JP 62171687	HCAPLUS
Anon	1987			JP 62228277	HCAPLUS
Anon	1987			JP 62265975	
Anon	1988			JP 63141587	
Anon	1988			WO 8804322	
Anon	1989			EP 0343783	HCAPLUS
Anon	1989			JP 1141582	
Anon	1989			WO 8902464	HCAPLUS
Anon	1989			WO 8903426	HCAPLUS
Anon	1990			EP 0362758	HCAPLUS
Anon	1990			JP 2131584	
Anon	1990			JP 2131585	
Anon	1990			JP 2186993	
Anon	1991			JP 3195485	HCAPLUS
Anon	1991			WO 9118103	HCAPLUS
Anon	1992			EP 0472772	HCAPLUS
Anon	1992			JP 4027393	
Anon	1994			JP 6349068	
Anon	1994			AT 680890	
Anon	1994			WO 9421117	HCAPLUS
Anon	1995			JP 7180029	
Anon	1995			JP 7320720	
Anon	1996			DE 4440386	HCAPLUS
Anon	1996			WO 9628199	HCAPLUS
Anon	1997			EP 0798309	HCAPLUS
Anon	1998			CN 1195997	HCAPLUS
Anon	1998			WO 9824490	HCAPLUS
Anon	2001			WO 0124830	HCAPLUS
Anon	2002			CA 2214800	HCAPLUS
Anon	1975		598	Preparation of certa	
Asakami	1990	9	892	J. Mater. Sci. Lett.	HCAPLUS
Baer	1992			US 5128257 A	HCAPLUS
Barsoum	1990			US 4956288 A	HCAPLUS
Behrndt	1991	A139	58	Materials Sciences a	HCAPLUS
Bertoncini	1992			US 5114681 A	HCAPLUS
Boulton	1981			US 4252628 A	HCAPLUS
Buican	1992			US 5100627 A	HCAPLUS
Busta	1992			US 5137817 A	HCAPLUS
CRC Press	1995		1650	Biological Buffers,	
Calvin	1992			US 5098843 A	HCAPLUS
Capizzi	1993	72	3495	Cancer	HCAPLUS
Casnig	1992			US 5134070 A	
Chang	1989			US 4822470 A	HCAPLUS
Chang	1990			US 4970154 A	HCAPLUS
Chassy	1988	6	303	Trends in Biotechnol	HCAPLUS
Coll	1992			Metallurgical and Tr	
Dower	1990			US 4910140 A	HCAPLUS
Dunican	1998	7	1067	BIO/Technology	
Dzekunov	2003			US 20030073238 A1	

Dzekunov	2004			US 20040197883 A1	
Egorov	1991	29	705	Sov. Powder Metall M	
Einck	1998		357	Tissue Oxygenation i	HCAPLUS
Firth	1993			US 5232856 A	HCAPLUS
Franco	1984			US 4478824 A	HCAPLUS
Franco	1990			US 4931276 A	HCAPLUS
Gersonde	1980	46	81	Biblthca Haemat.	
Gersonde	1979	39	1	Blut, Improvement of	MEDLINE
Gersonde	1982		277	Origins of Cooperati	HCAPLUS
Gersonde	1982	22	279	Toxicology	HCAPLUS
Goodrich	1989			US 4874690 A	HCAPLUS
Goodrich	1991			US 5043261 A	HCAPLUS
Gossling	1960			US 2955076 A	
Hibi	1989			US 4800163 A	
Hilliard	1987			US 4695547 A	HCAPLUS
Hilliard	1989			US 4882281 A	HCAPLUS
Hirai	1987	40	607	J. of Antibiotics	HCAPLUS
Hofmann	1996			US 5501662 A	
Hofmann	1996			US 5545130 A	
Hofmann	1997			US 5676646 A	
Hofmann	1986		6	IEEE Engineering in	HCAPLUS
Holaday	2001			US 20010001064 A1	HCAPLUS
Holmstrm	1998			US 5728281 A	HCAPLUS
Kaali	1992			US 5139684 A	HCAPLUS
Kearney	1995			US 5424209 A	
Kinosita	1979	554	479	Biochimica et Biophy	HCAPLUS
Kobayashi	1989	97	1189	J. Ceram. Soc. Jpn.	HCAPLUS
Kullmann	1993	8	83	Am. J. Respir. Cell	HCAPLUS
Kurtz	1987	15	229	Sol. Energy Mater.	HCAPLUS
Lehninger	1982		181	Principles of Bioche	
Littlehales	1989			US 4840714 A	
Marshall	1989			US 4849089 A	HCAPLUS
Marshall	1990			US 4906576 A	HCAPLUS
Marshall	1990			US 4923814 A	HCAPLUS
Marshall	1990			US 4946793 A	HCAPLUS
Matschke	1987			US 4699881 A	HCAPLUS
Matschke	1988			US 4764473 A	HCAPLUS
Maurer	1993	11	865	J. Orthop. Res.	HCAPLUS
Merz	1991	941	47	Unfallchirurg, Deter	
Meserol	1998			US 5720921 A	HCAPLUS
Meserol	2000			US 6074605 A	HCAPLUS
Meserol	2000			US 6090617 A	HCAPLUS
Meserol	2002			US 6485961 B1	HCAPLUS
Mochizuki	1989			US 4804450 A	HCAPLUS
Mouneimne	1990	275	117	FEBS Letters	HCAPLUS
Multi-Arc, Inc	1996			Ion Bond 16 Zirconiu	
Multi-Arc, Inc	1995			Ion Bond 17 Titanium	
Multi-Arc, Inc	1995			Ion Bond 19 Chromium	
Multi-Arc, Inc	1995			Ion Bond Coatings fo	
Multi-Arc, Inc	1995			Ion Bond Coatings fo	
Multi-Arc, Inc	1995			The Ion Bond Network	
Narayan	1994	B25	5	Materials Sciences a	
Nicolau	1980			US 4192869 A	HCAPLUS
Nicolau	1982			US 4321259 A	HCAPLUS
Nicolau	1984			US 4473563 A	HCAPLUS
Nicolau	1997			US 5612207 A	HCAPLUS
Nicolau	1985	51	92	Biblthca haemat.	HCAPLUS
Nicolau	1986		265	Phytic Acid: Chemist	HCAPLUS
Pietra	1990	115	1025	Analyst	HCAPLUS
Pohl	1984			US 4476004 A	

Ray	1988			US 4784737 A	HCAPLUS
Ropars	1987			US 4652449 A	HCAPLUS
Ropars	1988			US 4752586 A	HCAPLUS
Ropars	1985	445	304	Improved oxygen deli	MEDLINE
Sanford	1990			US 4945050 A	
Sanford	1991			US 5036006 A	
Sanford	1992			US 5100792 A	
Satomi	1988	15	339	Annals Rehab.	HCAPLUS
Schaldach	1989	34	185	Biomed. Technik.	MEDLINE
Schoendorfer	1992			US 5135667 A	HCAPLUS
Shoji	1982	41	1097	Appl. Phys. Lett.	HCAPLUS
Smith	1972			US 3676325 A	HCAPLUS
Sowers	1986			US 4622302 A	
Susuki	1981	19	114	Jpn. J. Med. Electro	MEDLINE
Tada	1992			US 5124259 A	HCAPLUS
Taheri	1994	90	376	Electroencephalograp	MEDLINE
Tait	1991	7	327	Surf. Eng.	HCAPLUS
Takahashi	1991			US 5007995 A	HCAPLUS
Teisseire	1985	58	1810	J. Appl. Phys.	MEDLINE
Teisseire			153	Significance of low	
Teissere	1987	84	6894	Proc. Natl. Acad. Sc	
Therin	1991	2	1	J. Materials Science	
Vasilenko	1973	13	39	Poroshkovaia Metallu	HCAPLUS
Weiner	1983	47	65	Biol. of the Cell	HCAPLUS
Weisel	1978	83	682	Surgery	MEDLINE
Wisbey	1987	8	477	Biomaterials	HCAPLUS
Wisbey	1989	C384/	9	ImechE	
Wong	1987			US 4663292 A	HCAPLUS
Wong	1989			US 4849355 A	HCAPLUS
Xylander	1978			US 4075076 A	
Zhao	1991	42	1109	Vacuum	HCAPLUS
Zhu	1994	9	295	Biosensors and Bioel	HCAPLUS
Ziegler	1991			US 4995957 A	HCAPLUS
Zimmermann	1978			US 4081340 A	HCAPLUS

L98 ANSWER 9 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:683276 HCAPLUS Full-text
DOCUMENT NUMBER: 140:122445
TITLE: Pharmacological characterization of the new stable antiarrhythmic peptide analog Ac-D-Tyr-D-Pro-D-Hyp-*Gly*-D-*Ala*-*Gly*-NH2 (ZP123): In vivo and in vitro studies
AUTHOR(S): Kjolbye, Anne Louise; Knudsen, Carsten Boye; Jepsen, Trine; Larsen, Bjarne Due; Petersen, Jorgen Soberg
CORPORATE SOURCE: Department of Pharmacology, Zealand Pharma A/S, Smedeland, Den.
SOURCE: Journal of Pharmacology and Experimental Therapeutics (2003), 306(3), 1191-1199
CODEN: JPETAB; ISSN: 0022-3565
PUBLISHER: American Society for Pharmacology and Experimental Therapeutics
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Antiarrhythmic peptides (AAPs) are a group of compds. with antiarrhythmic properties; however, their use has been hampered by very low plasma stability. The aim of this study was to compare the in vitro and in vivo stability of our new stable AAP analog Ac-D-Tyr-D-Pro-D-Hyp-*Gly* -D-*Ala*-*Gly*-NH2 (ZP123) with the previously described AAP analog AAP10. Moreover, the effect of the two compds. was examined in a murine in vivo model of ouabain-induced second degree AV-block, and the effect on dispersion of action potential duration

(APD dispersion) was studied during hypokalemic-ischemia in isolated perfused rabbit hearts. The in vitro t1/2 of ZP123 in rat and human plasma was about 1,700 times longer than t1/2 of AAP10. Due to rapid elimination, it was not possible to obtain an in vivo pharmacokinetic characterization of AAP10; however, calcns. suggested that the clearance of ZP123 was at least 140 times slower than for AAP10. AAP10 and ZP123 produced a dose-dependent delay in onset of ouabain-induced AV-block in mice at doses of 10-11 to 10-7 mol/kg i.v. ZP123 and 10-11 to 10-6 mol/kg i.v. AAP10. Maximal efficacy of ZP123 was reached at a 10-fold lower dose (10-8 mol/kg i.v.) than with AAP10. In the isolated rabbit hearts, ZP123 and AAP10 had no effect on dispersion during control conditions. The increased APD dispersion during hypokalemic ischemia is considered a major arrhythmic substrate and only ZP123 prevented the increase in APD dispersion. In conclusion, ZP123 is a new potent AAP analog with improved stability.

CC 1-8 (Pharmacology)
Section cross-reference(s): 14, 63

IT Peptides, biological studies
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antiarrhythmics; pharmacol. characterization with in vivo and in vitro studies of new stable antiarrhythmic peptide analog Ac-D-Tyr-D-Pro-D-Hyp-*Gly*-D-*Ala*-*Gly*-NH2 (ZP123))

IT Cardiovascular agents
Cytoprotective agents
(cardioprotective agents; pharmacol. characterization with in vivo and in vitro studies of new stable antiarrhythmic peptide analog Ac-D-Tyr-D-Pro-D-Hyp-*Gly*-D-*Ala*-*Gly*-NH2 (ZP123))

IT Drug delivery systems
(injections, i.v.; pharmacol. characterization with in vivo and in vitro studies of new stable antiarrhythmic peptide analog Ac-D-Tyr-D-Pro-D-Hyp-*Gly*-D-*Ala*-*Gly*-NH2 (ZP123))

IT Antiarrhythmics
Disease models
Human
(pharmacol. characterization with in vivo and in vitro studies of new stable antiarrhythmic peptide analog Ac-D-Tyr-D-Pro-D-Hyp-*Gly*-D-*Ala*-*Gly*-NH2 (ZP123))

IT *355151-12-1*
RL: *DMA (Drug mechanism of action)*; *PAC (Pharmacological activity)*; *PKT (Pharmacokinetics)*; *THU (Therapeutic use)*; BIOL (Biological study); USES (Uses)
(ZP 123; pharmacol. characterization with in vivo and in vitro studies of new stable antiarrhythmic peptide analog Ac-D-Tyr-D-Pro-D-Hyp-*Gly*-D-*Ala*-*Gly*-NH2 (ZP123))

IT *355151-12-1*
RL: *DMA (Drug mechanism of action)*; *PAC (Pharmacological activity)*; *PKT (Pharmacokinetics)*; *THU (Therapeutic use)*; BIOL (Biological study); USES (Uses)
(ZP 123; pharmacol. characterization with in vivo and in vitro studies of new stable antiarrhythmic peptide analog Ac-D-Tyr-D-Pro-D-Hyp-*Gly*-D-*Ala*-*Gly*-NH2 (ZP123))

RN 355151-12-1 HCAPLUS

CN Glycinamide, N-acetyl-D-tyrosyl-D-prolyl-(4S)-4-hydroxy-D-prolylglycyl-D-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Aonuma, S	1980	28	3332	Chem Pharm Bull (Tok	HCAPLUS
Aonuma, S	1982	5	40	J Pharmacobiodyn	HCAPLUS
Argentieri, T	1989	45	737	Experientia	HCAPLUS
Dhein, S	1994	350	174	Naunyn-Schmiedeberg'	HCAPLUS
Dikshit, M	1988	26	874	Indian J Exp Biol	HCAPLUS
Echt, D	1991	324	781	N Engl J Med	MEDLINE
Gabrielson, J	2000		21	Pharmacokinetic and	
Hjalmarson, A	1984	29	145	Cardiologia	MEDLINE
ISIS-1	1986	2	57	Lancet	
Kjolbye, A	2002	40	770	J Cardiovasc Pharmac	HCAPLUS
Kohama, Y	1987	35	3928	Chem Pharm Bull (Tok	HCAPLUS
Kohama, Y	1988	36	4597	Chem Pharm Bull (Tok	HCAPLUS
Muller, A	1997	327	65	Eur J Pharmacol	MEDLINE
Muller, A	1997	356	76	Naunyn-Schmiedeberg'	MEDLINE
Naccarelli, G	2000	15	64	Curr Opin Cardiol	MEDLINE
Ronsberg, M	1986	14	350	Med Sci	HCAPLUS
Rowland, M	1989		438	Clinical Pharmacokin	
Waldo, A	1996	348	7	Lancet	HCAPLUS
Waldo, A	1996	348	416	published erratum ap	
Xing, D	2003	14	510	J Cardiovasc Electro	

L98 ANSWER 10 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:116197 HCAPLUS Full-text
DOCUMENT NUMBER: 141:167468
TITLE: Effects of the new antiarrhythmic peptide ZP123 on epicardial activation and repolarization pattern
AUTHOR(S): Dhein, Stefan; Larsen, Bjarne D.; Petersen, Jorgen S.; Mohr, Friedrich-Wilhelm
CORPORATE SOURCE: Clinic for Cardiac Surgery, Heart Center, University of Leipzig, Leipzig, Germany
SOURCE: Cell Communication & Adhesion (2003), 10(4-6), 371-378
CODEN: CCAEBH; ISSN: 1541-9061
PUBLISHER: Taylor & Francis, Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Antiarrhythmic peptides such as AAP10 (*Gly*-*Ala*- *Gly*-4Hyp-Pro-Tyr-CONH2) have antiarrhythmic properties related to their stimulatory effect on gap junctional coupling. However, most of these peptides are not stable in enzymic environment which limits studies with these compds. in vivo. ZP123 is a new antiarrhythmic peptide constructed using a retro-all-D-amino acid design of the AAP10 template (Ac-D-Tyr-D-Pro-D-4Hyp-*Gly*-D-*Ala*-*Gly*-NH2). The aim of this study was to compare the effects of AAP10 and ZP123 on epicardial

activation and repolarization patterns in isolated perfused rabbit hearts. In addition, we tested the effect of these compds. on PKC activation in cultured HeLa-Cx43 cells. Rabbit hearts were perfused according to the Langendorff technique with Tyrode solution at constant pressure (70 cm H2O). After 45 min equilibration, either AAP10 (n = 7) or ZP123 (n = 7) was infused intracoronarily in concns. of 0.1, 1, 10, 100, and 1000 nM (15 min for each concentration) in the presence of 0.05% bovine serum albumine. 256 AgCl electrodes were attached to the hearts surface and connected to the inputs of a 256 channel mapping system in a unipolar circuit (4 kHz/channel, 0.04 mV vertical resolution, 1 mm spatial resolution). For each electrode the activation and repolarization timepoint were determined We found that both peptides significantly reduced epicardial dispersion by a maximum of about 20% thereby enhancing the homogeneity of epicardial action potential duration, while the action potential duration itself was not affected. The beat-to-beat variability of the epicardial activation pattern was stabilized by both peptides as compared to an untreated time-control series. Other parameters such as LVP, CF, heart rate, or total activation time were not effected by either of the peptides. In a second protocol, rectangular pulses were delivered to the back wall and the propagation velocity was determined longitudinal and transversal to the fiber axis. We found an increase in both longitudinal and transversal conduction velocity. Using a com. PKC assay on HeLa-Cx43 cells we found that 50 nM AAP10 and 50 nM ZP123 increased activity by 99±6% and 146±54%, resp. The PKC activation induced by either of these compds. was completely blocked using the selective PKCα inhibitor GCP54345. We conclude that AAP10 and ZP123 have similar effects in vitro, but the superior enzymic stability of ZP123 makes this compound the preferred substance for in vivo studies of antiarrhythmic peptides.

CC 1-8 (Pharmacology)

IT *159503-65-8 355151-12-1*, ZP123
RL: *DMA (Drug mechanism of action)*; *PAC (Pharmacological activity)*; PRP (Properties); *THU (Therapeutic use)*; BIOL (Biological study); USES (Uses)
(ZP123, AAP10 reduced epicardial dispersion, increased longitudinal and transversal conduction velocity without affecting cardiac parameters in rabbit and induced PKCα activity in HeLA-Cx43 cell but ZP123 showed better enzymic stability)

IT *159503-65-8 355151-12-1*, ZP123
RL: *DMA (Drug mechanism of action)*; *PAC (Pharmacological activity)*; PRP (Properties); *THU (Therapeutic use)*; BIOL (Biological study); USES (Uses)
(ZP123, AAP10 reduced epicardial dispersion, increased longitudinal and transversal conduction velocity without affecting cardiac parameters in rabbit and induced PKCα activity in HeLA-Cx43 cell but ZP123 showed better enzymic stability)

RN 159503-65-8 HCAPLUS

CN retro-Antiarrhythmic peptide (cattle atrium), 6-L-tyrosinamide- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 355151-12-1 HCAPLUS
CN Glycinamide, N-acetyl-D-tyrosyl-D-prolyl-(4S)-4-hydroxy-D-prolylglycyl-D-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Arisi, G	1983	52	706	Circ Res	MEDLINE
Buchanan, J	1985	56	696	Circ Res	HCAPLUS
Dhein, S	1999	128	1375	Br J Pharmacol	HCAPLUS
Dhein, S	2001	8	257	Cell Commun Adhesion	HCAPLUS
Dhein, S	1993	87	617	Circulation	HCAPLUS
Dhein, S	1995	49	851	Drugs	HCAPLUS
Dhein, S	1994	350	174	Naunyn Schmiedeberg'	HCAPLUS
Grover, R	2001	22	1011	Peptides	HCAPLUS
Hofmann, J	1997	11	649	FASEB J	HCAPLUS
Joyner, R	1982	50	192	Circ Res	MEDLINE
Kjolbye, A	2003	306	1191	J Pharmacol Exp Ther	HCAPLUS
Kuo, C	1983	67	1356	Circulation	MEDLINE
Lesh, M	1989	65	1426	Circ Res	MEDLINE
Muller, A	1997	356	76	Naunyn Schmiedeberg'	MEDLINE
Weingart, R	1988	63	72	Circ Res	MEDLINE
Weng, S	2002	16	1114	FASEB J	HCAPLUS
Wit, A	1993		127	Cardiac Mapping	
Xing, D	2003	14	510	J Cardiovasc Electro	

L98 ANSWER 11 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:829575 HCAPLUS Full-text
DOCUMENT NUMBER: 138:378882
TITLE: Anti-arrhythmic peptide N-3-(4-Hydroxyphenyl)propionyl Pro-Hyp-*Gly*-*Ala*-*Gly*-OH

reduces dispersion of action potential duration during ischemia/reperfusion in rabbit hearts

AUTHOR(S): Kjolbye, Anne Louise; Holstein-Rathlou, Niels-Henrik; Petersen, Jorgen Soberg

CORPORATE SOURCE: Zealand Pharma, Glostrup, Den.

SOURCE: Journal of Cardiovascular Pharmacology (2002), 40(5), 770-779
CODEN: JCPCDT; ISSN: 0160-2446

PUBLISHER: Lippincott Williams & Wilkins

DOCUMENT TYPE: Journal

LANGUAGE: English

AB During ischemia, cardiac gap junctions close and neighboring cells uncouple. This leads to slow conduction, increased dispersion of APD (duration from action potential beginning to 90% of repolarization), nonuniform anisotropy, and unidirectional conduction block, all of which favor the induction of reentry arrhythmias. It was suggested that anti-arrhythmic peptides increase gap junction conductance during states of reduced coupling. The aim of this study was to test the effect of the anti-arrhythmic peptide N-3-(4-hydroxyphenyl)propionyl Pro-Hyp-*Gly* -*Ala*-*Gly*-OH (HP-5) (10-10 M) on dispersion of epicardial APD during both normokalemic and hypokalemic ischemia/reperfusion in isolated perfused rabbit hearts. HP-5 did not affect average APD , heart rate, left ventricular contractility (LVP dP/dtmax), or mean coronary flow. HP-5 significantly reduced the epicardial APD dispersion during hypokalemic ischemia (HP-5 treated: 24.1 ms, untreated: 33.9 ms) and during normokalemic reperfusion but not during normokalemic ischemia or control conditions. In addition, among untreated hearts subjected to hypokalemic ischemia/reperfusion, 7 of 10 developed ventricular fibrillation, whereas only 3 of 9 hearts perfused with HP-5 developed ventricular fibrillation. These results show that HP-5 is able to reduce APD90 dispersion during hypokalemic ischemia in rabbit hearts.

CC 1-8 (Pharmacology)
Section cross-reference(s): 2

IT *111915-92-5*
RL: ***PAC (Pharmacological activity)***; ***THU (Therapeutic use)***; BIOL (Biological study); USES (Uses)
(antiarrhythmic peptide HP-5 reduces dispersion of action potential duration)

IT *111915-92-5*
RL: ***PAC (Pharmacological activity)***; ***THU (Therapeutic use)***; BIOL (Biological study); USES (Uses)
(antiarrhythmic peptide HP-5 reduces dispersion of action potential duration)

RN 111915-92-5 HCAPLUS

CN Antiarrhythmic peptide (cattle atrium), 1-deglycine-2-[1-[3-(4-hydroxyphenyl)-1-oxopropyl]-L-proline]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Anon	1998	97	651	Circulation	
Aonuma, S	1980	28	3332	Chem Pharm Bull (Tok	HCAPLUS
Aonuma, S	1982	5	40	J Pharmacobiodyn	HCAPLUS
Argentieri, T	1989	45	737	Experientia	HCAPLUS
Dhein, S	1999	128	1375	Br J Pharmacol	HCAPLUS
Dhein, S	1995	49	851	Drugs	HCAPLUS
Dhein, S	1994	350	174	Naunyn Schmiedebergs	HCAPLUS
Dikshit, M	1988	26	874	Indian J Exp Biol	HCAPLUS
Gottwald, E	1998	79	474	Heart	MEDLINE
Kohama, Y	1987	35	3928	Chem Pharm Bull (Tok	HCAPLUS
Kohama, Y	1988	36	4597	Chem Pharm Bull (Tok	HCAPLUS
Kuo, C	1983	67	1356	Circulation	MEDLINE
Lesh, M	1989	65	1426	Circ Res	MEDLINE
Merx, W	1977	94	603	Am Heart J	MEDLINE
Muller, A	1997	327	65	Eur J Pharmacol	MEDLINE
Muller, A	1997	356	76	Naunyn Schmiedebergs	MEDLINE
Peters, N	1993	88	864	Circulation	HCAPLUS
Peters, N	1997	95	988	Circulation	MEDLINE
Wolk, R	1999	84	207	Pharmacol Ther	HCAPLUS

L98 ANSWER 12 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:935626 HCAPLUS Full-text
DOCUMENT NUMBER: 136:64121
TITLE: Peptide conjugates modified n- and/or c-terminally by short charged peptide chains
INVENTOR(S): *Larsen, Bjarne Due*; *Petersen, Jorgen Soberg*; Kapusta, Daniel R.; Harlow, Kenneth William
PATENT ASSIGNEE(S): Zealand Pharmaceuticals A/S, Den.
SOURCE: PCT Int. Appl., 72 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2001098324	A1	20011227	WO 2001-US19113		20010615 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
CA 2410224	A1	20011227	CA 2001-2410224		20010615 <--
EP 1294746	A1	20030326	EP 2001-952155		20010615 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
JP 2004516811	T	20040610	JP 2002-504279		20010615 <--
PRIORITY APPLN. INFO.:			DK 2000-944	A	20000616 <--
			DK 2000-1485	A	20001005 <--

US 2000-251671P	P	20001206 <--
US 2001-298186P	P	20010613
WO 2001-US19113	W	20010615
WO 2001-US41008	A	20010615

OTHER SOURCE(S): MARPAT 136:64121

AB Disclosed are a variety of peptide conjugates represented by the following general formula R1-Z-X-Z'-R2, wherein X represents a hexapeptide of the formula A1-A2-A3-A4-A5-A6 wherein A1 represents Arg, Lys, or His, A2 represents Tyr, Trp, or Phe, A3 represents Tyr, Asn, Trp or Phe, A4 represents Lys, Arg or His, A5 represents Phe, Tyr, Trp, Leu, Val or Ile, and A6 represents Arg, Lys, or His and wherein each amino acid residue in said hexapeptide may be in the L or D form; Z represents a charged peptide chain of from 4 to 20 amino acid residues having the D or L configuration or is missing; and Z' represents a charged peptide chain of from 4 to 20 amino acid residues having the D or L configuration or is missing, providing that not both of Z and Z' are missing; R1 represents H or an acyl group; R2 represents NR3R4 where each of R3 and R4 independently represents hydrogen, C(1-6)alkoxy, aryloxy, or a lower alkyl as defined herein; or R2 represents OH; the peptide conjugates of formula (I) being optionally further linked to a transport moiety; and salts, hydrates and solvates thereof, and C-terminally amidated or esterified derivs. thereof with suitable organic or inorg. acids, including methods or making and using such conjugates. Also provided are antibodies that specifically bind the peptide conjugates. The present invention has a wide spectrum of important applications including use in the treatment of disorders impacted by nociceptin and related opioid-like peptides.

IC ICM C07K007-08
ICS C07K014-00; C07K016-44; A61K038-16; C07K007-06; C07K014-575; A61K038-04

CC 1-8 (Pharmacology)
Section cross-reference(s): 15, 34, 63

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Lapalu, S	1997	417	333	FEBS LETTERS	HCAPLUS
Meunier, J	2000	21	893	PEPTIDES	HCAPLUS
Novonordisk As	1999			WO 9944627 A	HCAPLUS

L98 ANSWER 13 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:504962 HCAPLUS Full-text
DOCUMENT NUMBER: 135:298164
TITLE: Structure-activity relationships of novel peptides related to the antiarrhythmic peptide AAP10 which reduce the dispersion of epicardial action potential duration
AUTHOR(S): Grover, R.; Dhein, S.
CORPORATE SOURCE: Institute of Pharmacology, University of Cologne, Cologne, 50931, Germany
SOURCE: Peptides (New York, NY, United States) (2001), 22(7), 1011-1021
CODEN: PPTDD5; ISSN: 0196-9781
PUBLISHER: Elsevier Science Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB We report the first study on short peptide structure-activity relationships (SAR) for the antiarrhythmic peptide AAP10 and its putative receptor. Synthetic improvements on the natural antiarrhythmic peptide AAPnat (H-*Gly*-Pro-Hyp-*Gly*-*Ala*-*Gly*) isolated from bovine atria led us to the synthesis of our lead mol. AAP10 (H-*Gly*-*Ala*-*Gly*-Hyp-Pro-Tyr-NH2) which reduces dispersion of epicardial potential duration and acts antiarrhythmically in isolated rabbit

hearts. The aim of our study was to elucidate structure-activity relationships for AAP10 based on Langendorff expts. and mol. modeling. Mutation of the amino acid sequence led to 11 different peptides which were tested analogous to the lead mol. Among these new synthetic peptides various including the cyclopeptide cAAP10RG, cyclo[CF3C(OH)-*Gly-Ala-Gly*-Hyp-Pro-Tyr] showed promising activities. (supported by the DFG and Koln-Fortune).

CC 1-3 (Pharmacology)

IT *81771-37-1*, Antiarrhythmic peptide (cattle atrium)
159503-65-8 366800-46-6 366800-47-7 366800-48-8
366800-49-9 366800-50-2 366800-51-3 366800-52-4 *366800-53-5*
366800-54-6 366800-55-7 366800-56-8 366800-57-9 366800-58-0
366800-59-1
RL: *BAC (Biological activity or effector, except adverse)*; BSU (Biological study, unclassified); PRP (Properties); *THU (Therapeutic use)*; BIOL (Biological study); USES (Uses)
(structure-activity relationships of novel peptides related to antiarrhythmic peptide AAP10 which reduce dispersion of epicardial action potential duration)

IT *81771-37-1*, Antiarrhythmic peptide (cattle atrium)
159503-65-8 366800-53-5
RL: *BAC (Biological activity or effector, except adverse)*; BSU (Biological study, unclassified); PRP (Properties); *THU (Therapeutic use)*; BIOL (Biological study); USES (Uses)
(structure-activity relationships of novel peptides related to antiarrhythmic peptide AAP10 which reduce dispersion of epicardial action potential duration)

RN 81771-37-1 HCAPLUS

CN Antiarrhythmic peptide (cattle atrium) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 159503-65-8 HCAPLUS

CN retro-Antiarrhythmic peptide (cattle atrium), 6-L-tyrosinamide- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 366800-53-5 HCAPLUS
CN L-Tyrosinamide, glycyl-L-alanylglycyl-L-prolyl-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Atherton, E	1989			Solid phase peptide	
Beck-Sickinger, A	1991	4	88	Pept res	HCAPLUS
Bhacca, N	1962			High resolution NMR	
Carpino, L	1972	37	3404	J Org Chem	HCAPLUS
Curphey, T	1979	44	2805	J Org Chem	HCAPLUS
Dhein, S	1999	128	1375	Br J Pharmacol	HCAPLUS
Dhein, S	1993	87	617	Circulation	HCAPLUS
Dhein, S	1997	96	I-292	Circulation	
Dhein, S	1995	49	851	Drugs	HCAPLUS
Dhein, S	1997	2	51	Exp Clin Cardiol	
Dhein, S	1994	350	174	Naunyn Schmiedebergs	HCAPLUS
Dhein, S	1994	349	R55	Naunyn Schmiedebergs	
Dhein, S	1999	359	R7	Naunyn Schmiedebergs	
Dhein, S	1995	429	R91	Pflug Arch Eur J Phy	
Dhein, S	1998		163	Proceedings of Inter	HCAPLUS
Durrer, D	1954	47	192	Am Heart J	MEDLINE
Friebolin, H	1988			Ein-Und Zweidimensio	
Gottwald, E	1998	79	474	Heart	MEDLINE
Grover, R	1998	19	1725	Peptides	HCAPLUS
Han, J	1964	16	46	Circ Res	
Kjolbye, A	2000	14	A698	The FASEB J	
Kuo, C	1983	67	1356	Circulation	MEDLINE
Lesh, M	1989	65	1426	Circ Res	MEDLINE
Meyer, V	1978			Praxis in der HPLC	
Millar, C	1985	72	1372	Circulation	MEDLINE
Mueller, A	1997	327	65	Eur J Pharmacol	HCAPLUS
Mueller, A	1997	356	76	Naunyn Schmiedebergs	HCAPLUS
Nomizu, M	1994	20	2691	Tetrahedron	
Patrick, G	1995			An introduction to m	
Rink, H	1987	28	3787	Tetrahedron Lett	HCAPLUS
Viswanadhan, V	1989	29	163	J chem inf comput sc	HCAPLUS
Wang, S	1973	95	1328	J Amer Chem Soc	HCAPLUS
Wiener, S	1984	106	765	J Am Chem Soc	

L98 ANSWER 14 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2000:144722 HCAPLUS Full-text
DOCUMENT NUMBER: 132:185454
TITLE: Use of anti-angiogenic agents for inhibiting vessel wall injury
INVENTOR(S): Brown, Charles L., III; Gorlin, Steve
PATENT ASSIGNEE(S): Global Vascular Concepts, Inc., USA
SOURCE: PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000010552	A2	20000302	WO 1999-US19218	19990824 <--
WO 2000010552	A3	20001123		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 9956871	A1	20000314	AU 1999-56871		19990824 <--
PRIORITY APPLN. INFO.:			US 1998-97579P	P	19980824 <--
			WO 1999-US19218	W	19990824 <--

AB Use of anti-angiogenic agents to inhibit an undesirable response to vessel wall injury, including stent neointima, dialysis graft neointima, vascular graft-induced neointima, and the treatment of benign hypertrophic scar formation as well as the treatment and passivation of unstable atherosclerotic plaques are provided. The invention provides for the use of catheter-based devices for enhancing the local delivery of anti-angiogenic agents into the endothelial tissues of blood vessels of the living body.

IC ICM A61K031-00
CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 1
IT 50-28-2, Estradiol, biological studies 50-35-1, Thalidomide 50-81-7D, Ascorbic acid, ethers, biological studies 52-01-7, Spironolactone 53-05-4, Tetrahydrocortisone 53-86-1, Indomethacin 60-33-3, Linoleic acid, biological studies 60-54-8, Tetracycline 68-96-2, 17α-Hydroxyprogesterone 128-13-2, Ursodeoxycholic acid 145-63-1, Suramin 152-58-9, Cortexolone 302-79-4, Retinoic acid 362-07-2, 2-Methoxyestradiol 446-72-0, Genistein 465-21-4, Bufalin 566-35-8 2609-46-3, Amiloride 4431-00-9, Aurine tricarboxylic acid 10118-90-8, Minocycline 12772-57-5, Radicicol 19545-26-7, Wortmannin 33069-62-4, Taxol 34031-32-8, Auranofin 37270-94-3, Platelet factor 4 38096-31-0, Diaminoanthraquinone 38194-50-2, Sulindac 50903-99-6, L-Name 53902-12-8, Tranilast *57381-26-7*, Irsogladine 62571-86-2, Captopril 62996-74-1, Staurosporine 65646-68-6, Fenretinide 70563-58-5, Herbimycin A 79831-76-8, Castanospermine 86090-08-6, Angiostatin 100827-28-9, Erbstatin 103909-75-7, 22-Oxa-1α-25-dihydroxyvitamin D3 105219-56-5, WEB 2086 110124-55-5, MDL 27032 125697-92-9, Lavendustin A 126509-46-4, Eponemycin 129298-91-5, TNP-470 130370-60-4, BB-94 134633-29-7, Tecogalan sodium 142186-14-9, FR-118487 148717-90-2, Squalamine 154039-60-8, Marimastat 171784-03-5, Louisianine A 171784-04-6, Louisianine B 171784-06-8, Louisianine D 187888-07-9, Endostatin

188417-67-6, CM 101 204005-46-9, SU5416
RL: *THU (Therapeutic use)*; BIOL (Biological study); USES (Uses)
(anti-angiogenic agents for inhibiting vessel wall injury)

IT *57381-26-7*, Irsogladine
RL: *THU (Therapeutic use)*; BIOL (Biological study); USES (Uses)
(anti-angiogenic agents for inhibiting vessel wall injury)

RN 57381-26-7 HCAPLUS

CN 1,3,5-Triazine-2,4-diamine, 6-(2,5-dichlorophenyl)- (9CI) (CA INDEX NAME)



L98 ANSWER 15 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2000:37178 HCAPLUS Full-text

DOCUMENT NUMBER: 132:343088

TITLE: Protective effect of irsogladine on monochloramine-induced gastric mucosal lesions in rats: a comparative study with Rebamipide

AUTHOR(S): Yamamoto, H.; Umeda, M.; Mizoguchi, H.; Kato, S.; Takeuchi, K.

CORPORATE SOURCE: Department of Pharmacology and Experimental Therapeutics, Kyoto Pharmaceutical University, Kyoto, 607-8414, Japan

SOURCE: World Journal of Gastroenterology (*1999*), 5(6), 477-482
CODEN: WJGAF2; ISSN: 1007-9327

PUBLISHER: World Journal of Gastroenterology

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Aim: To examine the effect of irsogladine, a novel antiulcer drug, on the mucosal ulcerogenic response to monochloramine (NH2Cl) in rat stomach, in comparison with Rebamipide, another antiulcer drug with cytoprotective activity. Methods and Results: Oral administration of NH2Cl (120 mM) produced severe hemorrhagic lesions in unanesthetized rat stomachs. Both irsogladine (1-10 mg/kg, orally) and Rebamipide (30-100 mg/kg, orally) dose-dependently prevented the development of these lesions in response to NH2Cl; the effect of irsogladine was significant at ≥3 mg/kg and that of Rebamipide only at 100 mg/kg. The protective effect of irsogladine on NH2Cl-induced gastric lesions was significantly reduced by NG-nitro-L-arginine Me ester (L-NAME) but not by indomethacin, while that of Rebamipide was significantly mitigated by indomethacin but not by L-NAME. Topical application of NH2Cl (20 mM) caused a marked reduction of p.d. (PD) in ex-vivo stomachs. This PD reduction was not affected by mucosal application of irsogladine but significantly prevented by Rebamipide. The mucosal exposure to NH4OH (120 mM) also caused a marked PD reduction in the ischemic stomach (bleeding from the carotid artery), resulting in gastric lesions. These ulcerogenic and PD responses caused by NH4OH plus ischemia were also significantly mitigated by Rebamipide, in an indomethacin-sensitive manner, while irsogladine potently prevented such lesions without affecting the PD response, in a L-NAME-sensitive manner. Conclusions: These results suggest that (1) NH2Cl generated either exogenously or endogenously damages the gastric mucosa, (2) both irsogladine and

Rebamipide protect the stomach against injury caused by NH2Cl, and (3) the mechanism underlying the protective action of irsogladine is partly mediated by endogenous nitric oxide while that of Rebamipide is in part mediated by endogenous prostaglandins.

CC 1-9 (Pharmacology)

IT *57381-26-7*, Irsogladine 90098-04-7, Rebamipide
RL: *BAC (Biological activity or effector, except adverse)*; BSU (Biological study, unclassified); *THU (Therapeutic use)*; BIOL (Biological study); USES (Uses)
(protective effect of irsogladine on monochloramine-induced gastric mucosal lesions in rats compared to Rebamipide)

IT *57381-26-7*, Irsogladine
RL: *BAC (Biological activity or effector, except adverse)*; BSU (Biological study, unclassified); *THU (Therapeutic use)*; BIOL (Biological study); USES (Uses)
(protective effect of irsogladine on monochloramine-induced gastric mucosal lesions in rats compared to Rebamipide)

RN 57381-26-7 HCAPLUS

CN 1,3,5-Triazine-2,4-diamine, 6-(2,5-dichlorophenyl)- (9CI) (CA INDEX NAME)



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Badwey, J	1980	46	695	Ann Rev Biochem	
Dekigai, H	1995	40	1332	Dig Dis Sci	MEDLINE
Graham, D	1989	96	615	Gastroenterology	
Grisham, M	1986	251	G567	Am J Physiol	HCAPLUS
Grisham, M	1984	259	10404	J Biol Chem	HCAPLUS
Ishihara, K	1992	42	1462	Arzneimittelforschun	HCAPLUS
Ivy, K	1970	59	683	Gastroenterology	
Kato, S	1977	42	2156	Dig Dis Sci	
Klevanoff, S	1980	93	480	Ann Intern Med	
Marshall, B	1983	1	1273	Lancet	
Marshall, B	1983	1	965	Lancet	
Murakami, M	1995	40	268	Dig Dis Sci	HCAPLUS
Murakami, M	1993	105	1710	Gastroenterology	HCAPLUS
Nishiwaki, H	1997	29	713	Gen Pharmacol	HCAPLUS
Okabe, S	1984	24	683	Pharmacometrics	
Svanes, K	1982	82	1409	Gastroenterology	HCAPLUS
Takeuchi, K	1989	49	235	Jpn J Pharmacol	HCAPLUS
Tepperman, B	1992	105	171	Br J Pharmacol	HCAPLUS
Ueda, F	1984	34P	474	Arzneimittelforschun	
Ueda, F	1984	34	478	Arzneimittelforschun	HCAPLUS
Whitehead, R	1972	25	1	J Clin Pathol	MEDLINE
Whittle, B	1990	99	607	Br J Pharmacol	HCAPLUS
Yamasaki, K	1987	142	23	Eur J Pharmacol	HCAPLUS
Yoshikawa, T	1993	43	363	Arzneimittelforschun	HCAPLUS

L98 ANSWER 16 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1998:714418 HCAPLUS Full-text
DOCUMENT NUMBER: 130:119294
TITLE: Effects of an antiarrhythmic peptide on intercellular coupling via gap junctions
AUTHOR(S): Dhein, Stefan; Gottwald, Michaela; Schaefer, Thomas; Muller, Andreas; Tudyka, Tatjana; Krusemann, Kathi; Grover, Rajiv
CORPORATE SOURCE: Institute of Pharmacology, University of Cologne, Cologne, D-50931, Germany
SOURCE: Gap Junctions, Proceedings of the International Gap Junction Conference, 8th, Key Largo, Fla., July 12-17, 1997 (*1998*), Meeting Date 1997, 163-167. Editor(s): Werner, Rudolf. IOS Press: Amsterdam, Neth.
CODEN: 66XYAX
DOCUMENT TYPE: Conference
LANGUAGE: English
AB We recently reported on a synthetic antiarrhythmic peptide (AAP10, NH2- *GLY*-*ALA*-*GLY*-HYP-PRO-TYR-CONH2) which was found to be effective against arrhythmia in the late ischemic period in isolated rabbit hearts. This peptide enhanced gap junctional current in pairs of adult guinea pig cardiomyocytes. In this study we wanted to investigate whether AAP10 acts on uncoupled guinea pig papillary muscles. After 30 min of equilibration at normoxic conditions the muscles were submitted to hypoxia with glucose free superfusion for 20 min with or without pretreatment with 10 nM AAP10. Under these conditions intracellular action potentials were recorded and the delay between stimulus and propagated action potential (stimulus-response interval, SRI) was evaluated. We found no effect of AAP10 under normoxic conditions on SRI or on action potential morphol. Resting membrane potential, amplitude, action potential duration, dU/dtmax were not altered. However, while in untreated muscles uncoupling occurred after 12 min, this was not the case in muscles treated with AAP10. In addnl. expts., we could demonstrate that uncoupling via 50 mM Na-propionate could be antagonized by 10 nM AAP10 without affecting other parameters than SRI. This AAP10 effect could be fully inhibited by 10 μM genistein and 1 μM bisindolylmaleimide I (a specific inhibitor of PKC), but not by 2 μM H8 (a specific PKA blocker) and not by 5 μM genistein. Using 14C-labeled AAP10 we found that the substance binds to membrane proteins but not to connexin 43. From these results we conclude that AAP10 can enhance intercellular coupling especially in situations with reduced coupling probably via a protein kinase C mediated mechanism.
CC 1-8 (Pharmacology)
IT *159503-65-8*, AAP10
RL: *BAC (Biological activity or effector, except adverse)*; BSU (Biological study, unclassified); *THU (Therapeutic use)*; BIOL (Biological study); USES (Uses)
(effects of an antiarrhythmic peptide on intercellular coupling via gap junctions)
IT *159503-65-8*, AAP10
RL: *BAC (Biological activity or effector, except adverse)*; BSU (Biological study, unclassified); *THU (Therapeutic use)*; BIOL (Biological study); USES (Uses)
(effects of an antiarrhythmic peptide on intercellular coupling via gap junctions)
RN 159503-65-8 HCAPLUS
CN retro-Antiarrhythmic peptide (cattle atrium), 6-L-tyrosinamide- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Aonuma, S	1980	28	3340	Chem Pharm Bull	HCAPLUS
Dhein, S	1997			Cardiac gap junction	
Dhein, S	1993	87	617	Circulation	HCAPLUS
Dhein, S	1995	92	I	Circulation	
Dhein, S	1996	94	I	Circulation	
Dhein, S	1995	49	851	Drugs	HCAPLUS
Dhein, S	1997	2	51	J Clin Exp Cardiol	
Dhein, S	1994	350	174	Naunyn Schmiedeberg'	HCAPLUS
Echt, D	1991	324	781	New Engl J Med	MEDLINE
Kwak, B	1995	6	1707	Mol Biol Cell	HCAPLUS
Lesh, M	1989	65	1426	Circ Res	MEDLINE
Manjunath, C	1987	142	228	Biochem Biophys Res	HCAPLUS
Muller, A	1993	88	11	Basic Res Cardiol	MEDLINE
Muller, A	1997	327	65	Eur J Pharmacol	MEDLINE
Muller, A	1997	356	76	Naunyn Schmiedeberg'	MEDLINE
Podrid, P	1985	29	33	Drugs	
Spray, D	1981	77	77	J Gen Physiol	MEDLINE
Takens-Kwak, B	1992	422	198	Pfluger's Arch	HCAPLUS
Weingart, R	1986	370	267	J Physiol (Lond)	MEDLINE

L98 ANSWER 17 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1997:278971 HCAPLUS Full-text
DOCUMENT NUMBER: 127:17689
TITLE: Process for preparation of triazine derivatives by cyclization
INVENTOR(S): Yagishita, Kenichi; Sato, Toyozo; Yokogoshi, Kiyonori
PATENT ASSIGNEE(S): Permachem Asia, Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 3 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 09087256	A	19970331	JP 1995-276084	19950920 <--
PRIORITY APPLN. INFO.:			JP 1995-276084	19950920 <--

OTHER SOURCE(S): CASREACT 127:17689
AB The title compds., useful for prevention and treatment of ulcer (no data), are prepared in an industrial manner efficiently and economically. Thus, 2,5-

dichlorobenzamidine is reacted with NaN(CN)2 in (HOCH2)2 to give 90% 2,4-diamino-6-(2,5-dichlorophenyl)-1,3,5-triazine.

IC ICM C07D251-18
ICS C07D251-18; A61K031-53

CC 28-14 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1

IT *57381-26-7P* 57381-27-8P
RL: *BAC (Biological activity or effector, except adverse)*; BSU (Biological study, unclassified); IMF (Industrial manufacture); SPN (Synthetic preparation); *THU (Therapeutic use)*; BIOL (Biological study); PREP (Preparation); USES (Uses)
(process for preparation of triazine derivs. by cyclization)

IT *57381-26-7P*
RL: *BAC (Biological activity or effector, except adverse)*; BSU (Biological study, unclassified); IMF (Industrial manufacture); SPN (Synthetic preparation); *THU (Therapeutic use)*; BIOL (Biological study); PREP (Preparation); USES (Uses)
(process for preparation of triazine derivs. by cyclization)

RN 57381-26-7 HCAPLUS

CN 1,3,5-Triazine-2,4-diamine, 6-(2,5-dichlorophenyl)- (9CI) (CA INDEX NAME)



L98 ANSWER 18 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1997:693510 HCAPLUS Full-text

DOCUMENT NUMBER: 128:18349

TITLE: N-oxidation of irsogladine by the CYP2C subfamily in the rat, dog, monkey and man

AUTHOR(S): Nakamura, A.; Hirota, T.; Morino, A.; Shimada, T.; Uematsu, T.

CORPORATE SOURCE: Research Laboratories, Nippon Shinyaku Co., Ltd., Kyoto, 601, Japan

SOURCE: Xenobiotica (*1997*), 27(10), 995-1003
CODEN: XENOBH; ISSN: 0049-8254

PUBLISHER: Taylor & Francis

DOCUMENT TYPE: Journal

LANGUAGE: English

AB 1. The metabolism of irsogladine (ISG) was studied in hepatic microsomes from the rat, dog, monkey and man, and marked species differences were observed in N-oxidation of ISG. The rank order of the activity of the N-oxidation was shown to be man < monkey < dog < rat. 2. Anti-NADPH-P 450 reductase antibody inhibited the formation of the N-oxidized metabolite of ISG (ISG-N-oxide) in hepatic microsomes from rats by 74%. Anti-CYP2C11 antibody also inhibited the formation of ISG-N-oxide in hepatic microsomes from rat by 73 %, whereas anti-CYP2E1, 3A2 and 4A1 antibody did not inhibit N-oxidation Thus, CYP2C11 in the rat is at least partially responsible for the N-oxidation of ISG in the rat. 3. Anti-CYP2C11 antibody also inhibited the formation of ISG-N-oxide in hepatic microsomes from the dog and monkey by 61 and 46 % resp. Therefore, a isoform(s) similar to CYP2C11 partially contributed to the N-oxidation of ISG in the dog and monkey. In contrast, human CYP2C9, a member of the human CYP2C subfamily, did not catalyze the N-oxidation of ISG. 4. These findings show

that the marked species difference in the N-oxidation of ISG is caused by the difference in the catalytic properties of CYP2C among the species examined

CC 1-2 (Pharmacology)
Section cross-reference(s): 13

IT *57381-26-7*, Irsogladine
RL: BPR (Biological process); BSU (Biological study, unclassified); *THU (Therapeutic use)*; BIOL (Biological study); PROC (Process); USES (Uses)
(N-oxidation of irsogladine by CYP2C subfamily in rat, dog, monkey and man)

IT *57381-26-7*, Irsogladine
RL: BPR (Biological process); BSU (Biological study, unclassified); *THU (Therapeutic use)*; BIOL (Biological study); PROC (Process); USES (Uses)
(N-oxidation of irsogladine by CYP2C subfamily in rat, dog, monkey and man)

RN 57381-26-7 HCAPLUS
CN 1,3,5-Triazine-2,4-diamine, 6-(2,5-dichlorophenyl)- (9CI) (CA INDEX NAME)



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Ando, T	1989	36	1221	Arzneimittel Forschu	
Cashman, J	1993	21	492	Drug Metabolism and	HCAPLUS
Chiba, K	1995	10	391	Xenobiotic Metabolis	HCAPLUS
Funae, Y	1993		221	Handbook of Experime	HCAPLUS
Gonzalez, F	1993		239	Handbook of Experime	HCAPLUS
Imaoka, S	1996	51	1041	Biochemical Pharmaco	HCAPLUS
Komori, M	1989	38	235	Biochemical Pharmaco	HCAPLUS
Lowry, O	1981	193	265	Journal of Biologica	
Mani, C	1993	21	645	Drug Metabolism and	HCAPLUS
Mani, C	1993	21	657	Drug Metabolism and	HCAPLUS
Miura, T	1989	49	365	Japan Journal of Pha	HCAPLUS
Nakashima, M	1984	34	492	Arzneimittel Forschu	HCAPLUS
Nedelcheva, V	1994	24	1151	Xenobiotica	HCAPLUS
Ohta, O	1983	996	142	Biochimica et Biophy	
Prough, R	1977	180	363	Archives of Biochemi	HCAPLUS
Rodrigues, A	1994	22	788	Drug Metabolism and	HCAPLUS
Rouer, E	1987	15	524	Drug Metabolism and	HCAPLUS
Shimada, T	1994	270	414	Journal of Pharmacol	HCAPLUS
Smith, D	1991	23	355	Drug Metabolism Revi	HCAPLUS
Sugiyama, M	1989	36	1229	Arzneimittel Forschu	
Uchida, T	1990	38	644	Molecular Pharmacolo	HCAPLUS
Ueda, F	1984	34	474	Arzneimittel Forschu	HCAPLUS
Ueda, F	1984	34	478	Arzneimittel Forschu	HCAPLUS
Ueda, F	1991	57	321	Japan Journal of Pha	HCAPLUS
Ueda, F	1994	271	397	Journal of Pharmacol	HCAPLUS
Weaver, R	1994	47	763	Biochemical Pharmaco	HCAPLUS
Zins, G	1965	150	109	Journal of Pharmacol	HCAPLUS

Zins, G |1967 |159 |194 |Journal of Pharmacol|

L98 ANSWER 19 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1997:424142 HCAPLUS Full-text
DOCUMENT NUMBER: 127:130662
TITLE: Actions of the antiarrhythmic peptide AAP10 on intercellular coupling
AUTHOR(S): Mueller, Andreas; Schaefer, Thomas; Linke, Werner; Tudyka, Tatjana; Gottwald, Michaela; Klaus, Wolfgang; Dhein, Stefan
CORPORATE SOURCE: Institute of Pharmacology, University of Koln, Koln, D-50931, Germany
SOURCE: Naunyn-Schmiedeberg's Archives of Pharmacology (*1997*), 356(1), 76-82
CODEN: NSAPCC; ISSN: 0028-1298
PUBLISHER: Springer
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Disturbances in gap junction distribution and a decrease in the connexin43 content of the heart were shown to occur after myocardial infarction and in ischemic heart disease, resp. These changes are now thought to play an important role in the genesis of arrhythmias associated with these diseases. It is thought that agents that can increase cellular coupling might be beneficial in these situations. Recently, we presented data showing that the synthetic peptide AAP10 acts antiarrhythmically in a model of regional ischemia. The data suggested that AAP10 might act via an increase in cellular coupling. The goal of this study was to establish whether AAP10 can interact with cardiac gap junctions. Measurements of the stimulus-response-interval (SRI) in guinea pig papillary muscle showed that high concns. of AAP10 (1 μM) can decrease the SRI by about 10% under normoxic conditions. At lower concns. (10 nM) AAP10 had no effect on SRI under normoxic conditions but prevented the increase in the SRI induced by perfusion with hypoxic, glucose-free Tyrode's solution Double-cell voltage-clamp expts. confirmed that AAP10 can interact with cardiac gap junctions. 10 NM AAP10 could either diminish or reverse the run-down of gap junction conductance normally observed in pairs of guinea pig ventricular myocytes. During control gap junction conductance decreased with a rate of -2.5±2.0 nS/min. After application of 10 nM AAP10 gap junction conductance increased with a rate of +1.0±0.7 nS/min. After washout of AAP10 gap junction conductance decreased again with a rate not significantly different from control. Our results show that AAP10 does interact with gap junctions. Because no other effects of AAP10 on other electrophysiol. parameters could be found, this action on gap junctions might be the basis of AAP10's antiarrhythmic effect seen in previous studies.

CC 1-8 (Pharmacology)
IT *159503-65-8*, AAP 10
RL: *BAC (Biological activity or effector, except adverse)*; BSU (Biological study, unclassified); *THU (Therapeutic use)*; BIOL (Biological study); USES (Uses)
(actions of antiarrhythmic peptide AAP10 on intercellular coupling)
IT *159503-65-8*, AAP 10
RL: *BAC (Biological activity or effector, except adverse)*; BSU (Biological study, unclassified); *THU (Therapeutic use)*; BIOL (Biological study); USES (Uses)
(actions of antiarrhythmic peptide AAP10 on intercellular coupling)
RN 159503-65-8 HCAPLUS
CN retro-Antiarrhythmic peptide (cattle atrium), 6-L-tyrosinamide- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L98 ANSWER 20 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1997:331424 HCAPLUS Full-text
DOCUMENT NUMBER: 127:44651
TITLE: Increase in gap junction conductance by an antiarrhythmic peptide
AUTHOR(S): Mueller, Andreas; Gottwald, Michaela; Tudyka, Tatjana; Linke, Werner; Klaus, Wolfgang; Dhein, Stefan
CORPORATE SOURCE: Institute of Pharmacology, University of Koeln, Gleueler Strasse 24, Koln, D-50931, Germany
SOURCE: European Journal of Pharmacology (*1997*), 327(1), 65-72
CODEN: EJPHAZ; ISSN: 0014-2999
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Impaired cellular coupling is thought to be a very important factor for the genesis of cardiac arrhythmia. Cellular coupling is mediated by gap junctions. However, there are no therapeutic agents or exptl. substances yet that increase cellular coupling. In addition, it has been shown that most antiarrhythmic drugs available now possess serious adverse effects. Thus, there is an urgent need for new antiarrhythmic agents. Previous studies using epicardial mapping in isolated rabbit hearts provided indirect evidence supporting the hypothesis that a newly synthesized antiarrhythmic peptide (*Gly-Ala-Gly* -4Hyp-Pro-Tyr-CONH2 = AAP10) might act via an increase in cellular, i.e., gap junctional coupling. The aim of the present study was to test this hypothesis. Measurement of the stimulus-response interval in papillary muscle showed a decrease of about 10% after application of 1 μM AAP10. These results are compatible with the hypothesis of AAP10 acting on gap junctions. In order to prove this hypothesis, gap junction conductance was measured directly by performing double-cell voltage-clamp expts. in isolated pairs of guinea-pig myocytes. During a 10 min control period gap junction conductance slowly decreased with a rate of -2.5±2.0 nS/min. After application of 10 nM AAP10 this behavior reversed and gap junction conductance now increased with +1.0±0.7 nS/min. Upon washout of AAP10 gap junction conductance again decreased with a rate similar to that under control conditions. Another important finding was that we could not detect any other actions of AAP10 on cardiac myocytes. All parameters of the transmembrane action potential remained unchanged and, similarly, no changes in the IV relationship of single cardiac myocytes treated with 10 nM AAP10 could be observed We conclude that AAP10 increases gap junction conductance, i.e., cellular coupling in the heart. This finding might be the first step towards the development of a new class of antiarrhythmic agents.

CC 1-8 (Pharmacology)
IT Antiarrhythmics
(antiarrhythmic peptide AAP10 (*Gly-Ala-Gly*

-4Hyp-Pro-Tyr-CONH2) increases gap junction conductance)

IT Cell junction
(gap junction, coupling; antiarrhythmic peptide AAP10 (*Gly-Ala-Gly*-4Hyp-Pro-Tyr-CONH2) increases gap junction conductance)

IT *159503-65-8*, AAP 10
RL: *BAC (Biological activity or effector, except adverse)*; BSU (Biological study, unclassified); *THU (Therapeutic use)*; BIOL (Biological study); USES (Uses)
(antiarrhythmic peptide AAP10 (*Gly-Ala-Gly*-4Hyp-Pro-Tyr-CONH2) increases gap junction conductance 180268740)

IT *159503-65-8*, AAP 10
RL: *BAC (Biological activity or effector, except adverse)*; BSU (Biological study, unclassified); *THU (Therapeutic use)*; BIOL (Biological study); USES (Uses)
(antiarrhythmic peptide AAP10 (*Gly-Ala-Gly*-4Hyp-Pro-Tyr-CONH2) increases gap junction conductance 180268740)

RN 159503-65-8 HCAPLUS

CN retro-Antiarrhythmic peptide (cattle atrium), 6-L-tyrosinamide- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Aonuma, S	1980	28	3332	Chem Pharm Bull	HCAPLUS
Balke, C	1988	63	879	Circ Res	MEDLINE
Bastide, B	1993	73	1138	Circ Res	HCAPLUS
Cai, D	1994	41	217	IEEE Trans Biomed En	MEDLINE
Cole, W	1988	53	809	Biophys J	MEDLINE
de-Carvalho, C	1992	70	733	Circ Res	
Dhein, S	1995	49	851	Drugs	HCAPLUS
Dhein, S	1994	350	174	Naunyn-Schmiedeberg'	HCAPLUS
Halliwell, J	1994		17	Microelectrode Techn	
Hamill, O	1981	391	85	Pflug Arch	MEDLINE
Jarolimek, W	1993	425	491	Pflug Arch	HCAPLUS
Kleber, A	1987	61	271	Circ Res	MEDLINE
Kuo, C	1983	67	1356	Circulation	MEDLINE
Lesh, M	1989	65	1426	Circ Res	MEDLINE
Merx, W	1977	94	603	Am Heart J	MEDLINE
Metzger, P	1985	366	177	J Physiol (London)	MEDLINE
Muller, A	1993	88	11	Basic Res Cardiol	MEDLINE
Page, E	1992		1003	The Heart and Cardio	
Peters, N	1993	88	864	Circulation	HCAPLUS

Saffitz, J	1993	87	1742	Circulation	MEDLINE
Severs, N	1994	5	462	J Cardiovasc Electro	MEDLINE
Smith, J	1991	139	801	Am J Pathol	MEDLINE
Spach, M	1994	90	1103	Circulation	MEDLINE
Spray, D	1981	77	77	J Gen Physiol	MEDLINE
Steendijk, P	1993	88	167	Basic Res Cardiol	MEDLINE
Veenstra, R	1990	258	C662	Am J Physiol	MEDLINE
Wang, H	1992	63	139	Biophys J	HCAPLUS
Weingart, R	1988	63	72	Circ Res	MEDLINE
Weingart, R	1986	370	267	J Physiol (London)	MEDLINE
Wilders, R	1992	63	942	Biophys J	MEDLINE

L98 ANSWER 21 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1997:86895 HCAPLUS Full-text
DOCUMENT NUMBER: 126:194926
TITLE: Triazine derivatives inhibit rat hepatocarcinogenesis but do not enhance gap junctional intercellular communication
AUTHOR(S): Hori, Takaaki; Asamoto, Makoto; Krutovskikh, Vladimir; Iwahori, Yoshio; Maeda, Mitsuaki; Toriyama-Baba, Hiroyasu; Takasuka, Nobuo; Tsuda, Hiroyuki
CORPORATE SOURCE: Chemotherapy Division, National Cancer Center Research Institute, Tokyo, 104, Japan
SOURCE: Japanese Journal of Cancer Research (*1997*), 88(1), 12-17
CODEN: JJCREP; ISSN: 0910-5050
PUBLISHER: Japanese Cancer Association
DOCUMENT TYPE: Journal
LANGUAGE: English

AB We report here novel candidate chemopreventive agents active against exptl. hepatocarcinogenesis. The triazine derivs. 6-(2-chlorophenyl)-2,4- diamino-1,3,5-triazine (2CPDAT), 6-(3-chlorophenyl)-2,4-diamino-1,3,5- triazine (3CPDAT), 6-(4-chlorophenyl)-2,4-diamino-1,3,5-triazine (4CPDAT), 6-(4-pyridyl)-2,4-diamino-1,3,5-triazine (PyDAT), and 6-(pyridine N-oxid-4-yl)-2,4-diamino-1,3,5-triazine (PyNODAT), synthesized in our laboratory, in addition to 6-(2,5-dichlorophenyl)-2,4-diamino-1,3,5-triazine (DCPDAT), or irsogladine, which is a widely used anti-ulcer drug, were investigated for potential chemopreventive effects in a rat liver medium-term bioassay system. A significant inhibitory influence on enzyme-altered liver foci was found for 2CPDAT, 3CPDAT, 4CPDAT, and PyNODAT, but not for DCPDAT or PyDAT. The involvement of gap junctional intercellular communication in the inhibition was studied, but no change in gap junctional intercellular communication capacity in rat liver cells in vitro or in gap junction protein (connexin 32) expression in rat liver in vivo was noted. These results indicate that, although these irsogladine analogs exert inhibitory effects on rat liver carcinogenesis, their action is independent of modification of gap junctional intercellular communication.

CC 1-6 (Pharmacology)
IT 4514-53-8 4514-54-9 29366-77-6 33237-20-6 *57381-26-7* 187753-86-2
RL: *BAC (Biological activity or effector, except adverse)*; BSU (Biological study, unclassified); *THU (Therapeutic use)*; BIOL (Biological study); USES (Uses)
(triazine derivs. inhibit hepatocarcinogenesis but do not enhance gap junctional intercellular communication)
IT *57381-26-7*
RL: *BAC (Biological activity or effector, except adverse)*; BSU (Biological study, unclassified); *THU (Therapeutic use)*; BIOL (Biological study); USES (Uses)
(triazine derivs. inhibit hepatocarcinogenesis but do not enhance gap

junctional intercellular communication)
RN 57381-26-7 HCAPLUS
CN 1,3,5-Triazine-2,4-diamine, 6-(2,5-dichlorophenyl)- (9CI) (CA INDEX NAME)



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Asamoto, M	1991	4	322	Mol Carcinog	HCAPLUS
Bertram, J	1994	234	235	Methods Enzymol	HCAPLUS
Bertram, J	1989	18	562	Prev Med	HCAPLUS
Bex, V	1995	13	69	Cell Biochem Funct	HCAPLUS
Budunova, I	1994	10	71	Cell Biol Toxicol	HCAPLUS
Demilo, A	1981	29	82	J Agric Food Chem	HCAPLUS
El-Fouly, M	1987	168	422	Exp Cell Res	HCAPLUS
Hirose, Y	1996	87	549	Jpn J Cancer Res	HCAPLUS
Holder, J	1993	53	3475	Cancer Res	HCAPLUS
Hosokawa, T	1992	118	565	J Cancer Res Clin On	MEDLINE
Ito, N	1988	9	387	Carcinogenesis	HCAPLUS
Ito, N	1989	17	630	Toxicol Pathol	HCAPLUS
Jansen, L	1996	17	333	Carcinogenesis	HCAPLUS
Klaunig, J	1990	62	135	Lab Invest	HCAPLUS
Krutovskikh, V	1991	12	1701	Carcinogenesis	HCAPLUS
Kumar, N	1986	103	767	J Cell Biol	HCAPLUS
Lalezari, I	1971	16	117	J Chem Eng Data	HCAPLUS
Loewenstein, W	1979	560	1	Biochim Biophys Acta	HCAPLUS
McKarns, S	1992	8	89	Cell Biol Toxicol	HCAPLUS
Mesnil, M	1986	165	391	Exp Cell Res	HCAPLUS
Murray, A	1979	91	395	Biochem Biophys Res	HCAPLUS
Murray, A	1982	7	587	Carcinogenesis	MEDLINE
Ogino, A	1980	23	437	J Med Chem	HCAPLUS
Ruch, R	1987	87	111	Toxicol Appl Pharmac	HCAPLUS
Saez, J	1989	257	1	Am J Physiol	
Sato, Y	1993	322	155	FEBS Lett	HCAPLUS
Satoh, K	1985	82	3964	Proc Natl Acad Sci U	HCAPLUS
Slaga, T	1981	213	1023	Science	HCAPLUS
Smyrl, N	1982	19	493	J Heterocycl Chem	HCAPLUS
Sumi, N	1986	36	251	Pharmacometrics	
Trosko, J	1993	53	1	Life Sci	HCAPLUS
Tsushimoto, G	1983	12	721	Arch Environ Contam	HCAPLUS
Ueda, F	1984	34	478	Arzneim Forsch	HCAPLUS
Ueda, F	1991	57	321	Jpn J Pharmacol	HCAPLUS
Williams, G	1981	11	339	Cancer Lett	HCAPLUS
Yamasaki, H	1995	333	181	Mutat Res	HCAPLUS
Yotti, L	1979	206	1089	Science	HCAPLUS
Zhang, L	1991	12	2109	Carcinogenesis	HCAPLUS

L98 ANSWER 22 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1996:385934 HCAPLUS Full-text
DOCUMENT NUMBER: 125:41767

TITLE: Synthesis and formulation of triazine derivatives as hepatitis remedies
INVENTOR(S): Ueda, Fusao; Ozaki, Takayuki; Nakamura, Ken-ichi
PATENT ASSIGNEE(S): Nippon Shinyaku Co., Ltd., Japan
SOURCE: PCT Int. Appl., 56 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9604914	A1	19960222	WO 1995-JP1577	19950808 <--
W: AU, BR, CA, CN, FI, HU, JP, KR, MX, NO, NZ, RU, UA, US, VN				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2197091	A1	19960222	CA 1995-2197091	19950808 <--
AU 9531920	A	19960307	AU 1995-31920	19950808 <--
AU 703263	B2	19990325		
EP 775487	A1	19970528	EP 1995-927992	19950808 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, PT, SE				
CN 1155244	A	19970723	CN 1995-194521	19950808 <--
BR 9508539	A	19971028	BR 1995-8539	19950808 <--
HU 77735	A2	19980728	HU 1997-355	19950808 <--
RU 2147233	C1	20000410	RU 1997-103983	19950808 <--
US 5962453	A	19991005	US 1997-776992	19970206 <--
PRIORITY APPLN. INFO.:			JP 1994-185810 A	19940808 <--
			WO 1995-JP1577 W	19950808 <--

OTHER SOURCE(S): MARPAT 125:41767
GI



I

AB A medicine useful as a hepatitis remedy is claimed which contains as the active ingredient a triazine derivative represented by general formula (I), a solvate thereof, or a salt thereof, wherein R1 and R2 represent each independently hydrogen or (un)substituted alkyl, aralkyl or alkenyl, or NR1R2 represents a cyclic amino group which may bear, in addition to the pertinent nitrogen atom, nitrogen, oxygen or sulfur as the ring atom and may be substituted, provided the case where NR1R2 represents NH2 is excluded. Studies in mouse and rat models of hepatitis indicate the remedial efficacy of various I.

IC ICM A61K031-53
ICS A61K031-535; A61K031-54; A61K031-55
CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 1, 28
IT *57381-26-7DP*, derivs. 178105-27-6P 178105-28-7P 178105-29-8P 178105-31-2P 178105-32-3P 178105-48-1P 178105-57-2P 178105-59-4P

178105-60-7P 178105-61-8P 178105-65-2P 178105-85-6P 178105-91-4P
RL: *BAC (Biological activity or effector, except adverse)*; BSU (Biological study, unclassified); SPN (Synthetic preparation); *THU (Therapeutic use)*; BIOL (Biological study); PREP (Preparation); USES (Uses)
(synthesis and formulation of triazine derivs. as hepatitis remedies)

IT 51-35-4, 4-Hydroxyproline 56-40-6, *Glycine*, reactions 62-53-3, Aniline, reactions 64-04-0, Phenethylamine 68-12-2, N,N-Dimethylformamide, reactions 74-89-5, Methylamine, reactions 92-54-6, N-Phenylpiperazine 100-36-7, N,N-Diethylethylenediamine 100-46-9, Benzylamine, reactions 103-67-3, N-Methylbenzylamine 103-76-4, N-(2-Hydroxyethyl)piperazine 107-15-3, 1,2-Ethanediamine, reactions 108-18-9, Diisopropylamine 109-05-7, 2-Methylpiperidine 109-83-1, N-Methyl-N-(2-hydroxyethyl)amine 109-85-3, 2-Methoxyethylamine 109-96-6, 3-Pyrroline 110-85-0, Piperazine, reactions 110-89-4, Piperidine, reactions 110-91-8, Morpholine, reactions 111-42-2, reactions 111-49-9, Hexamethylenimine 123-75-1, Pyrrolidine, reactions 123-90-0, Thiomorpholine 124-40-3, Dimethylamine, reactions 124-63-0, Methanesulfonyl chloride 141-43-5, Ethanolamine, reactions 141-91-3, 2,6-Dimethylmorpholine 147-85-3, (s)-Proline, reactions 503-29-7, Azetidine 535-75-1, 2-Carboxypiperidine 598-41-4, Glycinamide 660-68-4, Diethylamine hydrochloride 841-77-0, 1-Diphenylmethylpiperazine 1499-56-5, trans-4-Hydroxy-L-proline methyl ester 1664-40-0, N-Phenylethylenediamine 1758-46-9, 2-Phenoxyethylamine 2038-03-1, 4-Morpholineethanamine 4360-51-4, Cinnamylamine 5082-74-6, 3-Hydroxymethylpyrrolidine 5382-16-1, 4-Hydroxypiperidine 5625-67-2, 2-Oxopiperazine 6457-49-4, 4-Hydroxymethylpiperidine 6859-99-0, 3-Hydroxypiperidine 18471-40-4, 3-Amino-1-benzylpyrrolidine 19130-96-2, 1,5-Dideoxy-1,5-imino-D-glucitol 20980-22-7 23356-96-9 24252-67-3 27578-60-5, 2-Piperidinoethylamine 31252-42-3, 4-Benzylpiperidine 40499-83-0, 3-Hydroxypyrrolidine 40807-61-2, 4-Hydroxy-4-phenylpiperidine 41661-47-6, 4-Oxopiperidine 45347-82-8, 3-Azetidinol 55276-43-2 68832-13-3 72351-36-1 81530-73-6 103706-76-9 138304-74-2 149366-79-0 178105-24-3 178105-25-4 178105-26-5 178105-46-9 178105-69-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(synthesis and formulation of triazine derivs. as hepatitis remedies)

IT *57381-26-7DP*, derivs.
RL: *BAC (Biological activity or effector, except adverse)*; BSU (Biological study, unclassified); SPN (Synthetic preparation); *THU (Therapeutic use)*; BIOL (Biological study); PREP (Preparation); USES (Uses)
(synthesis and formulation of triazine derivs. as hepatitis remedies)

RN 57381-26-7 HCAPLUS
CN 1,3,5-Triazine-2,4-diamine, 6-(2,5-dichlorophenyl)- (9CI) (CA INDEX NAME)



L98 ANSWER 23 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1996:203525 HCAPLUS Full-text
DOCUMENT NUMBER: 124:278316

TITLE: Inhibition of tumor growth and neovascularization by an anti-gastric ulcer agent irsogladine
AUTHOR(S): Ono, Mayumi; Kawahara, Naoyuki; Goto, Daisuke; Wakabayashi, Yukihiro; Ushiro, Shin; Yoshida, Shigeo; Izumi, Hiroto; Kuwano, Michihiko; Sato, Yashufumi
CORPORATE SOURCE: School Medicine, Kyushu Univ., Fukuoka, 812-82, Japan
SOURCE: Cancer Research (*1996*), 56(7), 1512-16
CODEN: CNREA8; ISSN: 0008-5472
PUBLISHER: American Association for Cancer Research
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Irsogladine used clin. as an anti-gastric ulcer agent, at 10-6-10-4 M, inhibited cell proliferation and tubular morphogenesis of vascular endothelial cells, but the proliferation of human epidermoid cancer of glioma cells was not inhibited by this drug, even at 10-4 M. In vivo studies demonstrated that p.o. administration of irsogladine significantly inhibited tumor growth of human glioma cells in mice, and histol. anal. showed a dramatic decrease of the neovascularization in the tumors. In mice transplanted with chambers containing human glioma cells or hepatic cancer cells, irsogladine also inhibited angiogenesis. These in vivo and in vitro assays demonstrate that irsogladine may be a unique and potent inhibitor of tumor angiogenesis.

CC 1-6 (Pharmacology)
IT *57381-26-7*, Irsogladine
RL: *BAC (Biological activity or effector, except adverse)*; BSU (Biological study, unclassified); *THU (Therapeutic use)*; BIOL (Biological study); USES (Uses)
(inhibition of tumor growth and neovascularization by irsogladine)
IT *57381-26-7*, Irsogladine
RL: *BAC (Biological activity or effector, except adverse)*; BSU (Biological study, unclassified); *THU (Therapeutic use)*; BIOL (Biological study); USES (Uses)
(inhibition of tumor growth and neovascularization by irsogladine)
RN 57381-26-7 HCAPLUS
CN 1,3,5-Triazine-2,4-diamine, 6-(2,5-dichlorophenyl)- (9CI) (CA INDEX NAME)



L98 ANSWER 24 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1996:387151 HCAPLUS Full-text
DOCUMENT NUMBER: 125:104423
TITLE: Suppressing effects of 6-(2,5-dichlorophenyl)-2,4-diamino-1,3,5-triazine and related synthetic compounds on azoxymethane-induced aberrant crypt foci in rat colon
AUTHOR(S): Hirose, Yoshinobu; Tanaka, Takuji; Makita, Hiroki; Yang, Muzheng; Satoh, Kumiko; Hara, Akira; Maeda, Mitsuaki; Toriyama, Hiroyasu Baba; Mori, Hideki; Tsuda, Hiroyuki
CORPORATE SOURCE: First Dep. Pathol., Gifu Univ. Sch. Med., Gifu, 500, Japan
SOURCE: Japanese Journal of Cancer Research (*1996*),

87(6), 549-554
CODEN: JJCREP; ISSN: 0910-5050
PUBLISHER: Japanese Cancer Association
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The modifying effects of dietary administration of 6-(2,5-dichlorophenyl)-2,4-diamino-1,3,5-triazine and 5 related compds. on the occurrence of azoxymethane (AOM)-induced colonic aberrant crypt foci (ACF) were investigated in rats. Male F344 rats were given s.c. injections of AOM (15 mg/kg body weight) once a wk for 3 wks to induce ACF. They also received a diet containing 200 ppm test compound for 5 wks, starting one wk before the first dosing of AOM. At the termination of the experiment, all of the compds. had caused a significant reduction in ACF frequency, which might by associated with suppression of the expression of proliferation biomarkers. The apoptotic index in the colonic mucosal epithelium of rats killed at 6 h after the first AOM exposure revealed no blocking activity of the compds.

CC 1-6 (Pharmacology)

IT 4514-53-8 4514-54-9 29366-77-6 33237-20-6 *57381-26-7* 178991-22-5
RL: *BAC (Biological activity or effector, except adverse)*; BSU (Biological study, unclassified); *THU (Therapeutic use)*; BIOL (Biological study); USES (Uses)
(suppressing effects of 6-(2,5-dichlorophenyl)-2,4-diamino-1,3,5-triazine and related synthetic compds. on azoxymethane-induced aberrant crypt foci in rat colon)

IT *57381-26-7*
RL: *BAC (Biological activity or effector, except adverse)*; BSU (Biological study, unclassified); *THU (Therapeutic use)*; BIOL (Biological study); USES (Uses)
(suppressing effects of 6-(2,5-dichlorophenyl)-2,4-diamino-1,3,5-triazine and related synthetic compds. on azoxymethane-induced aberrant crypt foci in rat colon)

RN 57381-26-7 HCAPLUS
CN 1,3,5-Triazine-2,4-diamine, 6-(2,5-dichlorophenyl)- (9CI) (CA INDEX NAME)



L98 ANSWER 25 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1995:750055 HCAPLUS Full-text
DOCUMENT NUMBER: 123:188182
TITLE: Irsogladine activates gap-junctional intercellular communication through M1 muscarinic acetylcholine receptor
AUTHOR(S): Ueda, Fusao; Ban, Keiko; Ishima, Tsuyoshi
CORPORATE SOURCE: Discovery Research Laboratories II, Nippon Shinyaku Co. Ltd., Kyoto, 601, Japan
SOURCE: Journal of Pharmacology and Experimental Therapeutics (*1995*), 274(2), 815-19
CODEN: JPETAB; ISSN: 0022-3565
PUBLISHER: Williams & Wilkins
DOCUMENT TYPE: Journal

LANGUAGE: English

AB Irsogladine, an agent that protects gastric mucosa against various ulcerogenic stimuli through increasing cAMP in surface mucous cells, has been reported to dose-dependently (10-7 to 10-5 M) facilitate gap-junctional intercellular communication (GJIC) in gastric epithelial cells. The beta adrenergic agonist, isoproterenol, stimulates GJIC in resting cells and inhibits GJIC in cells activated by 3-isobutyl-1- methylxanthine. In this study, we investigated whether irsogladine acts on GJIC in a manner similar to that shown by isoproterenol. Irsogladine, which bound to M1 muscarinic acetylcholine receptors (mAChR), did not inhibit, but failed to further facilitate the 3-isobutyl-1-methylxanthine- enhanced GJIC, measured by Lucifier yellow transfer. The enhancement of GJIC by irsogladine was inhibited by the M1 mAChR antagonist, pirenzepine. A selective M1 mAChR agonist, McN-A-343, enhanced GJIC. Isoproterenol (10-8 to 10-6 M), which alone did not affect GJIC, inhibited the GJIC enhanced by 10-5 M irsogladine. Conversely, 10-10 to 10-6 M irsogladine, which alone did not affect GJIC, inhibited the GJIC enhanced by 10-5 M isoproterenol. McN-A-343 also converted the action of 10-5 M isoproterenol from facilitation to inhibition of GJIC. These results indicate that GJIC is heterologously down-regulated by cross-talk between M1 mAChR and beta adrenergic receptors. In addition, the effects of irsogladine and isoproterenol at low concns. suggest the involvement of another mechanism for down-regulating GJIC.

CC 1-9 (Pharmacology)

IT *57381-26-7*, Irsogladine
RL: *BAC (Biological activity or effector, except adverse)*; BSU (Biological study, unclassified); *THU (Therapeutic use)*; BIOL (Biological study); USES (Uses)
(irsogladine activates gap-junctional intercellular communication through M1 muscarinic acetylcholine receptor)

IT *57381-26-7*, Irsogladine
RL: *BAC (Biological activity or effector, except adverse)*; BSU (Biological study, unclassified); *THU (Therapeutic use)*; BIOL (Biological study); USES (Uses)
(irsogladine activates gap-junctional intercellular communication through M1 muscarinic acetylcholine receptor)

RN 57381-26-7 HCAPLUS

CN 1,3,5-Triazine-2,4-diamine, 6-(2,5-dichlorophenyl)- (9CI) (CA INDEX NAME)



L98 ANSWER 26 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1995:633350 HCAPLUS Full-text

DOCUMENT NUMBER: 123:74593

TITLE: Effects of irsogladine, cimetidine and cetraxate on prostaglandin biosynthesis in cultured rabbit gastric epithelial cells

AUTHOR(S): Ueda, Fusao; Ideguchi, Kyoichi

CORPORATE SOURCE: Discovery Res. Lab., Nippon Shinyaku Co. Ltd., Kyoto, 601, Japan

SOURCE: Yakuri to Chiryo (*1995*), 23(2), 327-31
CODEN: YACHDS; ISSN: 0386-3603

PUBLISHER: Raifu Saiensu Shuppan K.K.
DOCUMENT TYPE: Journal
LANGUAGE: Japanese

AB The effects of antiulcer drugs on prostaglandin (PG) biosynthesis were investigated in 1-14C-arachidonic acid (AA)-prelabeled gastric epithelial cells. Irsogladine and cimetidine did not affect basal PG biosynthesis. Cetraxate decreased the release of polar substances (phospholipids and probably peptide leukotrienes) and increased AA release. All these antiulcer drugs inhibited norepinephrine-induced PGE2 biosynthesis. These results suggest that PGE2 is not important in gastric defense functions. In addition, the inhibition of PGE2 biosynthesis by the antiulcer drugs might be involved in their mechanisms for inhibiting gastric ulcers.

CC 1-9 (Pharmacology)

IT 34675-84-8, Cetraxate 51481-61-9, Cimetidine *57381-26-7*, Irsogladine
RL: *BAC (Biological activity or effector, except adverse)*; BSU (Biological study, unclassified); *THU (Therapeutic use)*; BIOL (Biological study); USES (Uses)
(effects of irsogladine, cimetidine and cetraxate on prostaglandin biosynthesis in cultured rabbit gastric epithelial cells)

IT *57381-26-7*, Irsogladine
RL: *BAC (Biological activity or effector, except adverse)*; BSU (Biological study, unclassified); *THU (Therapeutic use)*; BIOL (Biological study); USES (Uses)
(effects of irsogladine, cimetidine and cetraxate on prostaglandin biosynthesis in cultured rabbit gastric epithelial cells)

RN 57381-26-7 HCAPLUS

CN 1,3,5-Triazine-2,4-diamine, 6-(2,5-dichlorophenyl)- (9CI) (CA INDEX NAME)



L98 ANSWER 27 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1995:954085 HCAPLUS Full-text
DOCUMENT NUMBER: 124:21526
TITLE: Irsogladine inhibits ionomycin-induced decrease in intercellular communication in cultured rabbit gastric epithelial cells
AUTHOR(S): kameda, Yukiaki; Ueda, Fusao
CORPORATE SOURCE: Res. Lab., Nippon shinyaku Co., Ltd., Kyoto, 601, Japan
SOURCE: Japanese Journal of Pharmacology (*1995*), 69(3), 223-8
CODEN: JJPAAZ; ISSN: 0021-5198
PUBLISHER: Japanese Pharmacological Society
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Effects of irsogladine on ionomycin-induced decreased in intercellular communication and increase in intracellular concentration of Ca2+ ([Ca2+]i) were investigated in cultured rabbit gastric epithelial cells. Ionomycin (10-7-10-16 M) transiently and concentrate-dependently inhibited intercellular communication concomitantly with the elevation of [Ca2+]i in the presence and

absence of extracellular Ca2+. Irsogladine (0-5 M), which has been shown to facilitate intercellular communication, suppressed the ionomycin-induced elevation of [Ca2+]i and decrease in intercellular communication. The suppression of the ionomycin effects by irsogladine was independent of extracellular Ca2+. TMB-8 [8-(diethylamino)octyl-3,4,5- trimethoxybenzoate hydrochloride] (10-6 M) also suppressed the ionomycin-induced elevation of [Ca2+]i and decrease in intercellular communication. These results indicate that the ionomycin-induced decrease in intercellular communication may be due to Ca2+ mobilization from intracellular stores. Inhibitory effects of irsogladine and TMB-8 on the ionomycin-induced decrease in intercellular communication may be produced by suppressing Ca2+ mobilization.

CC 1-9 (Pharmacology)

IT *57381-26-7*, Irsogladine
RL: *BAC (Biological activity or effector, except adverse)*; BSU (Biological study, unclassified); *THU (Therapeutic use)*; BIOL (Biological study); USES (Uses)
(irsogladine inhibits ionomycin-induced decrease in intercellular communication in gastric epithelium)

IT *57381-26-7*, Irsogladine
RL: *BAC (Biological activity or effector, except adverse)*; BSU (Biological study, unclassified); *THU (Therapeutic use)*; BIOL (Biological study); USES (Uses)
(irsogladine inhibits ionomycin-induced decrease in intercellular communication in gastric epithelium)

RN 57381-26-7 HCAPLUS

CN 1,3,5-Triazine-2,4-diamine, 6-(2,5-dichlorophenyl)- (9CI) (CA INDEX NAME)



L98 ANSWER 28 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1995:126565 HCAPLUS Full-text

DOCUMENT NUMBER: 122:616

TITLE: A new synthetic antiarrhythmic peptide reduces dispersion of epicardial activation recovery interval and diminishes alterations of epicardial activation patterns induced by regional ischemia: a mapping study

AUTHOR(S): Dhein, S.; Manicone, N.; Muller, A.; Gerwin, R.; Ziskoven, U.; Irankhahi, A.; Minke, C.; Klaus, W.

CORPORATE SOURCE: Inst. Pharmakologie, Univ. Koln, Koln, D-50931, Germany

SOURCE: Naunyn-Schmiedeberg's Archives of Pharmacology (*1994*), 350(2), 174-84
CODEN: NSAPCC; ISSN: 0028-1298

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Common antiarrhythmic agents affect ionic membrane channels and thereby alter cellular elec. activity. Since this accounts for the proarrhythmic effects as well the authors tried to find new substances with different profiles of actions. A new antiarrhythmic peptide, H2,N-*Gly*- *Ala*-*Gly*-4 Hyp-Pro-Tyr-CONH2 (AAP 10), was synthesized using the Fmoc-strategy. This peptide was analyzed for its electrophysiol. profile of action in normal isolated rabbit hearts

perfused according to the Langendorff technique either under control conditions or after induction of a regional ischemia. For this purpose 256 channel epicardial mapping was employed allowing the determination of the time points of activation at each electrode thus identifying the origins of epicardial activation (so called breakthrough-points, BTP). Epicardial spread of activation was then described math. by activation vectors which gave direction and velocity of the epicardial activation wave at each electrode. Single heart beats were analyzed under control conditions and under treatment with AAP10 or under regional ischemia with or without AAP 10-pretreatment (10-8 mol./L). The authors calculated the percentage of similar vectors (VEC) with unaltered direction (deviation <5°) and the percentage of identical breakthrough points (deviation ≤ 1 mm) compared to control conditions. In addition, apparent epicardial velocities, total activation time of a given region and activation-recovery interval (ARI) as well as dispersion of ARI (i.e. standard deviation of ARI) and distribution of ARI were analyzed. Under control conditions treatment with AAP 10 (10-10 to 3+10-7 mol/L) led to a significant decrease in ARI-dispersion without alteration of any of the other parameters under investigation. Left ventricular regional ischemia resulted in a marked alteration of the activation patterns (a significant decrease in vector-field- and breakthrough point-similarity) which could be significantly inhibited by pretreatment with AAP10. In addition, the authors found that AAP10 depressed the increase in ARI-dispersion during the first minutes of ischemia and accelerated normalization of ARI-dispersion during reperfusion. In addnl. expts., it could be shown that AAP 10 did not alter action potential duration maximum dU/dt, amplitude or resting membrane potential of isolated guinea pig muscles using a common intracellular action potential recording technique. From these results it is concluded that (a) AAP 10 inhibits ischemia induced alterations of the activation pattern (b) that it decreases ARI-dispersion (c) that this effect seems not to be due to an action on ionic channels (d) that the effect of AAP 10 may be due to an improvement of cellular coupling and finally (e) that AAP 10 may be an interesting new approach to the problem of prophylaxis of ischemia-associated ventricular arrhythmias.

CC 1-8 (Pharmacology)

IT *159503-65-8*
RL: *BAC (Biological activity or effector, except adverse)*; BSU (Biological study, unclassified); *THU (Therapeutic use)*; BIOL (Biological study); USES (Uses)
(prevention of ischemia-associated ventricular arrhythmias by synthetic peptide AAP 10)

IT *159503-65-8*
RL: *BAC (Biological activity or effector, except adverse)*; BSU (Biological study, unclassified); *THU (Therapeutic use)*; BIOL (Biological study); USES (Uses)
(prevention of ischemia-associated ventricular arrhythmias by synthetic peptide AAP 10)

RN 159503-65-8 HCAPLUS

CN retro-Antiarrhythmic peptide (cattle atrium), 6-L-tyrosinamide- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L98 ANSWER 29 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1993:38951 HCAPLUS Full-text
DOCUMENT NUMBER: 118:38951
TITLE: Preparation of 2,4-diamino-6-phenyl-1,3,5-triazine derivatives as anticancer agents and anticancer pharmaceutical compositions containing them
INVENTOR(S): Mishina, Hitoshi; Ueda, Fusao
PATENT ASSIGNEE(S): Nippon Shinyaku Co., Ltd., Japan
SOURCE: PCT Int. Appl., 46 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9211247	A1	19920709	WO 1991-JP1734	19911219 <--
W: AU, BR, CA, FI, HU, JP, KR, NO, SU, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE				
AU 9190979	A	19920722	AU 1991-90979	19911219 <--
EP 563386	A1	19931006	EP 1992-901441	19911219 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, SE				

PRIORITY APPLN. INFO.: JP 1990-413461 A 19901220 <--
JP 1991-96372 A 19910401 <--
WO 1991-JP1734 A 19911219 <--
OTHER SOURCE(S): MARPAT 118:38951
GI



I

AB The title compds. (I; R1, R2 = H, halo, amino, aralkylamino, NO2, alkyl, alkoxy, alkoxyalkyl, aralkyloxy, acyl; R3, R4 = H, nicotinoyl, Bz, alkoxy; n = 0, 1) are prepared An anticancer pharmaceutical composition contains I. Thus, a mixture of p-HOC6H4CN, PhCH2Cl, and K2CO3 in MeCN was refluxed for 5 h to give p-PhCH2OC6H4CN which was heated with dicyandiamide and KOH in diethylene glycol di-Me ether at 100° for 8 h to give I (R1 = 4-PhCH2O, R2 = R3 = R4 = H, n = 0). I.maleate (R1 = 2-Cl, R2 = 5-Cl, R3 = R4 = H, n = 0) (irsogladine) (II), administered to mice at 10 mg/kg p.o. per day from day 14 to 18 after implantation of human colon cancer WiDr cells, showed the tumor volume ratio (the tumor volume after 18 days/the initial volume) 1.52 vs. 2.00 (control) and 1.52 for cyclophosphamide administered at 10 mg/kg i.p. once on day 14. I also enhanced the antitumor activity of 5-fluorouracil derivs., e.g. Mifurol and Sunfurol, and in vitro inhibited the uptake of 5-fluorouracil in MDCK cells. Clin. trials of II were also described. Tablet, powder, and injection solution formulations containing II were given.

IC ICM C07D251-18
ICS A61K031-53

CC 28-19 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1

IT 4514-54-9P 20317-65-1P 27374-29-4P 29366-71-0P 29366-73-2P 30354-89-3P 34095-30-2P 36303-44-3P ***57381-26-7P***, Irsogladine 57381-33-6P, Irsogladine maleic acid salt 57381-45-0P 57381-50-7P 57381-57-4P 57381-58-5P 59386-77-5P 65052-46-2P 68215-75-8P 81530-52-1P 81530-54-3P 116118-75-3P 145176-29-0P 145176-30-3P 145176-31-4P 145176-32-5P 145176-33-6P 145176-34-7P 145176-35-8P 145176-36-9P 145176-37-0P 145176-38-1P 145176-39-2P
RL: ***BAC (Biological activity or effector, except adverse)***; BSU (Biological study, unclassified); SPN (Synthetic preparation); ***THU (Therapeutic use)***; BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as anticancer agent)

IT ***57381-26-7P***, Irsogladine
RL: ***BAC (Biological activity or effector, except adverse)***; BSU (Biological study, unclassified); SPN (Synthetic preparation); ***THU (Therapeutic use)***; BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as anticancer agent)

RN 57381-26-7 HCAPLUS

CN 1,3,5-Triazine-2,4-diamine, 6-(2,5-dichlorophenyl)- (9CI) (CA INDEX NAME)



L98 ANSWER 30 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1990:515835 HCAPLUS Full-text
DOCUMENT NUMBER: 113:115835
TITLE: Antiarrhythmic activity of a novel analog of AAP
AUTHOR(S): Kundu, Bijoy; Rizvi, Shaheena Yasmeen; Mathur, Krishna Behari; Kar, Karunamoy
CORPORATE SOURCE: Div. Biopolym., Cent. Drug Res. Inst., Lucknow, 226 001, India
SOURCE: Collection of Czechoslovak Chemical Communications (

1990), 55(2), 575-80
CODEN: CCCCAK; ISSN: 0010-0765
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Antiarrhythmic peptide (AAP) analogs H-*Gly*-X-X1-*Gly*- *Ala*-*Gly*-OH [I; X-X1 = Sar-Pro (Sar = MeGly), Pro-Sar, Sar-Sar] have been synthesized in order to obtain peptides with enhanced antiarrhythmic activity. Their antiarrhythmic activity has been evaluated against aconitine induced arrhythmia in rats. I (X-X1 = Sar-Sar) is more active than AAP (I, X-X1 = Pro-Hyp). It is equipotent to the commonly used antiarrhythmic drug quinidine, so far as delay in the onset of ventricular tachycardia, ventricular fibrillation and cardiac arrest are concerned. Relationships of biol. activities of these peptides with their CD spectra are discussed. The spatial structure of I (X-X1 = Sar-Sar) attributed to Sar2-Sar3 linkage might be contributing to its higher antiarrhythmic activity.

CC 34-3 (Amino Acids, Peptides, and Proteins)
Section cross-reference(s): 1

IT *81771-37-1DP*, Antiarrhythmic peptide (ox atrium), analogs
129164-97-2P 129164-98-3P 129164-99-4P 129165-00-0P 129165-01-1P
129165-02-2P
RL: *BAC (Biological activity or effector, except adverse)*; BSU (Biological study, unclassified); SPN (Synthetic preparation); *THU (Therapeutic use)*; BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and antiarrhythmic activity of)

IT *81771-37-1DP*, Antiarrhythmic peptide (ox atrium), analogs
RL: *BAC (Biological activity or effector, except adverse)*; BSU (Biological study, unclassified); SPN (Synthetic preparation); *THU (Therapeutic use)*; BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and antiarrhythmic activity of)

RN 81771-37-1 HCAPLUS
CN Antiarrhythmic peptide (cattle atrium) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L98 ANSWER 31 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1989:568091 HCAPLUS Full-text
DOCUMENT NUMBER: 111:168091
TITLE: Antiarrhythmic peptide has no direct cardiac actions
AUTHOR(S): Argentieri, T.; Cantor, E.; Wiggins, J. R.
CORPORATE SOURCE: Berlex Lab., Inc., Cedar Knolls, NJ, 07927, USA
SOURCE: Experientia (*1989*), 45(8), 737-8
CODEN: EXPEAM; ISSN: 0014-4754
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The electrophysiol., inotropic, and muscarinic effects of antiarrhythmic peptide (AAP) were examined in canine cardiac Purkinje fibers, ferret papillary muscle, and canine cardiac membranes, resp. Aside from a prolongation of time to peak force in papillary muscle, no biol. significant effects of AAP could be determined in any preparation, suggesting that its antiarrhythmic effects are not mediated by direct membrane actions.

CC 2-10 (Mammalian Hormones)

IT *81771-37-1*, Antiarrhythmic peptide
RL: *BAC (Biological activity or effector, except adverse)*; BSU (Biological study, unclassified); BIOL (Biological study)
(heart response to)

IT *81771-37-1*, Antiarrhythmic peptide
RL: *BAC (Biological activity or effector, except adverse)*; BSU (Biological study, unclassified); BIOL (Biological study)
(heart response to)

RN 81771-37-1 HCAPLUS

CN Antiarrhythmic peptide (cattle atrium) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L98 ANSWER 32 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1989:147197 HCAPLUS Full-text

DOCUMENT NUMBER: 110:147197

TITLE: Effect of N-3-(4-hydroxyphenyl)propionyl Pro-Pro-*Gly-Ala-Gly* on calcium-induced arrhythmias

AUTHOR(S): Kohama, Yasuhiro; Kuwahara, Shigeki; Yamamoto, Koji; Okabe, Masaru; Mimura, Tsutomu; Fukaya, Chikara; Watanabe, Masahiro; Yokoyama, Kazumasa

CORPORATE SOURCE: Fac. Pharm. Sci., Osaka Univ., Suita, 565, Japan

SOURCE: Chemical & Pharmaceutical Bulletin (*1988*), 36(11), 4597-9
CODEN: CPBTAL; ISSN: 0009-2363

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The present investigation was done to examine whether or not the presence of hydroxyproline in N-3-(4-hydroxyphenyl)propionyl Pro-Hyp-*Gly- Ala-Gly* (HP-5) is essential for its antiarrhythmic activity. Pretreatment of mice with 10 mg/kg of [Pro2]-HP-5 provided better protection against calcium-induced arrhythmias than did pretreatment with HP-5. Thus, the prolyl residue was more favorable than the hydroxyprolyl residue for antiarrhythmic activity of these analogs.

CC 1-3 (Pharmacology)
Section cross-reference(s): 2, 34

IT *111915-92-5*
RL: *BAC (Biological activity or effector, except adverse)*; BSU (Biological study, unclassified); *THU (Therapeutic use)*; BIOL

(Biological study); USES (Uses)
(antiarrhythmic activity of, structure in relation to)

IT *111915-92-5*
RL: *BAC (Biological activity or effector, except adverse)*; BSU (Biological study, unclassified); *THU (Therapeutic use)*; BIOL (Biological study); USES (Uses)
(antiarrhythmic activity of, structure in relation to)

RN 111915-92-5 HCAPLUS

CN Antiarrhythmic peptide (cattle atrium), 1-deglycine-2-[1-[3-(4-hydroxyphenyl)-1-oxopropyl]-L-proline]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L98 ANSWER 33 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1988:16410 HCAPLUS Full-text
DOCUMENT NUMBER: 108:16410
TITLE: A new antiarrhythmic peptide, N-3-(4-hydroxyphenyl)propionyl Pro-Hyp-*Gly-Ala-Gly*
AUTHOR(S): Kohama, Yasuhiro; Okimoto, Naotsugu; Mimura, Tsutomu; Fukaya, Chikara; Watanabe, Masahiro; Yokoyama, Kazumasa
CORPORATE SOURCE: Fac. Pharm. Sci., Osaka Univ., Suita, 565, Japan
SOURCE: Chemical & Pharmaceutical Bulletin (*1987*), 35(9), 3928-30
CODEN: CPBTAL; ISSN: 0009-2363
DOCUMENT TYPE: Journal
LANGUAGE: English

AB In order to increase the antiarrhythmic activity of the naturally occurring antiarrhythmic peptide (Pro-Hyp-*Gly-Ala- Gly*; (P-5)), P-5 analogs with 3 diffeent hydrophobic substituents, N-3-(4-hydroxyphenyl)propionyl (H), N-3-phenylpropionyl (I) and N-3-phenylpropyl (P), were prepared and their activities were evaluated in CaCl2-induced arrhythmias in mice. HP-5 showed potent antiarrhythmic activity at 1 mg/kg, i.v. and its potency was much higher than that of P-5 at 10 mg/kg, i.v. IP-5 showed similar potency to P-5, but PP-5 was inactive. Pro-Hyp-*Gly-Ala*, Pro-Hyp-*Gly* and Pro-Hyp with the substituent H, were also ineffective. Thus, 3-(4-hydroxyphenyl)propionylation of the imino nitrogen of Pro in P-5 led to increased potency.

CC 2-2 (Mammalian Hormones)

IT 111915-91-4DP, analogs *111915-92-5P* 111915-93-6P 111915-94-7P 111915-95-8P 111915-96-9P 111915-97-0P
RL: *BAC (Biological activity or effector, except adverse)*; BSU (Biological study, unclassified); SPN (Synthetic preparation); *THU (Therapeutic use)*; BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and antiarrhythmic activity of, structure in relation to)

IT *111915-92-5P*
RL: *BAC (Biological activity or effector, except adverse)*; BSU (Biological study, unclassified); SPN (Synthetic preparation); *THU (Therapeutic use)*; BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and antiarrhythmic activity of, structure in relation to)
RN 111915-92-5 HCAPLUS
CN Antiarrhythmic peptide (cattle atrium), 1-deglycine-2-[1-[3-(4-hydroxyphenyl)-1-oxopropyl]-L-proline]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L98 ANSWER 34 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1984:133284 HCAPLUS Full-text
DOCUMENT NUMBER: 100:133284
TITLE: Studies on heart. XXXIV. Inhibitory effect of antiarrhythmic peptide (AAP) on experimental thromboses
AUTHOR(S): Aonuma, Shigeru; Kohama, Yasuhiro; Makino, Toshitake; Hattori, Kunihiro; Kawahara, Yusuke
CORPORATE SOURCE: Fac. Pharm. Sci., Osaka Univ., Suita, 565, Japan
SOURCE: Chemical & Pharmaceutical Bulletin (*1984*), 32(1), 219-27
CODEN: CPBTAL; ISSN: 0009-2363
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The antithrombotic action of antiarrhythmic peptide (*Gly* -Pro-Hyp-*Gly*-*Ala*-*Gly*)(aAP) [81771-37-1] was studied by using various in vivo thrombosis models. AAP (1, 10, or 100 mg/kg, i.v.; 10 mg/kg, i.p.; or 100 mg/kg, orally) significantly inhibited white thrombus formation on a silk thread in the extracorporeal shunt models in rats, its ED50 being about 30 mg/kg, i.v. AAP (10 mg/kg, i.v.) was effective in protecting rats against the decrease in platelet count, against the incidence of electrocardiog. alterations (T-wave inversion and ST-segment depression) typical of myocardial ischemia, and against development of ectopic beats during coronary thromboembolism induced by i.v. infusion of ADP. The peptide (10 mg/kg, i.p.) was also effective in preventing thrombus formation in the lung and the decrease of platelet count induced by lactic acidosis in rats, and it (10 mg/kg, i.v.) clearly inhibited thromboembolic death induced by rapid i.v. injection of collagen in mice. Daily treatments with the peptide (10 mg/kg/d, i.p.) resulted in significant delay of the progression of gangrene and mummification in laurate-induced peripheral arterial occlusive disease in rats. AAP did not affect venous thrombus formation, blood flow through the carotid artery, plasma recalcification time or fibrinolytic activity in rats. It is likely that the potent antithrombotic action of AAP is mainly due to its anti-platelet-aggregating action in vivo. Ticlopidine (100 mg/kg, orally) also showed a

comparatively wide antithrombotic spectrum, like AAP, in the present thrombosis models; but ticlopidine, like aspirin (50 mg/kg, s.c.), lacked activity against myocardial ischemia.

CC 2-9 (Mammalian Hormones)

IT *81771-37-1*
RL: *BAC (Biological activity or effector, except adverse)*; BSU (Biological study, unclassified); BIOL (Biological study)
(antithrombotic activity of)

IT *81771-37-1*
RL: *BAC (Biological activity or effector, except adverse)*; BSU (Biological study, unclassified); BIOL (Biological study)
(antithrombotic activity of)

RN 81771-37-1 HCAPLUS

CN Antiarrhythmic peptide (cattle atrium) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L98 ANSWER 35 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1983:482255 HCAPLUS Full-text

DOCUMENT NUMBER: 99:82255

TITLE: Studies on heart. XXII. Inhibitory effect of an atrial peptide (AAP) on several drug-induced arrhythmias in vivo

AUTHOR(S): Aonuma, Shigeru; Kohama, Yasuhiro; Makino, Toshitake; Hattori, Kunihiro

CORPORATE SOURCE: Fac. Pharm. Sci., Osaka Univ., Suita, 565, Japan

SOURCE: Yakugaku Zasshi (*1983*), 103(6), 662-6
CODEN: YKKZAJ; ISSN: 0031-6903

DOCUMENT TYPE: Journal

LANGUAGE: Japanese

AB The effect of an atrial peptide, *Gly*-Pro-4Hyp-*Gly*- *Ala*-*Gly* (AAP) [81771-37-1], on several drug-induced arrhythmias in anesthetized dogs, rats and mice was investigated. AAP (10 mg/kg, i.v.) significantly reversed the persistent arrhythmias consisting of atrio-ventricular (A-V) block, ectopic beat, and/or ventricular tachycardia induced by aconitine pretreatment prevented development of ventricular fibrillation in dogs and rats. AAP (10, 25 mg/kg, i.v.) prolonged onset time of A-V block or ectopic beat and onset time of ventricular tachycardia induced by aconitine infusion in mice. This peptide (10 mg/kg, i.v.) significantly prolonged the onset time of A-V block or ectopic beat induced by CaCl2 infusion and the time until ventricular fibrillation induced by ouabain infusion in mice, and shortened the duration of arrhythmia induced by ADP in rats, but did not affect the mouse epinephrine-induced arrhythmia. The peptide (25 mg/kg, i.v.) prolonged the QTc interval and had no effect on the PQ interval heart rate, respiratory rate, and blood pressure in dogs. AAP (1 g/kg, i.v.v., i.p., and orally) did not show acute toxicity in mice. AAP had antiarrhythmic activity with few side effects.

CC 1-8 (Pharmacology)
Section cross-reference(s): 2
IT *81771-37-1*
RL: *BAC (Biological activity or effector, except adverse)*; BSU (Biological study, unclassified); *THU (Therapeutic use)*; BIOL (Biological study); USES (Uses)
(antiarrhythmic activity of)
IT *81771-37-1*
RL: *BAC (Biological activity or effector, except adverse)*; BSU (Biological study, unclassified); *THU (Therapeutic use)*; BIOL (Biological study); USES (Uses)
(antiarrhythmic activity of)
RN 81771-37-1 HCAPLUS
CN Antiarrhythmic peptide (cattle atrium) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L98 ANSWER 36 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1980:157536 HCAPLUS Full-text
DOCUMENT NUMBER: 92:157536
TITLE: Structure-activity study of antiulcerous and antiinflammatory drugs by discriminant analysis
AUTHOR(S): Ogino, Akio; Matsumura, Shingo; Fujita, Toshio
CORPORATE SOURCE: Res. Lab., Nippon Shinyaku Co., Ltd., Kyoto, 601, Japan
SOURCE: Journal of Medicinal Chemistry (*1980*), 23(4), 437-44
CODEN: JMCMAR; ISSN: 0022-2623
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



AB The structure activity of 34 antiulcer benzoguanamines I (R = H, halogen, Me, NO2, SCF3, etc.; n = 0-2),and that of 22 antiinflammatory phenylacetic acids II (R = H, OH, Me, OEt, Ph, etc.; n = 0-2), and 24 aminouracils III (R1 = Et, Me, Ph, substituted Ph, etc.; R2 = alkyl, CH2CH2OH, etc.; NR3N4 = NHPr, NMe2, NHBu, morpholins, etc.) were studied in rats by discriminant anal. For antiulcer activity the drug effect was evaluated in terms of averaged ulcer indexes and the percent inhibition value against the injury was expressed relative to the averaged index of the control group; the error involved was <10%. For the antiinflammatory activity the inhibitory effect was represented as the percent value relative to the average volume of control; the error in the percent value was <10%. The discriminant variables were selected from the physicochem. parameters used to analyze the variation in hydrophobicity due to structural modifications. The potency scores divided into 3 groups for each of the 3 series of compds. were predicted with >80% accuracy.

CC 1-3 (Pharmacodynamics)
Section cross-reference(s): 22

IT 91-76-9 91-76-9D, derivs. 4514-53-8 4514-54-9 19338-12-6
29366-71-0 29366-72-1 29366-73-2 29366-77-6 30101-52-1
30508-75-9 30508-78-2 30530-43-9 30530-44-0 30530-48-4
57381-26-7 57381-35-8 57381-38-1 57381-40-5 57381-42-7
57381-45-0 57381-46-1 57381-50-7 57381-54-1 57381-57-4
57381-60-9 65052-47-3 65052-49-5 65052-50-8 65052-53-1
65052-55-3 72775-79-2 72775-80-5 72775-81-6 72781-91-0
RL: *BAC (Biological activity or effector, except adverse)*; BSU (Biological study, unclassified); *THU (Therapeutic use)*; BIOL (Biological study); USES (Uses)
(antiulcer activity of, discriminant anal. in evaluation of)

IT *57381-26-7*
RL: *BAC (Biological activity or effector, except adverse)*; BSU (Biological study, unclassified); *THU (Therapeutic use)*; BIOL (Biological study); USES (Uses)
(antiulcer activity of, discriminant anal. in evaluation of)

RN 57381-26-7 HCAPLUS
CN 1,3,5-Triazine-2,4-diamine, 6-(2,5-dichlorophenyl)- (9CI) (CA INDEX NAME)



L98 ANSWER 37 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1975:606332 HCAPLUS Full-text
DOCUMENT NUMBER: 83:206332
TITLE: Benzoguanamine derivatives
INVENTOR(S): Murai, Hiromu; Ohata, Katsuya; Aoyagi, Yoshiaki; Ueda, Fusao; Kitano, Masahiko; Takata, Satoshi; Tada, Shinichi
PATENT ASSIGNEE(S): Nippon Shinyaku Co., Ltd., Japan
SOURCE: Ger. Offen., 24 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2506814	A1	19750828	DE 1975-2506814	19750218 <--
DE 2506814	C3	19791115		
DE 2506814	B2	19790322		
JP 50111085	A	19750901	JP 1974-19211	19740218 <--
JP 55004751	B	19800131		
JP 50111086	A	19750901	JP 1974-19212	19740218 <--
JP 52046955	B	19771129		
US 3966728	A	19760629	US 1975-544176	19750127 <--
CH 592638	A5	19771031	CH 1975-1300	19750204 <--
CH 592639	A5	19771031	CH 1975-1301	19750204 <--
SE 7501273	A	19750819	SE 1975-1273	19750205 <--
SE 425245	B	19820913	SE 1975-1274	19750205 <--
SE 425245	C	19821230		
DK 7500436	A	19751020	DK 1975-436	19750207 <--
DK 138268	C	19790212		
DK 138116	B	19780717	DK 1975-437	19750207 <--
DK 138116	C	19781204		
NL 7501574	A	19750820	NL 1975-1574	19750211 <--
NL 157901	B	19780915		
NL 157902	B	19780915	NL 1975-1575	19750211 <--
FR 2261009	A1	19750912	FR 1975-4690	19750214 <--
BE 825673	A1	19750616	BE 1975-153471	19750218 <--
AT 7501200	A	19770315	AT 1975-1200	19750218 <--
AT 339909	B	19771110		
AT 7501197	A	19770515	AT 1975-1197	19750218 <--
AT 340941	B	19780110		

PRIORITY APPLN. INFO.: JP 1974-19211 A 19740218 <--
JP 1974-19212 A 19740218 <--

GI For diagram(s), see printed CA Issue.

AB Triazines I (R = 2-Cl, 2-F, 2-Br, 3-Cl, R1 = 5-Cl; R = 2-Cl, R1 = 5-Br, 4-Cl, 3-Cl, 6-Cl, 5-F; R = 2-Br, 2-F, R1 = 5-F, 5-Br, 4-Cl; R = 3-Cl, R1 = 4-Br) were prepared by treating RR1C6H3CN with dicyandiamide or dihalobenzoic acid derivs. with biguanide. I inhibit ulceration. Thus 20 mg/kg I (R = 2-Cl, R1 = 5-Cl) i.p. in rats gave total inhibition of Shay ulcers.

IC C07D

CC 28-21 (Heterocyclic Compounds (More Than One Hetero Atom))

IT *57381-26-7P* 57381-35-8P 57381-38-1P 57381-40-5P
57381-42-7P 57381-45-0P 57381-46-1P 57381-50-7P 57381-53-0P
57381-54-1P 57381-55-2P
RL: *BAC (Biological activity or effector, except adverse)*; BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and antiulcer activity of)

IT *57381-26-7P*
RL: *BAC (Biological activity or effector, except adverse)*; BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and antiulcer activity of)

RN 57381-26-7 HCAPLUS

CN 1,3,5-Triazine-2,4-diamine, 6-(2,5-dichlorophenyl)- (9CI) (CA INDEX NAME)



********REFERENCES TO QUERY ON CLAIM 56, STRUCTURE WAS SEARCHED WITH LIMITATIONS GIVEN BY EXAMINER*******

=> d que l4
L2 42 SEA FILE=REGISTRY ABB=ON PLU=ON [G'SAR']A[G'SAR']['HYP'P]['HYP'P]YN/SQSFP
L3 36 SEA FILE=HCAPLUS ABB=ON PLU=ON L2
L4 14 SEA FILE=HCAPLUS ABB=ON PLU=ON L3 AND (AY<2001 OR PY<2001 OR PRY<2001)

=> d ibib abs hitind hitstr retable l4 tot

L4 ANSWER 1 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:546915 HCAPLUS Full-text
DOCUMENT NUMBER: 141:83631
TITLE: Rice nucleic acid molecules and encoded proteins and their uses for plant improvement
INVENTOR(S): La Rosa, Thomas J.; Kovalic, David K.; Zhou, Yihua; Cao, Yongwei; Wu, Wei; Boukharov, Andrey A.; Barbazuk, Brad W.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 14 pp., Cont.-in-part of U.S. Ser. No. 837,604.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 27
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2004123343	A1	20040624	US 2003-437963		20030514 <--
US 2004123343	A1	20040624	US 2003-437963		20030514 <--
PRIORITY APPLN. INFO.:			US 2000-197872P	P	20000419 <--
			US 2001-837604	A2	20010418
			US 2003-437963	A	20030514

AB The present invention provides 102,483 cDNA sequences and their encoded protein sequences from rice (Oryza sativa). Bioinformatic anal. identified putative functions and uses for the nucleic acids/polypeptides. The disclosed polynucleotides and polypeptides find use in production of transgenic plants to produce plants having improved properties. [This abstract record is one of forty-one records for this document necessitated by the large number of index

entries required to fully index the document and publication system constraints.]..

IC ICM A01H001-00
ICS C12N015-82; C07H021-04; C12N009-24; C12N005-04

INCL 800278000; 435069100; 435200000; 435201000; 435419000; 536023200

CC 3-3 (Biochemical Genetics)
Section cross-reference(s): 6, 11

IT 716607-00-0 716607-01-1 716607-02-2 716607-03-3 716607-04-4
716607-05-5 716607-06-6 716607-07-7 716607-08-8 716607-09-9
716607-10-2 716607-11-3 716607-12-4 716607-13-5 716607-14-6
716607-15-7 716607-16-8 716607-17-9 716607-18-0 716607-19-1
716607-20-4 716607-21-5 716607-22-6 716607-23-7 716607-24-8
716607-25-9 716607-26-0 716607-27-1 716607-28-2 716607-29-3
716607-30-6 716607-31-7 716607-32-8 716607-33-9 716607-34-0
716607-35-1 716607-36-2 716607-37-3 716607-38-4 716607-39-5
716607-40-8 716607-41-9 716607-42-0 716607-43-1 716607-44-2
716607-45-3 716607-46-4 716607-47-5 716607-48-6 716607-49-7
716607-50-0 *716607-51-1* 716607-52-2 716607-53-3
716607-54-4 716607-55-5 716607-56-6 716607-57-7 716607-58-8
716607-59-9 716607-60-2 716607-61-3 716607-62-4 716607-63-5
716607-64-6 716607-65-7 716607-66-8 716607-67-9 716607-68-0
716607-69-1 716607-70-4 716607-71-5 716607-72-6 716607-73-7
716607-74-8 716607-75-9 716607-76-0 716607-77-1 716607-78-2
716607-79-3 716607-80-6 716607-81-7 716607-82-8 716607-83-9
716607-84-0 716607-85-1 716607-86-2 716607-87-3 716607-88-4
716607-89-5 716607-90-8 716607-91-9 716607-92-0 716607-93-1
716607-94-2 716607-95-3 716607-96-4 716607-97-5 716607-98-6
716607-99-7 716608-00-3 716608-01-4 716608-02-5 716608-03-6
716608-04-7 716608-05-8 716608-06-9 716608-07-0 716608-08-1
716608-09-2 716608-10-5 716608-11-6 716608-12-7 716608-13-8
716608-14-9 716608-15-0 716608-16-1 716608-17-2 716608-18-3
716608-19-4 716608-20-7 716608-21-8 716608-22-9 716608-23-0
716608-24-1 716608-25-2 716608-26-3 716608-27-4 716608-28-5
716608-29-6 716608-30-9 716608-31-0 716608-32-1 716608-33-2
716608-34-3 716608-35-4 716608-36-5 716608-37-6 716608-38-7
716608-39-8 716608-40-1 716608-41-2 716608-42-3 716608-43-4
716608-44-5 716608-45-6 716608-46-7 716608-47-8 716608-48-9
716608-49-0 716608-50-3 716608-51-4 716608-52-5 716608-53-6
716608-54-7 716608-55-8 716608-56-9 716608-57-0 716608-58-1
716608-59-2 716608-60-5 716608-61-6 716608-62-7 716608-63-8
716608-64-9 716608-65-0 716608-66-1 716608-67-2 716608-68-3
716608-69-4 716608-70-7 716608-71-8 716608-72-9 716608-73-0
716608-74-1 716608-75-2 716608-76-3 716608-77-4 716608-78-5
716608-79-6 716608-80-9 716608-81-0 716608-82-1 716608-83-2
716608-84-3 716608-85-4 716608-86-5 716608-87-6 716608-88-7
716608-89-8 716608-90-1 716608-91-2 716608-92-3 716608-93-4
716608-94-5 716608-95-6 716608-96-7 716608-97-8 716608-98-9
716608-99-0 716609-00-6 716609-01-7 716609-02-8 716609-03-9
716609-04-0 716609-05-1 716609-06-2 716609-07-3 716609-08-4
716609-09-5 716609-10-8 716609-11-9 716609-12-0 716609-13-1
716609-14-2 716609-15-3 716609-16-4 716609-17-5 716609-18-6
716609-19-7 716609-20-0 716609-21-1 716609-22-2 716609-23-3
716609-24-4 716609-25-5 716609-26-6 716609-27-7 716609-28-8
716609-29-9 716609-30-2 716609-31-3 716609-32-4 716609-33-5
716609-34-6
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); PRP (Properties); BIOL (Biological study); USES (Uses)
(amino acid sequence; rice nucleic acid mols. and encoded proteins and their uses for plant improvement)

IT *716607-51-1*

RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); PRP (Properties); BIOL (Biological study); USES (Uses)
(amino acid sequence; rice nucleic acid mols. and encoded proteins and their uses for plant improvement)
RN 716607-51-1 HCAPLUS
CN Protein (Oryza sativa clone PAT_MRT4530_21015C.1.pep fragment) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L4 ANSWER 2 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:80331 HCAPLUS Full-text
DOCUMENT NUMBER: 140:140710
TITLE: cDNAs encoding human NOVX proteins and their diagnostic and therapeutic use
INVENTOR(S): Shimkets, Richard A.; Patturajan, Meera; Vernet, Corine A. M.; Casman, Stacie J.; Malyankar, Uriel M.; Shenoy, Suresh G.; Spytek, Kimberly A.; Gangolli, Esha A.; Miller, Charles E.; Boldog, Ferenc L.; Li, Li; Taupier, Raymond J.; Kekuda, Ramesh; Smithson, Glennda; Zerhusen, Bryan D.; Liu, Xiaohong; Colman, Steven D.; Tchernev, Velizar T.; Si, Jingsheng; Edinger, Shlomit R.; Stone, David J.; Sciore, Paul; Millet, Isabelle; Rothenberg, Mark E.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 240 pp., Cont.-in-part of U.S. Ser. No. 28,248.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 173
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE	
US 2004018970	A1	20040129	US 2002-107782		20020327	<--
US 2003235882	A1	20031225	US 2001-28248		20011219	<--
US 2003203363	A1	20031030	US 2002-94466		20020307	
CA 2440337	A1	20020919	CA 2002-2440337		20020308	
CA 2440345	A1	20020919	CA 2002-2440345		20020308	
EP 1427749	A2	20040616	EP 2002-713788		20020308	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR						
AU 2005200106	A1	20050210	AU 2005-200106		20050112	<--
AU 2006201467	A1	20060504	AU 2006-201467		20060407	<--
PRIORITY APPLN. INFO.:			US 2000-256619P	P	20001219	<--
			US 2001-262959P	P	20010119	
			US 2001-272408P	P	20010228	
			US 2001-279344P	P	20010328	
			US 2001-285189P	P	20010420	
			US 2001-308039P	P	20010726	
			US 2001-311266P	P	20010809	
			US 2001-28248	A2	20011219	
			AU 2000-37360	A3	20000309	<--
			AU 2000-78680	A3	20001006	<--
			US 2001-274191P	P	20010308	
			US 2001-274194P	P	20010308	
			US 2001-274281P	P	20010308	
			US 2001-274322P	P	20010308	
			US 2001-274849P	P	20010309	

US 2001-275235P	P	20010312
US 2001-275578P	P	20010313
US 2001-275579P	P	20010313
US 2001-275601P	P	20010313
US 2001-276000P	P	20010314
US 2001-276776P	P	20010316
US 2001-276994P	P	20010319
US 2001-277239P	P	20010320
US 2001-277321P	P	20010320
US 2001-277327P	P	20010320
US 2001-277338P	P	20010320
US 2001-277791P	P	20010321
US 2001-277833P	P	20010322
US 2001-278152P	P	20010323
US 2001-278894P	P	20010326
US 2001-278999P	P	20010327
US 2001-279036P	P	20010327
US 2001-279995P	P	20010330
US 2001-280233P	P	20010330
US 2001-280802P	P	20010402
US 2001-280822P	P	20010402
US 2001-280900P	P	20010402
US 2001-281194P	P	20010404
US 2001-283675P	P	20010413
US 2001-287424P	P	20010430
US 2001-288066P	P	20010502
US 2001-288148P	P	20010502
US 2001-288342P	P	20010503
US 2001-288528P	P	20010503
US 2001-291190P	P	20010515
US 2001-291099P	P	20010516
US 2001-291240P	P	20010516
US 2001-294485P	P	20010530
US 2001-294821P	P	20010531
US 2001-294889P	P	20010531
US 2001-294899P	P	20010531
US 2001-335302P	P	20011031
US 2001-338375P	P	20011204

AB The present invention provides cDNAs encoding human NOVX proteins and their diagnostic and therapeutic use.

IC ICM C12Q001-68
ICS G01N033-53; C07K014-47; C12P021-02; C12N005-06; A61K038-17; C07K016-22; C07H021-04

INCL 514012000; 435069100; 435320100; 435325000; 530350000; 536023500; 530388150; 435006000; 435007100

CC 3-3 (Biochemical Genetics)
Section cross-reference(s): 1, 6, 13, 14

IT 651798-56-0 651798-57-1 651798-58-2 651798-64-0 651798-65-1
651798-66-2 651798-73-1, Protein NOV4b (human) 651798-79-7
651798-80-0 651798-81-1 651798-87-7 651798-93-5 651798-94-6
651799-00-7 651799-01-8 651799-07-4 651799-12-1 *651799-18-7*
651799-23-4 651799-29-0
RL: PRP (Properties)
(unclaimed protein sequence; cDNAs encoding human NOVX proteins and their diagnostic and therapeutic use)

IT *651799-18-7*
RL: PRP (Properties)
(unclaimed protein sequence; cDNAs encoding human NOVX proteins and their diagnostic and therapeutic use)

RN 651799-18-7 HCAPLUS

CN 103: PN: US20040018970 SEQID: 102 unclaimed protein (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L4 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:781492 HCAPLUS Full-text
DOCUMENT NUMBER: 138:1096
TITLE: Essential genes in microorganisms and their use as targets for antisense inhibition of proliferation and antibiotic screening
INVENTOR(S): Wang, Liangus; Zamudio, Carlos; Malone, Cheryl; Haselbeck, Robert; Ohlsen, Kari L.; Zyskind, Judith W.; Wall, Daniel; Trawick, John D.; Carr, Grant J.; Yamamoto, Robert; Forsyth, R. Allyn; Xu, H. Howard
PATENT ASSIGNEE(S): Elitra Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 1766 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 22
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002077183	A2	20021003	WO 2002-XO9107	20020321
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2002061569	A1	20020523	US 2001-815242	20010321 <--
WO 2002077183	A2	20021003	WO 2002-US9107	20020321
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.:

US 2001-815242	A	20010321
US 2001-948993	A	20010906
US 2001-342923P	P	20011025
US 2002-72851	A	20020208
US 2002-362699P	P	20020306
WO 2002-US9107	A	20020321
US 2000-191078P	P	20000321 <--
US 2000-206848P	P	20000523 <--
US 2000-207727P	P	20000526 <--
US 2000-242578P	P	20001023 <--
US 2000-253625P	P	20001127 <--
US 2000-257931P	P	20001222 <--
US 2001-269308P	P	20010216

AB The sequences of antisense nucleic acids which inhibit the proliferation of prokaryotes are disclosed. Thus, 6213 nucleic acid fragments are identified

for which expression inhibits proliferation or is required for proliferation in Enterococcus faecalis, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Salmonella typhimurium, and Staphylococcus aureus. Cell-based assays which employ the antisense nucleic acids to identify and develop antibiotics are also disclosed. The antisense nucleic acids can also be used to identify proteins required for proliferation, express these proteins or portions thereof, obtain antibodies capable of specifically binding to the expressed proteins, and to use those expressed proteins as a screen to isolate candidate mols. for rational drug discovery programs. The nucleic acids can also be used to screen for homologous nucleic acids that are required for proliferation in cells other than Staphylococcus aureus, Salmonella typhimurium, Klebsiella pneumoniae, and Pseudomonas aeruginosa. The invention provides 38,184 such proliferation-required gene sequences (plus their encoded protein sequences). The nucleic acids of the present invention can also be used in various assay systems to screen for proliferation required genes in other organisms. [This abstract record is one of twenty records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.].

IC ICM C12N

CC 3-3 (Biochemical Genetics)
Section cross-reference(s): 1, 6, 10

IT

477094-57-8	477094-58-9	477094-59-0	477094-60-3	477094-61-4
477094-62-5	477094-63-6	477094-64-7	477094-65-8	477094-66-9
477094-67-0	477094-68-1	477094-69-2	477094-70-5	477094-71-6
477094-72-7	477094-73-8	477094-74-9	477094-75-0	477094-76-1
477094-77-2	477094-78-3	477094-79-4	477094-80-7	477094-81-8
477094-82-9	477094-83-0	477094-84-1	477094-85-2	477094-86-3
477094-87-4	477094-88-5	477094-89-6	477094-90-9	477094-91-0
477094-92-1	477094-93-2	477094-94-3	477094-95-4	477094-96-5
477094-97-6	477094-98-7	477094-99-8	477095-00-4	477095-01-5
477095-02-6	477095-03-7	477095-04-8	477095-05-9	477095-06-0
477095-07-1	477095-08-2	477095-09-3	477095-10-6	477095-11-7
477095-12-8	477095-13-9	477095-14-0	477095-15-1	477095-16-2
477095-17-3	477095-18-4	477095-19-5	477095-20-8	477095-21-9
477095-22-0	477095-23-1	477095-24-2	477095-25-3	477095-26-4
477095-27-5	477095-28-6	477095-29-7	477095-30-0	477095-31-1
477095-32-2	477095-33-3	477095-34-4	477095-35-5	477095-36-6
477095-37-7	477095-38-8	477095-39-9	477095-40-2	477095-41-3
477095-42-4	477095-43-5	*477095-44-6*	477095-45-7	
477095-46-8	477095-47-9	477095-48-0	477095-49-1	477095-50-4
477095-51-5	477095-52-6	477095-53-7	477095-54-8	477095-55-9
477095-56-0	477095-57-1	477095-58-2	477095-59-3	477095-60-6
477095-61-7	477095-62-8	477095-63-9	477095-64-0	477095-65-1
477095-66-2	477095-67-3	477095-68-4	477095-69-5	477095-70-8
477095-71-9	477095-72-0	477095-73-1	477095-74-2	477095-75-3
477095-76-4	477095-77-5	477095-78-6	477095-79-7	477095-80-0
477095-81-1	477095-82-2	477095-83-3	477095-84-4	477095-85-5
477095-86-6	477095-87-7	477095-88-8	477095-89-9	477095-90-2
477095-91-3	477095-92-4	477095-93-5	477095-94-6	477095-95-7
477095-96-8	477095-97-9	477095-98-0	477095-99-1	477096-00-7
477096-01-8	477096-02-9	477096-03-0	477096-04-1	477096-05-2
477096-06-3	477096-07-4	477096-08-5	477096-09-6	477096-10-9
477096-11-0	477096-12-1	477096-13-2	477096-14-3	477096-15-4
477096-16-5	477096-17-6	477096-18-7	477096-19-8	477096-20-1
477096-21-2	477096-22-3	477096-23-4	477096-24-5	477096-25-6
477096-26-7	477096-27-8	477096-28-9	477096-29-0	477096-30-3
477096-31-4	477096-32-5	477096-33-6	477096-34-7	477096-35-8
477096-36-9	477096-37-0	477096-38-1	477096-39-2	477096-40-5
477096-41-6	477096-42-7	477096-43-8	477096-44-9	477096-45-0
477096-46-1	477096-47-2	477096-48-3	477096-49-4	477096-50-7

477096-51-8 477096-52-9 477096-53-0 477096-54-1 477096-55-2
477096-56-3 477096-57-4 477096-58-5 477096-59-6 477096-60-9
477096-61-0 477096-62-1 477096-63-2 477096-64-3 477096-65-4
477096-66-5 477096-67-6 477096-68-7 477096-69-8 477096-70-1
477096-71-2 477096-72-3 477096-73-4 477096-74-5 477096-75-6
477096-76-7 477096-77-8 477096-78-9 477096-79-0 477096-80-3
477096-81-4 477096-82-5 477096-83-6 477096-84-7 477096-85-8
477096-86-9 477096-87-0 477096-88-1 477096-89-2 477096-90-5
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(amino acid sequence; essential genes in microorganisms and their use as targets for antisense inhibition of proliferation and antibiotic screening)

IT *477095-44-6*
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(amino acid sequence; essential genes in microorganisms and their use as targets for antisense inhibition of proliferation and antibiotic screening)

RN 477095-44-6 HCAPLUS
CN Protein (Mycobacterium avium clone MAV104574 essential) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L4 ANSWER 4 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:754415 HCAPLUS Full-text
DOCUMENT NUMBER: 137:263304
TITLE: Synthesis of peptides and medical uses of intracellular communication facilitating compounds
INVENTOR(S): Larsen, Bjarne Due; Petersen, Jorgen Soberg; Meier, Eddie; Kjolbye, Anne Louise; Jorgensen, Niklas Rye; Nielsen, Morten Schak; Holstein-Rathlou, Niels-Henrik; Martins, James B.
PATENT ASSIGNEE(S): Zealand Pharmaceuticals A/S, Den.
SOURCE: PCT Int. Appl., 233 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002077017	A2	20021003	WO 2002-US5773	20020222
WO 2002077017	A3	20031009		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
WO 2001062775	A2	20010830	WO 2001-DK127	20010222 <--
WO 2001062775	A3	20020131		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 2003092609	A1	20030515	US 2001-792286	20010222 <--
CA 2439101	A1	20021003	CA 2002-2439101	20020222
EP 1370276	A2	20031217	EP 2002-723240	20020222
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2005506295	T	20050303	JP 2002-576275	20020222
BR 2002007476	A	20060124	BR 2002-7476	20020222
NO 2003003641	A	20031020	NO 2003-3641	20030815
US 2005113293	A1	20050526	US 2003-646294	20030822 <--
IN 2003DN01336	A	20050527	IN 2003-DN1336	20030822
US 2005075280	A1	20050407	US 2004-772774	20040204 <--

PRIORITY APPLN. INFO.:	US 2001-792286	A	20010222
	WO 2001-DK127	A	20010222
	US 2001-314470P	P	20010823
	DK 2000-288	A	20000223 <--
	DK 2000-738	A	20000504 <--
	US 2000-251659P	P	20001206 <--
	WO 2002-US5773	W	20020222

OTHER SOURCE(S): MARPAT 137:263304

AB The invention relates to novel peptides, including novel antiarrhythmic peptides of linear or cyclic structure, having improved stability in vitro and/or in vivo, to compns. comprising these peptides, and to uses of the peptides for the preparation of medicaments. The invention also relates to the use of compds. that facilitate the intercellular communication for the preparation of medicaments for the treatment of a range of diseases characterized in impaired intercellular gap junctional communication. The invention further relates to a method of treating diseases, such as bladder incontinence, disorders of alveolar tissue and bronchial tissue, impaired hearing due to diseases of the cochlea, endothelial lesions, diabetic retinopathy and diabetic neuropathy, ischemia of the central nervous system and spinal cord, dental tissue disorders including periodontal disease, kidney diseases leading to hypertension, and a method of preventing failures of bone marrow transplantation. Ac-D-Tyr-D-Pro-D-4Hyp-Gly-D-Ala-Gly-NH2 (Hyp = hydroxyprolyl) was prepared by the solid-phase method and assayed for biol. activity. Graphs include those for relative cell-to-cell conductance, PI-turnover in neonatal rat cardiomyocytes, and ventricular APD90 dispersion.

IC ICM C07K007-00

CC 34-3 (Amino Acids, Peptides, and Proteins)
Section cross-reference(s): 1, 6, 63

IT 81771-37-1P, Antiarrhythmic peptide (cattle atrium) 111915-92-5P
159503-65-8P 355151-11-0P 355151-12-1P 355151-13-2P 355151-14-3P
355151-15-4P 355151-16-5P 355151-17-6P 355151-18-7P 355151-19-8P
355151-20-1P 355151-23-4P 355151-25-6P 355151-26-7P 355151-27-8P
355151-29-0P 355151-30-3P 355151-31-4P 355151-32-5P
355151-33-6P 355151-34-7P 355151-35-8P 355151-36-9P
355151-37-0P 355151-38-1P 355151-39-2P 355151-40-5P 355151-41-6P
355151-43-8P *355151-45-0P* *355151-46-1P*
355151-47-2P 355151-49-4P 355151-50-7P 355151-51-8P
355151-52-9P 355151-53-0P 355151-54-1P 355151-55-2P 355151-56-3P
355151-74-5P 463362-31-4P 463362-32-5P 463362-33-6P 463362-34-7P
463362-35-8P 463362-36-9P 463362-37-0P 463362-38-1P 463362-40-5P
463362-42-7P 463944-96-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(synthesis of peptides and medical uses of intracellular communication facilitating compds.)

IT 35919-99-4 212570-15-5 366800-53-5 463362-43-8 *463362-44-9* 463362-45-0 463362-46-1 463362-47-2 463362-48-3 463362-49-4 463362-50-7 463362-51-8 463362-52-9 463362-53-0 463362-54-1 463362-55-2 463362-56-3
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(synthesis of peptides and medical uses of intracellular communication facilitating compds.)

IT *355151-33-6P 355151-45-0P 355151-46-1P 355151-47-2P*
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(synthesis of peptides and medical uses of intracellular communication facilitating compds.)

RN 355151-33-6 HCAPLUS
CN D-Asparagine, glycyl-D-alanylglycyl-(4S)-4-hydroxy-D-prolyl-D-prolyl-D-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 355151-45-0 HCAPLUS
CN Cyclo[L-alanylglycyl-(4R)-4-hydroxy-L-prolyl-L-prolyl-L-tyrosyl-L-glutaminylglycyl] (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 355151-46-1 HCAPLUS
CN Cyclo[L-alanylglycyl-(4R)-4-hydroxy-L-prolyl-L-prolyl-L-tyrosyl-L-asparaginylglycyl] (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 355151-47-2 HCAPLUS
CN Cyclo(L-alanylglycyl-L-prolyl-L-prolyl-L-tyrosyl-L-asparaginylglycyl) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT *463362-44-9*
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(synthesis of peptides and medical uses of intracellular communication facilitating compds.)

RN 463362-44-9 HCAPLUS
CN L-Aspartamide, glycyl-L-alanylglycyl-(4R)-4-hydroxy-L-prolyl-L-prolyl-L-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 5 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:575239 HCAPLUS Full-text
DOCUMENT NUMBER: 137:136135
TITLE: Human cDNA sequences and their encoded proteins and diagnostic and therapeutic uses
INVENTOR(S): Shimkets, Richard A.; Patturajan, Meera; Vernet, Corine A. M.; Casman, Stacie J.; Malyankar, Uriel; Shenoy, Suresh; Spytek, Kimberly A.; Gangolli, Esha; Miller, Charles; Boldog, Ferenc; Li, Li; Taupier, Raymond J., Jr.; Kekuda, Ramesh; Smithson, Glennda; Zerhusen, Bryan D.; Liu, Xiaohong; Colman, Steven D.; Tchernev, Velizar; Si, Jingsheng; Edinger, Schlomit; Stone, David; Sciore, Paul; Millet, Isabelle; Rothenberg, Mark
PATENT ASSIGNEE(S): Curagen Corporation, USA
SOURCE: PCT Int. Appl., 363 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 173
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002059315	A2	20020801	WO 2001-US50076	20011219 <--
WO 2002059315	A3	20031009		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002246808	A1	20020806	AU 2002-246808	20011219 <--
AU 2005200106	A1	20050210	AU 2005-200106	20050112 <--
AU 2006201467	A1	20060504	AU 2006-201467	20060407 <--
PRIORITY APPLN. INFO.:			US 2000-256619P P	20001219 <--

US 2001-262959P	P	20010119	
US 2001-272408P	P	20010228	
US 2001-285189P	P	20010420	
US 2001-308039P	P	20010726	
US 2001-311266P	P	20010809	
AU 2000-37360	A3	20000309	<--
AU 2000-78680	A3	20001006	<--
WO 2001-US50076	W	20011219	

AB Disclosed herein are 20 cDNA sequences that encode novel human polypeptides that are members of the following protein families: stabilin, CD44-like precursor/fascilin domain, polydom, transmembrane IIIb protein, serine proteinase, Wnt-7a protein, apical endosomal glycoprotein, ADAM13, leucine-rich F box-containing protein, steroid-binding protein, steroid dehydrogenase, myosin heavy chain, and pancreatitis-associated protein. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies, which immunospecifically-bind to the polypeptide, as well as derivs., variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.

IC ICM C12N015-12
ICS C07K014-47

CC 3-3 (Biochemical Genetics)
Section cross-reference(s): 1, 6, 9, 13

IT 444213-89-2 444213-92-7 444213-96-1 444213-97-2 444213-98-3
444214-00-0 444214-01-1 444214-02-2 444214-03-3 444214-04-4
444214-05-5 444214-06-6 444214-07-7
RL: PRP (Properties)
(unclaimed protein sequence; human cDNA sequences and their encoded proteins and diagnostic and therapeutic uses)

IT *444214-05-5*
RL: PRP (Properties)
(unclaimed protein sequence; human cDNA sequences and their encoded proteins and diagnostic and therapeutic uses)

RN 444214-05-5 HCAPLUS
CN 50: PN: WO02059315 SEQID: 102 unclaimed protein (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L4 ANSWER 6 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:	2002:293812 HCAPLUS Full-text
DOCUMENT NUMBER:	136:290020
TITLE:	Nucleic acids and their encoded polypeptides from human tissues
INVENTOR(S):	Tang, Y. Tom; Liu, Chenghua; Zhou, Ping; Asundi, Vinod; Zhang, Jie; Zhao, Qing A.; Ren, Feiyan; Xue, Aidong J.; Yang, Yonghong; Wehrman, Tom; Drmanac, Radoje T.
PATENT ASSIGNEE(S):	Hyseq, Inc., USA
SOURCE:	PCT Int. Appl., 357 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	127

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
WO 2002031111	A2	20020418	WO 2001-US27760	20011011	<--
WO 2002031111	A3	20021017			

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2425827	A1	20020418	CA 2001-2425827	20011011 <--
AU 200196235	A	20020422	AU 2001-96235	20011011 <--
EP 1325120	A2	20030709	EP 2001-977088	20011011 <--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

PRIORITY APPLN. INFO.:	US 2000-687527	A2	20001012 <--
	WO 2001-US27760	W	20011011

AB The present invention provides novel nucleic acids, novel polypeptide sequences encoded by these nucleic acids and uses thereof. Thus, 446 novel nucleic acids were obtained from cDNA libraries prepared from various human tissues and in some cases isolated from a genomic library derived from human chromosomes using standard PCR, SBH (sequencing-by-hybridization) sequence signature anal., and Sanger sequencing techniques. Novel contigs of the invention were assembled from sequences that were obtained from a cDNA library by the above methods, and in some cases sequences obtained from one or more public databases, using a recursive algorithm to extend the seed EST into an extended assemblage. Tissue expression profiles and nearest neighbor sequence homologies are provided. The sequences of this invention have applications in nucleic acid or polypeptide arrays, in the identification of binding mols., and in treatment of diseases.

IC ICM C12N

CC 3-3 (Biochemical Genetics)
Section cross-reference(s): 6, 13, 63

IT
408551-77-9P	408551-78-0P	408551-79-1P	408551-80-4P	408551-81-5P
408551-82-6P	408551-83-7P	408551-84-8P	408551-85-9P	408551-86-0P
408551-87-1P	408551-88-2P	408551-89-3P	408551-90-6P	408551-91-7P
408551-92-8P	408551-93-9P	408551-94-0P	408551-95-1P	408551-96-2P
408551-97-3P	408551-98-4P	408551-99-5P	408552-00-1P	408552-01-2P
408552-02-3P	*408552-03-4P*	408552-04-5P	408552-05-6P	
408552-06-7P	408552-07-8P	408552-08-9P	408552-09-0P	408552-10-3P
408552-11-4P	408552-12-5P	408552-13-6P	408552-14-7P	408552-15-8P
408552-16-9P	408552-17-0P	408552-18-1P	408552-19-2P	408552-20-5P
408552-21-6P	408552-22-7P	408552-23-8P	408552-24-9P	408552-25-0P
408552-26-1P	408552-27-2P	408552-28-3P	408552-29-4P	408552-30-7P
408552-31-8P	408552-32-9P	408552-33-0P	408552-34-1P	408552-35-2P
408552-36-3P	408552-37-4P	408552-38-5P	408552-39-6P	408552-40-9P
408552-41-0P	408552-42-1P	408552-43-2P	408552-44-3P	408552-45-4P
408552-46-5P	408552-47-6P	408552-48-7P	408552-49-8P	408552-50-1P
408552-51-2P	408552-52-3P	408552-53-4P	408552-54-5P	408552-55-6P
408552-56-7P	408552-57-8P	408552-58-9P	408552-59-0P	408552-60-3P
408552-61-4P	408552-62-5P	408552-63-6P	408552-64-7P	408552-65-8P
408552-66-9P	408552-67-0P	408552-68-1P	408552-69-2P	408552-70-5P
408552-71-6P	408552-72-7P	408552-73-8P	408552-74-9P	408552-75-0P
408552-76-1P	408552-77-2P	408552-78-3P	408552-79-4P	408552-80-7P
408552-81-8P	408552-82-9P	408552-83-0P	408552-84-1P	408552-85-2P
408552-86-3P	408552-87-4P	408552-88-5P	408552-89-6P	408552-90-9P
408552-91-0P	408552-92-1P	408552-93-2P	408552-94-3P	408552-95-4P
408552-96-5P	408552-97-6P	408552-98-7P	408552-99-8P	408553-00-4P
408553-01-5P	408553-02-6P	408553-03-7P	408553-04-8P	408553-05-9P
408553-06-0P	408553-07-1P	408553-08-2P	408553-09-3P	408553-10-6P
408553-11-7P	408553-12-8P	408553-13-9P	408553-14-0P	408553-15-1P

408553-16-2P 408553-17-3P 408553-18-4P 408553-19-5P 408553-20-8P
408553-21-9P 408553-22-0P 408553-23-1P 408553-24-2P 408553-25-3P
408553-26-4P 408553-27-5P 408553-28-6P 408553-29-7P 408553-30-0P
408553-31-1P 408553-32-2P 408553-33-3P 408553-34-4P 408553-35-5P
408553-36-6P 408553-37-7P 408553-38-8P 408553-39-9P 408553-40-2P
408553-41-3P 408553-42-4P 408553-43-5P 408553-44-6P 408553-45-7P
408553-46-8P 408553-47-9P 408553-48-0P 408553-49-1P 408553-50-4P
408553-51-5P 408553-52-6P 408553-53-7P 408553-54-8P 408553-55-9P
408553-56-0P 408553-57-1P 408553-58-2P 408553-59-3P 408553-60-6P
408553-61-7P 408553-62-8P 408553-63-9P 408553-64-0P 408553-65-1P
408553-66-2P 408553-67-3P 408553-68-4P 408553-69-5P 408553-70-8P
408553-71-9P 408553-72-0P 408553-73-1P 408553-74-2P 408553-75-3P
408553-76-4P 408553-77-5P 408553-78-6P 408553-79-7P 408553-80-0P
408553-81-1P 408553-82-2P 408553-83-3P 408553-84-4P 408553-85-5P
408553-86-6P 408553-87-7P 408553-88-8P 408553-89-9P 408553-90-2P

RL: ANT (Analyte); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)
(amino acid sequence; nucleic acids and their encoded polypeptides from human tissues)

IT *408552-03-4P*

RL: ANT (Analyte); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)
(amino acid sequence; nucleic acids and their encoded polypeptides from human tissues)

RN 408552-03-4 HCAPLUS
CN Protein (human clone WO0231111-SEQID-704) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L4 ANSWER 7 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:828442 HCAPLUS Full-text
DOCUMENT NUMBER: 136:396989
TITLE: Human nucleic acids and polypeptides and their diagnostic and therapeutic uses
INVENTOR(S): Drmanac, Rodoje T.; Liu, Chenghua; Tang, Y. Tom
PATENT ASSIGNEE(S): Hyseq, Inc., USA
SOURCE: PCT Int. Appl., 103 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 127
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001075067	A2	20011011	WO 2001-XF8631	20010330 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
WO 2001075067	A2	20011011	WO 2001-US8631	20010330 <--
WO 2001075067	A3	20020404		
WO 2001075067	A9	20021031		

WO 2001075067 A8 20041014
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.: US 2000-540217 A 20000331 <--
US 2000-649167 A 20000823 <--
WO 2001-US8631 W 20010330

AB The present invention provides 30,368 nucleic acids and the 30,368 novel human polypeptide sequences encoded by these nucleic acids. A plurality of novel nucleic acids are obtained from cDNA libraries prepared from various human tissues and in some cases isolated from a genomic library derived from human chromosomes using standard PCR, sequencing by hybridization signature anal., and Sanger sequencing techniques. Nearest neighbor results are identified by sequence homol. searching. The invention also relates to therapeutic, diagnostic, and research utilities for these polynucleotides and proteins. [This abstract record is one of 10 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.].

IC ICM C12N
CC 3-3 (Biochemical Genetics)
Section cross-reference(s): 6, 13, 63

IT

429717-74-8	429717-75-9	429717-76-0	429717-77-1	429717-78-2
429717-79-3	429717-80-6	429717-81-7	429717-82-8	429717-83-9
429717-84-0	429717-85-1	429717-86-2	429717-87-3	429717-88-4
429717-89-5	429717-90-8	429717-91-9	429717-92-0	429717-93-1
429717-94-2	429717-95-3	429717-96-4	429717-97-5	429717-98-6
429717-99-7	429718-00-3	429718-01-4	429718-02-5	429718-03-6
429718-04-7	429718-05-8	429718-06-9	429718-07-0	429718-08-1
429718-09-2	429718-10-5	429718-11-6	429718-12-7	429718-13-8
429718-14-9	429718-15-0	429718-16-1	429718-17-2	429718-18-3
429718-19-4	429718-20-7	429718-21-8	429718-22-9	429718-23-0
429718-24-1	429718-25-2	429718-26-3	429718-27-4	429718-28-5
429718-29-6	429718-30-9	429718-31-0	429718-32-1	429718-33-2
429718-34-3	429718-35-4	429718-36-5	429718-37-6	429718-38-7
429718-39-8	429718-40-1	429718-41-2	429718-42-3	
429718-43-4	429718-44-5	429718-45-6	429718-46-7	429718-47-8
429718-48-9	429718-49-0	429718-50-3	429718-51-4	429718-52-5
429718-53-6	429718-54-7	429718-55-8	429718-56-9	429718-57-0
429718-58-1	429718-59-2	429718-60-5	429718-61-6	429718-62-7
429718-63-8	429718-64-9	429718-65-0	429718-66-1	429718-67-2
429718-68-3	429718-69-4	429718-70-7	429718-71-8	429718-72-9
429718-73-0	429718-74-1	429718-75-2	429718-76-3	429718-77-4
429718-78-5	429718-79-6	429718-80-9	429718-81-0	429718-82-1
429718-83-2	429718-84-3	429718-85-4	429718-86-5	429718-87-6
429718-88-7	429718-89-8	429718-90-1	429718-91-2	429718-92-3
429718-93-4	429718-94-5	429718-95-6	429718-96-7	429718-97-8
429718-98-9	429718-99-0	429719-00-6	429719-01-7	429719-02-8
429719-03-9	429719-04-0	429719-05-1	429719-06-2	429719-07-3
429719-08-4	429719-09-5	429719-10-8	429719-11-9	429719-12-0
429719-13-1	429719-14-2	429719-15-3	429719-16-4	429719-17-5
429719-18-6	429719-19-7	429719-20-0	429719-21-1	429719-22-2
429719-23-3	429719-24-4	429719-25-5	429719-26-6	429719-27-7
429719-28-8	429719-29-9	429719-30-2	429719-31-3	429719-32-4
429719-33-5	429719-34-6	429719-35-7	429719-36-8	429719-37-9

429719-38-0 429719-39-1 429719-40-4 429719-41-5 429719-42-6
429719-43-7 429719-44-8 429719-45-9 429719-46-0 429719-47-1
429719-48-2 429719-49-3 429719-50-6 429719-51-7 429719-52-8
429719-53-9 429719-54-0 429719-55-1 429719-56-2 429719-57-3
429719-58-4 429719-59-5 429719-60-8 429719-61-9 429719-62-0
429719-63-1 429719-64-2 429719-65-3 429719-66-4 429719-67-5
429719-68-6 429719-69-7 429719-70-0 429719-71-1 429719-72-2
429719-73-3 429719-74-4 429719-75-5 429719-76-6 429719-77-7
429719-78-8 429719-79-9 429719-80-2 429719-81-3 429719-82-4
429719-83-5 429719-84-6 429719-85-7 429719-86-8 429719-87-9
429719-88-0 429719-89-1 429719-90-4 429719-91-5 429719-92-6
429719-93-7 429719-94-8 429719-95-9 429719-96-0 429719-97-1
429719-98-2 429719-99-3 429720-00-3 429720-01-4 429720-02-5
429720-03-6 429720-04-7 429720-05-8 429720-06-9
RL: ANT (Analyte); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(amino acid sequence; human nucleic acids and polypeptides and their diagnostic and therapeutic uses)

IT *429718-39-8*
RL: ANT (Analyte); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(amino acid sequence; human nucleic acids and polypeptides and their diagnostic and therapeutic uses)

RN 429718-39-8 HCAPLUS
CN Protein (human clone WO0175067-SEQID-32147) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L4 ANSWER 8 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:781081 HCAPLUS Full-text
DOCUMENT NUMBER: 135:314493
TITLE: Novel nucleic acids encoding human bone marrow-expressed polypeptides
INVENTOR(S): Ford, John E.; Boyle, Bryan J.; Tang, Y. Tom; Asundi, Vinod; Yang, Yonghong; Liu, Chenghua; Drmanac, Radoje T.
PATENT ASSIGNEE(S): Hyseq, Inc., USA
SOURCE: PCT Int. Appl., 203 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 127
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001079447	A2	20011025	WO 2001-US12607	20010418 <--
WO 2001079447	A8	20030724		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 200155454	A	20011030	AU 2001-55454		20010418 <--
US 2003113847	A1	20030619	US 2002-232484		20020830 <--
PRIORITY APPLN. INFO.:			US 2000-552929	A	20000418 <--
			US 2000-695783	A	20001024 <--
			US 2000-250583P	P	20001130 <--
			US 2001-770160	A	20010126
			WO 2001-US12607	W	20010418

AB The present invention provides 67 novel bone marrow-expressed nucleic acids, novel polypeptide sequences encoded by these nucleic acids, and uses thereof. The novel nucleic acids were assembled from expressed sequence tags (ESTs) isolated mainly by sequencing by hybridization, Sanger sequencing techniques, and in some cases, sequences obtained from one or more public databases. A recursive algorithm was used to extend some of the seed ESTs into an extended assemblage, by pulling addnl. sequences from different databases. Clusters were identified which were expressed in bone marrow tissue cDNA libraries, but not in other tissues. The polynucleotides and polypeptides of the invention have uses in diagnosis and therapy, detecting bone-marrow cells or tissues, and in arrays to screen for binding agents.

IC ICM C12N

CC 3-3 (Biochemical Genetics)
Section cross-reference(s): 6, 13, 63

IT 218776-18-2 321453-13-8 367452-08-2 367620-05-1 367620-06-2
367620-07-3 367620-08-4 367620-09-5 367620-10-8 367620-11-9
367620-12-0 *367620-13-1* 367620-14-2 367620-15-3
367620-16-4 367620-17-5 367620-18-6 367620-19-7 367620-20-0
367620-21-1 367620-22-2 367620-47-1 367620-48-2 367620-49-3
367620-50-6 367620-51-7 367620-52-8 367620-53-9 367620-54-0
367620-55-1 367620-56-2 367620-57-3 367620-58-4 367620-59-5
367620-60-8 367620-61-9 367620-62-0 367620-63-1 367620-64-2
367620-65-3 367620-66-4 367620-67-5 367935-34-0 367935-37-3
367935-43-1 367935-50-0 367935-54-4 367935-57-7 367935-63-5
367935-65-7 367935-71-5 367935-78-2 367935-81-7 367943-61-1
367943-64-4 367943-67-7
RL: ANT (Analyte); BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
(amino acid sequence; nucleic acids encoding human bone marrow-expressed polypeptides)

IT *367620-13-1*
RL: ANT (Analyte); BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
(amino acid sequence; nucleic acids encoding human bone marrow-expressed polypeptides)

RN 367620-13-1 HCAPLUS

CN Bone marrow-specific protein (human clone WO0179447-SEQID-38 precursor) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L4 ANSWER 9 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:	2001:636085 HCAPLUS Full-text
DOCUMENT NUMBER:	135:180957
TITLE:	Preparation of novel antiarrhythmic peptides
INVENTOR(S):	Larsen, Bjarne Due; Petersen, Jorgen Soberg; Meier, Eddi; Kjolbye, Anne Louise; Jorgensen, Niklas Rye; Nielsen, Morten Schak; Holstein-Rathlou, Niels-Henrik; Martins, James B.
PATENT ASSIGNEE(S):	Zealand Pharmaceuticals A/S, Den.
SOURCE:	PCT Int. Appl., 189 pp.

CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001062775	A2	20010830	WO 2001-DK127	20010222 <--
WO 2001062775	A3	20020131		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2385659	A1	20010830	CA 2001-2385659	20010222 <--
EP 1226160	A2	20020731	EP 2001-907393	20010222 <--
EP 1226160	B1	20041215		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003528826	T	20030930	JP 2001-562556	20010222 <--
AT 284896	T	20050115	AT 2001-907393	20010222 <--
ES 2228807	T3	20050416	ES 2001-1907393	20010222 <--
PT 1226160	T	20050429	PT 2001-907393	20010222 <--
AU 781674	B2	20050602	AU 2001-35362	20010222 <--
CA 2439101	A1	20021003	CA 2002-2439101	20020222
WO 2002077017	A2	20021003	WO 2002-US5773	20020222
WO 2002077017	A3	20031009		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1370276	A2	20031217	EP 2002-723240	20020222
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2005506295	T	20050303	JP 2002-576275	20020222
BR 2002007476	A	20060124	BR 2002-7476	20020222
NO 2003003641	A	20031020	NO 2003-3641	20030815
US 2005113293	A1	20050526	US 2003-646294	20030822 <--
US 2005075280	A1	20050407	US 2004-772774	20040204 <--
AU 2005205785	A1	20050929	AU 2005-205785	20050902 <--

PRIORITY APPLN. INFO.:	DK 2000-288	A	20000223 <--
	DK 2000-738	A	20000504 <--
	US 2000-251659P	P	20001206 <--
	US 2001-792286	A	20010222
	WO 2001-DK127	W	20010222
	US 2001-314470P	P	20010823
	WO 2002-US5773	W	20020222

OTHER SOURCE(S): MARPAT 135:180957

AB Peptides X-A-B-Y and cyclo(X-A-B-Y) [A and B represents chemical moieties having an amino group (radical) and a carboxy group; X represents a peptide

sequence of 1 to 3 D- or L-amino acid residues or an N-terminal modification of the group A-B when Y represents a C-terminal peptide sequence of 2 to 5 D- or L-amino acid residues; X represents a peptide sequence of 2 to 5 D- or L-amino acid residues when Y represents a C-terminal peptide sequence of 1 to 3 D- or L-amino acid residues; for the linear peptide, X is optionally chemical modified at its N-terminal and has an optional linking group comprising 0-8 backbone atoms] and their mirror image or a retro analogs or pharmaceutically acceptable derivs. were prepared for treating cardiac arrhythmias. Thus, Ac-D-Tyr-D-pro-D-4Hyp-Gly- D-Ala-Gly-NH2 (4Hyp = 4-hydroxyprolyl) was prepared by the solid-phase method using TentaGel-S-Ram and examined for biol. activity [assays included effect on gap junction intercellular communication (GJIC) in cardiomyocytes, binding to tissue prepns. of murine heart, and effect on cAMP formation in CHO cells].

IC ICM C07K007-00

CC 34-3 (Amino Acids, Peptides, and Proteins)
Section cross-reference(s): 1, 63

IT 81771-37-1P, Antiarrhythmic peptide (cattle atrium) 159503-65-8P
355151-11-0P 355151-14-3P 355151-15-4P 355151-16-5P 355151-17-6P
355151-18-7P 355151-19-8P 355151-20-1P 355151-21-2P 355151-22-3P
355151-23-4P 355151-24-5P 355151-25-6P 355151-26-7P 355151-27-8P
355151-28-9P 355151-29-0P 355151-30-3P 355151-31-4P 355151-32-5P
355151-33-6P 355151-34-7P 355151-35-8P 355151-36-9P
355151-37-0P 355151-38-1P 355151-39-2P 355151-40-5P 355151-42-7P
355151-44-9P ***355151-45-0P 355151-46-1P***
355151-47-2P 355151-48-3P 355151-49-4P 355151-50-7P
355151-51-8P 355151-52-9P 355151-53-0P 355151-54-1P 355151-55-2P
355151-56-3P 355151-57-4P 355151-58-5P 355151-59-6P 355151-60-9P
355151-61-0P 355151-62-1P 355151-63-2P 355151-64-3P 355151-65-4P
355151-66-5P 355151-67-6P 355151-68-7P 355151-69-8P 355151-70-1P
355151-71-2P 355151-72-3P 355151-73-4P 355151-74-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of novel antiarrhythmic peptides)

IT ***355151-33-6P 355151-45-0P 355151-46-1P***
355151-47-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of novel antiarrhythmic peptides)

RN 355151-33-6 HCAPLUS

CN D-Asparagine, glycyl-D-alanylglycyl-(4S)-4-hydroxy-D-prolyl-D-prolyl-D-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 355151-45-0 HCAPLUS
CN Cyclo[L-alanylglycyl-(4R)-4-hydroxy-L-prolyl-L-prolyl-L-tyrosyl-L-glutaminylglycyl] (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 355151-46-1 HCAPLUS
CN Cyclo[L-alanylglycyl-(4R)-4-hydroxy-L-prolyl-L-prolyl-L-tyrosyl-L-asparaginylglycyl] (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 355151-47-2 HCAPLUS
CN Cyclo(L-alanylglycyl-L-prolyl-L-prolyl-L-tyrosyl-L-asparaginylglycyl) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L4 ANSWER 10 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2000:325646 HCAPLUS Full-text
DOCUMENT NUMBER: 133:247911
TITLE: Prediction of the coding sequences of unidentified human genes. XVII. the complete sequences of 100 new cDNA clones from brain which code for large proteins in vitro
AUTHOR(S): Nagase, Takahiro; Kikuno, Reiko; Ishikawa, Ken-Ichi; Hirosawa, Makoto; Ohara, Osamu
CORPORATE SOURCE: Kazusa DNA Research Institute, Chiba, 292-0812, Japan
SOURCE: DNA Research (*2000*), 7(2), 143-150
CODEN: DARSE8; ISSN: 1340-2838
PUBLISHER: Universal Academy Press
DOCUMENT TYPE: Journal
LANGUAGE: English
AB To provide information regarding the coding sequences of unidentified human genes, the authors have conducted a sequencing project of human cDNAs which encode large proteins. The authors herein present the entire sequences of 100 cDNA clones of unknown human genes, named KIAA1444 to KIAA1543, from two sets of size-fractionated human adult and fetal brain cDNA libraries. The average sizes of the inserts and corresponding open reading frames of cDNA clones analyzed here were 4.4 kb and 2.6 kb (856 amino acid residues), resp. Database searches of the predicted amino acid sequences classified 53 predicted gene products into the following five functional categories: cell signaling/communication, nucleic acid management, cell structure/motility, protein management and metabolism It was also revealed that homologues for 32 KIAA gene products were detected in the databases, which were similar in sequence through almost their entire regions. Addnl., the chromosomal loci of the genes were determined by using human-rodent hybrid panels unless their chromosomal loci were already assigned in the public databases. The expression levels of the genes were monitored in spinal cord, fetal brain and fetal liver, as well as in 10 human tissues and 8 brain regions, by reverse transcription-coupled polymerase chain reaction, products of which were quantified by ELISA.
CC 3-3 (Biochemical Genetics)
IT 295808-10-5 295808-11-6 295808-12-7 295808-13-8 295808-14-9
295808-15-0 295808-16-1 295808-17-2 295808-18-3 295808-19-4
295808-20-7 295808-21-8 295808-22-9 295808-23-0 295808-24-1
295808-25-2 295808-26-3 295808-27-4 295808-28-5 295808-29-6
295808-30-9 295808-31-0 *295808-32-1* 295808-33-2
295808-34-3 295808-35-4 295808-36-5 295808-37-6 295808-38-7
295808-39-8 295808-40-1 295808-41-2 295808-42-3 295808-43-4
295808-44-5 295808-45-6 295808-46-7 295808-47-8 295808-48-9
295808-49-0 295808-50-3 295808-51-4 295808-52-5 295808-53-6

295808-54-7 295808-55-8 295808-56-9 295808-57-0 295808-58-1
295808-59-2 295808-60-5 295808-61-6 295808-62-7 295808-63-8
295808-64-9 295808-65-0 295808-66-1 295808-67-2 295808-68-3
295808-69-4 295808-70-7 295808-71-8 295808-72-9 295808-73-0
295808-74-1 295808-75-2 295808-76-3 295808-77-4 295808-78-5
295808-79-6 295808-80-9 295808-81-0 295808-82-1 295808-83-2
295808-84-3 295808-85-4 295808-86-5 295808-87-6 295808-88-7
295808-89-8 295808-90-1 295808-91-2 295808-92-3 295808-93-4
295808-94-5 295808-95-6 295808-96-7 295808-97-8 295808-98-9
295808-99-0 295809-00-6 295809-01-7 295809-02-8 295809-03-9
295809-04-0 295809-05-1 295809-06-2 295809-07-3 295809-08-4
295809-09-5

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence; sequences of 100 cDNA clones of unknown human genes, named KIAA1444 to KIAA1543, from human adult and fetal brain cDNA libraries)

IT *295808-32-1*

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence; sequences of 100 cDNA clones of unknown human genes, named KIAA1444 to KIAA1543, from human adult and fetal brain cDNA libraries)

RN 295808-32-1 HCAPLUS

CN Protein (human clone fj01441 gene KIAA1466 fragment) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Anon	1998	282	2012	Science	
Bateman, A	1999	27	260	Nucleic Acids Res	HCAPLUS
Bleasby, A	1994	22	3574	Nucleic Acids Res	HCAPLUS
Deguchi, M	1998	273	26269	J Biol Chem	HCAPLUS
Dunham, I	1999	402	489	Nature	HCAPLUS
Goffeau, A	1996	274	546	Science	HCAPLUS
Gyapay, G	1996	5	339	Hum Mol Genet	HCAPLUS
Hirosawa, M	1999	6	329	DNA Res	HCAPLUS
Ishikawa, K	1997	4	307	DNA Res	HCAPLUS
Kikuno, R	2000	28	331	Nucleic Acids Res	HCAPLUS
Nagase, T	1998	5	277	DNA Res	HCAPLUS
Nagase, T	1998	5	31	DNA Res	HCAPLUS
Nagase, T	2000	7	65	DNA Res	HCAPLUS
Nomura, N	1994	1	27	DNA Res	HCAPLUS
Ohara, O	1997	4	53	DNA Res	HCAPLUS
Taguchi, A	1996	35	31	Brain Res Mol Brain	HCAPLUS

L4 ANSWER 11 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1999:379001 HCAPLUS Full-text
DOCUMENT NUMBER: 131:54612
TITLE: Complete genome sequence of an aerobic hyper-thermophilic crenarchaeon, Aeropyrum pernix K1
AUTHOR(S): Kawarabayasi, Yutaka; Hino, Yumi; Horikawa, Hiroshi; Yamazaki, Syuji; Haikawa, Yuji; Jin-No, Koji; Takahashi, Mikio; Sekine, Mitsuo; Baba, Sin-Ichi; Ankai, Akiho; Kosugi, Hiroki; Hosoyama, Akira; Fukui, Shigehiro; Nagai, Yoshimi; Nishijima, Keiko; Nakazawa, Hidekazu; Takamiya, Minako; Masuda, Sayaka; Funahashi,

Tomomichi; Tanaka, Toshihiro; Kudoh, Yutaka; Yamazaki, Jun; Kushida, Norihiro; Oguchi, Akio; Aoki, Ken-ichi; Kubota, Kenji; Nakamura, Yoshinobu; Nomura, Norimichi; Sako, Yoshihiko; Kikuchi, Hisasi
CORPORATE SOURCE: National Institute of Technology and Evaluation, Tokyo, 151-0066, Japan
SOURCE: DNA Research (*1999*), 6(2), 83-101, 145-152
CODEN: DARSE8; ISSN: 1340-2838
PUBLISHER: Universal Academy Press
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The complete sequence of the genome of an aerobic hyper-thermophilic crenarchaeon, Aeropyrum pernix K1, which optimally grows at 95°, was determined by the whole genome shotgun method with some modifications. The entire length of the genome was 1,669,695 bp. The authenticity of the entire sequence was supported by restriction anal. of long PCR products, which were directly amplified from the genomic DNA. As the potential protein-coding regions, a total of 2694 open reading frames (ORFs) were assigned. By similarity search against public databases, 633 (23.5%) of the ORFs were related to genes with putative function and 523 (19.4%) to the sequences registered but with unknown function. All the genes in the TCA cycle except for that of α-ketoglutarate dehydrogenase were included, and instead of the α-ketoglutarate dehydrogenase gene, the genes coding for the 2 subunits of 2-oxoacid:ferredoxin oxidoreductase were identified. The remaining 1538 ORFs (57.1%) did not show any significant similarity to the sequences in the databases. Sequence comparison among the assigned ORFs suggested that a considerable member of ORFs were generated by sequence duplication. The RNA genes identified were a single 16S-23S rRNA operon, two 5S rRNA genes, and 47 tRNA genes including 14 genes with intron structures. All the assigned ORFs and RNA coding regions occupied 89.12% of the whole genome. The data presented in this paper are available on the internet homepage (http://www.mild.nite.go.jp).
CC 3-3 (Biochemical Genetics)
Section cross-reference(s): 6, 10
IT

227780-17-8	227780-18-9	227780-19-0	227780-20-3	227780-21-4
227780-22-5	227780-23-6	227780-24-7	227780-25-8	227780-26-9
227780-27-0	227780-28-1	227780-29-2	227780-30-5	227780-32-7
227780-34-9	227780-35-0	227780-45-2	227780-49-6	227780-50-9
227780-51-0	227780-52-1	227780-53-2	227780-54-3	227780-55-4
227780-56-5	227780-57-6	227780-59-8	227780-63-4	227780-68-9
227780-69-0	227780-70-3	227780-71-4	227780-72-5	227780-73-6
227780-74-7	227780-75-8	227780-76-9	227780-77-0	227780-78-1
227780-92-9	227781-11-5	227781-12-6	227781-13-7	227781-14-8
227781-15-9	227781-16-0	227781-17-1	227781-18-2	227781-19-3
227781-20-6	227781-21-7	227781-22-8	227781-23-9	227781-24-0
227781-25-1	227781-33-1	227781-45-5	227781-54-6	227781-62-6
227781-74-0	227781-76-2	227781-77-3	227781-78-4	227781-79-5
227781-80-8	227781-81-9	227781-83-1	227781-88-6	227781-91-1
227781-95-5	227781-96-6	227782-00-5	227782-05-0	227782-15-2
227782-16-3	227782-17-4	227782-18-5	227782-19-6	227782-20-9
227782-24-3	227782-25-4	227782-26-5	227782-27-6	227782-28-7
227782-29-8	227782-30-1	227782-31-2	227782-32-3	227782-33-4
227782-34-5	227782-35-6	227782-36-7	227782-37-8	227782-38-9
227782-39-0	227782-40-3	227782-41-4	227782-42-5	227782-43-6
227782-44-7	227782-45-8	227782-46-9	227782-47-0	227782-48-1
227782-49-2	227782-50-5	227782-51-6	227782-52-7	227782-53-8
227782-54-9	227782-55-0	227782-56-1	227782-57-2	227782-58-3
227782-59-4	227782-60-7	227782-61-8	227782-62-9	227782-63-0
227782-65-2	227782-66-3	227782-69-6	227782-70-9	227782-71-0
227782-72-1	227782-73-2	227782-74-3	227782-75-4	227782-78-7

227782-79-8 227782-81-2 227782-82-3 227782-83-4 227782-89-0
227782-93-6 227782-94-7 227782-95-8 227782-97-0 227783-01-9
227783-11-1 227783-18-8 227783-19-9 227783-20-2 227783-21-3
227783-22-4 227783-23-5 227783-24-6 227783-25-7 227783-27-9
227783-29-1 227783-31-5 227783-32-6 227783-33-7 227783-34-8
227783-35-9 227783-36-0 227783-37-1 227783-38-2 227783-39-3
227783-40-6 227783-41-7 227783-42-8 227783-43-9 227783-44-0
227783-45-1 227783-46-2 227783-47-3 227783-48-4 227783-49-5
227783-50-8 227783-51-9 227783-52-0 227783-53-1 227783-54-2
227783-55-3 227783-56-4 227783-57-5 227783-58-6 227783-59-7
227783-60-0 227783-61-1 227783-62-2 227783-64-4 227783-65-5
227783-66-6 227783-67-7 227783-68-8 227783-69-9 227783-70-2
227783-71-3 227783-72-4 227783-73-5 227783-74-6 227783-75-7
227783-76-8 227783-77-9 227783-78-0 227783-79-1 227783-80-4
227783-81-5 227783-82-6 227783-83-7 227783-84-8 227783-88-2
227783-90-6 227783-91-7 *227783-92-8* 227783-93-9
227783-94-0 227783-95-1 227783-96-2 227783-97-3 227783-98-4
227783-99-5 227784-00-1 227784-01-2 227784-02-3 227784-03-4
227784-04-5 227784-05-6 227784-06-7 227784-07-8 227784-08-9
227784-09-0 227784-10-3 227784-11-4 227784-12-5 227784-13-6
227784-14-7 227784-15-8 227784-16-9 227784-17-0 227784-18-1
227784-19-2 227784-20-5 227784-21-6
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence; complete genome sequence of Aeropyrum pernix K1)

IT *227783-92-8*
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence; complete genome sequence of Aeropyrum pernix K1)

RN 227783-92-8 HCAPLUS
CN 132Aa long protein (Aeropyrum pernix strain K1 gene APE1292) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Bult, C	1996	273	1058	Science	HCAPLUS
Ewing, B	1998	8	175	Genome Res	HCAPLUS
Ewing, B	1998	8	186	Genome Res	HCAPLUS
Hirata, R	1990	265	6726	J Biol Chem	HCAPLUS
Kane, P	1990	250	651	Science	HCAPLUS
Kawarabayasi, Y			147	DNA Res	
Kawarabayasi, Y	1998	5	55	DNA Res	HCAPLUS
Klenk, H	1997	390	364	Nature	HCAPLUS
Lowe, T	1997	25	955	Nuc Acids Res	HCAPLUS
Nakamura, Y	1997	2	299	Microbial & Comparat	HCAPLUS
Niehaus, F	1997	204	153	Gene	HCAPLUS
Nomura, N	1998	180	3635	J Bacteriol	HCAPLUS
Peler, F	1992	89	5577	Proc Natl Acad Sci	
Perler, F	1997	25	1087	Nuc Acids Res	HCAPLUS
Pietrokovski, S	1994	3	2340	Protein Science	HCAPLUS
Riera, J	1990	94	475	Proc Natl Acad Sci	
Sako, Y	1996	46	1070	International Journa	MEDLINE
Smith, C	1987	236	1448	Science	HCAPLUS
Smith, D	1997	179	7135	J Bacteriol	HCAPLUS
Smith, T	1981	147	195	J Mol Biol	MEDLINE
Takagi, M	1997	63	4504	Appl Environ Microbi	HCAPLUS
Xu, M	1993	75	1371	Cell	HCAPLUS

Zhang, Q	1996	120	587	J Biochem	HCAPLUS

L4 ANSWER 12 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1997:474887 HCAPLUS Full-text
DOCUMENT NUMBER: 127:174474
TITLE: In vivo evidence of the critical role of cadherin-5 in murine vascular integrity
AUTHOR(S): Matsuyoshi, Norihisa; Toda, Ken-Ichi; Horiguchi, Yuji; Tanaka, Toshihiro; Nakagawa, Shinichi; Takeichi, Masatoshi; Imamura, Sadao
CORPORATE SOURCE: Department of Dermatology, Graduate School of Medicine, Faculty of Science, Kyoto University, Kyoto, 606-01, Japan
SOURCE: Proceedings of the Association of American Physicians (*1997*), 109(4), 362-371
CODEN: PAAPFD; ISSN: 1081-650X
PUBLISHER: Blackwell
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Vascular endothelial cell-cell adhesion is crucial for the regulation of vascular functions and is associated with many circulatory disorders. We isolated a rat monoclonal antibody (VECD1) recognizing the mouse vascular endothelial cell adhesion mol. and found that it inhibited vascular endothelial cell-cell association We sequenced a full-length cDNA of the antigen that was identical to mouse cadherin-5. L-cells transfected with its cDNA acquired cell-cell adhesiveness, and these transfectants reacted with VECD1 at cell-cell contact areas. We studied the role of mouse cadherin-5 in vascular functions. The addition of VECD1 antibody to a cultured vascular endothelial cell line (F-2) caused the detachment of each cell. Although normal F-2 cells formed tubular structures on Matrigel, VECD1 disturbed the tubulogenesis. VECD1 also increased the permeability through the F-2 cell layer. To clarify the in vivo function of mouse cadherin-5, we i.p. injected the hybridomas producing VECD1 into adult mice. Severe venous stasis and s.c. hemorrhage were induced within several days after the injection, resulting in the early death of the animals. These findings are evidence of an essential role of cadherin-5 in the regulation of vascular endothelial cell-cell adhesion in vivo.

CC 13-6 (Mammalian Biochemistry)
Section cross-reference(s): 6

IT *193843-04-8*, Cadherin 5 (mouse F-2 cell)
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence; in vivo evidence of critical role of cadherin-5 in murine vascular integrity)

IT *173432-45-6*, Cadherin 5, prepro- (Mus musculus)
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(in vivo evidence of critical role of cadherin-5 in murine vascular integrity)

IT *193843-04-8*, Cadherin 5 (mouse F-2 cell)
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence; in vivo evidence of critical role of cadherin-5 in murine vascular integrity)

RN 193843-04-8 HCAPLUS
CN Cadherin 5 (mouse F-2 cell) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT *173432-45-6*, Cadherin 5, prepro- (Mus musculus)
RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); PRP (Properties); BIOL (Biological study)
(in vivo evidence of critical role of cadherin-5 in murine vascular integrity)
RN 173432-45-6 HCAPLUS
CN Cadherin 5, prepro- (Mus musculus) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L4 ANSWER 13 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1996:556341 HCAPLUS Full-text
DOCUMENT NUMBER: 125:239971
TITLE: A novel family of developmentally regulated mammalian transcription factors containing the TEA/ATTS DNA binding domain
AUTHOR(S): Jacquemin, Patrick; Hwang, Jung-Joo; Martial, Joseph A.; Dolle, Pascal; Davidson, Irwin
CORPORATE SOURCE: Inst. Genetique Biologie Moleculaire Cellulaire, College France, Illkirch, 163-67404, Fr.
SOURCE: Journal of Biological Chemistry (*1996*), 271(36), 21775-21785
CODEN: JBCHA3; ISSN: 0021-9258
PUBLISHER: American Society for Biochemistry and Molecular Biology
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The authors describe the mol. cloning of two novel human and murine transcription factors containing the TEA/ATTS DNA binding domain and related to transcriptional enhancer factor-1 (TEF-1). These factors bind to the consensus TEA/ATTS cognate binding site exemplified by the GT-IIC and Sph enhansons of the SV40 enhancer but differ in their ability to bind cooperatively to tandemly repeated sites. The human TEFs are differentially expressed in cultured cell lines and the mouse (m)TEFs are differentially expressed in embryonic and extra-embryonic tissues in early post-implantation embryos. Strikingly, at later stages of embryogenesis, mTEF-3 is specifically expressed in skeletal muscle precursors, whereas mTEF-1 is expressed not only in developing skeletal muscle but also in the myocardium. Together with previous data, these results point to important, partially redundant, roles for these TEF proteins in myogenesis and cardiogenesis. In addition, mTEF-1 is strongly coexpressed with mTEF-4 in mitotic neuroblasts, while accentuated mTEF-4 expression is also observed in the gut and the nephrogenic region of the kidney. These observations suggest addnl. roles for the TEF proteins in central nervous system development and organogenesis.
CC 3-4 (Biochemical Genetics)
Section cross-reference(s): 6, 13
IT 181829-00-5 *181829-01-6* 181829-02-7 181829-03-8
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence; a novel family of developmentally regulated mammalian transcription factors containing the TEA/ATTS DNA binding domain)
IT *181829-01-6*
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence; a novel family of developmentally regulated mammalian transcription factors containing the TEA/ATTS DNA binding domain)
RN 181829-01-6 HCAPLUS
CN RNA formation factor TEF-5 (human fragment reduced) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L4 ANSWER 14 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1996:49097 HCAPLUS Full-text
DOCUMENT NUMBER: 124:137260
TITLE: Molecular cloning and expression of murine vascular endothelial-cadherin in early stage development of cardiovascular system
AUTHOR(S): Breier, G.; Breviario, F.; Caveda, L.; Berthier, R.; Schnuerch, H.; Gotsch, U.; Vestweber, D.; Risau, W.; Dejana, E.
CORPORATE SOURCE: Max-Planck-Institut physiologische klinische Forschung, Bad Nauheim, Germany
SOURCE: Blood (*1996*), 87(2), 630-41
CODEN: BLOOAW; ISSN: 0006-4971
PUBLISHER: Saunders
DOCUMENT TYPE: Journal
LANGUAGE: English
AB An early step in the formation of the extraembryonic and intraembryonic vasculature is endothelial cell differentiation and organization in blood islands and vascular structures. This involves the expression and function of specific adhesive mols. at cell-to-cell junctions. Previous work showed that endothelial cells express a cell-specific cadherin (vascular endothelial [VE]-cadherin, or 7B4/cadherin-5) that is organized at cell-to-cell contacts in cultured cells and is able to promote intercellular adhesion. In this study, we investigated whether VE-cadherin could be involved in early cardiovascular development in the mouse embryo. We first cloned and sequenced the mouse VE-cadherin cDNA. At the protein level, murine VE-cadherin presented 75% identity (90%, considering conservative amino acid substitutions) with the human homolog. Transfection of murine VE-cadherin cDNA in L cells induced Ca++-dependent cell-to-cell aggregation and reduced cell detachment from monolayers. In situ hybridization of adult tissues showed that the murine mol. is specifically expressed by endothelial cells. In mouse embryos, VE-cadherin transcripts were detected at the very earliest stages of vascular development (E7.5) in mesodermal cells of the yolk sac mesenchyme. At E9.5, expression of VE-cadherin was restricted to the peripheral cell layer of blood islands that gives rise to endothelial cells. Hematopoietic cells in the center of blood islands were not labeled. At later embryonic stages, VE-cadherin transcripts were detected in vascular structures of all organs examined, e.g., in the ventricle of the heart, the inner cell lining of the atrium and the dorsal aorta, in intersomitic vessels, and in the capillaries of the developing brain. A comparison with flk-1 expression during brain angiogenesis revealed that brain capillaries expressed relatively low amts. of VE-cadherin. In the adult brain, the level of VE-cadherin transcript was further reduced. By immunohistochem., murine VE-cadherin protein was detected at cell-to-cell junctions of endothelial cells. Overall, these data demonstrate that VE-cadherin is an early, constitutive, and specific marker of endothelial cells. This distinguishes this mol. from other cadherins and suggests that its expression is associated with the early assembly of vascular structures.
CC 3-3 (Biochemical Genetics)
Section cross-reference(s): 6, 13
IT *173432-45-6*, Cadherin 5, prepro- (Mus musculus)
173432-46-7, Cadherin 5 (Mus musculus)
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); OCCU (Occurrence)
(amino acid sequence; cDNA sequence and tissue distribution of murine vascular endothelial-cadherin in early stage development of cardiovascular system)
IT *173432-45-6*, Cadherin 5, prepro- (Mus musculus)
173432-46-7, Cadherin 5 (Mus musculus)
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); OCCU (Occurrence)

(amino acid sequence; cDNA sequence and tissue distribution of murine vascular endothelial-cadherin in early stage development of cardiovascular system)

RN 173432-45-6 HCAPLUS
CN Cadherin 5, prepro- (Mus musculus) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 173432-46-7 HCAPLUS
CN Cadherin 5 (Mus musculus) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

******BELOW ARE REFERENCES TO QUERY ON CLAIM 41, WHERE A AND B ARE EQUAL TO 1 NOT A RANGE OF 0-1**********

=> d que l60
L52 STR



Structure attributes must be viewed using STN Express query preparation.
L54 2075 SEA FILE=REGISTRY SSS FUL L52
L57 STR



Structure attributes must be viewed using STN Express query preparation.
L59 4 SEA FILE=REGISTRY SUB=L54 SSS FUL L57
L60 2 SEA FILE=HCAPLUS ABB=ON PLU=ON L59

=> d ibib abs hitind hitstr retable l60 tot

L60 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:465364 HCAPLUS Full-text
DOCUMENT NUMBER: 144:460820
TITLE: Peptide antitumor agents
INVENTOR(S): Rosenberg, Martin Jay
PATENT ASSIGNEE(S): New York University, USA
SOURCE: PCT Int. Appl., 44 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006052775	A2	20060518	WO 2005-US40078	20051104
WO 2006052775	A3	20060720		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 2006258573	A1	20061116	US 2005-264684	20051031
US 7173110	B2	20070206		

PRIORITY APPLN. INFO.: US 2004-626220P P 20041108

AB Disclosed herein are isolated, purified peptides, biol. active fragments and analogs of the peptides having anti-tumor activity in mammals, pharmaceutical

formulations comprising the peptides, fragments and analogs and methods of treating mammals suffering from tumors using such materials.

CC 1-6 (Pharmacology)
Section cross-reference(s): 34, 63

IT *886751-53-7P* 886751-54-8P 886751-55-9P 886751-56-0P
886751-57-1P 886751-58-2P
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(peptide antitumor agents)

IT *886751-53-7P*
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(peptide antitumor agents)

RN 886751-53-7 HCAPLUS

CN Cyclo[(2S)-2-amino-4-(methylsulfinyl)butanoyl-(2S)-2-amino-4-(methylsulfinyl)butanoyl-L-cysteinyl-L-valyl-L-threonyl-L-histidyl-L-cysteinyl-L-asparaginylglycylglycyl], cyclic (3→7)-disulfide (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L60 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1995:615187 HCAPLUS Full-text
DOCUMENT NUMBER: 123:27638
TITLE: Peptides for neutralizing the toxicity of lipid A
INVENTOR(S): Porro, Massimo
PATENT ASSIGNEE(S): Biosynth S.r.L., Italy
SOURCE: PCT Int. Appl., 24 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9503327	A2	19950202	WO 1994-EP2413	19940721
WO 9503327	A3	19950504		
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN				
RW: KE, MW, SD, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5652211	A	19970729	US 1993-97830	19930726
CA 2167087	A1	19950202	CA 1994-2167087	19940721
AU 9474602	A	19950220	AU 1994-74602	19940721
AU 683920	B2	19971127		
EP 711307	A1	19960515	EP 1994-924272	19940721
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 09503489	T	19970408	JP 1994-504948	19940721

PRIORITY APPLN. INFO.:

US 1993-97830	A	19930726
US 1991-658744	B2	19910211
US 1992-819893	A2	19920116
US 1993-49871	A2	19930419
WO 1994-EP2413	W	19940721

AB A peptide composition for neutralizing the toxicity of lipid A exhibits the formula: (1) (A)n (A= Lys, Arg; n=integer ≥7); (2) (AB)m (A as in (1); B= Val,

```
     Leu, Ile, Tyr, Phe, Try; m=integer ≥3); or (3) (ABC)p (A=Lys, Arg; B, C=Leu,
     Ile, Tyr, Phe, Try; p=integer ≥2). The composition binds lipid-A of
     endotoxins and provides therapeutic and prophylactic uses. Novel 29 peptides
     capable of neutralizing the toxicity of lipid A are provided and their use on
     treating septic shock is claimed.
IC   ICM  C07K014-00
     ICS  C07K007-00
CC   4-9 (Toxicology)
     Section cross-reference(s): 1
IT   25104-18-1, Polylysine   38000-06-5, Polylysine   163912-71-8
     164123-00-6   164123-01-7   164123-02-8   164123-03-9   164123-04-0
     164123-05-1   164123-06-2   164123-07-3   164123-08-4   164123-09-5
     164123-10-8 164123-11-9 164123-12-0
     164123-13-1   164123-14-2   164123-15-3   164123-16-4   164123-17-5
     164123-18-6   164123-19-7   164123-20-0   164123-21-1   164123-22-2
     164123-23-3   164123-24-4   164176-08-3   164176-09-4
     RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
        (peptides for neutralizing the toxicity of lipid A of endotoxins)
IT   164123-10-8 164123-11-9 164123-12-0
     RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
        (peptides for neutralizing the toxicity of lipid A of endotoxins)
RN   164123-10-8  HCAPLUS
CN   Cyclo(L-cysteinyl-L-lysyl-L-phenylalanyl-L-lysyl-L-cysteinyl-L-lysyl-L-
     phenylalanyl-L-lysyl-L-phenylalanyl-L-lysyl), cyclic (1→5)-
     disulfide (9CI)  (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN   164123-11-9  HCAPLUS
CN   Cyclo(L-cysteinyl-L-lysyl-L-leucyl-L-lysyl-L-cysteinyl-L-lysyl-L-leucyl-L-
     lysyl-L-leucyl-L-lysyl), cyclic (1→5)-disulfide (9CI)  (CA INDEX
     NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN   164123-12-0  HCAPLUS
CN   Cyclo(L-arginyl-L-arginyl-L-cysteinyl-L-arginyl-L-threonyl-L-arginyl-L-
     cysteinyl-L-arginyl-L-phenylalanyl-L-lysyl), cyclic (3→7)-disulfide
     (9CI)  (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***


=> d his full

     (FILE 'HOME' ENTERED AT 13:10:47 ON 12 MAR 2007)

     FILE 'REGISTRY' ENTERED AT 13:11:19 ON 12 MAR 2007

     FILE 'LREGISTRY' ENTERED AT 13:13:27 ON 12 MAR 2007
L1            0 SEA ABB=ON  PLU=ON  [G'SAR']A[G'SAR']['HYP'P]['HYP'P]YN/SQSFP

     FILE 'REGISTRY' ENTERED AT 13:15:31 ON 12 MAR 2007
L2           42 SEA ABB=ON  PLU=ON  [G'SAR']A[G'SAR']['HYP'P]['HYP'P]YN/SQSFP

     FILE 'HCAPLUS' ENTERED AT 13:17:13 ON 12 MAR 2007
L3           36 SEA ABB=ON  PLU=ON  L2
L4           14 SEA ABB=ON  PLU=ON  L3 AND (AY<2001 OR PY<2001 OR PRY<2001)

     FILE 'REGISTRY' ENTERED AT 13:18:16 ON 12 MAR 2007
L5            0 SEA ABB=ON  PLU=ON  L2 AND MEDLINE/LC
```

```
L6              0 SEA ABB=ON  PLU=ON  L2 AND EMBASE/LC
L7              0 SEA ABB=ON  PLU=ON  L2 AND BIOSIS/LC
L8              0 SEA ABB=ON  PLU=ON  L2 AND CAOLD/LC

     FILE 'STNGUIDE' ENTERED AT 13:18:53 ON 12 MAR 2007

     FILE 'HCAPLUS' ENTERED AT 13:19:30 ON 12 MAR 2007
                E US2004-772774/APPS
L9              2 SEA ABB=ON  PLU=ON  US2004-772774/AP
                D SCAN
                SEL RN L9

     FILE 'REGISTRY' ENTERED AT 13:20:34 ON 12 MAR 2007
L10           107 SEA ABB=ON  PLU=ON  (159503-65-8/BI OR 355151-11-0/BI OR
                  355151-12-1/BI OR 355151-13-2/BI OR 355151-14-3/BI OR 355151-15
                  -4/BI OR 355151-16-5/BI OR 355151-17-6/BI OR 355151-18-7/BI OR
                  355151-19-8/BI OR 355151-20-1/BI OR 355151-23-4/BI OR 355151-25
                  -6/BI OR 355151-26-7/BI OR 355151-27-8/BI OR 355151-29-0/BI OR
                  355151-30-3/BI OR 355151-31-4/BI OR 355151-32-5/BI OR 355151-33
                  -6/BI OR 355151-34-7/BI OR 355151-35-8/BI OR 355151-36-9/BI OR
                  355151-37-0/BI OR 355151-38-1/BI OR 355151-39-2/BI OR 355151-40
                  -5/BI OR 355151-41-6/BI OR 355151-43-8/BI OR 355151-45-0/BI OR
                  355151-46-1/BI OR 355151-47-2/BI OR 355151-49-4/BI OR 355151-50
                  -7/BI OR 355151-51-8/BI OR 355151-52-9/BI OR 355151-53-0/BI OR
                  355151-54-1/BI OR 355151-55-2/BI OR 355151-56-3/BI OR 355151-74
                  -5/BI OR 81771-37-1/BI OR 111915-92-5/BI OR 133294-37-8/BI OR
                  212570-15-5/BI OR 355151-21-2/BI OR 355151-22-3/BI OR 355151-24
                  -5/BI OR 355151-28-9/BI OR 355151-42-7/BI OR 355151-44-9/BI OR
                  355151-48-3/BI OR 355151-57-4/BI OR 355151-58-5/BI OR 355151-59
                  -6/BI OR 355151-60-9/BI OR 355151-61-0/BI OR 355151-62-1/BI OR
                  355151-63-2/BI OR 355151-64-3/BI OR 355151-65-4/BI OR 355151-66
                  -5/BI OR 355151-67-6/BI OR 355151-68-7/BI OR 355151-69-8/BI OR
                  355151-70-1/BI OR 355151-71-2/BI OR 355151-72-3/BI OR 355151-73
                  -4/BI OR 355151-75-6/BI OR 355151-76-7/BI OR 35919-99-4/BI OR
                  366800-53-5/BI OR 463362-31-4/BI OR 463362-32-5/BI OR 463362-33
                  -6/BI OR 463362-34-7/BI OR 463362-35-8/BI OR 463362-36-9/BI OR
                  463362-37-0/BI OR 463362-38-1/BI OR 463362-40-5/BI OR 463362-42
                  -7/BI OR 463362-43-8/BI OR 463362-44-9/BI OR 463362-45-0/BI OR
                  463362-46-1/BI OR 463362-47-2/BI OR 463362-48-3/BI OR 463362-49
                  -4/BI OR 463362-50-7/BI OR 463362-51-8/BI OR 463362-52-9/BI OR
                  463362-53-0/BI OR 463362-54-1/BI OR 463362-55-2/BI OR 463362-56
                  -3/BI OR 463362-57-4/BI OR 463362-58-5/BI OR 463362-59-6/BI OR
                  463944-96-9/BI OR 476-70-0/BI OR 50-99-7/BI OR 501-36-0/BI OR
                  57381-26-7/BI OR 602-07-3/BI OR 7782-44-7/BI)
L11             5 SEA ABB=ON  PLU=ON  L10 AND L2

     FILE 'STNGUIDE' ENTERED AT 13:21:01 ON 12 MAR 2007

     FILE 'HCAPLUS' ENTERED AT 13:22:00 ON 12 MAR 2007
                E LARSEN B/AU
L12           177 SEA ABB=ON  PLU=ON  ("LARSEN B"/AU OR "LARSEN B DUE"/AU OR
                  "LARSEN BJARNE"/AU OR "LARSEN BJARNE D"/AU OR "LARSEN BJARNE
                  DUE"/AU)
                E PETERSEN J/AU
L*** DEL        0 S E3,E29,E122,E127,E129,E169,E175-E177.
L13           262 SEA ABB=ON  PLU=ON  ("PETERSEN J"/AU OR "PETERSEN J S"/AU OR
                  "PETERSEN JOERGEN"/AU OR "PETERSEN JOERGEN S"/AU OR "PETERSEN
                  JOERGEN SOEBERG"/AU OR "PETERSEN JORGEN"/AU OR "PETERSEN
                  JORGEN S"/AU OR "PETERSEN JORGEN SOBERG"/AU OR "PETERSEN
                  JORGEN SOEBERG"/AU)
```

```
                 E MEIER E/AU
L14          118 SEA ABB=ON  PLU=ON  ("MEIER E"/AU OR "MEIER E A"/AU OR "MEIER
                 E F"/AU OR "MEIER E G"/AU OR "MEIER E J J"/AU OR "MEIER E M
                 M"/AU OR "MEIER E P"/AU OR "MEIER E V"/AU OR "MEIER EDDI"/AU
                 OR "MEIER EDDIE"/AU)
                 E KJOLBYE A/AU
L15            7 SEA ABB=ON  PLU=ON  "KJOLBYE ANNE LOUISE"/AU
                 E JORGENSEN N/AU
L16           31 SEA ABB=ON  PLU=ON  ("JORGENSEN N"/AU OR "JORGENSEN N R"/AU OR
                 "JORGENSEN N RYE"/AU OR "JORGENSEN NIKLAS R"/AU OR "JORGENSEN
                 NIKLAS RYE"/AU)
                 E NIELSEN M/AU
L17          495 SEA ABB=ON  PLU=ON  ("NIELSEN M"/AU OR "NIELSEN M S"/AU OR
                 "NIELSEN M S WEBER"/AU OR "NIELSEN MORTEN"/AU OR "NIELSEN
                 MORTEN S"/AU OR "NIELSEN MORTEN SCHAK"/AU)
                 E MARTINS J/AU
L18          138 SEA ABB=ON  PLU=ON  ("MARTINS J"/AU OR "MARTINS J B"/AU OR
                 "MARTINS J B L"/AU OR "MARTINS JAMES"/AU OR "MARTINS JAMES
                 B"/AU)
                 E HOLSTEIN R/AU
L19           76 SEA ABB=ON  PLU=ON  ("HOLSTEIN R"/AU OR "HOLSTEIN RATHLOU N
                 H"/AU OR "HOLSTEIN RATHLOU N H N H"/AU OR "HOLSTEIN RATHLOU
                 NIELS H"/AU OR "HOLSTEIN RATHLOU NIELS HENRIK"/AU)
L20            2 SEA ABB=ON  PLU=ON  L12 AND L13 AND L14 AND L15 AND L16 AND
                 L17 AND L18 AND L19
L21           13 SEA ABB=ON  PLU=ON  L12 AND (L13 OR L14 OR L15 OR L16 OR L17
                 OR L18 OR L19)
L22           15 SEA ABB=ON  PLU=ON  L13 AND (L14 OR L15 OR L16 OR L17 OR L18
                 OR L19)
L23            4 SEA ABB=ON  PLU=ON  L14 AND (L15 OR L16 OR L17 OR L18 OR L19)
L24            5 SEA ABB=ON  PLU=ON  L15 AND (L16 OR L17 OR L18 OR L19)
L25            2 SEA ABB=ON  PLU=ON  L16 AND (L17 OR L18 OR L19)
L26            3 SEA ABB=ON  PLU=ON  L17 AND (L18 OR L19)
L27            2 SEA ABB=ON  PLU=ON  L18 AND L19
L28           21 SEA ABB=ON  PLU=ON  (L20 OR L21 OR L22 OR L23 OR L24 OR L25 OR
                 L26 OR L27)
L29            4 SEA ABB=ON  PLU=ON  L28 AND (AY<2001 OR PY<2001 OR PRY<2001)

     FILE 'HCAPLUS, MEDLINE, EMBASE, BIOSIS, DRUGU, WPIX' ENTERED AT 13:29:40
     ON 12 MAR 2007
L30         2579 SEA ABB=ON  PLU=ON  LARSEN B?/AU
L31         5774 SEA ABB=ON  PLU=ON  PETERSEN J?/AU
L32         1629 SEA ABB=ON  PLU=ON  MEIER E?/AU
L33           42 SEA ABB=ON  PLU=ON  KJOLBYE A?/AU
L34          977 SEA ABB=ON  PLU=ON  JORGENSEN N?/AU
L35         5171 SEA ABB=ON  PLU=ON  NIELSEN M?/AU
L36         2182 SEA ABB=ON  PLU=ON  MARTINS J?/AU
L37          595 SEA ABB=ON  PLU=ON  HOLSTEIN R?/AU
L38            2 SEA ABB=ON  PLU=ON  L30 AND L31 AND L32 AND L33 AND L34 AND
                 L35 AND L36 AND L37
L39            0 SEA ABB=ON  PLU=ON  (L30 OR L31 OR L32 OR L33 OR L34 OR L35 OR
                 L36 OR L37) AND (ANTI(2A) ARRYTHMIC?)
L40            2 SEA ABB=ON  PLU=ON  (L30 OR L31 OR L32 OR L33 OR L34 OR L35 OR
                 L36 OR L37) AND (ANTIARRYTHMIC?)
L41            4 SEA ABB=ON  PLU=ON  (L38 OR L40)
L42          856 SEA ABB=ON  PLU=ON  (L30 OR L31 OR L32 OR L33 OR L34 OR L35 OR
                 L36 OR L37) AND (PEPTIDE?)
L43            1 SEA ABB=ON  PLU=ON  L42 AND (ARRYTHM?)
L44            4 SEA ABB=ON  PLU=ON  (L43 OR L41)
```

```
     FILE 'STNGUIDE' ENTERED AT 13:33:02 ON 12 MAR 2007

     FILE 'REGISTRY' ENTERED AT 13:34:05 ON 12 MAR 2007
L45             STRUCTURE UPLOADED
L46             STRUCTURE UPLOADED
L47           0 SEA SSS SAM L46
L48           0 SEA SSS FUL L46

     FILE 'STNGUIDE' ENTERED AT 13:35:38 ON 12 MAR 2007

     FILE 'BEILSTEIN' ENTERED AT 13:35:43 ON 12 MAR 2007
L49           0 SEA SSS FUL L46

     FILE 'MARPAT' ENTERED AT 13:35:57 ON 12 MAR 2007

     FILE 'STNGUIDE' ENTERED AT 13:36:04 ON 12 MAR 2007

     FILE 'REGISTRY' ENTERED AT 13:38:12 ON 12 MAR 2007

     FILE 'STNGUIDE' ENTERED AT 14:02:36 ON 12 MAR 2007

     FILE 'REGISTRY' ENTERED AT 14:03:19 ON 12 MAR 2007
               D QUE L46
               D QUE L45
L50            STRUCTURE UPLOADED
               D QUE L50

     FILE 'STNGUIDE' ENTERED AT 14:04:58 ON 12 MAR 2007

     FILE 'REGISTRY' ENTERED AT 14:12:47 ON 12 MAR 2007
L51            STRUCTURE UPLOADED
L52            STRUCTURE UPLOADED
L53          50 SEA SSS SAM L52
               D QUE L52
L54        2075 SEA SSS FUL L52
               SAVE L54 TELLER/A TEMP
L55           0 SEA ABB=ON  PLU=ON  L54 AND L10

     FILE 'HCAPLUS' ENTERED AT 14:16:01 ON 12 MAR 2007
L56        1861 SEA ABB=ON  PLU=ON  L54

     FILE 'STNGUIDE' ENTERED AT 14:16:08 ON 12 MAR 2007

     FILE 'REGISTRY' ENTERED AT 14:22:05 ON 12 MAR 2007
L57            STRUCTURE UPLOADED
L58           0 SEA SUB=L54 SSS SAM L57
L59           4 SEA SUB=L54 SSS FUL L57

     FILE 'HCAPLUS' ENTERED AT 14:23:05 ON 12 MAR 2007
L60           2 SEA ABB=ON  PLU=ON  L59
               D BIB
               D BIB 2

     FILE 'REGISTRY' ENTERED AT 14:23:30 ON 12 MAR 2007
L61           0 SEA ABB=ON  PLU=ON  L59 AND MEDLINE/LC
L62           0 SEA ABB=ON  PLU=ON  L59 AND EMBASE/LC
L63           0 SEA ABB=ON  PLU=ON  L59 AND BIOSIS/LC
L64           0 SEA ABB=ON  PLU=ON  L59 AND CAOLD/LC
L65         528 SEA ABB=ON  PLU=ON  L54 AND (ALA OR ALANIN? OR GLY OR GLYCINE
               OR GLU OR GLUTAMIC? OR ASP OR ASPARTIC? OR DAB OR DOAMINOBUT?
```

```
                OR DAPA OR LYS OR LYSINE OR ASP OR ASPARAGINE OR GLN OR
                GLUTAMINE OR ORN OR ORNITHINE OR CYS OR CYSTEINE)

     FILE 'HCAPLUS' ENTERED AT 14:25:47 ON 12 MAR 2007
L66         300 SEA ABB=ON  PLU=ON  L65
L*** DEL 598742 S L10
                D SCAN L9
L67          56 SEA ABB=ON  PLU=ON  L65 (L)(THU OR PKT OR BAC OR PAC OR
                DMA)/RL
                D KWIC
L68           1 SEA ABB=ON  PLU=ON  L66 AND (?ARRYTHM? OR ?THROMB? OR OSTEOPORO
                SIS? OR CANCER?)
L69          56 SEA ABB=ON  PLU=ON  (L67 OR L68)
L70          50 SEA ABB=ON  PLU=ON  L69 AND (AY<2001 OR PY<2001 OR PRY<2001)
L71          48 SEA ABB=ON  PLU=ON  L69 AND (AY<2000 OR PY<2000 OR PRY<2000)
L72          38 SEA ABB=ON  PLU=ON  L70 AND (ALA OR ALANIN? OR GLY OR GLYCINE
                OR GLU OR GLUTAMIC? OR ASP OR ASPARTIC? OR DAB OR DOAMINOBUT?
                OR DAPA OR LYS OR LYSINE OR ASP OR ASPARAGINE OR GLN OR
                GLUTAMINE OR ORN OR ORNITHINE OR CYS OR CYSTEINE)
                D KWIC
L73          38 SEA ABB=ON  PLU=ON  L70 AND (ALA OR ALANIN? OR GLY OR GLYCINE
                OR GLU OR GLUTAMIC? OR ASP OR ASPARTIC? OR DAB OR DIAMINOBUT?
                OR DAPA OR LYS OR LYSINE OR ASP OR ASPARAGINE OR GLN OR
                GLUTAMINE OR ORN OR ORNITHINE OR CYS OR CYSTEINE)
L74          38 SEA ABB=ON  PLU=ON  (L68 OR L72 OR L73)
L75          38 SEA ABB=ON  PLU=ON  L74 NOT (L29 OR L4 OR L9)

     FILE 'BEILSTEIN' ENTERED AT 14:32:13 ON 12 MAR 2007
L76           0 SEA SSS FUL L57

     FILE 'MARPAT' ENTERED AT 14:32:29 ON 12 MAR 2007

     FILE 'REGISTRY' ENTERED AT 14:33:37 ON 12 MAR 2007
L77           0 SEA ABB=ON  PLU=ON  L65 AND L10
L78           0 SEA ABB=ON  PLU=ON  L10 AND SQL/CI

     FILE 'STNGUIDE' ENTERED AT 14:36:57 ON 12 MAR 2007

     FILE 'REGISTRY' ENTERED AT 14:38:24 ON 12 MAR 2007
L79           0 SEA ABB=ON  PLU=ON  L10 AND SQL
L80           0 SEA ABB=ON  PLU=ON  L10 AND SQL?
L81          84 SEA ABB=ON  PLU=ON  L10 AND SQL<10
L82          23 SEA ABB=ON  PLU=ON  L10 NOT L81
                D SCAN L82
L83         106 SEA ABB=ON  PLU=ON  L10 NOT O2/MF
L84         104 SEA ABB=ON  PLU=ON  L83 NOT C14H12O3
L85         104 SEA ABB=ON  PLU=ON  L83 NOT C14H12O3/MF
L86         103 SEA ABB=ON  PLU=ON  L85 NOT C19H21NO4/MF
L87         103 SEA ABB=ON  PLU=ON  L86 NOT C9H7C12N5/MF
L88         102 SEA ABB=ON  PLU=ON  L87 NOT C20H19NO6
L89         101 SEA ABB=ON  PLU=ON  L88 NOT C6H12O6/MF

     FILE 'HCAPLUS' ENTERED AT 14:43:59 ON 12 MAR 2007
L90         109 SEA ABB=ON  PLU=ON  L89
L91          66 SEA ABB=ON  PLU=ON  L89 (L)(THU OR BAC OR PAC OR DMA OR
                PKT)/RL
L92          26 SEA ABB=ON  PLU=ON  L91 AND (AY<2001 OR PY<2001 OR PRY<2001)
                D QUE L73
L93          20 SEA ABB=ON  PLU=ON  L91 AND (ALA OR ALANIN? OR GLY OR GLYCINE
                OR GLU OR GLUTAMIC? OR ASP OR ASPARTIC? OR DAB OR DIAMINOBUT?
```

```
                OR DAPA OR LYS OR LYSINE OR ASP OR ASPARAGINE  OR GLN OR
                GLUTAMINE OR ORN OR ORNITHINE OR CYS OR CYSTEINE)
L94          35 SEA ABB=ON  PLU=ON  (L92 OR L93)
L95          33 SEA ABB=ON  PLU=ON  L94 NOT (L4 OR L29)
L96          14 SEA ABB=ON  PLU=ON  (L9 OR L4)

     FILE 'STNGUIDE' ENTERED AT 14:46:29 ON 12 MAR 2007
                D QUE L29
                D QUE L44
                D QUE L4
                D QUE L60

     FILE 'HCAPLUS, WPIX' ENTERED AT 14:46:57 ON 12 MAR 2007
L97          18 DUP REM L29 L44 L4 L60 (6 DUPLICATES REMOVED)
                     ANSWERS '1-18' FROM FILE HCAPLUS
                D QUE L29
                D QUE L41
                D QUE L29
                D QUE L44
                D QUE L95
L98          37 DUP REM L29 L44 L95 (4 DUPLICATES REMOVED)
                     ANSWERS '1-37' FROM FILE HCAPLUS
                D IBIB ABS HITIND HITSTR RETABLE L98 TOT
                D QUE L4
                D IBIB ABS HITIND HITSTR RETABLE L4 TOT
                D QUE L60
                D IBIB ABS HITIND HITSTR RETABLE L60 TOT


     FILE HOME

     FILE REGISTRY
     Property values tagged with IC are from the ZIC/VINITI data file
     provided by InfoChem.

     STRUCTURE FILE UPDATES:   11 MAR 2007  HIGHEST RN 926007-42-3
     DICTIONARY FILE UPDATES:  11 MAR 2007  HIGHEST RN 926007-42-3

     New CAS Information Use Policies, enter HELP USAGETERMS for details.

     TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

       Please note that search-term pricing does apply when
       conducting SmartSELECT searches.

     REGISTRY includes numerically searchable data for experimental and
     predicted properties as well as tags indicating availability of
     experimental property data in the original document.  For information
     on property searching in REGISTRY, refer to:

     http://www.cas.org/ONLINE/UG/regprops.html

     FILE LREGISTRY
     LREGISTRY IS A STATIC LEARNING FILE

     NEW CAS INFORMATION USE POLICIES, ENTER HELP USAGETERMS FOR DETAILS.

     FILE HCAPLUS

     Copyright of the articles to which records in this database refer is
```

held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 12 Mar 2007 VOL 146 ISS 12
FILE LAST UPDATED: 11 Mar 2007 (20070311/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE STNGUIDE
FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Mar 9, 2007 (20070309/UP).

FILE MEDLINE
FILE LAST UPDATED: 10 Mar 2007 (20070310/UP). FILE COVERS 1950 TO DATE.

All regular MEDLINE updates from November 15 to December 16 have been added to MEDLINE, along with 2007 Medical Subject Headings (MeSH(R)) and 2007 tree numbers.

The annual reload will be available in early 2007.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE EMBASE
FILE COVERS 1974 TO 12 Mar 2007 (20070312/ED)

EMBASE is now updated daily. SDI frequency remains weekly (default) and biweekly.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE BIOSIS
FILE COVERS 1969 TO DATE.
CAS REGISTRY NUMBERS AND CHEMICAL NAMES (CNs) PRESENT
FROM JANUARY 1969 TO DATE.

RECORDS LAST ADDED: 7 March 2007 (20070307/ED)

FILE DRUGU
FILE LAST UPDATED: 9 MAR 2007 <20070309/UP>
>>> DERWENT DRUG FILE (SUBSCRIBER) <<<

>>> FILE COVERS 1983 TO DATE <<<
>>> THESAURUS AVAILABLE IN /CT <<<

FILE WPIX
FILE LAST UPDATED: 5 MAR 2007 <20070305/UP>

MOST RECENT THOMSON SCIENTIFIC UPDATE: 200716 <200716/DW>
DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> YOU ARE IN THE NEW AND ENHANCED DERWENT WORLD PATENTS INDEX <<<

>>> New display format FRAGHITSTR available <<<
SEE ONLINE NEWS and
http://www.stn-international.de/archive/stn_online_news/fraghitstr_ex.pdf

>>> IPC Reform reclassification data for the backfile is being loaded into the database during January 2007.
There will not be any update date (UP) written for the reclassified documents, but they can be identified by 20060101/UPIC. <<<

FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE, PLEASE VISIT:
http://www.stn-international.de/training_center/patents/stn_guide.pdf

FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE
http://scientific.thomson.com/support/patents/coverage/latestupdates/

PLEASE BE AWARE OF THE NEW IPC REFORM IN 2006, SEE
http://www.stn-international.de/stndatabases/details/ipc_reform.html and
http://scientific.thomson.com/media/scpdf/ipcrdwpi.pdf

>>> FOR DETAILS ON THE NEW AND ENHANCED DERWENT WORLD PATENTS INDEX PLEASE SEE
http://www.stn-international.de/stndatabases/details/dwpi_r.html <<<

FILE BEILSTEIN
FILE LAST UPDATED ON JANUARY 10, 2007

FILE COVERS 1771 TO 2006.
FILE CONTAINS 9,780,003 SUBSTANCES

>>>PLEASE NOTE: Reaction Data and substance data are stored in separate documents and can not be searched together in one query. Reaction data for BEILSTEIN compounds may be displayed immediately with the display codes PRE (preparations) and REA (reactions). A substance answer set retrieved after the search for a chemical name, a compounds with available reaction information by combining with PRE/FA, REA/FA or more generally with RX/FA. The BEILSTEIN Registry Number (BRN) is the link between a BEILSTEIN compound and belonging reactions. For mo detailed reaction searches BRNs can be searched as reaction partner BRNs Reactant BRN (RX.RBRN) or Product BRN (RX.PBRN).<<<

>>> FOR SEARCHING PREPARATIONS SEE HELP PRE <<<

****
* PLEASE NOTE THAT THERE ARE NO FORMATS FREE OF COST. *
* SET NOTICE FEATURE: THE COST ESTIMATES CALCULATED FOR SET NOTICE *
* ARE BASED ON THE HIGHEST PRICE CATEGORY. THEREFORE; THESE *
* ESTIMATES MAY NOT REFLECT THE ACTUAL COSTS. *
* FOR PRICE INFORMATION SEE HELP COST *
****

NEW
* *PATENT NUMBERS (PN) AND BABS ACCESSION NUMBERS (BABSAN) CAN NOW BE SEARCHED, SELECTED AND TRANSFERRED.*

* *NEW DISPLAY FORMATS ALLREF, ALLP AND BABSAN SHOW ALL REFERENCES, ALL PATENT REFERENCES, OR ALL BABS ACCESSION NUMBERS FOR A COMPOUND AT A GLANCE.*

FILE MARPAT
FILE CONTENT: 1961-PRESENT VOL 146 ISS 11 (20070309/ED)

SOME MARPAT RECORDS ARE DERIVED FROM INPI DATA FOR 1961-1987

MOST RECENT CITATIONS FOR PATENTS FROM MAJOR ISSUING AGENCIES
(COVERAGE TO THESE DATES IS NOT COMPLETE):

US	2007020715	25 JAN 2007
DE	102005032918	18 JAN 2007
EP	1743897	17 JAN 2007
JP	2007016265	25 JAN 2007
WO	2007012422	01 FEB 2007
GB	2427406	27 DEC 2006
FR	2888248	12 JAN 2007
RU	2291880	20 JAN 2007
CA	2551930	08 JAN 2007

Expanded G-group definition display now available.

Uploading l1.str



chain nodes :
31 32 33 34 35 36 37 38 39 40
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
24 25 26 27 28 29 30 41
chain bonds :
2-31 5-32 8-33 11-34 14-39 17-38 20-37 24-40 27-36 28-35
ring bonds :
1-2 1-23 2-3 3-4 4-5 5-6 6-7 7-8 7-41 8-9 9-10 10-11 11-25 12-13 12-
24
13-14 14-15 14-41 15-16 16-17 17-18 18-19 19-20 20-21 21-22 22-27 23-24
25-26 26-28
27-30 28-29 29-30
exact/norm bonds :
1-2 1-23 2-3 2-31 3-4 4-5 5-6 5-32 6-7 7-8 7-41 8-9 8-33 9-10 10-11
11-25 11-34 12-13 12-24 13-14 14-15 14-39 14-41 15-16 16-17 17-18 17-38
18-19 19-20
20-21 20-37 21-22 22-27 23-24 24-40 25-26 26-28 27-30 27-36 28-29 28-35
29-30

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom
22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom
31:CLASS 32:CLASS
33:CLASS 34:CLASS 35:CLASS 36:CLASS 37:CLASS 38:CLASS 39:CLASS 40:CLASS
41:Atom

Uploading l2.str



chain nodes :
31 32 33 34 35 36 37 38 39 40
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
24 25 26 27 28 29 30 41
chain bonds :
2-31 5-32 8-33 11-34 14-39 17-38 20-37 24-40 27-36 28-35
ring bonds :
1-2 1-23 2-3 3-4 4-5 5-6 6-7 7-8 7-41 8-9 9-10 10-11 11-25 12-13 12-
24
13-14 14-15 14-41 15-16 16-17 17-18 18-19 19-20 20-21 21-22 22-27 23-24
25-26 26-28
27-30 28-29 29-30
exact/norm bonds :
1-2 1-23 2-3 2-31 3-4 4-5 5-6 5-32 6-7 7-8 7-41 8-9 8-33 9-10 10-11
11-25 11-34 12-13 12-24 13-14 14-15 14-39 14-41 15-16 16-17 17-18 17-38
18-19 19-20
20-21 20-37 21-22 22-27 23-24 24-40 25-26 26-28 27-30 27-36 28-29 28-35
29-30

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom
22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom
31:CLASS 32:CLASS
33:CLASS 34:CLASS 35:CLASS 36:CLASS 37:CLASS 38:CLASS 39:CLASS 40:CLASS
41:Atom

Uploading l3.str



chain nodes :
31 32 33 34 35 36 37 38 39 40
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
24 25 26 27 28 29 30 41
chain bonds :
2-31 5-32 8-33 11-34 14-39 17-38 20-37 24-40 27-36 28-35
ring bonds :
1-2 1-23 2-3 3-4 4-5 5-6 6-7 7-8 7-41 8-9 9-10 10-11 11-25 12-13 12-
24
13-14 14-15 14-41 15-16 16-17 17-18 18-19 19-20 20-21 21-22 22-27 23-24
25-26 26-28
27-30 28-29 29-30
exact/norm bonds :
1-2 1-23 2-3 2-31 3-4 4-5 5-6 5-32 6-7 7-8 7-41 8-9 8-33 9-10 10-11
11-25 11-34 12-13 12-24 13-14 14-15 14-39 14-41 15-16 16-17 17-18 17-38
18-19 19-20
20-21 20-37 21-22 22-27 23-24 24-40 25-26 26-28 27-30 27-36 28-29 28-35
29-30

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom
22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom
31:CLASS 32:CLASS
33:CLASS 34:CLASS 35:CLASS 36:CLASS 37:CLASS 38:CLASS 39:CLASS 40:CLASS
41:Atom

Uploading l4.str



chain nodes :
31 32 33 34 35 36 37 38 39 40
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
24 25 26 27 28 29 30 41
chain bonds :
2-31 5-32 8-33 11-34 14-39 17-38 20-37 24-40 27-36 28-35
ring bonds :
1-2 1-23 2-3 3-4 4-5 5-6 6-7 7-8 7-41 8-9 9-10 10-11 11-25 12-13 12-
24
13-14 14-15 14-41 15-16 16-17 17-18 18-19 19-20 20-21 21-22 22-27 23-24
25-26 26-28
27-30 28-29 29-30

exact/norm bonds :
1-2 1-23 2-3 2-31 3-4 4-5 5-6 5-32 6-7 7-8 7-41 8-9 8-33 9-10 10-11
11-25 11-34 12-13 12-24 13-14 14-15 14-39 14-41 15-16 16-17 17-18 17-38
18-19 19-20
20-21 20-37 21-22 22-27 23-24 24-40 25-26 26-28 27-30 27-36 28-29 28-35
29-30

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom
22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom
31:CLASS 32:CLASS
33:CLASS 34:CLASS 35:CLASS 36:CLASS 37:CLASS 38:CLASS 39:CLASS 40:CLASS
41:Atom

Uploading 150.str



chain nodes :
31 32 33 34 35 36 37 38 39 40
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
24 25 26 27 28 29 30
chain bonds :
2-31 5-32 8-33 11-34 14-39 17-38 20-37 24-40 27-36 28-35
ring bonds :
1-2 1-23 2-3 3-4 4-5 5-6 6-7 7-8 8-9 9-10 10-11 11-25 12-13 12-24 13-
14
14-15 15-16 16-17 17-18 18-19 19-20 20-21 21-22 22-27 23-24 25-26 26-28
27-30 28-29
29-30
exact/norm bonds :
1-2 1-23 2-3 2-31 3-4 4-5 5-6 5-32 6-7 7-8 8-9 8-33 9-10 10-11 11-25
11-34 12-13 12-24 13-14 14-15 14-39 15-16 16-17 17-18 17-38 18-19 19-20
20-21 20-37
21-22 22-27 23-24 24-40 25-26 26-28 27-30 27-36 28-29 28-35 29-30

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom
22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom
31:CLASS 32:CLASS

33:CLASS 34:CLASS 35:CLASS 36:CLASS 37:CLASS 38:CLASS 39:CLASS 40:CLASS

Uploading l51.str



chain nodes :
31 32 33 34 35 36 37 38 39 40
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
24 25 26 27 28 29 30
chain bonds :
2-31 5-32 8-33 11-34 14-39 17-38 20-37 24-40 27-36 28-35
ring bonds :
1-2 1-23 2-3 3-4 4-5 5-6 6-7 7-8 8-9 9-10 10-11 11-25 12-13 12-24 13-
14
14-15 15-16 16-17 17-18 18-19 19-20 20-21 21-22 22-27 23-24 25-26 26-28
27-30 28-29
29-30
exact/norm bonds :
1-2 1-23 2-3 2-31 3-4 4-5 5-6 5-32 6-7 7-8 8-9 8-33 9-10 10-11 11-25
11-34 12-13 12-24 13-14 14-15 14-39 15-16 16-17 17-18 17-38 18-19 19-20
20-21 20-37
21-22 22-27 23-24 24-40 25-26 26-28 27-30 27-36 28-29 28-35 29-30

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom
22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom
31:CLASS 32:CLASS
33:CLASS 34:CLASS 35:CLASS 36:CLASS 37:CLASS 38:CLASS 39:CLASS 40:CLASS

Uploading l52.str



chain nodes :
31 32 33 34 35 36 37 38 39 40
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
24 25 26 27 28 29 30
chain bonds :
2-31 5-32 8-33 11-34 14-39 17-38 20-37 24-40 27-36 28-35
ring bonds :
1-2 1-23 2-3 3-4 4-5 5-6 6-7 7-8 8-9 9-10 10-11 11-25 12-13 12-24 13-
14
14-15 15-16 16-17 17-18 18-19 19-20 20-21 21-22 22-27 23-24 25-26 26-28
27-30 28-29
29-30
exact/norm bonds :
1-2 1-23 2-3 2-31 3-4 4-5 5-6 5-32 6-7 7-8 8-9 8-33 9-10 10-11 11-25
11-34 12-13 12-24 13-14 14-15 14-39 15-16 16-17 17-18 17-38 18-19 19-20
20-21 20-37
21-22 22-27 23-24 24-40 25-26 26-28 27-30 27-36 28-29 28-35 29-30

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom
22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom
31:CLASS 32:CLASS
33:CLASS 34:CLASS 35:CLASS 36:CLASS 37:CLASS 38:CLASS 39:CLASS 40:CLASS

Uploading 153.str



chain nodes :
31 32 33 34 35 36 37 38 39 40

ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
24 25 26 27 28 29 30
chain bonds :
2-31 5-32 8-33 11-34 14-39 17-38 20-37 24-40 27-36 28-35
ring bonds :
1-2 1-23 2-3 3-4 4-5 5-6 6-7 7-8 8-9 9-10 10-11 11-25 12-13 12-24 13-
14
14-15 15-16 16-17 17-18 18-19 19-20 20-21 21-22 22-27 23-24 25-26 26-28
27-30 28-29
29-30
exact/norm bonds :
1-2 1-23 2-3 2-31 3-4 4-5 5-6 5-32 6-7 7-8 8-9 8-33 9-10 10-11 11-25
11-34 12-13 12-24 13-14 14-15 14-39 15-16 16-17 17-18 17-38 18-19 19-20
20-21 20-37
21-22 22-27 23-24 24-40 25-26 26-28 27-30 27-36 28-29 28-35 29-30

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom
22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom
31:CLASS 32:CLASS
33:CLASS 34:CLASS 35:CLASS 36:CLASS 37:CLASS 38:CLASS 39:CLASS 40:CLASS

Uploading 157.str



chain nodes :
31 32 33 34 35 36 37 38 39 40
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
24 25 26 27 28 29 30 41
chain bonds :
2-31 5-32 8-33 11-34 14-39 17-38 20-37 24-40 27-36 28-35
ring bonds :
1-2 1-23 2-3 3-4 4-5 5-6 6-7 7-8 7-41 8-9 9-10 10-11 11-25 12-13 12-
24
13-14 14-15 15-16 15-41 16-17 17-18 18-19 19-20 20-21 21-22 22-27 23-24
25-26 26-28
27-30 28-29 29-30
exact/norm bonds :
1-2 1-23 2-3 2-31 3-4 4-5 5-6 5-32 6-7 7-8 7-41 8-9 8-33 9-10 10-11
11-25 11-34 12-13 12-24 13-14 14-15 14-39 15-16 15-41 16-17 17-18 17-38
18-19 19-20

20-21 20-37 21-22 22-27 23-24 24-40 25-26 26-28 27-30 27-36 28-29 28-35
29-30

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom
22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom
31:CLASS 32:CLASS
33:CLASS 34:CLASS 35:CLASS 36:CLASS 37:CLASS 38:CLASS 39:CLASS 40:CLASS
41:Atom

********BELOW ARE INVENTOR RESULTS ALONG WITH INVENTOR REGISTRY NUMBERS LIMITED BY THERAPEUTIC USE******

=> d que l29

L12 177 SEA FILE=HCAPLUS ABB=ON PLU=ON ("LARSEN B"/AU OR "LARSEN B DUE"/AU OR "LARSEN BJARNE"/AU OR "LARSEN BJARNE D"/AU OR "LARSEN BJARNE DUE"/AU)

L13 262 SEA FILE=HCAPLUS ABB=ON PLU=ON ("PETERSEN J"/AU OR "PETERSEN J S"/AU OR "PETERSEN JOERGEN"/AU OR "PETERSEN JOERGEN S"/AU OR "PETERSEN JOERGEN SOEBERG"/AU OR "PETERSEN JORGEN"/AU OR "PETERSEN JORGEN S"/AU OR "PETERSEN JORGEN SOBERG"/AU OR "PETERSEN JORGEN SOEBERG"/AU)

L14 118 SEA FILE=HCAPLUS ABB=ON PLU=ON ("MEIER E"/AU OR "MEIER E A"/AU OR "MEIER E F"/AU OR "MEIER E G"/AU OR "MEIER E J J"/AU OR "MEIER E M M"/AU OR "MEIER E P"/AU OR "MEIER E V"/AU OR "MEIER EDDI"/AU OR "MEIER EDDIE"/AU)

L15 7 SEA FILE=HCAPLUS ABB=ON PLU=ON "KJOLBYE ANNE LOUISE"/AU

L16 31 SEA FILE=HCAPLUS ABB=ON PLU=ON ("JORGENSEN N"/AU OR "JORGENSE N N R"/AU OR "JORGENSEN N RYE"/AU OR "JORGENSEN NIKLAS R"/AU OR "JORGENSEN NIKLAS RYE"/AU)

L17 495 SEA FILE=HCAPLUS ABB=ON PLU=ON ("NIELSEN M"/AU OR "NIELSEN M S"/AU OR "NIELSEN M S WEBER"/AU OR "NIELSEN MORTEN"/AU OR "NIELSEN MORTEN S"/AU OR "NIELSEN MORTEN SCHAK"/AU)

L18 138 SEA FILE=HCAPLUS ABB=ON PLU=ON ("MARTINS J"/AU OR "MARTINS J B"/AU OR "MARTINS J B L"/AU OR "MARTINS JAMES"/AU OR "MARTINS JAMES B"/AU)

L19 76 SEA FILE=HCAPLUS ABB=ON PLU=ON ("HOLSTEIN R"/AU OR "HOLSTEIN RATHLOU N H"/AU OR "HOLSTEIN RATHLOU N H N H"/AU OR "HOLSTEIN RATHLOU NIELS H"/AU OR "HOLSTEIN RATHLOU NIELS HENRIK"/AU)

L20 2 SEA FILE=HCAPLUS ABB=ON PLU=ON L12 AND L13 AND L14 AND L15 AND L16 AND L17 AND L18 AND L19

L21 13 SEA FILE=HCAPLUS ABB=ON PLU=ON L12 AND (L13 OR L14 OR L15 OR L16 OR L17 OR L18 OR L19)

L22 15 SEA FILE=HCAPLUS ABB=ON PLU=ON L13 AND (L14 OR L15 OR L16 OR L17 OR L18 OR L19)

L23 4 SEA FILE=HCAPLUS ABB=ON PLU=ON L14 AND (L15 OR L16 OR L17 OR L18 OR L19)

L24 5 SEA FILE=HCAPLUS ABB=ON PLU=ON L15 AND (L16 OR L17 OR L18 OR L19)

L25 2 SEA FILE=HCAPLUS ABB=ON PLU=ON L16 AND (L17 OR L18 OR L19)

L26 3 SEA FILE=HCAPLUS ABB=ON PLU=ON L17 AND (L18 OR L19)

```
L27           2 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L18 AND L19
L28          21 SEA FILE=HCAPLUS ABB=ON  PLU=ON  (L20 OR L21 OR L22 OR L23 OR
                L24 OR L25 OR L26 OR L27)
L29           4 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L28 AND (AY<2001 OR PY<2001
                OR PRY<2001)


=> d que 144
L30        2579 SEA LARSEN B?/AU
L31        5774 SEA PETERSEN J?/AU
L32        1629 SEA MEIER E?/AU
L33          42 SEA KJOLBYE A?/AU
L34         977 SEA JORGENSEN N?/AU
L35        5171 SEA NIELSEN M?/AU
L36        2182 SEA MARTINS J?/AU
L37         595 SEA HOLSTEIN R?/AU
L38           2 SEA L30 AND L31 AND L32 AND L33 AND L34 AND L35 AND L36 AND
                L37
L40           2 SEA (L30 OR L31 OR L32 OR L33 OR L34 OR L35 OR L36 OR L37) AND
                (ANTIARRYTHMIC?)
L41           4 SEA (L38 OR L40)
L42         856 SEA (L30 OR L31 OR L32 OR L33 OR L34 OR L35 OR L36 OR L37) AND
                (PEPTIDE?)
L43           1 SEA L42 AND (ARRYTHM?)
L44           4 SEA (L43 OR L41)


=> d que 195
L2           42 SEA FILE=REGISTRY ABB=ON  PLU=ON  [G'SAR']A[G'SAR']['HYP'P]['HY
                P'P]YN/SQSFP
L3           36 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L2
L4           14 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L3 AND (AY<2001 OR PY<2001 OR
                PRY<2001)
L10         107 SEA FILE=REGISTRY ABB=ON  PLU=ON  (159503-65-8/BI OR 355151-11-
                0/BI OR 355151-12-1/BI OR 355151-13-2/BI OR 355151-14-3/BI OR
                355151-15-4/BI OR 355151-16-5/BI OR 355151-17-6/BI OR 355151-18
                -7/BI OR 355151-19-8/BI OR 355151-20-1/BI OR 355151-23-4/BI OR
                355151-25-6/BI OR 355151-26-7/BI OR 355151-27-8/BI OR 355151-29
                -0/BI OR 355151-30-3/BI OR 355151-31-4/BI OR 355151-32-5/BI OR
                355151-33-6/BI OR 355151-34-7/BI OR 355151-35-8/BI OR 355151-36
                -9/BI OR 355151-37-0/BI OR 355151-38-1/BI OR 355151-39-2/BI OR
                355151-40-5/BI OR 355151-41-6/BI OR 355151-43-8/BI OR 355151-45
                -0/BI OR 355151-46-1/BI OR 355151-47-2/BI OR 355151-49-4/BI OR
                355151-50-7/BI OR 355151-51-8/BI OR 355151-52-9/BI OR 355151-53
                -0/BI OR 355151-54-1/BI OR 355151-55-2/BI OR 355151-56-3/BI OR
                355151-74-5/BI OR 81771-37-1/BI OR 111915-92-5/BI OR 133294-37-
                8/BI OR 212570-15-5/BI OR 355151-21-2/BI OR 355151-22-3/BI OR
                355151-24-5/BI OR 355151-28-9/BI OR 355151-42-7/BI OR 355151-44
                -9/BI OR 355151-48-3/BI OR 355151-57-4/BI OR 355151-58-5/BI OR
                355151-59-6/BI OR 355151-60-9/BI OR 355151-61-0/BI OR 355151-62
                -1/BI OR 355151-63-2/BI OR 355151-64-3/BI OR 355151-65-4/BI OR
                355151-66-5/BI OR 355151-67-6/BI OR 355151-68-7/BI OR 355151-69
                -8/BI OR 355151-70-1/BI OR 355151-71-2/BI OR 355151-72-3/BI OR
                355151-73-4/BI OR 355151-75-6/BI OR 355151-76-7/BI OR 35919-99-
                4/BI OR 366800-53-5/BI OR 463362-31-4/BI OR 463362-32-5/BI OR
                463362-33-6/BI OR 463362-34-7/BI OR 463362-35-8/BI OR 463362-36
                -9/BI OR 463362-37-0/BI OR 463362-38-1/BI OR 463362-40-5/BI OR
                463362-42-7/BI OR 463362-43-8/BI OR 463362-44-9/BI OR 463362-45
                -0/BI OR 463362-46-1/BI OR 463362-47-2/BI OR 463362-48-3/BI OR
                463362-49-4/BI OR 463362-50-7/BI OR 463362-51-8/BI OR 463362-52
```

-9/BI OR 463362-53-0/BI OR 463362-54-1/BI OR 463362-55-2/BI OR 463362-56-3/BI OR 463362-57-4/BI OR 463362-58-5/BI OR 463362-59-6/BI OR 463944-96-9/BI OR 476-70-0/BI OR 50-99-7/BI OR 501-36-0/BI OR 57381-26-7/BI OR 602-07-3/BI OR 7782-44-7/BI)

L12 177 SEA FILE=HCAPLUS ABB=ON PLU=ON ("LARSEN B"/AU OR "LARSEN B DUE"/AU OR "LARSEN BJARNE"/AU OR "LARSEN BJARNE D"/AU OR "LARSEN BJARNE DUE"/AU)

L13 262 SEA FILE=HCAPLUS ABB=ON PLU=ON ("PETERSEN J"/AU OR "PETERSEN J S"/AU OR "PETERSEN JOERGEN"/AU OR "PETERSEN JOERGEN S"/AU OR "PETERSEN JOERGEN SOEBERG"/AU OR "PETERSEN JORGEN"/AU OR "PETERSEN JORGEN S"/AU OR "PETERSEN JORGEN SOBERG"/AU OR "PETERSEN JORGEN SOEBERG"/AU)

L14 118 SEA FILE=HCAPLUS ABB=ON PLU=ON ("MEIER E"/AU OR "MEIER E A"/AU OR "MEIER E F"/AU OR "MEIER E G"/AU OR "MEIER E J J"/AU OR "MEIER E M M"/AU OR "MEIER E P"/AU OR "MEIER E V"/AU OR "MEIER EDDI"/AU OR "MEIER EDDIE"/AU)

L15 7 SEA FILE=HCAPLUS ABB=ON PLU=ON "KJOLBYE ANNE LOUISE"/AU

L16 31 SEA FILE=HCAPLUS ABB=ON PLU=ON ("JORGENSEN N"/AU OR "JORGENSE N N R"/AU OR "JORGENSEN N RYE"/AU OR "JORGENSEN NIKLAS R"/AU OR "JORGENSEN NIKLAS RYE"/AU)

L17 495 SEA FILE=HCAPLUS ABB=ON PLU=ON ("NIELSEN M"/AU OR "NIELSEN M S"/AU OR "NIELSEN M S WEBER"/AU OR "NIELSEN MORTEN"/AU OR "NIELSEN MORTEN S"/AU OR "NIELSEN MORTEN SCHAK"/AU)

L18 138 SEA FILE=HCAPLUS ABB=ON PLU=ON ("MARTINS J"/AU OR "MARTINS J B"/AU OR "MARTINS J B L"/AU OR "MARTINS JAMES"/AU OR "MARTINS JAMES B"/AU)

L19 76 SEA FILE=HCAPLUS ABB=ON PLU=ON ("HOLSTEIN R"/AU OR "HOLSTEIN RATHLOU N H"/AU OR "HOLSTEIN RATHLOU N H N H"/AU OR "HOLSTEIN RATHLOU NIELS H"/AU OR "HOLSTEIN RATHLOU NIELS HENRIK"/AU)

L20 2 SEA FILE=HCAPLUS ABB=ON PLU=ON L12 AND L13 AND L14 AND L15 AND L16 AND L17 AND L18 AND L19

L21 13 SEA FILE=HCAPLUS ABB=ON PLU=ON L12 AND (L13 OR L14 OR L15 OR L16 OR L17 OR L18 OR L19)

L22 15 SEA FILE=HCAPLUS ABB=ON PLU=ON L13 AND (L14 OR L15 OR L16 OR L17 OR L18 OR L19)

L23 4 SEA FILE=HCAPLUS ABB=ON PLU=ON L14 AND (L15 OR L16 OR L17 OR L18 OR L19)

L24 5 SEA FILE=HCAPLUS ABB=ON PLU=ON L15 AND (L16 OR L17 OR L18 OR L19)

L25 2 SEA FILE=HCAPLUS ABB=ON PLU=ON L16 AND (L17 OR L18 OR L19)

L26 3 SEA FILE=HCAPLUS ABB=ON PLU=ON L17 AND (L18 OR L19)

L27 2 SEA FILE=HCAPLUS ABB=ON PLU=ON L18 AND L19

L28 21 SEA FILE=HCAPLUS ABB=ON PLU=ON (L20 OR L21 OR L22 OR L23 OR L24 OR L25 OR L26 OR L27)

L29 4 SEA FILE=HCAPLUS ABB=ON PLU=ON L28 AND (AY<2001 OR PY<2001 OR PRY<2001)

L83 106 SEA FILE=REGISTRY ABB=ON PLU=ON L10 NOT O2/MF

L85 104 SEA FILE=REGISTRY ABB=ON PLU=ON L83 NOT C14H12O3/MF

L86 103 SEA FILE=REGISTRY ABB=ON PLU=ON L85 NOT C19H21NO4/MF

L87 103 SEA FILE=REGISTRY ABB=ON PLU=ON L86 NOT C9H7C12N5/MF

L88 102 SEA FILE=REGISTRY ABB=ON PLU=ON L87 NOT C20H19NO6

L89 101 SEA FILE=REGISTRY ABB=ON PLU=ON L88 NOT C6H12O6/MF

L91 66 SEA FILE=HCAPLUS ABB=ON PLU=ON L89 (L)(THU OR BAC OR PAC OR DMA OR PKT)/RL

L92 26 SEA FILE=HCAPLUS ABB=ON PLU=ON L91 AND (AY<2001 OR PY<2001 OR PRY<2001)

L93 20 SEA FILE=HCAPLUS ABB=ON PLU=ON L91 AND (ALA OR ALANIN? OR GLY OR GLYCINE OR GLU OR GLUTAMIC? OR ASP OR ASPARTIC? OR DAB OR DIAMINOBUT? OR DAPA OR LYS OR LYSINE OR ASP OR ASPARAGINE OR GLN OR GLUTAMINE OR ORN OR ORNITHINE OR CYS OR CYSTEINE)

```
L94           35 SEA FILE=HCAPLUS ABB=ON  PLU=ON  (L92 OR L93)
L95           33 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L94 NOT (L4 OR L29)


=> dup rem l29,l44,l95
PROCESSING COMPLETED FOR L29
PROCESSING COMPLETED FOR L44
PROCESSING COMPLETED FOR L95
L98           37 DUP REM L29 L44 L95 (4 DUPLICATES REMOVED)
                 ANSWERS '1-37' FROM FILE HCAPLUS

=> d ibib abs hitind hitstr retable l98 tot

L98  ANSWER 1 OF 37  HCAPLUS  COPYRIGHT 2007 ACS on STN DUPLICATE 1
ACCESSION NUMBER:         2002:754415  HCAPLUS  Full-text
DOCUMENT NUMBER:          137:263304
TITLE:                    Synthesis of peptides and medical uses of
                          intracellular communication facilitating compounds
INVENTOR(S):              Larsen, Bjarne Due; Petersen, Jorgen
                          Soberg; Meier, Eddie; Kjolbye,
                          Anne Louise; Jorgensen, Niklas Rye;
                          Nielsen, Morten Schak; Holstein-Rathlou,
                          Niels-Henrik; Martins, James B.
PATENT ASSIGNEE(S):        Zealand Pharmaceuticals A/S, Den.
SOURCE:                   PCT Int. Appl., 233 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   2
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.          DATE
     ---------------      ----   --------    --------------------     --------
     WO 2002077017         A2    20021003    WO 2002-US5773           20020222
     WO 2002077017         A3    20031009
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
             UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB,
             GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA,
             GN, GQ, GW, ML, MR, NE, SN, TD, TG
     WO 2001062775         A2    20010830    WO 2001-DK127            20010222 <--
     WO 2001062775         A3    20020131
         W:  AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,
             CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,
             IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,
             MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,
             SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
             DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     US 2003092609         A1    20030515    US 2001-792286           20010222 <--
     CA 2439101            A1    20021003    CA 2002-2439101          20020222
     EP 1370276            A2    20031217    EP 2002-723240           20020222
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
```

JP 2005506295	T	20050303	JP 2002-576275		20020222
BR 2002007476	A	20060124	BR 2002-7476		20020222
NO 2003003641	A	20031020	NO 2003-3641		20030815
US 2005113293	A1	20050526	US 2003-646294		20030822 <--
IN 2003DN01336	A	20050527	IN 2003-DN1336		20030822
US 2005075280	A1	20050407	US 2004-772774		20040204 <--
PRIORITY APPLN. INFO.:			US 2001-792286	A	20010222
			WO 2001-DK127	A	20010222
			US 2001-314470P	P	20010823
			DK 2000-288	A	20000223 <--
			DK 2000-738	A	20000504 <--
			US 2000-251659P	P	20001206 <--
			WO 2002-US5773	W	20020222

OTHER SOURCE(S): MARPAT 137:263304

AB The invention relates to novel peptides, including novel antiarrhythmic peptides of linear or cyclic structure, having improved stability in vitro and/or in vivo, to compns. comprising these peptides, and to uses of the peptides for the preparation of medicaments. The invention also relates to the use of compds. that facilitate the intercellular communication for the preparation of medicaments for the treatment of a range of diseases characterized in impaired intercellular gap junctional communication. The invention further relates to a method of treating diseases, such as bladder incontinence, disorders of alveolar tissue and bronchial tissue, impaired hearing due to diseases of the cochlea, endothelial lesions, diabetic retinopathy and diabetic neuropathy, ischemia of the central nervous system and spinal cord, dental tissue disorders including periodontal disease, kidney diseases leading to hypertension, and a method of preventing failures of bone marrow transplantation. Ac-D-Tyr-D-Pro-D-4Hyp-Gly-D-Ala-Gly-NH2 (Hyp = hydroxyprolyl) was prepared by the solid-phase method and assayed for biol. activity. Graphs include those for relative cell-to-cell conductance, PI-turnover in neonatal rat cardiomyocytes, and ventricular APD90 dispersion.

IC ICM C07K007-00

CC 34-3 (Amino Acids, Peptides, and Proteins)
Section cross-reference(s): 1, 6, 63

L98 ANSWER 2 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 2

ACCESSION NUMBER: 2001:636085 HCAPLUS Full-text

DOCUMENT NUMBER: 135:180957

TITLE: Preparation of novel antiarrhythmic peptides

INVENTOR(S): *Larsen, Bjarne Due; Petersen, Jorgen Soberg; Meier, Eddi; Kjolbye, Anne Louise; Jorgensen, Niklas Rye; Nielsen, Morten Schak; Holstein-Rathlou, Niels-Henrik; Martins, James B.*

PATENT ASSIGNEE(S): Zealand Pharmaceuticals A/S, Den.

SOURCE: PCT Int. Appl., 189 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001062775	A2	20010830	WO 2001-DK127	20010222 <--
WO 2001062775	A3	20020131		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,

SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2385659	A1	20010830	CA 2001-2385659	20010222 <--
EP 1226160	A2	20020731	EP 2001-907393	20010222 <--
EP 1226160	B1	20041215		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

JP 2003528826	T	20030930	JP 2001-562556	20010222 <--
AT 284896	T	20050115	AT 2001-907393	20010222 <--
ES 2228807	T3	20050416	ES 2001-1907393	20010222 <--
PT 1226160	T	20050429	PT 2001-907393	20010222 <--
AU 781674	B2	20050602	AU 2001-35362	20010222 <--
CA 2439101	A1	20021003	CA 2002-2439101	20020222
WO 2002077017	A2	20021003	WO 2002-US5773	20020222
WO 2002077017	A3	20031009		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1370276	A2	20031217	EP 2002-723240	20020222

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

JP 2005506295	T	20050303	JP 2002-576275	20020222
BR 2002007476	A	20060124	BR 2002-7476	20020222
NO 2003003641	A	20031020	NO 2003-3641	20030815
US 2005113293	A1	20050526	US 2003-646294	20030822 <--
US 2005075280	A1	20050407	US 2004-772774	20040204 <--
AU 2005205785	A1	20050929	AU 2005-205785	20050902 <--

PRIORITY APPLN. INFO.:

DK 2000-288	A	20000223 <--
DK 2000-738	A	20000504 <--
US 2000-251659P	P	20001206 <--
US 2001-792286	A	20010222
WO 2001-DK127	W	20010222
US 2001-314470P	P	20010823
WO 2002-US5773	W	20020222

OTHER SOURCE(S): MARPAT 135:180957

AB Peptides X-A-B-Y and cyclo(X-A-B-Y) [A and B represents chemical moieties having an amino group (radical) and a carboxy group; X represents a peptide sequence of 1 to 3 D- or L-amino acid residues or an N-terminal modification of the group A-B when Y represents a C-terminal peptide sequence of 2 to 5 D- or L-amino acid residues; X represents a peptide sequence of 2 to 5 D- or L-amino acid residues when Y represents a C-terminal peptide sequence of 1 to 3 D- or L-amino acid residues; for the linear peptide, X is optionally chemical modified at its N-terminal and has an optional linking group comprising 0-8 backbone atoms] and their mirror image or a retro analogs or pharmaceutically acceptable derivs. were prepared for treating cardiac arrhythmias. Thus, Ac-D-Tyr-D-pro-D-4Hyp-Gly- D-Ala-Gly-NH2 (4Hyp = 4-hydroxyprolyl) was prepared by the solid-phase method using TentaGel-S-Ram and examined for biol. activity [assays included effect on gap junction intercellular communication (GJIC) in cardiomyocytes, binding to tissue prepns. of murine heart, and effect on cAMP formation in CHO cells].

IC ICM C07K007-00

CC 34-3 (Amino Acids, Peptides, and Proteins)
Section cross-reference(s): 1, 63

L98 ANSWER 3 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:100738 HCAPLUS Full-text
DOCUMENT NUMBER: 144:198849
TITLE: Novel dosage form comprising modified-release and immediate-release active ingredients
INVENTOR(S): Vaya, Navin; Karan, Rajesh Singh; Sadanand, Sunil; Gupta, Vinod Kumar
PATENT ASSIGNEE(S): India
SOURCE: U.S. Pat. Appl. Publ., 49 pp., Cont.-in-part of U.S. Ser. No. 630,446.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006024365	A1	20060202	US 2005-134633	20050519
IN 193042	A1	20040626	IN 2002-MU697	20020805
IN 2003MU00080	A	20050204	IN 2003-MU80	20030122
IN 2003MU00082	A	20050204	IN 2003-MU82	20030122
US 2004096499	A1	20040520	US 2003-630446	20030729

PRIORITY APPLN. INFO.:

IN 2002-MU697	A	20020805
IN 2002-MU699	A	20020805
IN 2003-MU80	A	20030122
IN 2003-MU82	A	20030122
US 2003-630446	A2	20030729

AB A dosage form comprising of a high dose, high solubility active ingredient as modified release and a low dose active ingredient as immediate release where the weight ratio of immediate release active ingredient and modified release active ingredient is from 1:10 to 1:15000 and the weight of modified release active ingredient per unit is from 500 mg to 1500 mg; a process for preparing the dosage form. Tablets containing 10 mg sodium pravastatin and 1000 mg niacin were prepared The release of sodium pravastatin after 24 h was 67.7%, and the release of niacin after 1 h was 84.1%.

INCL 424468000
CC 63-6 (Pharmaceuticals)
IT 50-02-2, Dexamethasone 50-04-4, Cortisone acetate 50-06-6, Phenobarbital, biological studies 50-12-4, Mephenytoin 50-13-5, Meperidine hydrochloride 50-18-0, Cyclophosphamide 50-19-1, Hydroxyphenamate 50-23-7, Hydrocortisone 50-24-8, Prednisolone 50-27-1, Estriol 50-28-2, Estra-1,3,5(10)-triene-3,17-diol (17β)-, biological studies 50-33-9, Phenylbutazone, biological studies 50-34-0, Propantheline bromide 50-35-1, Thalidomide 50-36-2, Cocaine 50-52-2, Thioridazine 50-53-3, Chlorpromazine, biological studies 50-55-5, Reserpine 50-56-6, Oxytocin, biological studies 50-57-7, Lypressin 50-58-8, Phendimetrazine tartrate 50-59-9, Cephaloridine 50-65-7, Niclosamide 50-76-0, Dactinomycin 50-78-2, Aspirin 50-91-9, Floxuridine 51-05-8, Procaine hydrochloride 51-15-0, Pralidoxime chloride 51-21-8, Fluorouracil 51-30-9, Isoproterenol hydrochloride 51-40-1, Norepinephrine bitartrate 51-43-4, Epinephrine 51-52-5, Propylthiouracil 51-55-8, Atropine, biological studies 51-56-9, Homatropine hydrobromide 51-57-0, Methamphetamine hydrochloride 51-64-9, Dextroamphetamine 51-83-2, Carbachol 52-01-7, Spironolactone 52-24-4, Thiotepa 52-49-3, Trihexyphenidyl hydrochloride 52-68-6, Metrifonate 52-76-6, Lynestrenol 52-86-8, Haloperidol 52-88-0,

Methylatropine nitrate 52-89-1, *Cysteine* hydrochloride 53-03-2, Prednisone 53-16-7D, Estrone, esters 53-19-0, Mitotane 53-34-9, Fluprednisolone 53-39-4, Oxandrolone 53-43-0, Dehydroepiandrosterone 53-60-1, Promazine hydrochloride 53-73-6, Angiotensin amide 53-79-2, Puromycin 53-84-9, Nadide 53-86-1, Indometacin 54-03-5, Hexobendine 54-05-7, Chloroquine 54-21-7, Sodium salicylate 54-31-9, Furosemide 54-35-3, Penicillingprocaine 54-36-4, Metyrapone 54-42-2, Idoxuridine 54-64-8, Thimerosal 54-84-2, Cinanserin hydrochloride 54-85-3, Isoniazid 54-91-1, Pipobroman 55-03-8, Levothyroxine sodium 55-06-1, Liothyronine sodium 55-63-0, Nitroglycerin 55-86-7, Mechlorethamine hydrochloride 55-91-4, Isoflurophate 55-98-1, Busulfan 56-45-1, Serine, biological studies 56-47-3, Desoxycorticosterone acetate 56-53-1, Diethylstilbestrol 56-59-7, Felypressin 56-75-7, Chloramphenicol 56-84-8, *Aspartic* acid, biological studies 56-87-1, *Lysine*, biological studies 56-89-3, Cystine, biological studies 56-94-0, Demecarium bromide 57-13-6, Urea, biological studies 57-41-0, Phenytoin 57-47-6, Physostigmine 57-53-4, Meprobamate 57-63-6, Ethinyl estradiol 57-65-8, Thyromedan hydrochloride 57-66-9, Probenecid 57-68-1, Sulfamethazine 57-83-0, Progesterone, biological studies 57-91-0, 17-α Estradiol 57-94-3, Tubocurarine chloride 57-96-5, Sulfinpyrazone 58-08-2, Caffeine, biological studies 58-14-0, Pyrimethamine 58-18-4, Methyltestosterone 58-22-0, Testosterone 58-25-3, Chlordiazepoxide 58-28-6, Desipramine hydrochloride 58-32-2, Dipyridamole 58-33-3, Promethazine hydrochloride 58-38-8, Prochlorperazine 58-39-9, Perphenazine 58-54-8, Ethacrynic acid 58-55-9, Theophylline, biological studies 58-71-9, Cephalothin sodium 58-86-6, Xylose, biological studies 58-93-5, Hydrochlorothiazide 58-94-6, Chlorothiazide 59-05-2, Methotrexate 59-30-3, Folic acid, biological studies 59-33-6, Pyrilamine maleate 59-52-9, Dimercaprol 59-63-2, Isocarboxazid 59-67-6, Niacin, biological studies 59-87-0, Nitrofurazone 59-92-7, Levodopa, biological studies 59-97-2, Tolazoline hydrochloride 60-13-9, Amphetamine sulfate 60-18-4, Tyrosine, biological studies 60-23-1, Cysteamine 60-29-7, Ether, biological studies 60-45-7, Fenimide 60-54-8, Tetracycline 60-56-0, Methimazole 60-80-0, Antipyrine 60-99-1, Methotrimeprazine 61-25-6, Papaverine hydrochloride 61-56-3, Sulthiame 61-57-4, Niridazole 61-68-7, Mefenamic acid 61-73-4, Methylene blue 61-75-6, Bretylium tosylate 61-76-7, Phenylephrine hydrochloride 61-90-5, Leucine, biological studies 62-51-1, Methacholine chloride 62-68-0, Proadifen hydrochloride 62-73-7, Dichlorvos 62-90-8, Nandrolone phenpropionate 63-05-8, Androstenedione 63-12-7, Benzquinamide 63-39-8, Uridine triphosphate 63-45-6, Primaquine phosphate 63-68-3, Methionine, biological studies 63-89-8, Colfosceril palmitate 63-91-2, Phenylalanine, biological studies 63-92-3, Phenoxybenzamine hydrochloride 63-98-9, Phenacemide 64-31-3, Morphine sulfate 64-43-7, Amobarbital sodium 64-55-1, Mebutamate 64-77-7, Tolbutamide 64-86-8, Colchicine 65-28-1, Phentolamine mesylate 65-29-2, Gallamine triethiodide 65-45-2, Salicylamide 66-75-1, Uracil mustard 66-76-2, Dicumarol 66-81-9, Cycloheximide 67-20-9, Nitrofurantoin 67-43-6, Pentetic acid 67-45-8, Furazolidone 67-63-0, Isopropyl alcohol, biological studies 67-68-5, Dimethyl sulfoxide, biological studies 67-73-2, Fluocinolone acetonide 67-92-5, Dicyclomine hydrochloride 67-95-8, Quingestrone 67-96-9, Dihydrotachysterol 68-22-4, Norethindrone 68-23-5, Norethynodrel 68-35-9, Sulfadiazine 68-41-7, Cycloserine 68-89-3, Dipyrone 68-91-7, Trimethaphan camsylate 68-96-2, 17 Hydroxy progesterone 69-44-3, Amodiaquine hydrochloride 69-53-4, Ampicillin 69-57-8, Penicillingsodium 69-65-8, Mannitol 69-72-7, Salicylic acid, biological studies 69-74-9, Cytarabine hydrochloride 70-00-8, Trifluridine 70-10-0, Ticlatone 70-30-4,

Hexachlorophene 71-00-1, Histidine, biological studies 71-27-2, Succinylcholine chloride 71-58-9, Medroxyprogesterone acetate 71-63-6, Digitoxin 71-68-1, Hydromorphone hydrochloride 71-73-8, Thiopental sodium 71-81-8, Isopropamide iodide 72-18-4, Valine, biological studies 72-19-5, Threonine, biological studies 72-33-3, Mestranol 72-44-6, Methaqualone 73-09-6, Etozolin 73-22-3, Tryptophan, biological studies 73-31-4, Melatonin 73-32-5, Isoleucine, biological studies 73-48-3, Bendroflumethiazide 74-79-3, Arginine, biological studies 75-00-3, Ethyl chloride 75-19-4, Cyclopropane 76-38-0, Methoxyflurane 76-42-6, Oxycodone 76-43-7, Fluoxymesterone 76-57-3, Codeine 76-73-3, Secobarbital 76-74-4, Pentobarbital 76-90-4, Mepenzolate bromide 77-21-4, Glutethimide 77-26-9, Butalbital 77-27-0, Thiamylal 77-36-1, Chlorthalidone 77-41-8, Methsuximide 77-46-3, Acedapsone 77-67-8, Ethosuximide 77-86-1, Trometamol 78-11-5, Pentaerythritol tetranitrate 78-44-4, Carisoprodol 79-09-4, Propionic acid, biological studies 79-17-4, Pimagedine 79-57-2, Oxytetracycline 79-64-1, Dimethisterone 80-08-0, Dapsone 80-50-2, Anisotropine methylbromide 81-04-9, 1,5-Naphthalenedisulfonic acid 81-13-0, Dexpanthenol 81-23-2, Dehydrocholic acid 81-54-9, Purpurin 82-92-8, Cyclizine 83-43-2, Methylprednisolone 83-73-8, Iodoquinol 83-74-9, Ibogaine 84-17-3, Dienestrol
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(novel dosage form comprising modified-release and immediate-release active ingredients)

IT 55268-75-2, Cefuroxime 55294-15-0, Muzolimine 55298-68-5, Neomycin palmitate 55453-87-7, Isoxepac 55560-96-8, Tixocortol pivalate 55694-87-6, Pentizidone sodium 55695-56-2, Cloroperone hydrochloride 55721-11-4, Secalciferol 55774-33-9, Azathioprine sodium 55779-18-5, Arprinocid 55837-27-9, Piretanide 55837-29-1, Tiropramide 55870-64-9, Pentisomicin 55881-07-7, Miokamycin 55905-53-8, Clebopride 55981-09-4, Nitazoxanide 56030-54-7, Sufentanil 56049-88-8, Indacrinone 56079-80-2, Ropitoin hydrochloride 56093-45-9, Selenium sulfide 56119-96-1, Furodazole 56187-89-4, Ximoprofen 56208-01-6, Pifarnine 56211-40-6, Torasemide 56219-57-9, Arildone 56281-36-8, Motretinide 56290-94-9, Medroxalol 56383-05-2, Zindotrine 56391-55-0, Octazamide 56391-57-2, Netilmicin sulfate 56420-45-2, Epirubicin 56430-99-0, Flumecinol 56470-64-5, Anordrin 56605-16-4D, Spiromustine, di-Ph derivs. 56611-65-5, Oxagrelate 56689-42-0, Repromicin 56689-44-2, Nitramisole hydrochloride 56717-18-1, Isotiquimide 56741-95-8, Bropirimine 56784-39-5, Ozolinone 56796-20-4, Cefmetazole 56917-29-4, Fluretofen 56980-93-9, Celiprolol 56995-20-1, Flupirtine 57010-32-9, Tiapamil hydrochloride 57041-67-5, Desflurane 57067-46-6, Isamoxole 57109-90-7, Clorazepate dipotassium 57149-07-2, Naftopidil 57166-13-9, Napactadine hydrochloride 57248-88-1, Pamidronate disodium 57262-94-9, Setiptiline 57285-09-3, Folliculostatin *57381-26-7*, Irsogladine 57432-61-8, Methylergonovine maleate 57441-90-4, Nivimedone sodium 57540-79-1, Nisbuterol mesylate 57645-05-3, Sermetacin 57653-26-6, Fenobam 57666-60-1, Nitrafudam hydrochloride 57726-65-5, Nufenoxole 57773-63-4, Triptorelin 57773-65-6, Deslorelin 57775-22-1, Etoperidone hydrochloride 57781-15-4, Halopredone 57801-81-7, Brotizolam 57808-65-8, Closantel 57982-78-2, Budipine 57998-68-2, Diaziquone 58019-50-4, Menabitan hydrochloride 58019-65-1, Nabazenil 58066-85-6, Miltefosine 58152-03-7, Isepamicin 58167-78-5, Tandamine hydrochloride 58239-89-7, Moxazocine 58261-91-9, Mefenidil 58473-74-8, Cinromide 58493-49-5, Olvanil 58497-00-0, Procinonide 58503-79-0, Meobentine sulfate 58524-83-7, Ciprocinonide 58525-82-9, Azatyrosine 58581-89-8, Azelastine 58712-69-9, Traxanox 58795-03-2, Apalcillin sodium 58934-46-6, Lorcainide hydrochloride 58944-73-3, Sinefungin 58957-92-9, Idarubicin 58970-76-6, Ubenimex 59017-64-0, Ioxaglic acid

59018-13-2, Ioxaglate meglumine 59070-06-3, Ticarcillin cresyl sodium 59122-46-2, Misoprostol 59160-29-1, Lidofenin 59170-23-9, Bevantolol 59179-95-2, Lorzafone 59227-89-3, Laurocapram 59263-76-2, Meptazinol hydrochloride 59333-90-3, Exaprolol hydrochloride 59467-96-8, Midazolam hydrochloride 59497-39-1, Naflocort 59653-73-5, Teroxirone 59703-84-3, Piperacillin sodium 59729-33-8, Citalopram 59733-86-7, Butikacin 59756-39-7, Enolicam sodium 59794-18-2, Paulomycin 59803-98-4, Brimonidine 59804-37-4, Tenoxicam 59831-63-9, Doconazole 59831-64-0, Milenperone 59831-65-1, Halopemide 59917-39-4, Vindesine sulfate 59937-28-9, Malotilate 59954-01-7, Pamatolol sulfate 60019-19-4, Iotetric acid 60050-95-5, Sulfoxamine 60084-10-8, Tiazofurin 60086-22-8, Clopipazan mesylate 60135-22-0, Flumoxonide 60142-96-3, Gabapentin 60166-93-0, Iopamidol 60200-06-8, Clorsulon 60207-31-0, Azaconazole 60209-20-3, Lycetamine 60282-87-3, Gestodene 60325-46-4, Sulprostone 60398-23-4, Iodoamiloride 60400-92-2, Proxicromil 60525-15-7, Zimelidine hydrochloride 60560-33-0, Pinacidil 60569-19-9, Propiverine 60607-34-3, Oxatomide 60607-35-4, Topterone 60628-96-8, Bifonazole 60653-25-0, Orpanoxin 60719-84-8, Amrinone 60719-85-9, Ciprefadol succinate 60762-57-4, Pirlindole 60857-08-1, Prostratin 60925-61-3, Ceforanide 60940-34-3, Ebselen 60976-05-8 61036-62-2, Teicoplanin 61177-45-5, Clavulanate potassium 61220-69-7, Tiopinac 61260-05-7, Prenalterol hydrochloride 61263-35-2, Meteneprost 61270-78-8, Cefonicid sodium 61318-91-0, Sulconazole nitrate 61325-80-2, Flumezapine 61379-65-5, Rifapentine 61380-27-6, Carfentanil citrate 61380-41-4, Lofentanil oxalate 61413-54-5, Rolipram 61444-62-0, Nifluridide 61477-94-9, Pirmenol hydrochloride 61481-30-9, Dicranin 61484-39-7, Pareptide sulfate 61489-71-2, Menotropin 61570-90-9, Tioxidazole 61622-34-2, Cefotiam 61825-94-3, Oxaliplatin 61849-14-7, Epoprostenol sodium 61869-08-7, Paroxetine 62013-04-1, Dirithromycin 62087-72-3, Pentigetide 62134-34-3, Butoprozine hydrochloride 62220-58-0, Bipenamol hydrochloride 62265-68-3, Quinfamide 62304-98-7, Thymalfasin 62435-42-1, Perfosfamide 62488-57-7 62571-86-2, Captopril 62571-87-3, Minaxolone 62587-73-9, Cefsulodin 62613-82-5, Oxiracetam 62625-19-8, Pirogliride tartrate 62658-63-3, Bopindolol 62666-20-0, Progabide 62732-44-9, Ipidacrine 62816-98-2, Ormaplatin 62851-43-8, Zidometacin 62893-20-3, Cefoperazone sodium 62928-11-4, Iproplatin 62929-91-3, Procaterol hydrochloride 62973-76-6, Azanidazole 62973-77-7, Parconazole hydrochloride 62989-33-7, Sapropterin 62996-74-1, Staurosporine 63119-27-7, Anitrazafen 63198-97-0, Viroxime 63204-23-9, Oxmetidine hydrochloride 63245-28-3, Etifenin 63251-39-8, Sulfinalol hydrochloride 63269-31-8, Ciramadol 63358-49-6, Aspoxicillin 63534-64-5, Iosulamide meglumine 63585-09-1, Foscarnet sodium 63590-19-2, Balanol 63590-64-7, Terazosin 63612-50-0, Nilutamide 63659-18-7, Betaxolol 63659-19-8, Betaxolol hydrochloride 63675-72-9, Nisoldipine 63774-77-6, Somatomedin B 63941-73-1, Ioglucol 63941-74-2, Ioglucomide 63950-06-1, Esorubicin hydrochloride 64019-93-8, Dipivefrin hydrochloride 64059-66-1, Cetaben sodium 64063-83-8, Picotrin diolamine 64092-48-4, Zomepirac sodium 64211-45-6, Oxiconazole 64221-86-9, Imipenem 64228-81-5, Atracurium besylate 64318-79-2, Gemeprost 64379-93-7, Cinflumide 64420-40-2, Etibendazole 64461-82-1, Tizanidine hydrochloride 64485-93-4, Cefotaxime sodium 64706-54-3, Bepridil 64808-48-6, Lobenzarit sodium 64872-77-1, Butoconazole nitrate 64924-67-0, Halofuginone hydrobromide 64953-12-4, Moxalactam disodium 65009-35-0, Lidamidine hydrochloride 65043-22-3, Indeloxazine hydrochloride 65052-63-3, Cefetamet 65057-90-1, Talisomycin 65093-40-5, Cytarabine ocfosfate 65141-46-0, Nicorandil 65222-35-7, Pazelliptine 65271-80-9, Mitoxantrone 65277-42-1, Ketoconazole 65322-72-7, Endralazine mesylate 65454-13-9, Lateritin

RL: *THU (Therapeutic use)*; BIOL (Biological study); USES (Uses)
(novel dosage form comprising modified-release and immediate-release active ingredients)

IT *57381-26-7*, Irsogladine
RL: *THU (Therapeutic use)*; BIOL (Biological study); USES (Uses)
(novel dosage form comprising modified-release and immediate-release active ingredients)

RN 57381-26-7 HCAPLUS
CN 1,3,5-Triazine-2,4-diamine, 6-(2,5-dichlorophenyl)- (9CI) (CA INDEX NAME)



L98 ANSWER 4 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:1036916 HCAPLUS Full-text
DOCUMENT NUMBER: 142:33307
TITLE: Stable analogs of peptide and polypeptide therapeutics
INVENTOR(S): Bachovchin, William W.; Lai, Hung-Sen; Sanford, David George
PATENT ASSIGNEE(S): Trustees of Tufts College, USA
SOURCE: PCT Int. Appl., 83 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004103390	A2	20041202	WO 2004-US15488	20040517
WO 2004103390	A3	20050630		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004240630	A1	20041202	AU 2004-240630	20040517
CA 2525574	A1	20041202	CA 2004-2525574	20040517
US 2005049177	A1	20050303	US 2004-847220	20040517
EP 1633384	A2	20060315	EP 2004-752496	20040517
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
CN 1822851	A	20060823	CN 2004-80019850	20040517

PRIORITY APPLN. INFO.:
US 2003-471411P P 20030515
WO 2004-US15488 W 20040517

AB The present invention relates to compns. of peptide and polypeptide analogs that are resistant to proteolysis, pharmaceutical uses thereof, and methods of preparation thereof. The peptide and polypeptide analogs are resistant to cleavage by proteinases, i.e., a serine proteinase, metalloproteinase, *aspartic* proteinase, or *cysteine* e proteinase. For example, two substitutions at the P'1 *glutamic* acid of GLP1-(7-37) were made to obtain GLP-1 (3DMA), wherein the P'1 substitution was 3-dimethylaspartate, and GLP-1-(BM), wherein the P'1 substitution was 3-butylmethylglycine. Both GLP-1 (3DMA) and GLP-1-(BM) displayed robust resistance to degradation by the serine protease dipeptidyl peptidase IV (DPP IV) and retained biol. activities of native glucagon-like peptide 1 (GLP-1). They both retained the ability to bind to GLP-1 receptors of COS-7 cells, as well as to potentiate GLP-1 signaling via the GLP-1 receptor to an extent indistinguishable from native GLP-1.

IC ICM A61K038-00

CC 2-10 (Mammalian Hormones)
Section cross-reference(s): 1, 63

IT 50-56-6D, Oxytocin, analogs 58-82-2D, Bradykinin, analogs 581-05-5D, α-Melanotropin (swine), analogs 1393-25-5D, Secretin, analogs 1405-97-6D, Gramicidin, analogs 2002-44-0D, analogs 3397-23-7D, Ornipressin, analogs 9002-60-2D, Adrenocorticotropic hormone, analogs 9002-72-6D, Growth hormone, analogs 9002-76-0D, Gastrin, analogs 9002-79-3D, Melanocyte stimulating hormone, analogs 9004-10-8D, Insulin, analogs 9007-12-9D, Calcitonin, analogs 9007-92-5D, Glucagon, analogs 9011-97-6D, Cholecystokinin, analogs 9014-42-0D, Thrombopoietin, analogs 9015-71-8D, Corticotropin-releasing factor, analogs 9034-39-3D, Growth hormone releasing factor, analogs 9034-40-6D, Gonadotropin-releasing hormone, analogs 9034-50-8D, Vasotocin, analogs 9041-90-1D, Angiotensin I, analogs 11000-17-2D, Vasopressin, analogs 11002-13-4D, Angiotensinogen, analogs 11096-26-7D, Erythropoietin, analogs 11128-99-7D, Angiotensin II, analogs 24305-27-9D, Thyrotropin-releasing hormone, analogs 33507-63-0D, Substance P, analogs 39379-15-2D, Neurotensin, analogs 40077-57-4D, Vasoactive intestinal octacosapeptide (swine), analogs 51110-01-1D, Somatostatin, analogs 52232-67-4D, Human parathyroid hormone (1-34), analogs 52906-92-0D, Motilin, analogs 55123-66-5D, Leupeptin, analogs 58569-55-4D, Met-enkephalin, analogs 58822-25-6D, Leu-enkephalin, analogs 59392-49-3D, GIP, analogs 59763-91-6D, Pancreatic polypeptide, analogs 60118-07-2D, Endorphin, analogs 61912-98-9D, Insulin-like growth factor, analogs 62229-50-9D, Epidermal growth factor, analogs 64190-70-1D, FMRF-amide, analogs 67382-96-1D, Melanin-concentrating hormone, analogs 69431-45-4D, δ-Sleep inducing peptide, analogs 70904-56-2D, Kyotorphin, analogs 74913-18-1D, Dynorphin, analogs 80043-53-4D, Gastrin-releasing peptide, analogs 80448-90-4D, Dynorphin A (swine), analogs 80802-79-5D, Cecropin, analogs 81608-30-2D, Neuromedin C, analogs *81771-37-1D*, Antiarrhythmic peptide, analogs 82785-45-3D, Neuropeptide Y, analogs 83150-76-9D, Octreotide, analogs 83335-41-5D, Dynorphin B (swine), analogs 83652-28-2D, Calcitonin gene-related peptide, analogs 85637-73-6D, Atriopeptin, analogs 86933-74-6D, Neurokinin A, analogs 86933-75-7D, Neurokinin B (swine spinal cord), analogs 87616-84-0D, Growth hormone-releasing peptide 6, analogs 88526-44-7D, Paracelsin, analogs 89105-94-2, Fibrinogen-binding inhibitor peptide 89750-14-1D, GLP 1, analogs 89750-15-2D, Glucagon-like peptide II, analogs 97793-28-7D, Atriopeptin III, analogs 98084-68-5D, Atriopeptin I, analogs 98084-69-6D, Atriopeptin II, analogs 98824-26-1D, Calcitonin gene-related peptide II, analogs 99566-27-5D, Neuropeptide FF (cattle), analogs 102577-25-3D, Neuromedin N, analogs 103131-69-7D, Kinetensin (human), analogs 103220-14-0D, Corticostatin, analogs 103370-86-1D, Parathyroid hormone related peptide, analogs 106021-96-9D, analogs 106388-42-5D, Peptide YY, analogs 106441-70-7D, Neuropeptide K, analogs 111745-44-9D, Neuromedin U, analogs 114471-18-0D, Brain natriuretic

peptide, analogs 115150-59-9D, Antagonist G, analogs 116243-73-3D, Endothelin, analogs 119418-04-1D, Galanin, analogs 122752-15-2D, Deltorphin I, analogs 122752-16-3D, Deltorphin II, analogs 127830-04-0D, C-type natriuretic peptide, analogs 128245-93-2D, analogs 133249-66-8D, Elafin, analogs 137061-48-4D, Pituitary adenylate cyclase activating polypeptide, analogs 140896-21-5D, Indolicidin, analogs 141636-44-4, GR 83074 141801-26-5D, Endomorphin-2, analogs 151039-33-7D, PD-142893, analogs 151039-37-1D, PD-145065, analogs 154835-90-2D, Adrenomedullin, analogs 168317-35-9D, Guamerin, analogs 169494-85-3D, Leptin, analogs 170713-75-4D, Nociceptin, analogs 180201-29-0D, analogs 186901-48-4D, Cortistatin 14, analogs 188627-80-7D, Eptifibatide, analogs 189388-22-5D, Endomorphin-1, analogs 309247-07-2D, analogs 800379-40-2 800379-41-3D, analogs
RL: *THU (Therapeutic use)*; BIOL (Biological study); USES (Uses)
(proteinase-resistant analogs of peptide and polypeptide therapeutics)

IT 9002-04-4, Thrombin 37259-58-8, Serine proteinase 37353-41-6, *Cysteine* proteinase 54249-88-6, Dipeptidyl peptidase IV 78169-47-8, *Aspartic* proteinase 81669-70-7
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(resistance to; proteinase-resistant analogs of peptide and polypeptide therapeutics)

IT *81771-37-1D*, Antiarrhythmic peptide, analogs
RL: *THU (Therapeutic use)*; BIOL (Biological study); USES (Uses)
(proteinase-resistant analogs of peptide and polypeptide therapeutics)

RN 81771-37-1 HCAPLUS
CN Antiarrhythmic peptide (cattle atrium) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L98 ANSWER 5 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:394338 HCAPLUS Full-text
DOCUMENT NUMBER: 140:400107
TITLE: Compositions and methods for modulating connexin hemichannels for treating diseases
INVENTOR(S): Jensen, Peter Holme; Larsen, Bjarne Due; Hansen, Lars Bo Laurenborg; Petersen, Jorgen Soberg; Neve, Soren; Nielsen, Morten Schak; Meier, Eddi; Steiness, Eva
PATENT ASSIGNEE(S): Zealand Pharma A/S, Den.
SOURCE: U.S. Pat. Appl. Publ., 43 pp., Cont.-in-part of U.S. Provisional Ser. No. 352,717.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

US 2004092429	A1	20040513	US 2003-353549	20030129
US 7153822	B2	20061226		
CN 1638790	A	20050713	CN 2003-804968	20030129
US 2007042964	A1	20070222	US 2006-501402	20060809
PRIORITY APPLN. INFO.:			US 2002-352717P	P 20020129
			US 2003-353549	A3 20030129

AB Disclosed are compns. and methods for modulating hemichannel function in a cell, tissue or organ. The invention also relates to useful screens for detecting such compds., particularly those capable of modulating connexin phosphorylation. Further provided are therapeutic methods for preventing or treating conditions impacted by undesired hemichannel function in a mammal such as heart arrhythmia. Rats subjected to myocardial infarction but treated with Compound 1 (Ac-D-Tyr-D-Pro-D-4Hyp-*Gly*-D- *Ala*-*Gly*-NH2) for three weeks, had an improved cardiac function with less congestion in the left ventricle as demonstrated by a reduced left ventricular end-diastolic pressure.

IC ICM A61K038-17
INCL 514002000
CC 1-12 (Pharmacology)
Section cross-reference(s): 9
IT *355151-12-1 355151-50-7*
RL: BSU (Biological study, unclassified); *PAC (Pharmacological activity)*; PRP (Properties); *THU (Therapeutic use)*; BIOL (Biological study); USES (Uses)
(peptide compns. and methods for modulating connexin hemichannels for treating diseases)
IT *355151-12-1 355151-50-7*
RL: BSU (Biological study, unclassified); *PAC (Pharmacological activity)*; PRP (Properties); *THU (Therapeutic use)*; BIOL (Biological study); USES (Uses)
(peptide compns. and methods for modulating connexin hemichannels for treating diseases)
RN 355151-12-1 HCAPLUS
CN Glycinamide, N-acetyl-D-tyrosyl-D-prolyl-(4S)-4-hydroxy-D-prolylglycyl-D-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 355151-50-7 HCAPLUS
CN L-Tyrosinamide, N-acetylglycyl-L-asparaginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Abdullah, K	1999	10	35	Endocrine	HCAPLUS
Actions	1997	356	76	Naunyn Schmiedebergs	
Adibi	1982			US 4340592 A	HCAPLUS
Alexandre Stewart	2001			Abstract from Americ	
Alford, A	2001	208	L680	Am J Physiol Lung Ce	
Anon					
Anon	1993			DE 4122885 A1	HCAPLUS
Anon	1993			WO 9314777	HCAPLUS
Anon	1994			CA 2156618	HCAPLUS
Anon	1994			DE 4314260 A1	HCAPLUS
Anon	1994			WO 9403468	HCAPLUS
Anon	1994			WO 9412181	HCAPLUS
Anon	1994			WO 9414817	HCAPLUS
Anon	1994			WO 9415908	HCAPLUS
Anon	1995			WO 9513069	HCAPLUS
Anon	1996			WO 9619494	HCAPLUS
Anon	1996			WO 9621674 A1	HCAPLUS
Anon	1996			WO 9630395	HCAPLUS
Anon	1996			WO 9633209	HCAPLUS
Anon	1997			WO 9705889	HCAPLUS
Anon	1998			WO 9810653	HCAPLUS
Anon	1998			WO 9831359	HCAPLUS
Anon	1999			DE 19816932 A1	HCAPLUS
Anon	1999			WO 9911606	HCAPLUS
Anon	1999			WO 9931049	HCAPLUS
Anon	2000			WO 0075286	HCAPLUS
Anon	2001			WO 0100610 A1	HCAPLUS
Anon	2001			WO 0162775	HCAPLUS
Anon	2001			WO 0190085 A1	HCAPLUS
Anon	2001			WO 0192236 A1	HCAPLUS
Anon	2002			WO 02077017 A2	HCAPLUS
Anon	2002			WO 02077017	HCAPLUS
Anon	2002			WO 02101007 A2	HCAPLUS
Anon	2004			WO 2004028466 A2	HCAPLUS
Anon	2004			WO 2004048400 A1	HCAPLUS
Ashino, Y	2000	279	L5	Am J Physiol Lung Mo	HCAPLUS
Audia	2005			US 6888022 B1	HCAPLUS
Bailey	2001			US 6291640 B1	HCAPLUS
Bascom	1996			US 5492894 A	HCAPLUS
Beardslee, M	2000	87	656	Circ. Res.	HCAPLUS
Bennett, M	1991	6	305	Neuron	HCAPLUS
Beny	1994	266	H1465	Physiol Heart Circ P	MEDLINE
Black	2000			US 6136787 A	
Blasits, S	2000	440	710	Phlugers Arch	HCAPLUS

Bolanos	1996	66	2019	J Neurochem	
Bommarius	2001			US 6251625 B1	HCAPLUS
Brudnak	2004			US 20040005304 A1	HCAPLUS
Bruzzone, R	1996	238	1	Eur. J. Biochem.	HCAPLUS
Bruzzone, R	1997	9	1	J Eur Neurosci	MEDLINE
Bursell	1992	11	287	Curr Eye Res	MEDLINE
Buysse	2003			US 20030092634 A1	
Cai	2001	33	957	J Mol Cell Cardiol	HCAPLUS
Campos De Carvalbo	1994	5	686	Journal of Cardiovas	-
Carmeliet, E	1999	79	917	Physiol Rev	HCAPLUS
Castro Pineiro	2003			US 20030114387 A1	
Charash, W	1993	148	467	Am Rev Respir Dis	MEDLINE
Chatterjee	2004			US 20040102609 A1	
Chen	1996			US 5492920 A	HCAPLUS
Chen, X	1998	111	263	Chem Biol Interact	
Christ, G	1996	79	631	Circ Res.	HCAPLUS
Christ, G	2000	12	s15	Int J Import Res	
Colarusso	2004			US 20040142876 A1	
Collier	2003			US 20030202989 A1	
Colwell, C	2000	43	379	J Neurobiol	MEDLINE
Cook	1973			US 3740438 A	HCAPLUS
Cotrina, M	2000	20	2835	J Neurosci	HCAPLUS
Cotrina, M	1998	95	15735	Proc Natl Acad. Sci.	HCAPLUS
Cowsar	2003			US 20030228353 A1	
Cunha-Vaz	1975	59	649	Br J Ophthalmol	MEDLINE
Dankwardt	2002			US 20020169133 A1	
Darrow, B	1995	76		Circulation Research	HCAPLUS
Demuth	2002			US 20020049164 A1	
Demuth	2003			US 20030135023 A1	
Demuth	2004			US 20040171555 A1	
Do Carmo, A	1998	67	569	Exp Eye Res	HCAPLUS
Drauz	1996			US 5534538 A	HCAPLUS
Drauz	1996			US 5543397 A	HCAPLUS
Duerig, J	2000	111	416	Brit J Haematol	
Duggan	2000			US 6017925 A	HCAPLUS
Endo, K	1995	10	589	J Gastroenterol Hepa	MEDLINE
Eugenin	2001	98	4190	Proc. Natl. Acad. Sc	HCAPLUS
Fukuda	2000			US 6162828 A	HCAPLUS
Fukumoto, M	2001	69	247	Life Sciences	HCAPLUS
Gallant	1998			US 5798442 A	HCAPLUS
Gluckman	2001			US 6187906 B1	HCAPLUS
Gluckman	2004			US 6780848 B1	HCAPLUS
Gordon	1993			US 5223486 A	HCAPLUS
Griffith	2003			US 20030105165 A1	
Grubb	1991			US 5037957 A	HCAPLUS
Guerineau, N	1998	273	10389	J Biol Chem.	HCAPLUS
Guerrero	1997	99	1991	J Clin Invest	HCAPLUS
Gupta, P	1998	91	3724	Blood	HCAPLUS
Haefliger	2001	60	190	Kidney Int	HCAPLUS
Hagendorff, A	1999	99	1508	Circulation	MEDLINE
Hans-Ulrich	2001			US 20010020006 A1	
Hansson, L	2000	36	122	Nutrition and Cancer	
Hashitani, H	2001	530	273	J Physiol	HCAPLUS
Haslanger	1991			US 5061710 A	HCAPLUS
Henriques, J	2002	23	1112	Eur Heart J	MEDLINE
Iguchi, Y	1984	29	489	Arch Oral Biol	
Jarvinen	2005			US 20050059608 A1	
Jensen	2004			US 20040092429 A1	HCAPLUS
Johnstone, B	1989	408	77	J Physiol	MEDLINE
Kaprielian, R	1998	97	651	Circulation	MEDLINE

Kettner	1987			US 4636492 A	HCAPLUS
Kettner	1987			US 4652552 A	HCAPLUS
Kitaura	1987			US 4666890 A	HCAPLUS
Klaunig, J	1990	62	135	Lab Investigation	HCAPLUS
Knuetter	2004	21	61	European Journal of	
Koenig, W				Succinimidbildung be	
Kohner, E	1995	44	603	Diabetes	HCAPLUS
Kondo	2000	32	1859	J. Mol. Cell. Cardio	HCAPLUS
Kotake	2001			US 6255285 B1	HCAPLUS
Kuhner	2003			US 20030050247 A1	
Kuhner	2003			US 20030194445 A1	HCAPLUS
Kumar, N	1996	84	381	Cell	HCAPLUS
Kurtz	1997			US 5643955 A	HCAPLUS
Kwak, B	2001	12	831	Molec Biol Cell	HCAPLUS
Kyung-Sun Kang	2001	166	147	Cancer Letters	
Lagostena, L	2001	531	693	J Physiol	HCAPLUS
Lampe	2000	384	205	Archives of Biochemi	HCAPLUS
Larsen	2002			US 6353023 B1	HCAPLUS
Larsen	2002			US 6410585 B1	HCAPLUS
Larsen	2003			US 20030092609 A1	
Larsen	2005			US 20050075280 A1	
Larsen	2005			US 20050113293 A1	
Leoni	2002			US 6342481 B1	HCAPLUS
Levy, D	1999	260	207	Neurosci Lett	HCAPLUS
Li, F	2001	33	2145	J. Mol. Cell. Cardio	HCAPLUS
Lin, R	2001	154	815	The Journal Of Cell	HCAPLUS
Lipsky	1991			US 5047401 A	HCAPLUS
Lipsky	1993			US 5206221 A	HCAPLUS
Low, P	1991	40	873	Diabetes	HCAPLUS
Lynch, J	1981	3	49	J Cardiovasc. Pharma	MEDLINE
Madar	2004			US 20040121964 A1	
Masaya Tanno	2001			Abstract from Americ	
Masuda, M	2001	262	137	Anat Rec	HCAPLUS
Meier, E	2001			International Gap Ju	
Melman, A	2001	28	217	Urol Clinic North Am	MEDLINE
Mohammad Hossain	2000			Science's Stke, Pers	
Morriello	1996			US 5492916 A	HCAPLUS
Morriello	1996			US 5494919 A	HCAPLUS
Morriello	1997			US 5622973 A	HCAPLUS
Munoz	1999			US 5872101 A	HCAPLUS
Murakami, S	2001	203	367	Anat Embryol	HCAPLUS
Myers	1993			US 5252560 A	HCAPLUS
Nadya Lumelsky	2001	292	1389	Science	
Nagy, J	1996	7	745	Cell Growth Diff	HCAPLUS
Nargund	1999			US 5877182 A	HCAPLUS
Nicolson, G	1998	85	473	Proc. Natl Acad Sci	
Oku, H	2001	142	1915	Invest Ophthalmol Vi	
Orlic	2001	410	701	Nature	HCAPLUS
Oviedo-Orta	2001	15	768	FASEB	HCAPLUS
Oviedo-Orta	2000	99	578	Immunology	HCAPLUS
Pavia	1995			US 5446023 A	HCAPLUS
Pavia	1997			US 5637564 A	HCAPLUS
Pavia	1997			US 5650393 A	HCAPLUS
Penney	1999			US 5980913 A	HCAPLUS
Peters	1998	97	1746	Circulation	MEDLINE
Peters, N	1993	88	864	Circulation	HCAPLUS
Petersen, J	1991	258	1	J Pharmacol. Esp. Th	HCAPLUS
Phipps	2005			US 20050020482 A1	
Pitre, D	2001	303	67	Neurosci Lett	HCAPLUS
Pitt	2004			US 20040235752 A1	

Polacek, D	1997	34	19	J Vasc Res	HCAPLUS
Posposilik	2005			US 20050107308 A1	
Powers	1996			US 5514694 A	HCAPLUS
Powers	1997			US 5610297 A	HCAPLUS
Powers	1997			US 5650508 A	HCAPLUS
Powers	2001			US 6235929 B1	HCAPLUS
Powers	2004			US 20040127427 A1	
Quist, A	2000	148	1063	J. Cell Biol	HCAPLUS
Rehman, J	1997	272	H1960	AM J Physiol	HCAPLUS
Repolles Moliner	1995			US 5432159 A	
Riniker	1975			US 3862113 A	HCAPLUS
Ritzeler	2002			US 6358978 B1	HCAPLUS
Rodriguez	2004			US 20040167106 A1	
Rosendaal, M	1991	23	457	Tissue Cell	MEDLINE
Saffitz, J	1999	42	309	Cardiovascular Resea	HCAPLUS
Sakagami, K	1999	521	637	J Physiol (Lond)	HCAPLUS
Saunders, M	2001	61	1765	Cancer Res	HCAPLUS
Sawa Kostin	2001			Abstract from Americ	
Schuster, A	2001	280	H1088	Am J Physiol Heart C	HCAPLUS
Sharma	2004			US 20040167201 A1	HCAPLUS
Shigeto Kanno	2001			Abstract from Americ	
Shinohara, K	2000	286	107	Neurosci Lett.	HCAPLUS
Simon	1998			US 5811387 A	HCAPLUS
Simon, A	1998	8	295	Curr Biol	HCAPLUS
Stammler	2002			US 6384272 B1	HCAPLUS
Stevens, R	1999	2777	C448	Am J Physiol	
Sundstrom	2004			US 20040106560 A1	
Szeto	2004			US 20040029796 A1	
Taugner, R	1980	206	65	Cell Tissue Res	MEDLINE
Teetz	1989			US 4797471 A	HCAPLUS
Teilman, S	2001			International Gap Ju	
Thiele	1997			US 5602102 A	HCAPLUS
Todt, I	2001	181	107	J Membrane Biol	HCAPLUS
Tomoko Nao	2001			Abstract from Americ	
Torikata, C	1985	52	399	Lab Invest	HCAPLUS
Tung	1998			US 5849711 A	HCAPLUS
Turner, W	1997	75	77	Pharmacol Therap	HCAPLUS
Vitale, M	2001	64	625	Biol Reporo	HCAPLUS
Wang	2001	281	C75	Am J Physiol Cell Ph	HCAPLUS
Wang	2002	55	25	Cardiovasc Res	HCAPLUS
Wang	2001	6A	111	Urology	
Wang, Y	1995	270	26581	The Journal Of Biolo	HCAPLUS
Weisheng Bao	2001			Abstract from Americ	
Wolburg, H	1995	157	315	Int Rev Cytol	HCAPLUS
Wright, A	1998	80	89	Pharmacol Ther	HCAPLUS
Yamanaka, I	1997	72	166	European Journal Of	HCAPLUS
Yeh	1997	17	3174	Arterioscle Thromb V	HCAPLUS
Yoshida, M	1998	72	192	Arch Toxicol	HCAPLUS
Zhou, Z	2001	102	959	Neuroscience	HCAPLUS

L98 ANSWER 6 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:155086 HCAPLUS Full-text
DOCUMENT NUMBER: 138:188077
TITLE: Preparation of novel peptide conjugates
INVENTOR(S): *Larsen, Bjarne Due*; *Petersen, Jorgen Soberg*; Kapusta, Daniel R.; Harlow, Kenneth W.
PATENT ASSIGNEE(S): Zealand Pharmaceuticals A/S, Den.
SOURCE: U.S. Pat. Appl. Publ., 36 pp., Cont.-in-part of U. S. Provisional Ser. No. 298,186.
CODEN: USXXCO

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE	
US 2003040472	A1	20030227	US 2001-882291		20010615	<--
US 2006052284	A1	20060309	US 2005-102564		20050408	<--
PRIORITY APPLN. INFO.:			DK 2000-944	A	20000616	<--
			DK 2000-1485	A	20001005	<--
			US 2000-251671P	P	20001206	<--
			US 2001-298186P	P	20010613	
			US 2001-882291	A1	20010615	

OTHER SOURCE(S): MARPAT 138:188077

AB Disclosed are peptide conjugates R1-Z-A1-A2-A3-A4-A5-A6-Z'-R2 (A1, A4, R6 = Arg, Lys, His; A2 = Tyr, Trp, Phe; A3 = Tyr, Asn, Trp, Phe; A5 = Phe, Tyr, Trp, Leu, Val, Ile, where each amino acid residue in the hexapeptide may be in the L or D form; Z, Z' each represent a charged peptide chain of 4 to 20 amino acid residues having the D or L configuration or is missing, provided that not both Z and Z' are missing; R1 = H, acyl group; R2 is an amino group or OH) which are optionally further linked to a transport moiety, as well as their salts, hydrates, solvates, and C-terminally amidated or esterified derivs. Also provided are antibodies that specifically bind the peptide conjugates. The invention has a wide spectrum of important applications including use in the treatment of disorders impacted by nociceptin and related opioid-like peptides. Thus, Ac-Arg-Tyr-Tyr-Arg-Trp-Lys-Lys-Lys-Lys-Lys-Lys-Lys-NH2 was prepared on TentaGel resin and assayed for antibody production

IC ICM A61K038-16
ICS A61K038-10; A61K038-08; C07K007-08; C07K007-06
INCL 514012000; 514013000; 514014000; 514015000; 530324000; 530325000; 530326000; 530327000; 530328000
CC 34-3 (Amino Acids, Peptides, and Proteins)
Section cross-reference(s): 1, 15, 63

L98 ANSWER 7 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:610285 HCAPLUS Full-text
DOCUMENT NUMBER: 139:144011
TITLE: Compositions and methods for modulating connexin hemichannels for disease treatment
INVENTOR(S): Petersen, Jorgen Soberg; Neve, Soren; Nielsen, Morten Schak; Meier, Eddi; Steiness, Eva; Jensen, Peter Holme; Larsen, Bjarne Due; Hansen, Lars Bo Laurenborg
PATENT ASSIGNEE(S): Zealand Pharma A/S, Den.
SOURCE: PCT Int. Appl., 94 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003063891	A1	20030807	WO 2003-DK56	20030129
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2474788	A1	20030807	CA 2003-2474788	20030129
EP 1469875	A1	20041027	EP 2003-701478	20030129
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003007279	A	20041228	BR 2003-7279	20030129
JP 2005516054	T	20050602	JP 2003-563580	20030129
CN 1638790	A	20050713	CN 2003-804968	20030129
NO 2004003590	A	20040827	NO 2004-3590	20040827
PRIORITY APPLN. INFO.:			US 2002-352717P	P 20020129
			WO 2003-DK56	W 20030129

AB Disclosed are compns. and methods for modulating hemichannel function in a cell, tissue or organ. The invention also relates to useful screens for detecting such compds., particularly those capable of modulating connexin phosphorylation. Further provided are therapeutic methods for preventing or treating conditions impacted by undesired hemichannel function in a mammal such as heart arrhythmia. More preferred compds. suitable for use with the present invention include those represented by the following Formula (I, R1(NHR2(CH2)s(CO)p)aNHR3(CH2)t(CO)qNHR4COR5) wherein R1= H or Ac; R2,R4= a sidechain of one of the amino acids G, Y, D-Y, F and D-F; R3 = any amino acid sidechain; R5 = OH or NH2; and a, S, T, P and Q are integers and independently = 0 or 1. More specific compds. include those having the following Formula (II, R1-X1-X2-X3-R2) wherein X1 = 0, *Ala*, *Gly*, β-*Ala*, Tyr, D-Tyr, *Asp* ; X2 is 0, *Ala*-*Gly*-T4c-Pro, *Ala*-Sar-Hyp-Pro, *Ala*-Asn, D-Asn-D-*Ala*, D-Asn, *Gly*, *Ala* , D-*Ala*, β-*Ala*, Asn; X3 = Tyr, D-Tyr, *Gly* , or Phe; R1 = H or Ac, with the proviso that X1 and X2 are not both 0; and R2= OH, NH2.

IC ICM A61K038-08
ICS A61P009-06
CC 1-12 (Pharmacology)

IT *355151-12-1 355151-50-7*
RL: *PAC (Pharmacological activity)*; *THU (Therapeutic use)*; BIOL (Biological study); USES (Uses)
(immunoassay method for screening compds. that modulate connexin hemichannel function for use in disease treatment)

IT *355151-12-1 355151-50-7*
RL: *PAC (Pharmacological activity)*; *THU (Therapeutic use)*; BIOL (Biological study); USES (Uses)
(immunoassay method for screening compds. that modulate connexin hemichannel function for use in disease treatment)

RN 355151-12-1 HCAPLUS
CN Glycinamide, N-acetyl-D-tyrosyl-D-prolyl-(4S)-4-hydroxy-D-prolylglycyl-D-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 355151-50-7 HCAPLUS
CN L-Tyrosinamide, N-acetylglycyl-L-asparaginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Henrik, H	2001			WO 0162775 A	HCAPLUS
Holstein-Rathlou, N	2002			WO 02077017 A	HCAPLUS

L98 ANSWER 8 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:241921 HCAPLUS Full-text
DOCUMENT NUMBER: 138:260539
TITLE: Apparatus and method for flow electroporation of biological samples
INVENTOR(S): Dzekunov, Sergey M.; Lee, Hyung J.; Li, Linhong; Singh, Vininder; Liu, Linda; Holaday, John W.
PATENT ASSIGNEE(S): Maxcyte, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 59 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003059945	A1	20030327	US 2002-80272	20020221
US 7029916	B2	20060418		
PRIORITY APPLN. INFO.:			US 2001-269867P P	20010221
			US 2001-269868P P	20010221

AB The present invention relates to methods and apparatus for the encapsulation of biol.-active substances in various cell populations. More particularly, the present invention relates to a method and apparatus for the encapsulation of biol.-active substances in various cell populations in blood by electroporation to achieve therapeutically desirable changes in the phys. characteristics of the various cell populations in blood. Primary lymphocytes were suspended in B and K buffer (125 mM KCl, 15 mM NaCl, 1.2 mM MgCl2, 3 mM glucose, 25 mM Hepes, pH 7.4) and cell concentration was set from 1x107 cells/mL to 6x108 cells/mL together with DNA plasmid from 50 to 1 mg/mL. Electroporation, 2.3 kV/cm, 400 μs, 4 pulses for small volume expts. (15 μl) or 2.2 kV/cm, 1.6 ms, 1 pulse for large volume expts. (0.5 mL-2 mL) was performed at room temperature Following electroporation, cells were incubated in B&K buffer for 20 min at 37° C. for small volume expts., or diluted by 10+ volume of culture medium (RPMI-1640+10% fetal bovine serum+1% Pen-strep+2 mM

L-*glutamine*) for large volume expts. Cells were cultured in culture medium for various periods (up to 72 h) and the transfection efficiency was analyzed. Primary quiescence lymphocytes were shown refractory to retrovirus based gene transfer. HIV-based vector could transduce primary lymphocytes, but the efficiency is extremely low in the absence of HIV accessory genes. Other non-viral transfection methods also gave very low transfection efficiency. This is the first demonstration of high efficiency of transfection of primary lymphocytes by a non-viral method.

IC ICM C12M001-42
ICS C12N015-87

INCL 435461000; X43-528.52

CC 63-7 (Pharmaceuticals)
Section cross-reference(s): 3, 9

IT 50-35-1D, Thalidomide, derivs. 50-81-7D, Ascorbic acid, ethers, biological studies 52-01-7, Spironolactone 53-05-4, Tetrahydrocortisone 60-33-3, Linoleic acid, biological studies 60-54-8D, Tetracycline, derivs. 68-96-2, 17α-Hydroxyprogesterone 128-13-2, Ursodeoxycholic acid 145-63-1, Suramin 152-58-9, Cortexolone 302-79-4, Retinoic acid 362-07-2, 2-Methoxyestradiol 446-72-0, Genistein 465-21-4, Bufalin 566-35-8 1406-16-2D, Vitamin D, derivs. 2609-46-3, Amiloride 4431-00-9, Aurintricarboxylic acid 9001-91-6, Plasminogen 9061-61-4, NGF 10118-90-8, Minocycline 11096-26-7, Erythropoietin 12772-57-5, Radicicol 19545-26-7, Wortmannin 33069-62-4, Taxol 34031-32-8, Auranofin 37270-94-3, Platelet factor 4 37300-21-3, Pentosan polysulfate 38096-31-0, Diaminoanthraquinone 50903-99-6, L-NAME *57381-26-7*, Irsogladine 62031-54-3, Fibroblast growth factor 62571-86-2, Captopril 62683-29-8, Colony stimulating factor 62996-74-1, Staurosporine 65646-68-6, Fenretinide 70563-58-5, Herbimycin A 79831-76-8, Castanospermine 81627-83-0, M-CSF 83869-56-1, GM-CSF 86090-08-6, Angiostatin 86102-31-0, TIMP 98724-27-7, Proliferin-related protein 99519-84-3 100827-28-9, Erbstatin 103909-75-7, 22-Oxa-1α,25-dihydroxyvitamin D3 105219-56-5, WEB 2086 106096-93-9, Basic fibroblast growth factor 110124-55-5, MDL 27032 125697-92-9, Lavendustin A 126509-46-4, Eponemycin 127464-60-2, Vascular endothelial growth factor 129298-91-5, AGM-1470 130370-60-4, Batimastat 134633-29-7, Tecogalan sodium 142186-14-9, FR-118487 143011-72-7, G-CSF 148717-90-2, Squalamine 154039-60-8, Marimastat 169494-85-3, Leptin 171784-03-5, Louisianine A 171784-05-7, Louisianine C 171784-06-8, Louisianine D 187888-07-9, Endostatin 188417-67-6, CM101 204005-46-9, SU5416 271597-12-7, Myostatin
RL: *THU (Therapeutic use)*; BIOL (Biological study); USES (Uses)
(apparatus and method for flow electroporation of biol. samples)

IT *57381-26-7*, Irsogladine
RL: *THU (Therapeutic use)*; BIOL (Biological study); USES (Uses)
(apparatus and method for flow electroporation of biol. samples)

RN 57381-26-7 HCAPLUS

CN 1,3,5-Triazine-2,4-diamine, 6-(2,5-dichlorophenyl)- (9CI) (CA INDEX NAME)



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Abatti	1992	39	43	IEEE Trans. Biomed.	MEDLINE
Achelpohl	1984			US 4440386 A	
Andal Corp				Multi-Arc Scientific	
Anon	1975			DE 2405119	HCAPLUS
Anon	1985			EP 0137504	HCAPLUS
Anon	1987			DE 3603029	HCAPLUS
Anon	1987			JP 62151174	
Anon	1987			JP 62171687	HCAPLUS
Anon	1987			JP 62228277	HCAPLUS
Anon	1987			JP 62265975	
Anon	1988			JP 63141587	
Anon	1988			WO 8804322	
Anon	1989			EP 0343783	HCAPLUS
Anon	1989			JP 1141582	
Anon	1989			WO 8902464	HCAPLUS
Anon	1989			WO 8903426	HCAPLUS
Anon	1990			EP 0362758	HCAPLUS
Anon	1990			JP 2131584	
Anon	1990			JP 2131585	
Anon	1990			JP 2186993	
Anon	1991			JP 3195485	HCAPLUS
Anon	1991			WO 9118103	HCAPLUS
Anon	1992			EP 0472772	HCAPLUS
Anon	1992			JP 4027393	
Anon	1994			JP 6349068	
Anon	1994			AT 680890	
Anon	1994			WO 9421117	HCAPLUS
Anon	1995			JP 7180029	
Anon	1995			JP 7320720	
Anon	1996			DE 4440386	HCAPLUS
Anon	1996			WO 9628199	HCAPLUS
Anon	1997			EP 0798309	HCAPLUS
Anon	1998			CN 1195997	HCAPLUS
Anon	1998			WO 9824490	HCAPLUS
Anon	2001			WO 0124830	HCAPLUS
Anon	2002			CA 2214800	HCAPLUS
Anon	1975		598	Preparation of certa	
Asakami	1990	9	892	J. Mater. Sci. Lett.	HCAPLUS
Baer	1992			US 5128257 A	HCAPLUS
Barsoum	1990			US 4956288 A	HCAPLUS
Behrndt	1991	A139	58	Materials Sciences a	HCAPLUS
Bertoncini	1992			US 5114681 A	HCAPLUS
Boulton	1981			US 4252628 A	HCAPLUS
Buican	1992			US 5100627 A	HCAPLUS
Busta	1992			US 5137817 A	HCAPLUS
CRC Press	1995		1650	Biological Buffers,	
Calvin	1992			US 5098843 A	HCAPLUS
Capizzi	1993	72	3495	Cancer	HCAPLUS
Casnig	1992			US 5134070 A	
Chang	1989			US 4822470 A	HCAPLUS
Chang	1990			US 4970154 A	HCAPLUS
Chassy	1988	6	303	Trends in Biotechnol	HCAPLUS
Coll	1992			Metallurgical and Tr	
Dower	1990			US 4910140 A	HCAPLUS
Dunican	1998	7	1067	BIO/Technology	
Dzekunov	2003			US 20030073238 A1	

Dzekunov	2004			US 20040197883 A1	
Egorov	1991	29	705	Sov. Powder Metall M	
Einck	1998		357	Tissue Oxygenation i	HCAPLUS
Firth	1993			US 5232856 A	HCAPLUS
Franco	1984			US 4478824 A	HCAPLUS
Franco	1990			US 4931276 A	HCAPLUS
Gersonde	1980	46	81	Biblthca Haemat.	
Gersonde	1979	39	1	Blut, Improvement of	MEDLINE
Gersonde	1982		277	Origins of Cooperati	HCAPLUS
Gersonde	1982	22	279	Toxicology	HCAPLUS
Goodrich	1989			US 4874690 A	HCAPLUS
Goodrich	1991			US 5043261 A	HCAPLUS
Gossling	1960			US 2955076 A	
Hibi	1989			US 4800163 A	
Hilliard	1987			US 4695547 A	HCAPLUS
Hilliard	1989			US 4882281 A	HCAPLUS
Hirai	1987	40	607	J. of Antibiotics	HCAPLUS
Hofmann	1996			US 5501662 A	
Hofmann	1996			US 5545130 A	
Hofmann	1997			US 5676646 A	
Hofmann	1986		6	IEEE Engineering in	HCAPLUS
Holaday	2001			US 20010001064 A1	HCAPLUS
Holmstrm	1998			US 5728281 A	HCAPLUS
Kaali	1992			US 5139684 A	HCAPLUS
Kearney	1995			US 5424209 A	
Kinosita	1979	554	479	Biochimica et Biophy	HCAPLUS
Kobayashi	1989	97	1189	J. Ceram. Soc. Jpn.	HCAPLUS
Kullmann	1993	8	83	Am. J. Respir. Cell	HCAPLUS
Kurtz	1987	15	229	Sol. Energy Mater.	HCAPLUS
Lehninger	1982		181	Principles of Bioche	
Littlehales	1989			US 4840714 A	
Marshall	1989			US 4849089 A	HCAPLUS
Marshall	1990			US 4906576 A	HCAPLUS
Marshall	1990			US 4923814 A	HCAPLUS
Marshall	1990			US 4946793 A	HCAPLUS
Matschke	1987			US 4699881 A	HCAPLUS
Matschke	1988			US 4764473 A	HCAPLUS
Maurer	1993	11	865	J. Orthop. Res.	HCAPLUS
Merz	1991	941	47	Unfallchirurg, Deter	
Meserol	1998			US 5720921 A	HCAPLUS
Meserol	2000			US 6074605 A	HCAPLUS
Meserol	2000			US 6090617 A	HCAPLUS
Meserol	2002			US 6485961 B1	HCAPLUS
Mochizuki	1989			US 4804450 A	HCAPLUS
Mouneimne	1990	275	117	FEBS Letters	HCAPLUS
Multi-Arc, Inc	1996			Ion Bond 16 Zirconiu	
Multi-Arc, Inc	1995			Ion Bond 17 Titanium	
Multi-Arc, Inc	1995			Ion Bond 19 Chromium	
Multi-Arc, Inc	1995			Ion Bond Coatings fo	
Multi-Arc, Inc	1995			Ion Bond Coatings fo	
Multi-Arc, Inc	1995			The Ion Bond Network	
Narayan	1994	B25	5	Materials Sciences a	
Nicolau	1980			US 4192869 A	HCAPLUS
Nicolau	1982			US 4321259 A	HCAPLUS
Nicolau	1984			US 4473563 A	HCAPLUS
Nicolau	1997			US 5612207 A	HCAPLUS
Nicolau	1985	51	92	Biblthca haemat.	HCAPLUS
Nicolau	1986		265	Phytic Acid: Chemist	HCAPLUS
Pietra	1990	115	1025	Analyst	HCAPLUS
Pohl	1984			US 4476004 A	

Ray	1988			US 4784737 A	HCAPLUS
Ropars	1987			US 4652449 A	HCAPLUS
Ropars	1988			US 4752586 A	HCAPLUS
Ropars	1985	445	304	Improved oxygen deli	MEDLINE
Sanford	1990			US 4945050 A	
Sanford	1991			US 5036006 A	
Sanford	1992			US 5100792 A	
Satomi	1988	15	339	Annals Rehab.	HCAPLUS
Schaldach	1989	34	185	Biomed. Technik.	MEDLINE
Schoendorfer	1992			US 5135667 A	HCAPLUS
Shoji	1982	41	1097	Appl. Phys. Lett.	HCAPLUS
Smith	1972			US 3676325 A	HCAPLUS
Sowers	1986			US 4622302 A	
Susuki	1981	19	114	Jpn. J. Med. Electro	MEDLINE
Tada	1992			US 5124259 A	HCAPLUS
Taheri	1994	90	376	Electroencephalograp	MEDLINE
Tait	1991	7	327	Surf. Eng.	HCAPLUS
Takahashi	1991			US 5007995 A	HCAPLUS
Teisseire	1985	58	1810	J. Appl. Phys.	MEDLINE
Teisseire			153	Significance of low	
Teissere	1987	84	6894	Proc. Natl. Acad. Sc	
Therin	1991	2	1	J. Materials Science	
Vasilenko	1973	13	39	Poroshkovaia Metallu	HCAPLUS
Weiner	1983	47	65	Biol. of the Cell	HCAPLUS
Weisel	1978	83	682	Surgery	MEDLINE
Wisbey	1987	8	477	Biomaterials	HCAPLUS
Wisbey	1989	C384/	9	ImechE	
Wong	1987			US 4663292 A	HCAPLUS
Wong	1989			US 4849355 A	HCAPLUS
Xylander	1978			US 4075076 A	
Zhao	1991	42	1109	Vacuum	HCAPLUS
Zhu	1994	9	295	Biosensors and Bioel	HCAPLUS
Ziegler	1991			US 4995957 A	HCAPLUS
Zimmermann	1978			US 4081340 A	HCAPLUS

L98 ANSWER 9 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:683276 HCAPLUS Full-text
DOCUMENT NUMBER: 140:122445
TITLE: Pharmacological characterization of the new stable antiarrhythmic peptide analog Ac-D-Tyr-D-Pro-D-Hyp-*Gly*-D-*Ala*-*Gly*-NH2 (ZP123): In vivo and in vitro studies
AUTHOR(S): Kjolbye, Anne Louise; Knudsen, Carsten Boye; Jepsen, Trine; Larsen, Bjarne Due; Petersen, Jorgen Soberg
CORPORATE SOURCE: Department of Pharmacology, Zealand Pharma A/S, Smedeland, Den.
SOURCE: Journal of Pharmacology and Experimental Therapeutics (2003), 306(3), 1191-1199
CODEN: JPETAB; ISSN: 0022-3565
PUBLISHER: American Society for Pharmacology and Experimental Therapeutics
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Antiarrhythmic peptides (AAPs) are a group of compds. with antiarrhythmic properties; however, their use has been hampered by very low plasma stability. The aim of this study was to compare the in vitro and in vivo stability of our new stable AAP analog Ac-D-Tyr-D-Pro-D-Hyp-*Gly* -D-*Ala*-*Gly*-NH2 (ZP123) with the previously described AAP analog AAP10. Moreover, the effect of the two compds. was examined in a murine in vivo model of ouabain-induced second degree AV-block, and the effect on dispersion of action potential duration

(APD dispersion) was studied during hypokalemic-ischemia in isolated perfused rabbit hearts. The in vitro t1/2 of ZP123 in rat and human plasma was about 1,700 times longer than t1/2 of AAP10. Due to rapid elimination, it was not possible to obtain an in vivo pharmacokinetic characterization of AAP10; however, calcns. suggested that the clearance of ZP123 was at least 140 times slower than for AAP10. AAP10 and ZP123 produced a dose-dependent delay in onset of ouabain-induced AV-block in mice at doses of 10-11 to 10-7 mol/kg i.v. ZP123 and 10-11 to 10-6 mol/kg i.v. AAP10. Maximal efficacy of ZP123 was reached at a 10-fold lower dose (10-8 mol/kg i.v.) than with AAP10. In the isolated rabbit hearts, ZP123 and AAP10 had no effect on dispersion during control conditions. The increased APD dispersion during hypokalemic ischemia is considered a major arrhythmic substrate and only ZP123 prevented the increase in APD dispersion. In conclusion, ZP123 is a new potent AAP analog with improved stability.

CC 1-8 (Pharmacology)
Section cross-reference(s): 14, 63

IT Peptides, biological studies
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antiarrhythmics; pharmacol. characterization with in vivo and in vitro studies of new stable antiarrhythmic peptide analog Ac-D-Tyr-D-Pro-D-Hyp-*Gly*-D-*Ala*-*Gly*-NH2 (ZP123))

IT Cardiovascular agents
Cytoprotective agents
(cardioprotective agents; pharmacol. characterization with in vivo and in vitro studies of new stable antiarrhythmic peptide analog Ac-D-Tyr-D-Pro-D-Hyp-*Gly*-D-*Ala*-*Gly*-NH2 (ZP123))

IT Drug delivery systems
(injections, i.v.; pharmacol. characterization with in vivo and in vitro studies of new stable antiarrhythmic peptide analog Ac-D-Tyr-D-Pro-D-Hyp-*Gly*-D-*Ala*-*Gly*-NH2 (ZP123))

IT Antiarrhythmics
Disease models
Human
(pharmacol. characterization with in vivo and in vitro studies of new stable antiarrhythmic peptide analog Ac-D-Tyr-D-Pro-D-Hyp-*Gly*-D-*Ala*-*Gly*-NH2 (ZP123))

IT *355151-12-1*
RL: *DMA (Drug mechanism of action)*; *PAC (Pharmacological activity)*; *PKT (Pharmacokinetics)*; *THU (Therapeutic use)*; BIOL (Biological study); USES (Uses)
(ZP 123; pharmacol. characterization with in vivo and in vitro studies of new stable antiarrhythmic peptide analog Ac-D-Tyr-D-Pro-D-Hyp-*Gly*-D-*Ala*-*Gly*-NH2 (ZP123))

IT *355151-12-1*
RL: *DMA (Drug mechanism of action)*; *PAC (Pharmacological activity)*; *PKT (Pharmacokinetics)*; *THU (Therapeutic use)*; BIOL (Biological study); USES (Uses)
(ZP 123; pharmacol. characterization with in vivo and in vitro studies of new stable antiarrhythmic peptide analog Ac-D-Tyr-D-Pro-D-Hyp-*Gly*-D-*Ala*-*Gly*-NH2 (ZP123))

RN 355151-12-1 HCAPLUS

CN Glycinamide, N-acetyl-D-tyrosyl-D-prolyl-(4S)-4-hydroxy-D-prolylglycyl-D-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Aonuma, S	1980	28	3332	Chem Pharm Bull (Tok	HCAPLUS
Aonuma, S	1982	5	40	J Pharmacobiodyn	HCAPLUS
Argentieri, T	1989	45	737	Experientia	HCAPLUS
Dhein, S	1994	350	174	Naunyn-Schmiedeberg'	HCAPLUS
Dikshit, M	1988	26	874	Indian J Exp Biol	HCAPLUS
Echt, D	1991	324	781	N Engl J Med	MEDLINE
Gabrielson, J	2000		21	Pharmacokinetic and	
Hjalmarson, A	1984	29	145	Cardiologia	MEDLINE
ISIS-1	1986	2	57	Lancet	
Kjolbye, A	2002	40	770	J Cardiovasc Pharmac	HCAPLUS
Kohama, Y	1987	35	3928	Chem Pharm Bull (Tok	HCAPLUS
Kohama, Y	1988	36	4597	Chem Pharm Bull (Tok	HCAPLUS
Muller, A	1997	327	65	Eur J Pharmacol	MEDLINE
Muller, A	1997	356	76	Naunyn-Schmiedeberg'	MEDLINE
Naccarelli, G	2000	15	64	Curr Opin Cardiol	MEDLINE
Ronsberg, M	1986	14	350	Med Sci	HCAPLUS
Rowland, M	1989		438	Clinical Pharmacokin	
Waldo, A	1996	348	7	Lancet	HCAPLUS
Waldo, A	1996	348	416	published erratum ap	
Xing, D	2003	14	510	J Cardiovasc Electro	

L98 ANSWER 10 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:116197 HCAPLUS Full-text
DOCUMENT NUMBER: 141:167468
TITLE: Effects of the new antiarrhythmic peptide ZP123 on epicardial activation and repolarization pattern
AUTHOR(S): Dhein, Stefan; Larsen, Bjarne D.; Petersen, Jorgen S.; Mohr, Friedrich-Wilhelm
CORPORATE SOURCE: Clinic for Cardiac Surgery, Heart Center, University of Leipzig, Leipzig, Germany
SOURCE: Cell Communication & Adhesion (2003), 10(4-6), 371-378
CODEN: CCAEBH; ISSN: 1541-9061
PUBLISHER: Taylor & Francis, Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Antiarrhythmic peptides such as AAP10 (*Gly-Ala- Gly*-4Hyp-Pro-Tyr-CONH2) have antiarrhythmic properties related to their stimulatory effect on gap junctional coupling. However, most of these peptides are not stable in enzymic environment which limits studies with these compds. in vivo. ZP123 is a new antiarrhythmic peptide constructed using a retro-all-D-amino acid design of the AAP10 template (Ac-D-Tyr-D-Pro-D-4Hyp-*Gly*-D-*Ala*-*Gly*-NH2). The aim of this study was to compare the effects of AAP10 and ZP123 on epicardial

activation and repolarization patterns in isolated perfused rabbit hearts. In addition, we tested the effect of these compds. on PKC activation in cultured HeLa-Cx43 cells. Rabbit hearts were perfused according to the Langendorff technique with Tyrode solution at constant pressure (70 cm H2O). After 45 min equilibration, either AAP10 (n = 7) or ZP123 (n = 7) was infused intracoronarily in concns. of 0.1, 1, 10, 100, and 1000 nM (15 min for each concentration) in the presence of 0.05% bovine serum albumine. 256 AgCl electrodes were attached to the hearts surface and connected to the inputs of a 256 channel mapping system in a unipolar circuit (4 kHz/channel, 0.04 mV vertical resolution, 1 mm spatial resolution). For each electrode the activation and repolarization timepoint were determined We found that both peptides significantly reduced epicardial dispersion by a maximum of about 20% thereby enhancing the homogeneity of epicardial action potential duration, while the action potential duration itself was not affected. The beat-to-beat variability of the epicardial activation pattern was stabilized by both peptides as compared to an untreated time-control series. Other parameters such as LVP, CF, heart rate, or total activation time were not effected by either of the peptides. In a second protocol, rectangular pulses were delivered to the back wall and the propagation velocity was determined longitudinal and transversal to the fiber axis. We found an increase in both longitudinal and transversal conduction velocity. Using a com. PKC assay on HeLa-Cx43 cells we found that 50 nM AAP10 and 50 nM ZP123 increased activity by 99±6% and 146±54%, resp. The PKC activation induced by either of these compds. was completely blocked using the selective PKCα inhibitor GCP54345. We conclude that AAP10 and ZP123 have similar effects in vitro, but the superior enzymic stability of ZP123 makes this compound the preferred substance for in vivo studies of antiarrhythmic peptides.

CC 1-8 (Pharmacology)

IT *159503-65-8 355151-12-1*, ZP123
RL: *DMA (Drug mechanism of action)*; *PAC (Pharmacological activity)*; PRP (Properties); *THU (Therapeutic use)*; BIOL (Biological study); USES (Uses)
(ZP123, AAP10 reduced epicardial dispersion, increased longitudinal and transversal conduction velocity without affecting cardiac parameters in rabbit and induced PKCα activity in HeLA-Cx43 cell but ZP123 showed better enzymic stability)

IT *159503-65-8 355151-12-1*, ZP123
RL: *DMA (Drug mechanism of action)*; *PAC (Pharmacological activity)*; PRP (Properties); *THU (Therapeutic use)*; BIOL (Biological study); USES (Uses)
(ZP123, AAP10 reduced epicardial dispersion, increased longitudinal and transversal conduction velocity without affecting cardiac parameters in rabbit and induced PKCα activity in HeLA-Cx43 cell but ZP123 showed better enzymic stability)

RN 159503-65-8 HCAPLUS

CN retro-Antiarrhythmic peptide (cattle atrium), 6-L-tyrosinamide- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 355151-12-1 HCAPLUS
CN Glycinamide, N-acetyl-D-tyrosyl-D-prolyl-(4S)-4-hydroxy-D-prolylglycyl-D-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Arisi, G	1983	52	706	Circ Res	MEDLINE
Buchanan, J	1985	56	696	Circ Res	HCAPLUS
Dhein, S	1999	128	1375	Br J Pharmacol	HCAPLUS
Dhein, S	2001	8	257	Cell Commun Adhesion	HCAPLUS
Dhein, S	1993	87	617	Circulation	HCAPLUS
Dhein, S	1995	49	851	Drugs	HCAPLUS
Dhein, S	1994	350	174	Naunyn Schmiedeberg'	HCAPLUS
Grover, R	2001	22	1011	Peptides	HCAPLUS
Hofmann, J	1997	11	649	FASEB J	HCAPLUS
Joyner, R	1982	50	192	Circ Res	MEDLINE
Kjolbye, A	2003	306	1191	J Pharmacol Exp Ther	HCAPLUS
Kuo, C	1983	67	1356	Circulation	MEDLINE
Lesh, M	1989	65	1426	Circ Res	MEDLINE
Muller, A	1997	356	76	Naunyn Schmiedeberg'	MEDLINE
Weingart, R	1988	63	72	Circ Res	MEDLINE
Weng, S	2002	16	1114	FASEB J	HCAPLUS
Wit, A	1993		127	Cardiac Mapping	
Xing, D	2003	14	510	J Cardiovasc Electro	

L98 ANSWER 11 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:829575 HCAPLUS Full-text
DOCUMENT NUMBER: 138:378882
TITLE: Anti-arrhythmic peptide N-3-(4-Hydroxyphenyl)propionyl Pro-Hyp-*Gly*-*Ala*-*Gly*-OH

reduces dispersion of action potential duration during ischemia/reperfusion in rabbit hearts

AUTHOR(S): Kjolbye, Anne Louise; Holstein-Rathlou, Niels-Henrik; Petersen, Jorgen Soberg

CORPORATE SOURCE: Zealand Pharma, Glostrup, Den.

SOURCE: Journal of Cardiovascular Pharmacology (2002), 40(5), 770-779
CODEN: JCPCDT; ISSN: 0160-2446

PUBLISHER: Lippincott Williams & Wilkins

DOCUMENT TYPE: Journal

LANGUAGE: English

AB During ischemia, cardiac gap junctions close and neighboring cells uncouple. This leads to slow conduction, increased dispersion of APD (duration from action potential beginning to 90% of repolarization), nonuniform anisotropy, and unidirectional conduction block, all of which favor the induction of reentry arrhythmias. It was suggested that anti-arrhythmic peptides increase gap junction conductance during states of reduced coupling. The aim of this study was to test the effect of the anti-arrhythmic peptide N-3-(4-hydroxyphenyl)propionyl Pro-Hyp-*Gly* -*Ala*-*Gly*-OH (HP-5) (10-10 M) on dispersion of epicardial APD during both normokalemic and hypokalemic ischemia/reperfusion in isolated perfused rabbit hearts. HP-5 did not affect average APD , heart rate, left ventricular contractility (LVP dP/dtmax), or mean coronary flow. HP-5 significantly reduced the epicardial APD dispersion during hypokalemic ischemia (HP-5 treated: 24.1 ms, untreated: 33.9 ms) and during normokalemic reperfusion but not during normokalemic ischemia or control conditions. In addition, among untreated hearts subjected to hypokalemic ischemia/reperfusion, 7 of 10 developed ventricular fibrillation, whereas only 3 of 9 hearts perfused with HP-5 developed ventricular fibrillation. These results show that HP-5 is able to reduce APD90 dispersion during hypokalemic ischemia in rabbit hearts.

CC 1-8 (Pharmacology)
Section cross-reference(s): 2

IT *111915-92-5*
RL: *PAC (Pharmacological activity)*; *THU (Therapeutic use)*; BIOL (Biological study); USES (Uses)
(antiarrhythmic peptide HP-5 reduces dispersion of action potential duration)

IT *111915-92-5*
RL: *PAC (Pharmacological activity)*; *THU (Therapeutic use)*; BIOL (Biological study); USES (Uses)
(antiarrhythmic peptide HP-5 reduces dispersion of action potential duration)

RN 111915-92-5 HCAPLUS

CN Antiarrhythmic peptide (cattle atrium), 1-deglycine-2-[1-[3-(4-hydroxyphenyl)-1-oxopropyl]-L-proline]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Anon	1998	97	651	Circulation	
Aonuma, S	1980	28	3332	Chem Pharm Bull (Tok	HCAPLUS
Aonuma, S	1982	5	40	J Pharmacobiodyn	HCAPLUS
Argentieri, T	1989	45	737	Experientia	HCAPLUS
Dhein, S	1999	128	1375	Br J Pharmacol	HCAPLUS
Dhein, S	1995	49	851	Drugs	HCAPLUS
Dhein, S	1994	350	174	Naunyn Schmiedebergs	HCAPLUS
Dikshit, M	1988	26	874	Indian J Exp Biol	HCAPLUS
Gottwald, E	1998	79	474	Heart	MEDLINE
Kohama, Y	1987	35	3928	Chem Pharm Bull (Tok	HCAPLUS
Kohama, Y	1988	36	4597	Chem Pharm Bull (Tok	HCAPLUS
Kuo, C	1983	67	1356	Circulation	MEDLINE
Lesh, M	1989	65	1426	Circ Res	MEDLINE
Merx, W	1977	94	603	Am Heart J	MEDLINE
Muller, A	1997	327	65	Eur J Pharmacol	MEDLINE
Muller, A	1997	356	76	Naunyn Schmiedebergs	MEDLINE
Peters, N	1993	88	864	Circulation	HCAPLUS
Peters, N	1997	95	988	Circulation	MEDLINE
Wolk, R	1999	84	207	Pharmacol Ther	HCAPLUS

L98 ANSWER 12 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:935626 HCAPLUS Full-text
DOCUMENT NUMBER: 136:64121
TITLE: Peptide conjugates modified n- and/or c-terminally by short charged peptide chains
INVENTOR(S): *Larsen, Bjarne Due; Petersen, Jorgen Soberg*; Kapusta, Daniel R.; Harlow, Kenneth William
PATENT ASSIGNEE(S): Zealand Pharmaceuticals A/S, Den.
SOURCE: PCT Int. Appl., 72 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2001098324	A1	20011227	WO 2001-US19113		20010615 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
CA 2410224	A1	20011227	CA 2001-2410224		20010615 <--
EP 1294746	A1	20030326	EP 2001-952155		20010615 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
JP 2004516811	T	20040610	JP 2002-504279		20010615 <--
PRIORITY APPLN. INFO.:			DK 2000-944	A	20000616 <--
			DK 2000-1485	A	20001005 <--

	US 2000-251671P	P	20001206 <--
	US 2001-298186P	P	20010613
	WO 2001-US19113	W	20010615
	WO 2001-US41008	A	20010615

OTHER SOURCE(S): MARPAT 136:64121

AB Disclosed are a variety of peptide conjugates represented by the following general formula R1-Z-X-Z'-R2, wherein X represents a hexapeptide of the formula A1-A2-A3-A4-A5-A6 wherein A1 represents Arg, Lys, or His, A2 represents Tyr, Trp, or Phe, A3 represents Tyr, Asn, Trp or Phe, A4 represents Lys, Arg or His, A5 represents Phe, Tyr, Trp, Leu, Val or Ile, and A6 represents Arg, Lys, or His and wherein each amino acid residue in said hexapeptide may be in the L or D form; Z represents a charged peptide chain of from 4 to 20 amino acid residues having the D or L configuration or is missing; and Z' represents a charged peptide chain of from 4 to 20 amino acid residues having the D or L configuration or is missing, providing that not both of Z and Z' are missing; R1 represents H or an acyl group; R2 represents NR3R4 where each of R3 and R4 independently represents hydrogen, C(1-6)alkoxy, aryloxy, or a lower alkyl as defined herein; or R2 represents OH; the peptide conjugates of formula (I) being optionally further linked to a transport moiety; and salts, hydrates and solvates thereof, and C-terminally amidated or esterified derivs. thereof with suitable organic or inorg. acids, including methods or making and using such conjugates. Also provided are antibodies that specifically bind the peptide conjugates. The present invention has a wide spectrum of important applications including use in the treatment of disorders impacted by nociceptin and related opioid-like peptides.

IC ICM C07K007-08
ICS C07K014-00; C07K016-44; A61K038-16; C07K007-06; C07K014-575; A61K038-04

CC 1-8 (Pharmacology)
Section cross-reference(s): 15, 34, 63

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Lapalu, S	1997	417	333	FEBS LETTERS	HCAPLUS
Meunier, J	2000	21	893	PEPTIDES	HCAPLUS
Novonordisk As	1999			WO 9944627 A	HCAPLUS

L98 ANSWER 13 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:504962 HCAPLUS Full-text
DOCUMENT NUMBER: 135:298164
TITLE: Structure-activity relationships of novel peptides related to the antiarrhythmic peptide AAP10 which reduce the dispersion of epicardial action potential duration
AUTHOR(S): Grover, R.; Dhein, S.
CORPORATE SOURCE: Institute of Pharmacology, University of Cologne, Cologne, 50931, Germany
SOURCE: Peptides (New York, NY, United States) (2001), 22(7), 1011-1021
CODEN: PPTDD5; ISSN: 0196-9781
PUBLISHER: Elsevier Science Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB We report the first study on short peptide structure-activity relationships (SAR) for the antiarrhythmic peptide AAP10 and its putative receptor. Synthetic improvements on the natural antiarrhythmic peptide AAPnat (H-*Gly*-Pro-Hyp-*Gly*-*Ala*-*Gly*) isolated from bovine atria led us to the synthesis of our lead mol. AAP10 (H-*Gly*-*Ala*-*Gly*-Hyp-Pro-Tyr-NH2) which reduces dispersion of epicardial potential duration and acts antiarrhythmically in isolated rabbit

hearts. The aim of our study was to elucidate structure-activity relationships for AAP10 based on Langendorff expts. and mol. modeling. Mutation of the amino acid sequence led to 11 different peptides which were tested analogous to the lead mol. Among these new synthetic peptides various including the cyclopeptide cAAP10RG, cyclo[CF3C(OH)-*Gly-Ala-Gly*-Hyp-Pro-Tyr] showed promising activities. (supported by the DFG and Koln-Fortune).

CC 1-3 (Pharmacology)

IT *81771-37-1*, Antiarrhythmic peptide (cattle atrium)
159503-65-8 366800-46-6 366800-47-7 366800-48-8
366800-49-9 366800-50-2 366800-51-3 366800-52-4 *366800-53-5*
366800-54-6 366800-55-7 366800-56-8 366800-57-9 366800-58-0
366800-59-1
RL: *BAC (Biological activity or effector, except adverse)*; BSU (Biological study, unclassified); PRP (Properties); *THU (Therapeutic use)*; BIOL (Biological study); USES (Uses)
(structure-activity relationships of novel peptides related to antiarrhythmic peptide AAP10 which reduce dispersion of epicardial action potential duration)

IT *81771-37-1*, Antiarrhythmic peptide (cattle atrium)
159503-65-8 366800-53-5
RL: *BAC (Biological activity or effector, except adverse)*; BSU (Biological study, unclassified); PRP (Properties); *THU (Therapeutic use)*; BIOL (Biological study); USES (Uses)
(structure-activity relationships of novel peptides related to antiarrhythmic peptide AAP10 which reduce dispersion of epicardial action potential duration)

RN 81771-37-1 HCAPLUS

CN Antiarrhythmic peptide (cattle atrium) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 159503-65-8 HCAPLUS

CN retro-Antiarrhythmic peptide (cattle atrium), 6-L-tyrosinamide- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 366800-53-5 HCAPLUS
CN L-Tyrosinamide, glycyl-L-alanylglycyl-L-prolyl-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Atherton, E	1989			Solid phase peptide	
Beck-Sickinger, A	1991	4	88	Pept res	HCAPLUS
Bhacca, N	1962			High resolution NMR	
Carpino, L	1972	37	3404	J Org Chem	HCAPLUS
Curphey, T	1979	44	2805	J Org Chem	HCAPLUS
Dhein, S	1999	128	1375	Br J Pharmacol	HCAPLUS
Dhein, S	1993	87	617	Circulation	HCAPLUS
Dhein, S	1997	96	I-292	Circulation	
Dhein, S	1995	49	851	Drugs	HCAPLUS
Dhein, S	1997	2	51	Exp Clin Cardiol	
Dhein, S	1994	350	174	Naunyn Schmiedebergs	HCAPLUS
Dhein, S	1994	349	R55	Naunyn Schmiedebergs	
Dhein, S	1999	359	R7	Naunyn Schmiedebergs	
Dhein, S	1995	429	R91	Pflug Arch Eur J Phy	
Dhein, S	1998		163	Proceedings of Inter	HCAPLUS
Durrer, D	1954	47	192	Am Heart J	MEDLINE
Friebolin, H	1988			Ein-Und Zweidimensio	
Gottwald, E	1998	79	474	Heart	MEDLINE
Grover, R	1998	19	1725	Peptides	HCAPLUS
Han, J	1964	16	46	Circ Res	
Kjolbye, A	2000	14	A698	The FASEB J	
Kuo, C	1983	67	1356	Circulation	MEDLINE
Lesh, M	1989	65	1426	Circ Res	MEDLINE
Meyer, V	1978			Praxis in der HPLC	
Millar, C	1985	72	1372	Circulation	MEDLINE
Mueller, A	1997	327	65	Eur J Pharmacol	HCAPLUS
Mueller, A	1997	356	76	Naunyn Schmiedebergs	HCAPLUS
Nomizu, M	1994	20	2691	Tetrahedron	
Patrick, G	1995			An introduction to m	
Rink, H	1987	28	3787	Tetrahedron Lett	HCAPLUS
Viswanadhan, V	1989	29	163	J chem inf comput sc	HCAPLUS
Wang, S	1973	95	1328	J Amer Chem Soc	HCAPLUS
Wiener, S	1984	106	765	J Am Chem Soc	

L98 ANSWER 14 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2000:144722 HCAPLUS Full-text
DOCUMENT NUMBER: 132:185454
TITLE: Use of anti-angiogenic agents for inhibiting vessel wall injury
INVENTOR(S): Brown, Charles L., III; Gorlin, Steve
PATENT ASSIGNEE(S): Global Vascular Concepts, Inc., USA
SOURCE: PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000010552	A2	20000302	WO 1999-US19218	19990824 <--
WO 2000010552	A3	20001123		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9956871	A1	20000314	AU 1999-56871	19990824 <--
PRIORITY APPLN. INFO.:			US 1998-97579P P	19980824 <--
			WO 1999-US19218 W	19990824 <--

AB Use of anti-angiogenic agents to inhibit an undesirable response to vessel wall injury, including stent neointima, dialysis graft neointima, vascular graft-induced neointima, and the treatment of benign hypertrophic scar formation as well as the treatment and passivation of unstable atherosclerotic plaques are provided. The invention provides for the use of catheter-based devices for enhancing the local delivery of anti-angiogenic agents into the endothelial tissues of blood vessels of the living body.

IC ICM A61K031-00
CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 1
IT 50-28-2, Estradiol, biological studies 50-35-1, Thalidomide 50-81-7D, Ascorbic acid, ethers, biological studies 52-01-7, Spironolactone 53-05-4, Tetrahydrocortisone 53-86-1, Indomethacin 60-33-3, Linoleic acid, biological studies 60-54-8, Tetracycline 68-96-2, 17α-Hydroxyprogesterone 128-13-2, Ursodeoxycholic acid 145-63-1, Suramin 152-58-9, Cortexolone 302-79-4, Retinoic acid 362-07-2, 2-Methoxyestradiol 446-72-0, Genistein 465-21-4, Bufalin 566-35-8 2609-46-3, Amiloride 4431-00-9, Aurine tricarboxylic acid 10118-90-8, Minocycline 12772-57-5, Radicicol 19545-26-7, Wortmannin 33069-62-4, Taxol 34031-32-8, Auranofin 37270-94-3, Platelet factor 4 38096-31-0, Diaminoanthraquinone 38194-50-2, Sulindac 50903-99-6, L-Name 53902-12-8, Tranilast *57381-26-7*, Irsogladine 62571-86-2, Captopril 62996-74-1, Staurosporine 65646-68-6, Fenretinide 70563-58-5, Herbimycin A 79831-76-8, Castanospermine 86090-08-6, Angiostatin 100827-28-9, Erbstatin 103909-75-7, 22-Oxa-1α-25-dihydroxyvitamin D3 105219-56-5, WEB 2086 110124-55-5, MDL 27032 125697-92-9, Lavendustin A 126509-46-4, Eponemycin 129298-91-5, TNP-470 130370-60-4, BB-94 134633-29-7, Tecogalan sodium 142186-14-9, FR-118487 148717-90-2, Squalamine 154039-60-8, Marimastat 171784-03-5, Louisianine A 171784-04-6, Louisianine B 171784-06-8, Louisianine D 187888-07-9, Endostatin

188417-67-6, CM 101 204005-46-9, SU5416
RL: *THU (Therapeutic use)*; BIOL (Biological study); USES (Uses)
(anti-angiogenic agents for inhibiting vessel wall injury)
IT *57381-26-7*, Irsogladine
RL: *THU (Therapeutic use)*; BIOL (Biological study); USES (Uses)
(anti-angiogenic agents for inhibiting vessel wall injury)
RN 57381-26-7 HCAPLUS
CN 1,3,5-Triazine-2,4-diamine, 6-(2,5-dichlorophenyl)- (9CI) (CA INDEX NAME)



L98 ANSWER 15 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2000:37178 HCAPLUS Full-text
DOCUMENT NUMBER: 132:343088
TITLE: Protective effect of irsogladine on monochloramine-induced gastric mucosal lesions in rats: a comparative study with Rebamipide
AUTHOR(S): Yamamoto, H.; Umeda, M.; Mizoguchi, H.; Kato, S.; Takeuchi, K.
CORPORATE SOURCE: Department of Pharmacology and Experimental Therapeutics, Kyoto Pharmaceutical University, Kyoto, 607-8414, Japan
SOURCE: World Journal of Gastroenterology (*1999*), 5(6), 477-482
CODEN: WJGAF2; ISSN: 1007-9327
PUBLISHER: World Journal of Gastroenterology
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Aim: To examine the effect of irsogladine, a novel antiulcer drug, on the mucosal ulcerogenic response to monochloramine (NH2Cl) in rat stomach, in comparison with Rebamipide, another antiulcer drug with cytoprotective activity. Methods and Results: Oral administration of NH2Cl (120 mM) produced severe hemorrhagic lesions in unanesthetized rat stomachs. Both irsogladine (1-10 mg/kg, orally) and Rebamipide (30-100 mg/kg, orally) dose-dependently prevented the development of these lesions in response to NH2Cl; the effect of irsogladine was significant at ≥3 mg/kg and that of Rebamipide only at 100 mg/kg. The protective effect of irsogladine on NH2Cl-induced gastric lesions was significantly reduced by NG-nitro-L-arginine Me ester (L-NAME) but not by indomethacin, while that of Rebamipide was significantly mitigated by indomethacin but not by L-NAME. Topical application of NH2Cl (20 mM) caused a marked reduction of p.d. (PD) in ex-vivo stomachs. This PD reduction was not affected by mucosal application of irsogladine but significantly prevented by Rebamipide. The mucosal exposure to NH4OH (120 mM) also caused a marked PD reduction in the ischemic stomach (bleeding from the carotid artery), resulting in gastric lesions. These ulcerogenic and PD responses caused by NH4OH plus ischemia were also significantly mitigated by Rebamipide, in an indomethacin-sensitive manner, while irsogladine potently prevented such lesions without affecting the PD response, in a L-NAME-sensitive manner. Conclusions: These results suggest that (1) NH2Cl generated either exogenously or endogenously damages the gastric mucosa, (2) both irsogladine and